



US 20250248377A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2025/0248377 A1

Tang et al.

(43) Pub. Date: Aug. 7, 2025

(54) NON-HUMAN ANIMALS HAVING A HUMANIZED TSLP GENE, A HUMANIZED TSLP RECEPTOR GENE, AND/OR A HUMANIZED IL7RA GENE

(71) Applicant: Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)

(72) Inventors: **Yajun Tang**, White Plains, NY (US); **Susannah Brydges**, Scarsdale, NY (US); **Subhashini Srivatsan**, Wilton, CT (US); **Davor Frleta**, Forest Hills, NY (US); **Cagan Gurur**, Chappaqua, NY (US); **Andrew J. Murphy**, Croton-on-Hudson, NY (US)

(21) Appl. No.: 19/189,370

(22) Filed: Apr. 25, 2025

Related U.S. Application Data

(62) Division of application No. 17/555,550, filed on Dec. 20, 2021.

(60) Provisional application No. 63/128,258, filed on Dec. 21, 2020.

Publication Classification

(51) Int. Cl.

A01K 67/0278 (2024.01)
A61K 49/00 (2006.01)
C12N 15/85 (2006.01)
C12N 15/89 (2006.01)
G01N 33/50 (2006.01)

(52) U.S. Cl.


CPC A01K 67/0278 (2013.01); A61K 49/0008 (2013.01); C12N 15/8509 (2013.01); C12N 15/89 (2013.01); G01N 33/5088 (2013.01); A01K 2207/15 (2013.01); A01K 2217/052 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A01K 2267/0387 (2013.01); G01N 2500/10 (2013.01)

(57)

ABSTRACT

Disclosed herein are rodents (such as, but not limited to, mice and rats) genetically modified to comprise a humanized *Tslp* gene, a humanized *Tslpr* gene, a humanized *Il7ra* gene, or a combination thereof. Compositions and methods for making such genetically modified rodents, as well as methods of using such genetically modified rodents as an animal model for diseases such as allergic diseases and cancer are provided.

Specification includes a Sequence Listing.



Mouse *Tslp*




FIG. 1A





FIG. 1B

Targeted Allele MAID# 7466



Targeted Allele, Cassette Removed MAID# 7467




FIG. 1C

Mouse Tslp protein (NP_067342):

Signal Peptide: 1-19

MVLLRSLEFILOQVLVRMGLTYNFSNCNFTSITK^YCNIFHDLTGDLKGAKFEQIEDCESKPACCLL^KI^EYYTLNPIP
GCPSLPDKTFARRTREALNDHCPGYPETERNDGTQEMAQE^VQNICLNQTSQILRLWYSFMQSPE (SEQ ID NO: 1)

Human TSLP protein (NP_149024):

Signal Peptide: 1-28

MFPFALLVYVLSVSFRK/FILQLVGLVLTYDFTNCDFE^KIKAA^YLSTISKDLITYMSGT^KSTE^FNNTVCSNRP^H
CLTEI/QSLT^FNPTAGC^ASLAKEM^FAM^KTKA^ALA^IWCPGYSETQ^INATQ^AMIKKRRKRVTTNKCLEQVSQL
QGLW^RRFNRPLLKQQ (SEQ ID NO: 3)

Mouse/Human Hybrid protein:

Signal Peptide: 1-19

MVLLRSLEFILOQVLVRMGLTYDFTNCDFE^KIKAA^YLSTISKDLITYMSGT^KSTE^FNNTVCSNRP^HCLTEI^QSQLT
FNPTAGC^ASLAKEM^FAM^KTKA^ALA^IWCPGYSETQ^INATQ^AMIKKRRKRVTTNKCLEQVSQLQGLW^RRF
NRPLLKQQ (SEQ ID NO: 5)

FIG. 1D

Mouse Tslp mRNA (NM_021367) (CDS):

Signal Peptide: 1-57

ATGGTTCTTCAGGAGCCCTCTTCAATCCTGCAAGTAGTAGTACGGATGGGGCTAACCTTCTAA
CTGGAACCTCACGTCAATTACGAAAATATTTGTAACATAATTGTAACATAATTGTAACATAATT
GGCTAAGTTGAGCAAATCGAGGACTGTGAGAGCAAGCCAGCTGTCTCTGAAATCGAGTAGCTACTA
CTCAATCCTATCCCTGGCTGCCCTCACTCCCCGACAAACATTGCCGGAGAACAAAGAACAGCCCTCA
ATGACCACTGCCAGGGCTACCCCTGAAACTGAGAGAAAATGACGGTACTCAGGAAATGGCACAAAGAGTCC
AAAACATCTGCCTGAATCAAACCTACAATTCAGATTCTAACAAATTCTAACAACTCAAAATCTCCAGAATAA
(SEQ ID NO: 2)

Human TSLP mRNA (NM_033035) (CDS):

Signal Peptide: 1-84


ATGTTCCCTTTGCCCTTACTATATGTTCTGTCAGTTCTTCAAGAAAATCTTCATCTTACAACCTGTAGGG
CTGGTGTTAACTTACCGACTTCACTAACTGTGACTTTGAGAAGATTAAGCAGCTATCTCAGTAGCTATT
CTAAAGACCTGATTACATATGAGTTGGGACCAAAAGTACCGAGTTCAACAAACACCGTCTCTGTAGCA
ATCGGCCACATTGCCCTTACTGAAATCCAGAGCCTAACCTTCAACCCACCCGGCTGCCGCTCGCCTC
GCCAAAGAAATGTTGCCCATGAAACTAAAGGCTGCTTCTAGCTATCTGGTCCCAGGCTATTCTGGAAC
CAGATAAAATGCTACTCAGGCCAATGAAGAAGAGGAGAAAAGGAAAGTCACAACCAATAATGTCAGGA
ACAAGTGTCAACAATTACAAGGGATTGTGGCCTCGCTTCAATCGACCTTTACTGAAACACAGTAA (SEQ
ID NO: 4)

Mouse/Human Hybrid mRNA (CDS):

ATGGTTCTTCAGGAGCCCTCTTCAATCCTGCAAGTAGTAGTACGGATGGGGCTAACCTTCTAA
CTGTGACTTGTAGAAAGATTAAGCAGCTATCTCAGTAGCTATTCTAAAGACCTGATTACATATGAGTGC
GACCAAAAGTACCCGAGTTCAACAAACACCGTCTCTGTAGCAATCGGCCACATTGCCCTACTGAAATCCAG
AGCCCTAACCTTCAATTCCACCCGGGGCTGCCGCTCGCTCGCCAAAGAAATGTTGCCCATGAAAAACTAAG
GCTGCCCTAGCTATCTGGTCCCAGGCTATTCTGGAAACTCAGATAAAATGCTACTCAGGCCAATGAAAGAAGA
GGAGAAAAAGGAAAGTCACAACCAATAATGTCAGGAAAGTGTCAACAAATTACAAGGATTGTGGCGTC
GCTTCAATCGACCTTTACTGAAACACAGTAA (SEQ ID NO: 6)

FIG. 1E

Human/hybrid/mouse Tsip protein alignment



上
下
中
上




FIG. 1G




FIG. 2A





FIG. 2B

Targeted Allele MAID# 7558



Targeted Allele, Cassette Removed MAID# 7559




FIG. 2C

Mouse Tslpr protein (NP_001158207):

Signal Peptide: 1-19

TM: 244-264

MAWALAVILLPRLLAAAAAAAVTSRGDVTVCVCHDLETVETWGSGPDDHGANLSLEFRYGTGALQPCPRYF
LSGAGVTSGCILPAARAGLIELALR DGGGAMVFKARQRASAWLKPRPPWNNTLLWTPDGDVTVSWPAHSYL
GLDYEVQHRESNDDDAWQQTTSGPCCCDLTVGGLDPVRCYDFVRASPRAAHYGLEAQPSEWTAVTRLSGA
ASAGDPCAAHLPPLASCTASPAPSPALAPPLPLLGCGGLAALLTLSLLAALRLRRRVKDALLPCVPDPSGSFPGL
FEKHHGNFQAWIADAQATAPPARTEEEDDLIHTKAKRVEPEDGTSLCTVPRPPSFEPRRGPGGGAMVSVGGA
TFMVGDSGYMTL (SEQ ID NO: 21)

Human TSLPR protein (NP_071431):

Signal Peptide: 1-22

TM: 232-252

MGRLVLLWGAAVFL LGGM/MALGQGGAAEGVQ/QIYFNLETVQVTWNASKYSRTNLTFHYRFNGDEAYDQ
CTNYLLQEGETSGCLLDAEQRDDILYFSIRNGTHPVFTASRWWVYYLKPKSSPKHVRFSWHQDAVTVTCSDL
SYGDLLYEVQYRSPFDTEWQS KQENTCNVIEGLDAEKCYSFWVVRVKAMEDVYGPDTYPSDWSEVTCWQ
RGERDACAETPTPKPKL SKFILISLAILLMVSSLILSLWKLWWRVKKFLIPSVPDPKSIFPGLFEIHQGNFQE
WITDTQNV AHLHKMAGAEQESGPEEPLVVQLAKEAESPRLMDPQTEEKEASGGSLQLPHQPLQGGDW
TIGGFTFVMNDRSYVAL (SEQ ID NO: 23)

Mouse/Human Hybrid protein:

Signal Peptide: 1-19

TM: 232-252

MAWALAVILLPRLLAAAAAAAVTSRAEGVQ/QIYFNLETVQVTWNASKYSRTNLTFHYRFNGDEAYDQ
CTNYLLQEGETSGCLLDAEQRDDILYFSIRNGTHPVFTASRWWVYYLKPKSSPKHVRFSWHQDAVTVTCSDL
YGDLLYEVQYRSPFDTEWQS KQENTCNVIEGLDAEKCYSFWVVRVKAMEDVYGPDTYPSDWSEVTCWQ
RGERDACAETPTPKPKL SKLPLLGCGGLAALLTLSLLAALRLRRRVKDALLPCVPDPSGSFPGLFEKHGN
FQAWIADAQATAPPARTEEEDDLIHTKAKRVEPEDGTSLCTVPRPPSFEPRRGPGGGAMVSVGGATFMVGD
SGYMTL (SEQ ID NO: 25)

FIG. 2D

Mouse Tslipr mRNA (NM_001164735) (CDS)

Signal Peptide: 1-57

TM: 730-792

Human TSLPR mRNA (NM_022148) (CDS):

Signal Peptide: 1-66

ATGGGGGGCTGGTTCTGCTGGAGCTGCCGTCTTCTGGATGGCTGGGCAAGGAGGAGCAGA
 AGGAGTACAGATTAGAAACCGTGAGGTGACATGGAAATGCCAAATACTCCAGGACCAACCT
 GACTTCCACTACAGATTCAACGGTGTAGGSCCTATGACCAGTGCACCAACTACTCGGGGTG
 CCTCTAGACCGAGGAGGAGACGAGACGACATTCCTATGCCAAACTACTCTCCAGGAAGGGTCA
 GATGGTTATTACCTGAAACCCAGTCCCCGAGGGACCTGAGATTTCGTTGACGGTGAACGTTCTGA
 CCCCCTGTCTTACGGGATCTCCTATGAGGTTCACTACGGGAGGCCCCCTGACACCGAGTGGCAGTCC
 AAACGTCACCATAGAAGGCTGGATGCCAGGAAAGTGTACTCTGGGTCAAGGGTATGGAGGATGATA
 AACACACATACCAAGGACTGGGACTGAGGTGACATGCTGGCAGAGGGCAGATTGGGATGCC
 CCCTCCCAACCAAGGCTGTCAAATTAAATTTCAGGCCATTCCTCTGTCATGGCTCTGCTTATG
 GAAAATTATGGAGAGTGAAGAAGTTCATTCCAGGCCAACCTCCAGGCTCTTGGATACACCA
 AGGGAACTTCCAGGAGTGGATCACAGACACCCAGAACGTTGCCACCTCCAAGATGGCAGGGTGCAG
 GAGCTGGCCAGGAGCCCCCTGGTAGTCCAGTGGCCAAAGACTGAAGCCGAGTCTGGACCC
 AGGGCCTCTGGGATCCCTCCAGTCCCCACAGGCCCTCAAGGGCTGATGTGGTCACAATCGGG
 ATGAAATGACCCCTGCTACGGCTGCA (SEQ ID NO: 24)

三二六

Mouse/Human Hybrid mRNA (CDS)

Signal Peptide: 1-57

TM: 694-756

FIG. 2E (Continued)




FIG. 2F




FIG. 3A





FIG. 3B

Targeted Allele MAID# 7266



Targeted Allele, Cassette Removed MAID# 7267



FIG. 3C

Mouse IL7ra protein (NP_032398):

MMAL GRAFAIV FCLIQAV SGESGNAQ DGDLEDADDHSFW CHSQLEV DGSQHLL CAFNDSDINTANL
QICGALLRV KCLTNKLQDIYFIKTSEFLIGSSNICVKLGQKNLTCKNMAINTVKAEAPSDLKVVRKEAND
LVTFNAPPHLKKVKHDVAYRPARGESNWTHVSLFHTRTTIPQRKLRPKAMYEIKVRSIHDYF
SEWSPSSTFETPEPKNQGGWDPVLPSVTISLFSVELLVAHVLWKRIKPVWNPSLPDHKKTLEHLC
KTSINVSFNPESFLDCQIHRVDDIQAREVEGFLQDTFPQQLEESEKQRLGDVQSPNCPSEDVWIT
PESFGRDSSLTCLGNVSACDAPISSRSLDCRESGKNGPHVYQDLLSLGTTNSTLPPFSLQSGILTL
NPVAQGQPILTSLGSNQEEAYVTMSSFYQNQ (SEQ ID NO: 41)

Human IL7RA protein (NP_002176):

MTIL GTTFGMVFSIL QWSGESGYA QNGDEAELDDSFSCYSQLEVNGSQHSLTCAFEDPDVNITNL
FEICGALVEVKCLNFRKLQEIYFETKKFLQIGKSNICVKGEKSITCKKIDLTTIVKPEAFFDLSVVYR
GANDFVWTFNTSHLQKKVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSI
DHYFKGFWSEWSPSYYFRTPEINNSSGGWDPVLPSVTISLFSVFLVIAHVLWKKRIKPVVWPSLD
KKTLEOQLCKKPKTSLNVSFNPESFLDCQIEVKGVEARDEVESFLPNDLPAQPEELTOGHRAV/HSANR
SPETSVSPPETVRRESPLRCLANLSTCNAPPLSSRSRPDYRDGDRNRPPVYQDLLPNSGNTNVPV

QPLPFQSGILPVSQRQIPSTSSFYQNQ (SEQ ID NO: 43)

Mouse/Human Hybrid protein:

MMAL GRAFAIV FCLIQAV SGESGNAQ DGDLEDAEDDHSFW CHSQLEV DGSQHSLTCAFEDPDVNITNL
EFEICGALVEVKCLNFRKLQEIYFETKKFLQIGKSNICVKGEKSITCKKIDLTTIVKPEAFFDLSVVYR
GANDFVWTFNTSHLQKKVKVLMHDVAYRQEKDENKWTHVNLSSTKLTLLQRKLQPAAMYEIKVRSI
DHYFKGFWSEWSPSYYFRTPEINNSSGGWDPVLPSVTISLFSVFLVIAHVLWKKRIKPVVWPSLD
KKTLEOQLCKKPKTSLNVSFNPESFLDCQIEVKGVEARDEVESFLPNDLPAQPEELTOGHRAV/HSANR
SPETSVSPPETVRRESPLRCLANLSTCNAPPLSSRSRPDYRDGDRNRPPVYQDLLPNSGNTNV

QPLPFQSGILPVSQRQIPSTSSFYQNQ (SEQ ID NO: 45)

FIG. 3D

Mouse Il7ra mRNA (NM_008372) (CDS):

ATGATGGCTCTGGGTAGAGCTTCTGCTTACATTCAAGCTGTTCTGGAGAAAGTGGAAATGCCAGGATGGAG
ACCTAGAAGATGCAGAGCGGGAGATCACTCCCTCTGGCACAGCCAGTGGAAAGTGGATGGAAATGCCAAACATTATTGACTTG
TGCTTTTAATGACTCAGACATCAACAGCTAACTGGAAATTCAAGCTTAAAGGAAATTCAGAAATTCTTAAAGGAAATGGCTTAACITCAA
CAAGCTGGCAAGATAATAATTAAAGAACATCAGAATTCTTAACTGATTGGTAGCAGGAATAATATGGTGAAGCTGGACAAAGAA
TTAACACTTGCAAAAATATGGCTATAAACACAAATAGTTAAAGCAGGCTCCCTCTGACCTGAAAGTGGCTTATGCCAAAGAAGCAA
ATGATTTTTGGTGCACATTAAATGCAACCTCAACTTGAAGAAATATTAAAGAACATGATGTTGGCCTACCCGCCAGCAA
GGGTGAAAGGAAACTGGGACCGOATGATGTTATTCACAGGAAACTACAGAACAAATCCOACAGAACAAATGGCTTATGGTGAAGAA
TGAAATCAAAGTCCCCTACCATTOCCCATAACGATTACTTCAAAAGGCTTCTGGAGCGAGTGGAGTCCAAAGTCTACCTTCCGAAACTC
CAGAACCCAAAGAATCAAGGGAGGATGGGATCTGTGCTTGGCAAGTGTACCCATTCTGAGTTGGCAGTGGTCAAGTGGTCACT
TTAGCCCCATGTGCTATGGCTTAACCTGTGCTATGGCTTATGGCTAGTGTCTCCCGATCATAAAGAAAACACTGGAACAACTATG
TAAGAAGCCAAAACAGAGTCTGAATGTGAGTTCAATCCCGAAAGTTCCTGGACTGCCAGATTCTGGACTTGGAAATGGGTTGAA
GCCAGGGGAGGAGGTGAAAGTTCTGCCCAATGATCTCCCTGCCACAGCCAGGGAGTTGGAGACACAGGGACACAGAGGCC
TGTACACAGTCCAACACCGCTCGGCTGAGACTTCAGTCAGGCCACCCAGAAACAGTTAGAAAGAGGTACCCCTTAAGATGCC
AGAAATCTGAGTACCTGCAATGCCCTCCACCTTCCACCTTCCAGTGGCTCCCTGACIATAGAGATGGTACAGAGAAATGGC
TGTATCAAGAGCTTGTGCCAAACTCTGGAAACACAAATGTCCTCAACCATTGGCTTCCACCTTCCAGTACTGAATGTC
GATACCAAGTTCTCAGAGACAGGCCATCTCCACCTTCCAGTACTGAATGTCACCATTGTCAGTACTGAATGTC
AAAAACAAATGA (SEQ ID NO: 42)


Human IL7RA mRNA (NM_002185) (CDS):

ATGACAATTCTAGGTACAACCTTGGCATGGTTTCTTACTTCAAGTCGTTCTGGAGAAAGTGGCTATGGCTCAAATGGAG
ACTTGGAAAGATGGCAGAACCTGGATGACTACTCATTCTCATGCTTATAGCCAGTGGAAAGTGAATGGATGCCAGGACTCAGTGACC
TGTGCTTTAGGACCCAGATGCAAGCATGCAACCTGGAGACAAATCTGGAAATTGAAATATGGGGCCCTGGGGAGGTTGGCT
TTTCAAGGAAACTACAAGGAGATAATTGATCGAGACAAAGAAATAGACCTAACCACTATAGTTAACCTGAGGCTCCTTGA
AGAAAAGAGGCTAACCTGCAAAAATAGACCTAACCACTATAGTTAACCTGAGGCTCCTTGA
GGAAAGGGCCAATGACTTGTGGTGCACATTAAATCATCACACTGCCAGCAGAAAGAATGATGTAAGGTTTAATGCA
GCTTACCGGCCAGGAAAGGATGAAACAAATGGAGGCATGTCGATCCATCCCTGATCACTATTAAAGGCTGACACTCC
TCCAACCGGGAGCAATGATGAGATTAAGGATGTCGATCCATCCCTGATCACTATTAAAGGCTGAGGTTGGAGTCC
GTTATTACCTCAGAGATCAAAATAGCTCAGGGGAGATGATGCCATCTTAACTAACCATTGCA
CTCTGTCGCTCTGGTGCATCTGGCTGTTGTTGATCTGGAAAGGATTAAGGCCATATGCGCCAGTCTCCCGATCA
TAAGAAGACTCTGGAAACATCTTGTGAAAGGTTCAATCTGTGAGTTCTGGAAAGGTTCTGCAAGATACTGAGTT
GATTCACTAGGGTGGATGACATTCAAGCTAGAGATGAAGTGGAGGGTCTGCAAGGCCCAACTGCCCCATCTGAGGATGTA
CTGAGAAGGAGGCTGGAGGGGATGTCGAGAGGCCAACTGCCCCATCTGAGGATGTA
AAGAGATTCACTCCCTCACATGCTCTGCACTGGCTGGAAATGTCAGTGGCA
CAGGGAGAGTGGCAAGGAATGGCCTCATGTTACAGGACCTCCCTGCTTGGACTACAAACAGGACGCTGCCCC
CCATTCTCTCCAATCTGGAATGCTGACATTGCAACCCAGTGGCTCAGGGCATTCTTACTTCCCTGGATCAAATCAA
GAAGAAGGCAATATGTCACCATGTCAGCTTCAACAAAGCAGTGA (SEQ ID NO: 44)

FIG. 3E

Mouse/Human Hybrid mRNA (CDS):

FIG. 3E (Continued)



三

FIG. 4A

Lung Eosinophils




FIG. 4B

Muc5ac




FIG. 4C

Ova-specific IgE





FIG. 4D

Ova-specific IgG1






FIG. 4E

**NON-HUMAN ANIMALS HAVING A
HUMANIZED TSLP GENE, A HUMANIZED
TSLP RECEPTOR GENE, AND/OR A
HUMANIZED IL7RA GENE**

**CROSS REFERENCE TO RELATED
APPLICATIONS**

[0001] This application is a divisional of U.S. patent application Ser. No. 17/555,550, filed Dec. 20, 2021, which claims the benefit of priority from U.S. Provisional Application No. 63/128,258, filed Dec. 21, 2020, the entire contents of which are incorporated herein by reference.

**INCORPORATION BY REFERENCE OF
SEQUENCE LISTING**

[0002] The Sequence Listing in the XML file, named as 37301A_10589US02_SequenceListing of 222,967 bytes, created on Apr. 16, 2025 and submitted to the United States Patent and Trademark Office via Patent Center, is incorporated herein by reference.

BACKGROUND

[0003] Thymic stromal lymphopoietin (TSLP) acts through a heterodimer receptor composed of a chain specific for TSLP (referred to as “TSLPR” or “Tslpr”) and the IL7 receptor α chain, and is implicated in allergic diseases and certain cancer. Effective *in vivo* systems are desired for gaining a better understanding of pathogenesis of allergic diseases and cancer and for development of therapeutics.

SUMMARY

[0004] In some embodiments, disclosed herein is a genetically modified rodent animal comprising a humanized Tslp gene in its genome, wherein the humanized Tslp gene comprises a rodent Tslp nucleic acid sequence and a human TSLP nucleic acid sequence, wherein the humanized Tslp gene encodes a humanized Tslp polypeptide comprising a mature protein sequence substantially identical to the mature protein sequence of a human TSLP protein.

[0005] In some embodiments, the humanized Tslp polypeptide comprises a mature protein sequence identical to the mature protein sequence of a human TSLP protein.

[0006] In some embodiments, the humanized Tslp protein comprises a signal peptide substantially identical to the signal peptide of a rodent Tslp protein. In some embodiments, the humanized Tslp protein comprises a signal peptide identical to the signal peptide of a rodent Tslp protein, e.g., an endogenous rodent Tslp protein.

[0007] In some embodiments, the human TSLP nucleic acid sequence in a humanized Tslp gene encodes at least a substantial portion of the mature protein sequence of a human TSLP protein. In some embodiments, the human TSLP nucleic acid sequence encodes the mature protein sequence of a human TSLP protein, e.g., amino acids 29-159 of a human TSLP protein (e.g., the human TSLP protein as set forth in SEQ ID NO: 3). In some embodiments, the human TSLP nucleic acid sequence comprises exon 1 from the codon encoding the first amino acid of the mature protein sequence, through the STOP codon in exon 4, of a human TSLP gene.

[0008] In some embodiments, the rodent Tslp nucleic acid sequence in a humanized Tslp gene comprises exonic sequences of a rodent Tslp gene (e.g., an endogenous rodent

Tslp gene) that encode a rodent Tslp signal peptide. In some embodiments, the rodent animal is a mouse, and the rodent nucleic acid sequence in a humanized Tslp gene comprises exon 1, and a 5' portion of exon 2 coding for signal peptide amino acids, of a mouse Tslp gene. In some embodiments, the rodent Tslp nucleic acid sequence in a humanized Tslp gene also comprises the 3' UTR of a rodent Tslp gene (e.g., an endogenous rodent Tslp gene).

[0009] In some embodiments, the rodent animal is a mouse, and the humanized Tslp gene comprises (i) exon 1, and a 5' portion of exon 2 coding for signal peptide amino acids, of a mouse Tslp gene, and (ii) exon 1 from the codon encoding the first amino acid of the mature protein sequence, through the STOP codon in exon 4, of a human TSLP gene. In some embodiments, the humanized Tslp gene further comprises the 3' UTR of a mouse Tslp gene. In various embodiments, a mouse Tslp gene is an endogenous mouse Tslp gene.

[0010] In some embodiments, a humanized Tslp gene is operably linked to a rodent Tslp promoter, such as an endogenous rodent Tslp promoter.

[0011] In some embodiments, a humanized Tslp gene is located at a locus other than an endogenous rodent Tslp locus. In some embodiments, a humanized Tslp gene is located at an endogenous rodent Tslp locus.

[0012] In some of the embodiments where a humanized Tslp gene is located at an endogenous rodent Tslp locus, the humanized Tslp gene is formed as a result of replacement of a rodent Tslp genomic DNA at an endogenous rodent Tslp locus with a human TSLP nucleic acid. In some embodiments, the humanized Tslp gene is formed as a result of replacement of a rodent genomic DNA comprising exonic sequences encoding at least a substantial portion of the mature protein sequence of the endogenous rodent Tslp protein, with a human TSLP nucleic acid which encodes at least a substantial portion of the mature protein sequence of a human TSLP protein. In some embodiments, a humanized Tslp gene is formed as a result of replacement of a rodent genomic DNA comprising exonic sequences encoding the mature protein sequence of the endogenous rodent Tslp protein, with a human TSLP nucleic acid which encodes the mature protein sequence of a human TSLP protein. In some embodiments, the rodent animal is a mouse, and the mouse genomic DNA being replaced comprises exon 2 from the codon encoding the first amino acid of the mature mouse Tslp protein through the STOP codon in exon 5 of the endogenous mouse Tslp gene, and the human genomic DNA comprises exon 1 from the codon encoding the first amino acid of the mature human TSLP protein through the STOP codon in exon 4 of a human TSLP gene.

[0013] In some embodiments, the rodent animal is homozygous for a humanized Tslp gene. In some embodiments, the rodent animal is heterozygous for a humanized Tslp gene.

[0014] In some embodiments, a humanized Tslp polypeptide is expressed in a rodent animal from a humanized Tslp gene.

[0015] In some embodiments, a rodent animal further comprises in its genome, a humanized Tslpr gene, a humanized Il7ra gene, or a combination thereof.

[0016] In some embodiments, the rodent is a mouse or a rat.

[0017] In some embodiments, disclosed herein is an isolated rodent tissue or cell, whose genome comprises a

humanized Tslp gene described herein. In some embodiments, the rodent cell is a rodent embryonic stem cell. In some embodiments, the rodent cell is an egg or a sperm. In some embodiments, an isolated rodent tissue or cell is a mouse tissue or cell, or a rat tissue or cell.

[0018] In some embodiments, disclosed herein is a rodent embryo comprising a rodent embryonic stem cell which comprises a humanized Tslp gene described herein.

[0019] In some embodiments, disclosed herein is a method of making a genetically modified rodent. In some embodiments, the method comprises modifying a rodent genome to comprise a humanized Tslp gene, wherein the humanized Tslp gene comprises a rodent Tslp nucleic acid sequence and a human TSLP nucleic acid sequence, and encodes a humanized Tslp polypeptide comprising a mature protein sequence substantially identical with the mature protein sequence of a human TSLP protein; and making a rodent comprising the modified rodent genome.

[0020] In some embodiments, modifying a rodent genome comprises the steps of introducing a nucleic acid molecule comprising a human TSLP nucleic acid sequence into the genome of a rodent embryonic stem(ES) cell, obtaining a rodent ES cell in which the human TSLP nucleic acid sequence has been integrated into an endogenous Tslp locus to replace a rodent Tslp genomic DNA thereby forming an humanized Tslp gene, and generating a rodent animal from the obtained rodent ES cell. In some embodiments, the human TSLP nucleic acid sequence encodes at least a substantial portion of the mature protein sequence of a human TSLP protein. In some embodiments, the nucleic acid molecule introduced into the ES cell further comprises a 5' homology arm and a 3' homology arm flanking the human TSLP nucleic acid sequence, and wherein the 5' and 3' homology arms are homologous to nucleic acid sequences at the endogenous rodent locus flanking the rodent Tslp genomic DNA to be replaced. In some embodiments, the humanized Tslp gene is operably linked to a rodent Tslp promoter, e.g., an endogenous rodent Tslp promoter at the endogenous rodent Tslp locus.

[0021] In some embodiments of the method, the rodent is a mouse or a rat.

[0022] In some embodiments, disclosed herein is a targeting nucleic acid construct, comprising a human TSLP nucleic acid sequence to be integrated into a rodent Tslp gene at an endogenous rodent Tslp locus, flanked by a 5' nucleotide sequence and a 3' nucleotide sequence that are homologous to nucleotide sequences at the rodent Tslp locus, wherein integration of the human TSLP nucleic acid sequence into the rodent Tslp gene results in a replacement of a rodent Tslp genomic DNA with the human TSLP nucleic acid sequence thereby forming a humanized Tslp gene, and wherein the human TSLP nucleic acid sequence encodes at least a substantial portion of the mature protein sequence of a human TSLP protein. In some embodiments of a targeting nucleic acid, the rodent is a mouse or a rat.

[0023] In some embodiments, disclosed herein is an in vitro method for generating a genetically modified rodent cell, comprising introducing into a rodent cell a targeting vector comprising a human TSLP nucleic sequence that encodes at least a substantial portion of the mature protein sequence of a human TSLP protein, flanked by rodent homology arms that mediate integration of the human TSLP nucleotide sequence into an endogenous rodent Tslp locus, which results in replacement of a rodent Tslp genomic DNA

with the human TSLP nucleic acid sequence to form a humanized Tslp gene as described herein, thereby generating a genetically modified rodent cell. In some embodiments, the rodent cell is mouse cell or a rat cell. In some embodiments, the rodent cell is a rodent ES cell, and the method generates a genetically modified rodent ES cell.

[0024] In some embodiments, disclosed herein is a genetically modified rodent animal comprising a humanized Tslpr gene in its genome, wherein the humanized Tslpr gene comprises a rodent Tslpr nucleic acid sequence and a human TSL PR nucleic acid sequence, wherein the humanized Tslpr gene encodes a humanized Tslpr polypeptide comprising an ectodomain substantially identical to the ectodomain of a human TSLPR protein.

[0025] In some embodiments, the humanized Tslpr protein comprises a transmembrane-cytoplasmic sequence substantially identical to the transmembrane-cytoplasmic sequence of a rodent Tslpr protein (e.g., an endogenous rodent Tslpr protein). In some embodiments, the humanized Tslpr protein comprises a transmembrane-cytoplasmic sequence identical to the transmembrane-cytoplasmic sequence of a rodent Tslpr protein (e.g., an endogenous rodent Tslpr protein).

[0026] In some embodiments, the humanized Tslpr protein comprises a signal peptide substantially identical to the signal peptide of a rodent Tslpr protein. In some embodiments, the humanized Tslpr protein comprises a signal peptide identical to the signal peptide of a rodent Tslpr protein (e.g., an endogenous rodent Tslpr protein).

[0027] In some embodiments, the human TSLPR nucleic acid sequence in a humanized Tslpr gene encodes at least a substantial portion of the ectodomain of the human TSLPR protein. In some embodiments, the human TSLPR nucleic acid sequence in a humanized Tslpr gene encodes amino acids 29-231 of a human TSLPR (e.g., the human TSLPR as set forth in SEQ ID NO: 23). In some embodiments, the human TSL PR nucleic acid sequence comprises exon 2 through the codon encoding the last ectodomain amino acid in exon 6 of a human TSLPR gene.

[0028] In some embodiments, the rodent Tslpr nucleic acid sequence in a humanized Tslpr gene comprises exonic sequences of a rodent Tslpr gene that encode at least a substantial portion of the transmembrane-cytoplasmic sequence of a rodent Tslpr protein (e.g., an endogenous rodent Tslpr protein). In some embodiments, the rodent animal is a mouse, and the rodent Tslpr nucleic acid sequence comprises exon 6 from the codon encoding the first amino acid of the transmembrane domain through exon 8 of a mouse Tslpr gene (e.g., an endogenous mouse Tslpr gene).

[0029] In some embodiments, the rodent Tslpr nucleic acid sequence in a humanized Tslpr gene comprises exonic sequences of a rodent Tslpr gene that encode the signal peptide of a rodent Tslpr protein (e.g., an endogenous rodent Tslpr protein). In some embodiments, the rodent animal is a mouse, and the rodent nucleic acid sequence comprises exon 1 of a mouse Tslpr gene (e.g., an endogenous mouse Tslpr gene).

[0030] In some embodiments, the rodent animal is a mouse, and the humanized Tslpr gene comprises (i) exon 1 of a mouse Tslpr gene (e.g., an endogenous mouse Tslpr gene), (ii) exon 2 through the codon encoding the last amino acid of the ectodomain in exon 6 of a human TSLPR gene;

and (iii) exon 6 from the codon encoding the first amino acid of the transmembrane domain through exon 8 of the mouse Tslpr gene.

[0031] In some embodiments, a humanized Tslpr gene is operably linked to a rodent Tslpr promoter, such as an endogenous rodent Tslpr promoter.

[0032] In some embodiments, a humanized Tslpr gene is located at a locus other than an endogenous rodent Tslpr locus. In some embodiments, a humanized Tslpr gene is located at an endogenous rodent Tslpr locus.

[0033] In some of the embodiments where a humanized Tslpr gene is located at an endogenous rodent Tslpr locus, the humanized Tslpr gene is formed as a result of replacement of a rodent Tslpr genomic DNA at an endogenous rodent Tslpr locus with a human TSLPR nucleic acid. In some embodiments, a humanized Tslpr gene is formed as a result of replacement of a rodent genomic DNA comprising exonic sequences encoding at least a substantial portion of the ectodomain of the endogenous rodent Tslpr protein, with the human TSLPR nucleic acid which encodes at least a substantial portion of the ectodomain of the human TSLPR protein. In some embodiments, the rodent animal is a mouse, and wherein the mouse genomic DNA being replaced comprises exon 2 through the codon encoding the last amino acid of the ectodomain in exon 6 of the endogenous mouse Tslpr gene, and the human genomic DNA comprises exon 2 through the codon encoding the last amino acid of the ectodomain in exon 6 of a human TSLPR gene.

[0034] In some embodiments, a rodent animal is heterozygous for a humanized Tslpr gene. In some embodiments, a rodent animal is homozygous for a humanized Tslpr gene.

[0035] In some embodiments, a humanized Tslpr polypeptide is expressed in a rodent animal from a humanized Tslpr gene.

[0036] In some embodiments, a rodent animal further comprises in its genome, a humanized Tsip gene, a humanized Il7ra gene, or a combination thereof.

[0037] In some embodiments, the rodent is a mouse or a rat.

[0038] In some embodiments, disclosed herein is an isolated rodent tissue or cell, whose genome comprises a humanized Tslpr gene described herein. In some embodiments, the rodent cell is a rodent embryonic stem cell. In some embodiments, the rodent cell is an egg or a sperm. In some embodiments, an isolated rodent tissue or cell is a mouse tissue or cell, or a rat tissue or cell.

[0039] In some embodiments, disclosed herein is a rodent embryo comprising a rodent embryonic stem cell which comprises a humanized Tslpr gene described herein.

[0040] In some embodiments, disclosed herein is a method of making a genetically modified rodent. In some embodiments, the method comprises modifying a rodent genome to comprise a humanized Tslpr gene, wherein the humanized Tslpr gene comprises a rodent Tslpr nucleic acid sequence and a human TSLPR nucleic acid sequence, and encodes a humanized Tslpr polypeptide comprising an ectodomain substantially identical with the ectodomain of a human TSLPR protein; and making a rodent comprising the modified rodent genome.

[0041] In some embodiments, modifying a rodent genome comprises the steps of introducing a nucleic acid molecule comprising a human TSLPR nucleic acid sequence into the genome of a rodent embryonic stem(ES) cell, obtaining a rodent ES cell in which the human TSLPR nucleic acid

sequence has been integrated into an endogenous Tslpr locus to replace a rodent Tslpr genomic DNA thereby forming a humanized Tslpr gene, and generating a rodent animal from the obtained rodent ES cell. In some embodiments, the human TSLPR nucleic acid sequence encodes at least a substantial portion of the ectodomain of a human TSLPR protein. In some embodiments, the nucleic acid molecule introduced into the ES cell further comprises a 5' homology arm and a 3' homology arm flanking the human TSLPR nucleic acid sequence, and wherein the 5' and 3' homology arms are homologous to nucleic acid sequences at the endogenous rodent locus flanking the rodent Tslpr genomic DNA to be replaced. In some embodiments, the humanized Tslpr gene is operably linked to a rodent Tslpr promoter, e.g., an endogenous rodent Tsip promoter at the endogenous rodent Tslpr locus.

[0042] In some embodiments of the method, the rodent is a mouse or a rat.

[0043] In some embodiments, disclosed herein is a targeting nucleic acid construct, comprising a human TSLPR nucleic acid sequence to be integrated into a rodent Tslpr gene at an endogenous rodent Tslpr locus, flanked by a 5' nucleotide sequence and a 3' nucleotide sequence that are homologous to nucleotide sequences at the rodent Tslpr locus, wherein integration of the human TSLPR nucleic acid sequence into the rodent Tslpr gene results in a replacement of a rodent Tslpr genomic DNA with the human TSLPR nucleic acid sequence thereby forming a humanized Tslpr gene, and wherein the human TSLPR nucleic acid sequence encodes at least a substantial portion of the ectodomain of a human TSLPR protein. In some embodiments of a targeting nucleic acid, the rodent is a mouse or a rat.

[0044] In some embodiments, disclosed herein is an in vitro method for generating a genetically modified rodent cell, comprising introducing into a rodent cell a targeting vector comprising a human TSLPR nucleic sequence that encodes at least a substantial portion of the ectodomain of a human TSLPR protein, flanked by rodent homology arms that mediate integration of the human TSLPR nucleotide sequence into an endogenous rodent Tslpr locus, which results in replacement of a rodent Tslpr genomic DNA with the human TSLPR nucleic acid sequence to form a humanized Tslpr gene as described herein, thereby generating a genetically modified rodent cell. In some embodiments, the rodent cell is mouse cell or a rat cell. In some embodiments, the rodent cell is a rodent ES cell, and the method generates a genetically modified rodent ES cell.

[0045] In some embodiments, disclosed herein is a genetically modified rodent animal comprising a humanized Il7ra gene in its genome, wherein the humanized Il7ra gene comprises a rodent Il7ra nucleic acid sequence and a human IL7RA nucleic acid sequence, wherein the humanized Il7ra gene encodes a humanized Il7ra polypeptide comprising an ectodomain substantially identical to the ectodomain of a human IL7RA protein.

[0046] In some embodiments, the humanized Il7ra protein comprises a transmembrane-cytoplasmic sequence substantially identical to the transmembrane-cytoplasmic sequence of a rodent Il7ra protein (e.g., an endogenous rodent Il7ra protein). In some embodiments, the humanized Il7ra protein comprises a transmembrane-cytoplasmic sequence identical to the transmembrane-cytoplasmic sequence of a rodent Il7ra protein (e.g., an endogenous rodent Il7ra protein).

[0047] In some embodiments, the humanized Il7ra protein comprises a signal peptide substantially identical to the signal peptide of a rodent Il7ra protein. In some embodiments, the humanized Il7ra protein comprises a signal peptide identical to the signal peptide of a rodent Il7ra protein (e.g., an endogenous rodent Il7ra protein).

[0048] In some embodiments, the human IL7RA nucleic acid sequence in a humanized Il7ra gene encodes at least a substantial portion of the ectodomain of the human IL7RA protein. In some embodiments, the human IL7RA nucleic acid sequence in a humanized Il7ra gene encodes amino acids 21-236 of a human IL7RA protein (e.g., the human IL7RA protein as set forth in SEQ ID NO: 43). In some embodiments, the human IL7RA nucleic acid sequence comprises from the codon in exon 1 encoding the first amino acid of the mature protein through exon 5 of a human IL7RA gene.

[0049] In some embodiments, the rodent Il7ra nucleic acid sequence in a humanized Il7ra gene comprises sequences of a rodent Il7ra gene that encode at least a substantial portion of the transmembrane-cytoplasmic sequence of a rodent Il7ra protein (e.g., an endogenous rodent Il7ra protein). In some embodiments, the rodent animal is a mouse, and the rodent Il7ra nucleic acid sequence comprises exon 6 through exon 8 of a mouse Il7ra gene (e.g., an endogenous mouse Il7ra gene).

[0050] In some embodiments, the rodent Il7ra nucleic acid sequence in a humanized Il7ra gene comprises a portion of exon 1 of a rodent Il7ra gene that encode the signal peptide of a rodent Il7ra protein (e.g., an endogenous rodent Il7ra protein). In some embodiments, the rodent animal is a mouse, and the rodent nucleic acid sequence comprises a portion of exon 1 of a mouse Il7ra gene (e.g., an endogenous mouse Il7ra gene) that includes both the 5' UTR and encodes the signal peptide of the mouse Il7ra.

[0051] In some embodiments, the rodent animal is a mouse, and the humanized Il7ra gene comprises (i) a portion of exon 1 of a mouse Il7ra gene (e.g., an endogenous mouse Il7ra gene) that encodes the signal peptide of the mouse Il7ra protein; (ii) exon 1 from the codon encoding the first amino acid of the mature protein through exon 5 of a human IL7RA gene; and (iii) exon 6 through exon 8 of the mouse Il7ra gene.

[0052] In some embodiments, a humanized Il7ra gene is operably linked to a rodent Il7ra promoter, such as an endogenous rodent Il7ra promoter.

[0053] In some embodiments, a humanized Il7ra gene is located at a locus other than an endogenous rodent Il7ra locus. In some embodiments, a humanized Il7ra gene is located at an endogenous rodent Il7ra locus.

[0054] In some of the embodiments where a humanized Il7ra gene is located at an endogenous rodent Il7ra locus, the humanized Il7ra gene is formed as a result of replacement of a rodent Il7ra genomic DNA at an endogenous rodent Il7ra locus with a human IL7RA nucleic acid. In some embodiments, a humanized Il7ra gene is formed as a result of replacement of a rodent genomic DNA comprising exonic sequences encoding at least a substantial portion of the ectodomain of the endogenous rodent Il7ra protein, with the human IL7RA nucleic acid which encodes at least a substantial portion of the ectodomain of the human IL7RA protein. In some embodiments, the rodent animal is a mouse, and wherein the mouse genomic DNA being replaced comprises from the codon in exon 1 encoding the first amino acid

of the mature protein sequence through exon 5 of the endogenous mouse Il7ra gene, and the human genomic DNA comprises from the codon in exon 1 encoding the first amino acid of the mature protein sequence through exon 5 of a human IL7RA gene.

[0055] In some embodiments, a rodent animal is heterozygous for a humanized Il7ra gene. In some embodiments, a rodent animal is homozygous for a humanized Il7ra gene.

[0056] In some embodiments, a humanized Il7ra polypeptide is expressed in a rodent animal from a humanized Il7ra gene.

[0057] In some embodiments, a rodent animal further comprises in its genome, a humanized Tslp gene, a humanized Tslpr gene, or a combination thereof.

[0058] In some embodiments, the rodent is a mouse or a rat.

[0059] In some embodiments, disclosed herein is an isolated rodent tissue or cell, whose genome comprises a humanized Il7ra gene described herein. In some embodiments, the rodent cell is a rodent embryonic stem cell. In some embodiments, the rodent cell is an egg or a sperm. In some embodiments, an isolated rodent tissue or cell is a mouse tissue or cell, or a rat tissue or cell.

[0060] In some embodiments, disclosed herein is a rodent embryo comprising a rodent embryonic stem cell which comprises a humanized Il7ra gene described herein.

[0061] In some embodiments, disclosed herein is a method of making a genetically modified rodent. In some embodiments, the method comprises modifying a rodent genome to comprise a humanized Il7ra gene, wherein the humanized Il7ra gene comprises a rodent Il7ra nucleic acid sequence and a human IL7RA nucleic acid sequence, and encodes a humanized Il7ra polypeptide comprising an ectodomain substantially identical with the ectodomain of a human IL7RA protein; and making a rodent comprising the modified rodent genome.

[0062] In some embodiments, modifying a rodent genome comprises the steps of introducing a nucleic acid molecule comprising a human IL7RA nucleic acid sequence into the genome of a rodent embryonic stem(ES) cell, obtaining a rodent ES cell in which the human IL7RA nucleic acid sequence has been integrated into an endogenous Il7ra locus to replace a rodent Il7ra genomic DNA thereby forming a humanized Il7ra gene, and generating a rodent animal from the obtained rodent ES cell. In some embodiments, the human IL7RA nucleic acid sequence encodes at least a substantial portion of the ectodomain of a human IL7RA protein. In some embodiments, the nucleic acid molecule introduced into the ES cell further comprises a 5' homology arm and a 3' homology arm flanking the human IL7RA nucleic acid sequence, and wherein the 5' and 3' homology arms are homologous to nucleic acid sequences at the endogenous rodent locus flanking the rodent Il7ra genomic DNA to be replaced. In some embodiments, the humanized Il7ra gene is operably linked to a rodent Il7ra promoter, e.g., an endogenous rodent Il7ra promoter at the endogenous rodent Il7ra locus.

[0063] In some embodiments of the method, the rodent is a mouse or a rat.

[0064] In some embodiments, disclosed herein is a targeting nucleic acid construct, comprising a human IL7RA nucleic acid sequence to be integrated into a rodent Il7ra gene at an endogenous rodent Il7ra locus, flanked by a 5' nucleotide sequence and a 3' nucleotide sequence that are

homologous to nucleotide sequences at the rodent Il7ra locus, wherein integration of the human IL7RA nucleic acid sequence into the rodent Il7ra gene results in a replacement of a rodent Il7ra genomic DNA with the human IL7RA nucleic acid sequence thereby forming a humanized Il7ra gene, and wherein the human IL7RA nucleic acid sequence encodes at least a substantial portion of the ectodomain of a human IL7RA protein. In some embodiments of a targeting nucleic acid, the rodent is a mouse or a rat.

[0065] In some embodiments, disclosed herein is an in vitro method for generating a genetically modified rodent cell, comprising introducing into a rodent cell a targeting vector comprising a human IL7RA nucleic sequence that encodes at least a substantial portion of the ectodomain of a human IL7RA protein, flanked by rodent homology arms that mediate integration of the human IL7RA nucleotide sequence into an endogenous rodent Il7ra locus, which results in replacement of a rodent Il7ra genomic DNA with the human IL7RA nucleic acid sequence to form a humanized Il7ra gene as described herein, thereby generating a genetically modified rodent cell. In some embodiments, the rodent cell is mouse cell or a rat cell. In some embodiments, the rodent cell is a rodent ES cell, and the method generates a genetically modified rodent ES cell.

[0066] In some embodiments, rodents disclosed herein comprise one or more additional genetic modifications in their genome such as a humanized Sirp α gene, a disruption in an endogenous RAG2 gene, a disruption in an endogenous IL-2RG gene, a humanized Tpo gene, and a humanized GM-CSF/IL-3 locus. A rodent can be heterozygous or homozygous for any of such additional genetic modifications.

[0067] In some embodiments, rodents disclosed herein comprise in their genome a humanized Tslp gene and a humanized Sirp α gene, and are homozygous null for both RAG2 and IL-2RG genes. In some such embodiments, a rodent further comprises in its genome a humanized Tpo gene and/or a humanized GM-CSF/IL-3 locus. A rodent can be heterozygous or homozygous for a humanized gene.

[0068] In some embodiments, rodents disclosed herein comprise in their genome a humanized Tslp gene, a humanized Tslpr gene, and a humanized Sirp α gene, and are homozygous null for both RAG2 and IL-2RG genes. In some such embodiments, a rodent further comprises in its genome a humanized Tpo gene and/or a humanized GM-CSF/IL-3 locus. Rodents can be homozygous or heterozygous for a humanized gene.

[0069] In some embodiments, rodents disclosed herein comprise in their genome a humanized Tslp gene, a humanized Tslpr gene, a humanized Il7ra gene, and a humanized Sirp α gene, and are homozygous null for both RAG2 and IL-2RG genes. In some such embodiments, a rodent further comprises in its genome a humanized Tpo gene and/or a humanized GM-CSF/IL-3 locus. Rodents can be homozygous or heterozygous for a humanized gene.

[0070] In some embodiments, a genetically modified rodent animal comprising a humanized Tslp gene, a humanized Tslpr gene, a humanized Il7ra gene, or a combination thereof, optionally with one or more additional genetic modifications, as disclosed herein, is used in the preparation of a rodent animal model of allergic diseases (e.g., airway or skin inflammation) or cancer.

[0071] In some embodiments, disclosed herein is a method of testing a candidate agent for treating an allergic condition,

the method comprising inducing an allergic condition in a genetically modified rodent animal disclosed herein, administering a candidate agent to the rodent animal; and determining whether the candidate agent inhibits the allergic condition in the rodent animal.

[0072] In some embodiments, disclosed herein is a method of testing a candidate agent for treating cancer, the method comprising engrafting human cancer cells in a genetically modified rodent animal disclosed herein, administering a candidate agent to the rodent animal; and determining whether the candidate agent inhibits the growth of the cancer cells in the rodent animal. In some embodiments, the cancer is a Th2 driven cancer, including e.g., breast cancer, lung cancer, and pancreatic cancer.

BRIEF DESCRIPTION OF THE DRAWINGS

[0073] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments and together with the description illustrate the disclosed compositions and methods.

[0074] FIG. 1A depicts an exemplary embodiment of a strategy for humanization of a mouse Tslp locus. The mouse Tslp gene and the human TSLP gene are represented by horizontal lines, with their exons being represented by boxes placed above the lines. A contiguous mouse Tslp genomic fragment of 3486 bp at an endogenous mouse Tslp locus, which begins from the codon in exon 2 encoding amino acid 20 through the STOP codon in exon 5, is replaced by a human TSLP genomic fragment of 4100 bp that begins from the codon in human TSLP exon 1 encoding amino acid 29 through the STOP codon in exon 4. The replacement results in a mouse-human hybrid ("humanized") Tslp protein that includes the mouse Tslp signal peptide and the human mature TSLP polypeptide. See also FIGS. 1D and 1F.

[0075] FIG. 1B depicts an exemplary embodiment of a strategy for humanization of a mouse TSLP locus, not to scale, of a nucleic acid comprising a mouse Tslp locus, and a targeting nucleic acid construct comprising a humanized mouse Tslp locus wherein a mouse genomic fragment of 3.49 KB at a mouse Tslp locus has been replaced with a humanization fragment comprising a Human Genomic Fragment 1 of 1.9 kb (from the codon in exon 1 encoding amino acid 29 through 257 bp after the 3' end of exon 3 of human TLSP), a Floxed HUb-Puro cassette of 4.4 kb (inserted in human TLSP intron 3), and a Human Genomic Fragment 2 of 2.2 kb (from 258 bp after the end of exon 3 through the STOP codon in exon 4 of human TLSP). The humanization fragment in the targeting construct is flanked by a mouse 5' homology arm of 114.3 kb and a mouse 3' homology arm of 65.3 kb. The targeting nucleic acid construct comprising the humanized mouse Tslp locus can be introduced into a mouse embryonic stem cell for targeted insertion into the mouse Tslp gene in the mouse genome. The locations of primers and probes used in human gain of allele and mouse loss of allele assays to confirm correct targeting are also indicated. The sequences of the primers and probes are set forth in Table 6.

[0076] FIG. 1C depicts an exemplary embodiment of a strategy for humanization of a mouse TSLP allele, not to scale, of the humanized Tslp allele designated as MAID #7466 resulting from the replacement of the mouse Tslp genomic fragment described above for FIG. 1B, with the humanization fragment which comprises the Human Genomic Fragment 1, the Floxed HUb-Puro cassette, and

the Human Genomic Fragment 2. After the Floxed HUb-Puro cassette has been removed, the humanized Tslp allele is designated as MAID #7467.

[0077] FIG. 1D shows exemplary embodiments of the protein sequences of mouse Tslp (SEQ ID NO: 1), human TSLP isoform 1 (SEQ ID NO: 3) (in bold italics), and humanized (hybrid) Tslp (SEQ ID NO: 5) (with the human portion in bold italics). The signal peptide is underlined in each protein sequence.

[0078] FIG. 1E shows exemplary embodiments of the mRNA sequences of mouse Tslp (SEQ ID NO: 2), human TSLP isoform 1 (SEQ ID NO: 4) (in bold italics), and humanized (hybrid) Tslp (SEQ ID NO: 6) (with the human portion in bold italics). The portion encoding the signal peptide is underlined in each mRNA.

[0079] FIG. 1F shows alignment of exemplary embodiments of mouse Tslp ("mTslp", SEQ ID NO: 1), human TSLP isoform 1 ("hTSLP", SEQ ID NO: 3), and humanized (hybrid) Tslp (SEQ ID NO: 5) protein sequences. The signal peptides of the proteins are boxed. The junctions between the mouse and human sequences in forming the humanized (hybrid) Tslp protein are indicated by the arrows at the 5' (N-terminal) and the 3' (C-terminal) of the molecules. The triangles represent the location of human intron 3 (2429 bp), into which the Floxed HUb-Puro cassette is inserted.

[0080] FIG. 1G shows, in exemplary embodiments, that mice heterozygous for Tslp humanization as described in Example 1 expressed mature human TSLP protein in mouse serum (middle), with mice without Tslp humanization as a negative control (left) and normal human serum as a positive control (right). Each dot represents one mouse.

[0081] FIG. 2A depicts an exemplary embodiment of a strategy for humanization of a mouse Tslpr locus. The mouse Tslpr gene and the human TSLPR gene are represented by horizontal lines, with their exons being represented by boxes placed above the lines. A contiguous mouse Tslpr genomic fragment of 2362 bp at an endogenous mouse Tslpr locus, which begins from intron 1 at 328 bp before exon 2 and ends at the 47th bp in exon 6, is replaced by a human TSLPR genomic fragment of 13743 bp that begins from intron 1 at 909 bp before exon 2 and ends at the 47th bp in exon 6. The replacement results in a deletion of amino acids 27 to 243 of mouse Tslpr, but preserves the mouse Tslpr signal peptide (amino acid 1-19), the first 7 amino acids of the mouse Tslpr mature protein, and the mouse Tslpr transmembrane domain (amino acids 244-264) and intracellular domain, and inserts a substantial portion of the human TSLPR ectodomain (beginning at amino acid 27, and ending at amino acid 231, just before the human transmembrane domain of amino acids 232-252). See also FIG. 2D.

[0082] FIG. 2B depicts an exemplary embodiment of a strategy for humanization of a mouse Tslpr locus, not to scale, of a nucleic acid comprising a mouse Tslpr locus, and a targeting nucleic acid construct comprising a humanized mouse Tslpr locus wherein a mouse genomic fragment of 2.36 KB at a mouse Tslpr locus has been replaced with a humanization fragment comprising Floxed HUb-Neo cassette of 4.8 kb and a human genomic fragment of 13.7 kb (comprising a 3' portion of intron 1, exon 2 through the 47th bp in exon 6 of human TSLPR). The humanization fragment in the targeting construct is flanked by a mouse 5' homology arm of 29.1 kb (up to 328 bp before exon 2 of mouse Tslpr) and a mouse 3' homology arm of 133.2 kb (from the 48th bp in exon 6 through exon 8 of mouse Tslpr, followed by mouse

3' genomic sequence). The targeting nucleic acid construct comprising the humanized mouse Tslpr locus can be introduced into a mouse embryonic stem cell for targeted insertion into the mouse genome. The locations of primers and probes used in human gain of allele and mouse loss of allele assays to confirm correct targeting are also indicated. The sequences of the primers and probes are set forth in Table 9.

[0083] FIG. 2C depicts an exemplary embodiment of a strategy for humanization of a mouse TSLP allele, not to scale, of the humanized Tslpr allele designated as MAID #7558 resulting from the replacement of the mouse Tslpr genomic fragment described above for FIG. 2B, with the humanization fragment which comprises the Floxed HUb-Neo cassette of 4.8 kb and the human TSLPR genomic fragment of 13743 bp. After the Floxed HUb-Neo cassette has been removed, the humanized Tslpr allele is designated as MAID #7559.

[0084] FIG. 2D shows exemplary embodiments of the protein sequences of mouse Tslpr (SEQ ID NO: 21), human TSLPR (SEQ ID NO: 23) (in bold italics), and humanized (hybrid) Tslpr (SEQ ID NO: 25) (with the human portion in bold italics). The signal peptide ("SP") and transmembrane segment ("TM") are underlined in each protein sequence.

[0085] FIG. 2E shows exemplary embodiments of the mRNA sequences of mouse Tslpr (SEQ ID NO: 22), human TSLPR (SEQ ID NO: 24) (in bold italics), and humanized (hybrid) Tslpr (SEQ ID NO: 26) (with the human portion in bold italics). The portions encoding the signal peptide and the transmembrane segment, respectively, are underlined in each mRNA.

[0086] FIG. 2F shows alignment of exemplary embodiments of mouse Tslpr ("mTslpr", SEQ ID NO: 21), human TSLPR ("hTSLPR", SEQ ID NO: 23), and humanized (hybrid) Tslpr (SEQ ID NO: 25) protein sequences. The signal peptides of the proteins are boxed with dashed lines. The transmembrane domains are boxed with solid lines. The junctions between the mouse and human sequences in forming the humanized (hybrid) Tslpr are indicated by triangles at the 5' (in intron 1) and the 3' (in exon 6) of the molecules.

[0087] FIG. 3A depicts an exemplary embodiment of a strategy for humanization of a mouse Il7ra locus. The mouse Il7ra gene and the human IL7RA gene are represented by horizontal lines, with their exons being represented by boxes placed above the lines. A contiguous mouse Il7ra genomic fragment of 19235 bp at an endogenous mouse Il7ra locus, which begins from the 69th bp in the coding sequence of exon 1 through a 5' portion of intron 5, is replaced by a human IL7RA genomic fragment of 17232 bp that includes from the 69th bp in the coding sequence of exon 1 through a 5' portion of intron 5. The replacement results in a mouse-human hybrid ("humanized") Tslp protein that includes the mouse IL7ra signal peptide, an ectodomain that is substantially human (except for the last two amino acids, Gly-Trp), and the transmembrane and intracellular domains of mouse Il7ra. See also FIG. 3D.

[0088] FIG. 3B depicts an exemplary embodiment of a strategy for humanization of a mouse IL7ra locus, not to scale, of a nucleic acid comprising a mouse IL7ra locus, and a targeting nucleic acid construct comprising a humanized mouse IL7ra locus wherein a mouse genomic fragment of 19.2 KB at a mouse IL7ra locus has been replaced with a humanization fragment comprising a Human Genomic Fragment 1 of 126 bp (including the last 14 bp in exon 1 and the

first 112 bp in intron 1 of human IL7RA), a Floxed HUB-Hyg cassette of 5.2 kb (inserted in human IL7RA intron 1), and a Human Genomic Fragment 2 of 17106 bp (including a 3' portion of intron 1, exon 2 through exon 5, and a 5' portion of intron 5 of human IL7RA). The humanization fragment in the targeting construct is flanked by a mouse 5' homology arm of 48.8 kb and a mouse 3' homology arm of 124.3 kb. The targeting nucleic acid construct comprising the humanized mouse Il7ra locus can be introduced into a mouse embryonic stem cell for targeted insertion into the mouse genome. The locations of primers and probes used in human gain of allele and mouse loss of allele assays to confirm correct targeting are also indicated. The sequences of the primers and probes are set forth in Table 12.

[0089] FIG. 3C depicts an exemplary embodiment of a strategy for humanization of a mouse Il7ra allele, not to scale, of the humanized Il7ra allele designated as MAID #7266 resulting from the replacement of the mouse IL7ra genomic fragment, described above for FIG. 3B, with the humanization fragment which comprises the Human Genomic Fragment 1 (126 bp), the Floxed HUB-Hyg cassette, and the Human Genomic Fragment 2 (17106 bp). After the Floxed HUB-hyg cassette has been removed, the humanized Il7ra allele is designated as MAID #7267.

[0090] FIG. 3D shows the protein sequences of mouse Il7ra (SEQ ID NO: 41), human IL7RA (SEQ ID NO: 43) (in bold italics), and humanized (hybrid) Il7ra (SEQ ID NO: 45) (with the human portion in bold italics). The signal peptide and transmembrane domain are underlined in each protein sequence.

[0091] FIG. 3E shows exemplary embodiments of the coding sequences (CDS) of mouse Il7ra (SEQ ID NO: 42), human IL7RA (SEQ ID NO: 44) (in bold italics), and humanized (hybrid) Il7ra (SEQ ID NO: 46) (with the human portion in bold italics). The portion of the human IL7RA sequence that is used in the humanization is underlined. The portion of the hybrid Il7ra sequence having the human origin is also underlined.

[0092] FIG. 3F shows alignment of exemplary embodiments of mouse Il7ra (SEQ ID NO: 41, top) and human IL7RA (SEQ ID NO: 43, bottom) protein sequences. The signal peptide and the transmembrane segment (in a box) of the proteins are indicated. The junctions between the mouse and human sequences in forming a humanized (hybrid) Il7ra described in FIGS. 3A-3E are indicated by a vertical line at the N-terminal (the "5' junction") and a line near the C-terminus of the ectodomain (the "3' junction"). The amino acids of the ectodomain involved in the humanization are highlighted (beginning from the amino acid immediately after the 5' junction and ending at the 3' junction). The triangles represent junctions of exons in the coding sequences.

[0093] FIG. 4A-4E. Mice were sensitized i.p. to either saline and alum (alum only) or ovalbumin and alum (Ova-alum) on day 0 and day 14, followed by 4 consecutive intranasal challenges with Ova on day 21 through 24. On day 25, lung tissue and serum were collected for further analysis. 4A. Assessment of lung cellular infiltrates by flow cytometry. Cell frequencies of lung tissue eosinophils are plotted as frequency of total live cells. 4B. Assessment of Muc5ac mRNA expression levels measured by real-time qPCR and expressed relative to β 2m (β 2-microglobulin) control mRNA expression. ELISA analysis of serum Ova-specific IgE (4C) and Ova-specific IgG1 (4D). Each point

represents a single mouse. Symbols represent statistical significance compared to saline control (*). 4E depicts the experimental scheme: Mice were sensitized i.p. to either saline and alum (alum only) or ovalbumin and alum (Ova-alum) on day 0 and day 14, followed by 4 consecutive intranasal challenges with Ova on day 21 through 24. On day 25, lung tissue and serum were collected for further analysis of the parameters shown in 4A-4D.

DETAILED DESCRIPTION

[0094] Disclosed herein are rodents (such as, but not limited to, mice and rats) genetically modified to comprise a humanized Tslp gene, a humanized Tslpr gene, a humanized Il7ra gene, or a combination thereof. The rodents disclosed herein can be used as, e.g., but not limited to, a model for Th2-driven allergic diseases, or as a model for inflammatory Th2-driven cancer. Compositions and methods for making such genetically modified rodents, as well as methods of using such genetically modified rodents for testing candidate therapeutic agents for the treatment of allergy or cancer are provided and further described below.

Tslp Humanized Rodents

[0095] Thymic stromal lymphopoietic (TSLP) is a member of the 4-helix bundle cytokine family and a distant paralog of interleukin-7 (IL-7). TSLP was initially discovered in the culture supernatant of a mouse thymic stromal cell line, and has been shown to act as a growth factor for T cells and B cells. See, e.g., Tsilingiri et al., *Cell Mol. Gastroenterology & Hepatology* 2017; 3:174-182, which is hereby incorporated by reference in its entirety. TSLP expressing cells include epithelial cells, keratinocytes, fibroblasts, stromal cells, dendritic cells, mast cells and basophils. See, Tsilingiri et al. (2017), *supra*. Two TSLP isoforms exist in human: the long TSLP isoform (isoform 1) which is expressed at low/undetectable level at steady state, and upregulated during inflammation in several tissues and is a hallmark of exacerbated Th2 responses in multiple Th2-related diseases (e.g., but not limited to, atopic dermatitis, asthma, allergic responses, and certain types of cancer); and the short TSLP isoform (isoform 2) which is constitutively expressed from a separate promoter and mediates certain immune homeostatic functions in the gut and the thymus. See, Tsilingiri et al. (2017), *supra*. Unless specifically indicated, the exon numberings of a human TSLP gene are based on exons encoding the long isoform (human TSLP protein isoform 1).

[0096] Exemplary sequences, including nucleic acid and protein sequences for human TSLP isoform 1, mouse Tslp, rat Tslp, and humanized Tslp are disclosed in the Sequence Listing and summarized in Table 1. Mouse and rat Tslp genes have a small coding exon 1 and a total of 5 exons, instead of 4 exons as in human TSLP gene. An alignment of human TSLP isoform 1, mouse Tslp, and humanized (hybrid) Tslp protein sequences is provided in FIG. 1F.

TABLE 1

SEQ ID NO	Description	Features
1	<i>Mus musculus</i> Tslp Protein, NP_067342	Length: 140 aa Signal peptide: 1-19 Mature protein: 20-140

TABLE 1-continued

SEQ ID NO	Description	Features
2	<i>Mus musculus</i> Tslp mRNA (CDS), NM_021367	Length: 423 bp
3	<i>Homo sapiens</i> TSLP protein isoform 1, NP_149024	Length: 159 aa Signal peptide: aa 1-28 Mature: aa 29-159
4	<i>Homo sapiens</i> TSLP mRNA (CDS), isoform 1, NM_033035	Length: 480 bp
5	Humanized mouse/human chimeric Tslp Protein	Length: 150 aa Signal peptide: 1-19 (from mouse) Mature protein: 20-150 (from human)
6	Humanized mouse/human chimeric Tslp CDS	Length: 453 bp
7	<i>Rattus norvegicus</i> Tslp Protein, XP_008770274	Length: 136 aa
8	<i>Rattus norvegicus</i> Tslp mRNA, XM_008772052	Length: 411 bp

[0097] In some embodiments, the rodents disclosed herein comprise a humanized Tslp gene in the germline.

[0098] In some embodiments, a rodent disclosed herein comprises a humanized Tslp gene in its genome that includes a nucleotide sequence of a rodent Tslp gene and a nucleotide sequence of a human TSLP gene. As used herein, “a nucleotide sequence of a gene” includes a genomic sequence, an mRNA or cDNA sequence, in full or in part of the gene. For example, a nucleotide sequence of a human TSLP gene can be a genomic sequence, an mRNA sequence, or a cDNA sequence, in full or in part of the human TSLP gene; and a nucleotide sequence of a rodent Tslp gene can be a genomic sequence, an mRNA sequence, or a cDNA sequence, in full or in part of the rodent Tslp gene (e.g., an endogenous rodent Tslp gene). The nucleotide sequence of the rodent Tslp gene and the nucleotide sequence of the human TSLP gene are operably linked to each other such that the humanized Tslp gene in the rodent genome encodes a humanized Tslp protein that performs the functions of a Tslp protein, e.g., binding to a Tslp receptor (Tslpr).

[0099] “Human TSLP” gene and protein, as used herein, refers to TSLP gene and protein of the human origin.

[0100] In some embodiments, a human TSLP protein comprises the amino acid sequence of SEQ ID NO: 3. In some embodiments, a human TSLP protein comprises an amino acid sequence at least 95% identical to the the amino acid sequence of SEQ ID NO: 3. In some embodiments, a human TSLP protein comprises an amino acid sequence at least 98% identical to the the amino acid sequence of SEQ ID NO: 3. In some embodiments, a human TSLP protein comprises an amino acid sequence at least 99% identical to the the amino acid sequence of SEQ ID NO: 3.

[0101] “Rodent Tslp” gene and protein, as used herein, refers to Tslp gene and protein of a rodent (e.g., mouse or rat) origin.

[0102] In some embodiments, a mouse Tslp protein comprises the amino acid sequence of SEQ ID NO: 1. In some embodiments, a mouse Tslp protein comprises an amino acid sequence at least 95% identical to the the amino acid sequence of SEQ ID NO: 1. In some embodiments, a mouse Tslp protein comprises an amino acid sequence at least 98% identical to the the amino acid sequence of SEQ ID NO: 1. In some embodiments, a mouse Tslp protein comprises an

amino acid sequence at least 99% identical to the the amino acid sequence of SEQ ID NO: 1.

[0103] In some embodiments, a rat Tslp protein comprises the amino acid sequence of SEQ ID NO: 7. In some embodiments, a rat Tslp protein comprises an amino acid sequence at least 95% identical to the the amino acid sequence of SEQ ID NO: 7. In some embodiments, a rat Tslp protein comprises an amino acid sequence at least 98% identical to the the amino acid sequence of SEQ ID NO: 7. In some embodiments, a rat Tslp protein comprises an amino acid sequence at least 99% identical to the the amino acid sequence of SEQ ID NO: 7.

[0104] In some embodiments, a genetically modified rodent comprises a humanized Tslp gene in its genome, wherein the humanized Tslp gene encodes a humanized Tslp protein that comprises a mature protein sequence that is substantially identical with the mature protein sequence of a human TSLP protein (such as the human TSLP protein as set forth in SEQ ID NO: 3).

[0105] A “mature protein” refers to the portion of a protein after an N-terminal signal peptide has been cleaved.

[0106] A mature protein sequence that is substantially identical with the mature protein sequence of a human TSLP protein can be (i) a polypeptide sequence that is at least 95% identical with the mature protein of a human TSLP protein, a polypeptide sequence that is at least 98% identical with the mature protein of a human TSLP protein, or a polypeptide sequence that is at least 99% identical with the mature protein of a human TSLP protein. A mature protein sequence that is substantially identical with the mature protein sequence of a human TSLP protein may be a polypeptide sequence identical with the mature protein sequence of a human TSLP protein. A mature protein sequence that is substantially identical with the mature protein sequence of a human TSLP protein may alternatively or additionally be (ii) a polypeptide sequence that differs from the mature protein sequence of a human TSLP protein by not more than 5 amino acids, a polypeptide sequence that differs from the mature protein sequence of a human TSLP protein by not more than 4 amino acids, a polypeptide sequence that differs from the mature protein sequence of a human TSLP protein by not more than 3 amino acids, a polypeptide sequence that differs from the mature protein sequence of a human TSLP protein by not more than 2 amino acids, or a polypeptide sequence that differs from the mature protein sequence of a human TSLP protein by not more than 1 amino acid. A mature protein sequence that is substantially identical with the mature protein sequence of a human TSLP protein may alternatively or additionally be (iii) a polypeptide that differs from the mature protein sequence of a human TSLP protein only at the N- or C-terminal portion of the domain, e.g., by having addition, deletion or substitution of amino acids (not more than 5 amino acids) at the N- or C-terminal portion of the mature protein; by “the N- or C-terminal portion of the mature protein” is meant within 5-10 amino acids from the N- or C-terminus of the mature protein. A mature protein sequence that is substantially identical with the mature protein sequence of a human TSLP protein may alternatively or additionally be (iv) a polypeptide having one or more features described in (i)-(iii) above, e.g., a polypeptide that is at least 95% identical with the mature protein of a human TSLP protein and differs from the mature protein sequence of a human TSLP protein only at the N- or C-terminal portion of the domain by not more than 5 amino acids, or a

polypeptide that is at least 98% identical with the mature protein of a human TSLP protein and differs from the mature protein sequence of a human TSLP protein only at the N- or C-terminal portion of the domain by not more than 3 amino acids.

[0107] In some embodiments, a human TSLP protein is the human TSLP protein isoform 1 as set forth in SEQ ID NO: 3, with amino acids 29-159 constituting the mature protein sequence. Accordingly, in some embodiments, a genetically modified rodent comprises a humanized Tslp gene in its genome that encodes a humanized Tslp protein that comprises a mature protein sequence that is substantially identical with the amino acid sequence as set forth in amino acids 29-159 of SEQ ID NO: 3. In some embodiments, a humanized Tslp protein comprises a mature protein sequence which comprises amino acids 29-159 of SEQ ID NO: 3. In some embodiments, a humanized Tslp protein comprises a mature protein sequence which comprises amino acids 30-159 of SEQ ID NO: 3. In some embodiments, a humanized Tslp protein comprises a mature protein sequence which comprises amino acids 31-159 of SEQ ID NO: 3. In some embodiments, a humanized Tslp protein comprises a mature protein sequence which comprises amino acids 32-159 of SEQ ID NO: 3. In some embodiments, a humanized Tslp protein comprises a mature protein sequence which comprises amino acids 29-158 of SEQ ID NO: 3. In some embodiments, a humanized Tslp protein comprises a mature protein sequence which comprises amino acids 29-157 of SEQ ID NO: 3. In some embodiments, a humanized Tslp protein comprises a mature protein sequence which comprises amino acids 29-156 of SEQ ID NO: 3. In some embodiments, a humanized Tslp protein comprises a mature protein sequence that is as set forth in amino acids 29-159 of SEQ ID NO: 3.

[0108] In some embodiments, the humanized Tslp gene encodes a humanized Tslp protein that comprises a signal peptide that is substantially identical with the signal peptide of a human TSLP protein. In some embodiments, a signal peptide that is substantially identical with the signal peptide of a human TSLP protein is a signal peptide that is at least 95% identical in sequence with the signal peptide of a human TSLP protein. A signal peptide that is substantially identical with the signal peptide of a human TSLP protein may be a signal peptide identical with the signal peptide of a human TSLP protein. Additionally or alternatively, a signal peptide that is substantially identical with the signal peptide of a human TSLP protein may be a signal peptide that differs from the signal peptide of a human TSLP protein by not more than 3 amino acids, by not more than 2 amino acids, or by not more than 1 amino acid. In specific embodiments, the signal peptide of a human TSLP protein comprises the amino acid sequence as set forth in amino acids 1-28 of SEQ ID NO: 3.

[0109] In some embodiments, the humanized Tslp gene encodes a humanized Tslp protein that comprises a signal peptide that is substantially identical with the signal peptide of a rodent Tslp protein, such as an endogenous rodent Tslp protein. In some embodiments, a signal peptide that is substantially identical with the signal peptide of a rodent Tslp protein is a signal peptide that is at least 95% identical in sequence with the signal peptide of a rodent Tslp protein; in some embodiments, a signal peptide that is substantially identical with the signal peptide of a rodent Tslp protein is a signal peptide that is identical in sequence with the signal

peptide of a rodent Tslp protein. In some embodiments, a signal peptide that is substantially identical with the signal peptide of a rodent Tslp protein is a signal peptide that differs from the signal peptide of a rodent Tslp protein protein by not more than 3 amino acids; in some embodiments, a signal peptide that is substantially identical with the signal peptide of a rodent Tslp protein is a signal peptide that differs from the signal peptide of a rodent Tslp protein protein by not more than 2 amino acids; in some embodiments, a signal peptide that is substantially identical with the signal peptide of a rodent Tslp protein is a signal peptide that differs from the signal peptide of a rodent Tslp protein protein by not more than 1 amino acid. In specific embodiments, a humanized Tslp protein comprises a signal peptide that is substantially identical with the signal peptide of a mouse Tslp protein, e.g., the signal peptide as set forth in amino acids 1-19 of SEQ ID NO: 1. In specific embodiments, a humanized Tslp protein comprises a signal peptide that is substantially identical with the signal peptide of a rat Tslp protein, e.g., the rat Tslp protein as set forth in SEQ ID NO: 7.

[0110] As described above, the humanized Tslp gene in the genome of a genetically modified rodent includes a nucleotide sequence of a human TSLP gene ("a human TSLP nucleotide sequence") and a nucleotide sequence of a rodent Tslp gene ("a rodent Tslp nucleotide sequence", e.g., an endogenous rodent Tslp nucleotide sequence).

[0111] In some embodiments, the human TSLP nucleotide sequence in a humanized Tslp gene encodes at least a substantial portion of the mature protein sequence of a human TSLP protein (e.g., a human TSLP protein isoform 1). A "substantial portion" of a mature Tslp protein sequence refers to a polypeptide that is nearly the full length of the mature protein sequence. In some embodiments, a substantial portion of a mature protein sequence refers to a polypeptide that is at least 95% of the full length mature protein sequence; in some embodiments, a substantial portion of a mature protein sequence refers to a polypeptide that is at least 98% of the full length mature protein sequence; in some embodiments, a substantial portion of a mature protein sequence refers to a polypeptide that is at least 99% of the full length mature protein sequence. In some embodiments, a substantial portion of a mature protein sequence refers to a polypeptide that differs from the mature protein sequence by lacking not more than 5 amino acids at the N- or C-terminus of the mature protein sequence; in some embodiments, a substantial portion of a mature protein sequence refers to a polypeptide that differs from the mature protein sequence by lacking not more than 4 amino acids at the N- or C-terminus of the mature protein sequence; in some embodiments, a substantial portion of a mature protein sequence refers to a polypeptide that differs from the mature protein sequence by lacking not more than 3 amino acids at the N- or C-terminus of the mature protein sequence; a substantial portion of a mature protein sequence refers to a polypeptide that differs from the mature protein sequence by lacking not more than 2 amino acids at the N- or C-terminus of the mature protein sequence; a substantial portion of a mature protein sequence refers to a polypeptide that differs from the mature protein sequence by lacking not more than 1 amino acid at the N- or C-terminus of the mature protein sequence. In some embodiments, the human TSLP nucleotide sequence in a humanized Tslp gene encodes the mature protein sequence of a human TSLP protein (e.g., a human TSLP protein isoform 1, such as the human TSLP protein

isoform 1 as set forth in SEQ ID NO: 3). In some embodiments, the human TSLP nucleotide sequence in a humanized Tslp gene encodes amino acids 29-159 of SEQ ID NO: 3. In some embodiments, the human TSLP nucleotide sequence in a humanized Tslp gene encodes amino acids 30-159 of SEQ ID NO: 3. In some embodiments, the human TSLP nucleotide sequence in a humanized Tslp gene encodes amino acids 31-159 of SEQ ID NO: 3. In some embodiments, the human TSLP nucleotide sequence in a humanized Tslp gene encodes amino acids 32-159 of SEQ ID NO: 3. In some embodiments, the human TSLP nucleotide sequence in a humanized Tslp gene encodes amino acids 29-158 of SEQ ID NO: 3. In some embodiments, the human TSLP nucleotide sequence in a humanized Tslp gene encodes amino acids 29-157 of SEQ ID NO: 3. In some embodiments, the human TSLP nucleotide sequence in a humanized Tslp gene encodes amino acids 29-156 of SEQ ID NO: 3.

[0112] In some embodiments, the human TSLP nucleotide sequence in a humanized Tslp gene is a cDNA sequence. In some embodiments, the human TSLP nucleotide sequence is a genomic fragment of a human TSLP gene. In some embodiments, the human TSLP nucleotide sequence is a genomic fragment comprising exonic sequences that encode at least a substantial portion of the mature protein sequence of a human TSLP protein. In some embodiments, the human TSLP nucleotide sequence is a genomic fragment comprising exonic sequences that encode the mature protein sequence of a human TSLP protein (e.g., a human TSLP protein isoform 1, such as the human TSLP protein isoform 1 as set forth in SEQ ID NO: 3). In some embodiments, the human TSLP nucleotide sequence is a genomic fragment of a human TSLP gene, which fragment comprises the mature protein amino acids encoding portion of exon 1, exon 2, exon 3, and the coding portion of exon 4 (i.e., through the STOP codon in exon 4).

[0113] In some embodiments, the human TSLP nucleotide sequence is a genomic fragment of a human TSLP gene, which fragment also comprises the 3' UTR of the human TSLP gene (a 3' portion of human TSLP exon 4).

[0114] In some embodiments, the rodent Tslp nucleotide sequence in a humanized Tslp gene encodes a polypeptide substantially identical to the signal peptide of a rodent Tslp protein (e.g., an endogenous rodent Tslp protein). In some embodiments, a polypeptide substantially identical to the signal peptide of a rodent Tslp protein includes a polypeptide that is at least 95% identical in sequence with the signal peptide of a rodent Tslp protein. In some embodiments, a polypeptide substantially identical to the signal peptide of a rodent Tslp protein includes a polypeptide that differs from the signal peptide of a rodent Tslp protein by not more than 3 amino acids. In some embodiments, a polypeptide substantially identical to the signal peptide of a rodent Tslp protein includes a polypeptide that differs from the signal peptide of a rodent Tslp protein by not more than 2 amino acids. In some embodiments, a polypeptide substantially identical to the signal peptide of a rodent Tslp protein includes a polypeptide that differs from the signal peptide of a rodent Tslp protein by not more than 1 amino acid. In some embodiments, the rodent Tslp nucleotide sequence in a humanized Tslp gene encodes the signal peptide of a rodent Tslp protein (e.g., an endogenous rodent Tslp protein, e.g., mouse or rat Tslp protein). In some embodiments, the rodent Tslp nucleotide sequence comprises exonic sequences of a rodent Tslp gene that

encode the signal peptide of the rodent Tslp protein. In some embodiments, the rodent Tslp nucleotide sequence is a mouse Tslp nucleotide sequence, and in some such embodiments, the mouse Tslp nucleotide sequence comprises exon 1 and the signal peptide amino acid-coding portion of exon 2 of a mouse Tslp gene (e.g., an endogenous mouse Tslp gene). In some embodiments, the rodent Tslp nucleotide sequence in a humanized Tslp gene comprises the 5' UTR of a rodent Tslp gene (e.g., a mouse or rat Tslp gene, such as an endogenous mouse or rat Tslp gene).

[0115] In some embodiments, the humanized Tslp gene is operably linked to rodent Tslp regulatory sequences, e.g., 5' transcriptional regulatory sequence(s) such as promoter and/or enhancer of a rodent Tslp gene, such as endogenous rodent 5' transcriptional regulatory sequence(s) at an endogenous rodent Tslp locus, such that expression of the humanized Tslp gene is under control of the rodent Tslp 5' regulatory sequence(s).

[0116] In some embodiments, the humanized Tslp gene is at an endogenous rodent Tslp locus. In some embodiments, the humanized Tslp gene is at a locus other than an endogenous rodent Tslp locus; e.g., as a result of random integration. In some embodiments where the humanized Tslp gene is at a locus other than an endogenous rodent Tslp locus, the rodents are incapable of expressing a rodent Tslp protein, e.g., as a result of inactivation (e.g., deletion in full or in part) of the endogenous rodent Tslp gene.

[0117] In some embodiments where a humanized Tslp gene is at an endogenous rodent Tslp locus, the humanized Tslp gene may result from a replacement of a nucleotide sequence of an endogenous rodent Tslp gene at the endogenous rodent Tslp locus with a nucleotide sequence of a human TSLP gene.

[0118] In some embodiments, the nucleotide sequence of a human TSLP gene that replaces a genomic fragment of a rodent Tslp gene at an endogenous rodent Tslp locus is a cDNA sequence. In some embodiments, the human TSLP nucleotide sequence that replaces a genomic fragment of a rodent Tslp gene at an endogenous rodent Tslp locus is a genomic fragment of a human TSLP gene. In some embodiments, the human TSLP nucleotide sequence encode at least a substantial portion of the mature protein sequence of the human TSLP protein. In some embodiments, the human TSLP nucleotide sequence is a genomic fragment of a human TSLP gene that includes includes exons, in full or in part, of a human TSLP gene, that encode at least a substantial portion of the mature protein sequence of the human TSLP protein. In some embodiments, the human genomic fragment comprises the mature protein amino acids encoding portion of exon 1, exon 2, exon 3, and the coding portion of exon 4 of a human TSLP gene. In some embodiments, the human genomic fragment can further comprise the 3' UTR portion of exon 4 of a human TSLP gene.

[0119] In some embodiments, the human nucleotide sequence integrated at an endogenous rodent Tslp locus is operably linked to a rodent Tslp nucleotide sequence that encodes a polypeptide substantially identical with the signal peptide of a rodent Tslp protein. In some embodiments, the human nucleotide sequence integrated at an endogenous rodent Tslp locus is operably linked to an endogenous rodent Tslp genomic sequence that encodes substantially the signal peptide of the endogenous rodent Tslp protein. In some embodiments, the human nucleotide sequence is integrated at an endogenous mouse Tslp locus and is operably linked to

a mouse Tslp nucleotide sequence that encodes a polypeptide substantially identical with the signal peptide of a mouse Tslp protein; and in some such embodiments, the mouse Tslp nucleotide sequence comprises exon 1 and the signal peptide amino acid-coding portion of exon 2 of a mouse Tslp gene (e.g., the endogenous mouse Tslp gene).

[0120] In some embodiments, a genomic fragment comprising exonic sequences coding for the mature protein sequence of an endogenous rodent Tslp protein at an endogenous rodent Tslp locus (e.g., a mouse genomic fragment that begins from the codon in exon 2 coding for the first amino acid of the mature mouse Tslp protein through the STOP codon) has been replaced with a genomic fragment of a human TSLP gene comprising exonic sequences coding for the mature protein sequence of the human TSLP protein (e.g., a genomic fragment that begins from the codon in exon 1 coding for the first amino acid of the mature human TSLP protein through the STOP codon in exon 4). As a result, a humanized Tslp gene is formed at the endogenous rodent Tslp locus. In some embodiments, a humanized Tslp gene is formed at an endogenous mouse Tslp locus and comprises mouse Tslp exon 1, the signal peptide amino acid coding portion of mouse Tslp exon 2, the codon in human TSLP exon 1 coding for the first amino acid of the mature human TSLP protein through the STOP codon in human TSLP exon 4, and the mouse 3' UTR in mouse Tslp exon 5. Such humanized Tslp gene encodes a humanized Tslp protein that comprises a mouse Tslp signal peptide and a mature human TSLP polypeptide.

[0121] In some embodiments, a rodent provided herein is heterozygous for a humanized Tslp gene in its genome. In some embodiments, a rodent provided herein is homozygous for a humanized Tslp gene in its genome.

[0122] In some embodiments, a humanized Tslp gene results in an expression of the encoded humanized Tslp protein in a rodent, e.g., in the serum of the rodent. In some embodiments, a humanized Tslp protein is expressed in cells and tissues in which a counterpart rodent Tslp protein is expressed in a control rodent (e.g., a rodent without the humanized Tslp gene); e.g., epithelial cells and keratinocytes in the skin, gut, lungs and ocular tissue, as well as dendritic cells, mast cells and basophils. See, e.g., Tsilingiri et al. (2017), *supra*.

[0123] In some embodiments, rodents disclosed herein are incapable of expressing a rodent Tslp protein, e.g., as a result of inactivation (e.g., deletion in full or in part) or replacement (in full or in part) of the endogenous rodent Tslp gene.

TSL PR Humanization

[0124] TSLP acts through a heterodimer composed of a chain specific for TSLP (referred to as “TSLPR” or “Tslpr”) and the IL7 receptor α chain. TSLPR contains a signal peptide, an extracellular domain (“ECD” or “ectodomain”), a transmembrane domain and an intracellular (cytoplasmic) domain.

[0125] Exemplary sequences, including nucleic acid and protein sequences for human TSLPR isoform 1, mouse Tslpr isoform 1, rat Tslpr isoform 1, and humanized (mouse-human hybrid) Tslpr, are disclosed in the Sequence Listing and summarized in Table 2. An alignment of human TSLPR isoform 1, mouse Tslpr isoform 1, and humanized (mouse-human hybrid) Tslpr protein sequences is provided in FIG. 2F. Unless specifically indicated, the exon numberings of

human and mouse genes are based on exons encoding human and mouse protein isoform 1.

TABLE 2

SEQ ID NO	Description	Features
21	<i>Mus musculus</i> Tslpr isoform 1 Protein, NP_001158207	Length: 370 aa Signal peptide: aa 1-19 Ectodomain: aa 20-243 Transmembrane: aa 244-264 Intracellular: aa 265-370
22	<i>Mus musculus</i> Tslpr mRNA (CDS), isoform 1, NM_001164735	Length: 1113 bp
23	<i>Homo sapiens</i> TSLPR protein isoform 1, NP_071431	Length: 371 aa Signal peptide: aa 1-22 Ectodomain: aa 23-231 Transmembrane: aa 232-252 Intracellular: aa 253-371
24	<i>Homo sapiens</i> TSLPR mRNA (CDS), isoform 1, NM_022148	Length: 1116 bp
25	Humanized mouse/human chimeric Tslpr Protein	Length: 358 aa Signal peptide: 1-19 (from mouse) Ectodomain: aa 20-231 (aa 20-26 from mouse and aa 27-231 from human) Transmembrane: aa 232-252 (from mouse) Intracellular: aa 253-358 (from mouse)
26	Humanized mouse/human chimeric Tslpr mRNA (CDS)	Length: 1077 bp
27	<i>Rattus norvegicus</i> Tslpr Protein, AAL90454.1.	Length: 360 aa
28	<i>Rattus norvegicus</i> Tslpr mRNA, AF404510.1	Length: 1209 bp

[0126] In some embodiments, the rodents disclosed herein comprise a humanized Tslpr gene in the germline.

[0127] In some embodiments, a rodent disclosed herein comprises a humanized Tslpr gene in its genome that includes a nucleotide sequence of a rodent Tslpr gene (e.g., an endogenous rodent Tslpr gene) and a nucleotide sequence of a human TSLPR gene. As used herein, “a nucleotide sequence of a gene” includes a genomic sequence, an mRNA or cDNA sequence, in full or in part of the gene. As a non-limiting example, a nucleotide sequence of a human TSLPR gene includes a genomic sequence, an mRNA or cDNA sequence, in full or in part of the human TSLPR gene. The nucleotide sequence of the rodent Tslpr gene and the nucleotide sequence of the human TSLPR gene are operably linked to each other such that the humanized Tslpr gene in the rodent genome encodes a humanized Tslpr protein that has a Tslpr protein structure (comprising an ectodomain, a transmembrane domain and a cytoplasmic domain) and performs Tslpr functions (e.g., binds a Tslp protein and forms a heterodimer with IL-7 receptor).

[0128] “Human TSLPR” gene and protein, as used herein, refers to TSLPR gene and protein of the human origin. In some embodiments, a human TSLPR protein comprises the amino acid sequence of SEQ ID NO: 23. In some embodiments, a human TSLPR protein comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 23. In some embodiments, a human TSLPR protein comprises an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO: 23. In some embodiments, a human TSLPR protein

comprises an amino acid sequence at least 99% identical to the the amino acid sequence of SEQ ID NO: 23.

[0129] “Rodent Tslpr” gene and protein, as used herein, refers to Tslpr gene and protein of a rodent (e.g., mouse or rat) origin. In some embodiments, a mouse Tslpr protein comprises the the amino acid sequence of SEQ ID NO: 21. In some embodiments, a mouse Tslpr protein comprises an amino acid sequence at least 95% identical to the the amino acid sequence of SEQ ID NO: 21. In some embodiments, a mouse Tslpr protein comprises an amino acid sequence at least 98% identical to the the amino acid sequence of SEQ ID NO: 21. In some embodiments, a mouse Tslpr protein comprises an amino acid sequence at least 99% identical to the the amino acid sequence of SEQ ID NO: 21. In some embodiments, a rat Tslpr protein comprises the the amino acid sequence of SEQ ID NO: 27. In some embodiments, a rat Tslpr protein comprises an amino acid sequence at least 95% identical to the the amino acid sequence of SEQ ID NO: 27. In some embodiments, a rat Tslpr protein comprises an amino acid sequence at least 98% identical to the the amino acid sequence of SEQ ID NO: 27. In some embodiments, a rat Tslpr protein comprises an amino acid sequence at least 99% identical to the the amino acid sequence of SEQ ID NO: 27.

[0130] In some embodiments, a genetically modified rodent contains a humanized Tslpr gene in its genome, wherein the humanized Tslpr gene encodes a humanized Tslpr protein that contains an ectodomain that is substantially identical with the ectodomain of a human TSLPR protein. In some embodiments, an ectodomain that is substantially identical with the ectodomain of a human TSLPR protein exhibits the same functionality (e.g., ligand binding properties) as the ectodomain of a human TSLPR protein. An ectodomain or polypeptide that is “substantially identical with the ectodomain of a human TSLPR protein” can be (i) a polypeptide that is at least 95% identical in sequence with the ectodomain of a human TSLPR protein, a polypeptide that is at least 98% identical in sequence with the ectodomain of a human TSLPR protein, or a polypeptide that is at least 99%, identical in sequence with the ectodomain of a human TSLPR protein. An ectodomain or polypeptide that is “substantially identical with the ectodomain of a human TSLPR protein” can be a polypeptide that is 100% identical in sequence with the ectodomain of a human TSLPR protein. Alternatively or additionally, an ectodomain or polypeptide that is “substantially identical with the ectodomain of a human TSLPR protein” can be (ii) a polypeptide that differs from the ectodomain of a human TSLPR protein by not more than 10 amino acids, a polypeptide that differs from the ectodomain of a human TSLPR protein by not more than 7 amino acids, a polypeptide that differs from the ectodomain of a human TSLPR protein by not more than 5 amino acids, a polypeptide that differs from the ectodomain of a human TSLPR protein by not more than 4 amino acids, a polypeptide that differs from the ectodomain of a human TSLPR protein by not more than 3 amino acids, a polypeptide that differs from the ectodomain of a human TSLPR protein by not more than 2 amino acids, a polypeptide that differs from the ectodomain of a human TSLPR protein by not more than 1 amino acid. Alternatively or additionally, an ectodomain or polypeptide that is “substantially identical with the ectodomain of a human TSLPR protein” can be (iii) a polypeptide that differs from the ectodomain of a human TSLPR protein only at the N- or C-terminal portion of the ectodomain, e.g.,

by having addition, deletion and/or substitution of amino acids at the N- and/or C-terminal portion of the ectodomain (i.e., within 5-10 amino acids from the N or C terminus of the ectodomain). Alternatively or additionally, an ectodomain or polypeptide that is “substantially identical with the ectodomain of a human TSLPR protein” can be (iv) a polypeptide that has one or more of the features delineated in (i)-(iii) above, e.g., a polypeptide that is at least 95% identical in sequence with the ectodomain of a human TSLPR protein and differs from the ectodomain of the human TSLPR protein only at the N- or C-terminal portion of the ectodomain by not more than 10 amino acids, a polypeptide that is at least 95% identical in sequence with the ectodomain of a human TSLPR protein and differs from the ectodomain of the human TSLPR protein only at the N- or C-terminal portion of the ectodomain by not more than 5 amino acids, or a polypeptide that is at least 98% identical in sequence with the ectodomain of a human TSLPR protein and differs from the ectodomain of the human TSLPR protein only at the N- or C-terminal portion of the ectodomain by not more than 3 amino acids. In some embodiments, a human TSLPR protein comprises the amino acid sequence as set forth in SEQ ID NO: 23, and its ectodomain is composed of amino acids 23-231 of SEQ ID NO: 23. In some embodiments, the humanized Tslpr gene encodes a humanized Tslpr protein whose ectodomain is substantially identical with the ectodomain of the human TSLPR protein as set forth in SEQ ID NO: 23, i.e., substantially identical with amino acids 23-231 of SEQ ID NO: 23. For example, the humanized Tslpr gene encodes a humanized Tslpr protein having an ectodomain that comprises amino acids 23-231, 24-231, 25-231, 26-231, 27-231, 28-231, 23-230, 23-229, 23-228, 23-227 or 23-226 of SEQ ID NO: 23. In some embodiments, the humanized Tslpr gene encodes a humanized Tslpr protein having an ectodomain that comprises amino acids 23-231 of SEQ ID NO: 23. In some embodiments, the humanized Tslpr gene encodes a humanized Tslpr protein having an ectodomain that comprises amino acids 25-231 of SEQ ID NO: 23. In some embodiments, the humanized Tslpr gene encodes a humanized Tslpr protein having an ectodomain that comprises amino acids 27-231 of SEQ ID NO: 23. In some embodiments, the humanized Tslpr gene encodes a humanized Tslpr protein having an ectodomain that comprises amino acids 23-228 of SEQ ID NO: 23. In some embodiments, the humanized Tslpr gene encodes a humanized Tslpr protein having an ectodomain that comprises amino acids 23-226 of SEQ ID NO: 23.

[0131] In some embodiments, the humanized Tslpr gene encodes a humanized Tslpr protein having an ectodomain that comprises amino acids from the N-terminus of the ectodomain of a rodent Tslpr (e.g., an endogenous rodent Tslpr), followed by the ectodomain of a human TSLPR or a substantial portion thereof. A “substantial portion of the ectodomain” of a human TSLPR (or a rodent Tslpr) protein refers to a polypeptide that is nearly the full ectodomain of the protein. In some embodiments, a substantial portion of the ectodomain of a human TSLPR protein refers to a polypeptide that is at least 95% of the full length ectodomain of the human TSLPR protein. In some embodiments, a substantial portion of the ectodomain of a human TSLPR protein refers to a polypeptide that is at least 98% of the full length ectodomain of the human TSLPR protein. Sequence. In some embodiments, a substantial portion of the ectodomain of a human TSLPR protein refers to a polypeptide that

differs from the full length ectodomain by lacking not more than 10 amino acids at the N- or C-terminus of the ectodomain. In some embodiments, a substantial portion of the ectodomain of a human TSLPR protein refers to a polypeptide that differs from the full length ectodomain by lacking not more than 5 amino acids at the N- or C-terminus of the ectodomain. In some embodiments, a substantial portion of the ectodomain of a human TSLPR protein refers to a polypeptide that differs from the full length ectodomain by lacking not more than 4 amino acids at the N- or C-terminus of the ectodomain. For example, the ectodomain of the human TSLPR protein as set forth in SEQ ID NO: 23 is defined by amino acids 23-231, and examples of a substantial portion of the ectodomain can include amino acids 25-231, 26-231, 27-231, 23-228, 23-227, or 23-226 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain of a human TSLPR protein comprises amino acids 25-231 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain of a human TSLPR protein comprises amino acids 27-231 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain of a human TSLPR protein comprises amino acids 23-228 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain of a human TSLPR protein comprises amino acids 23-226 of SEQ ID NO: 23. In some embodiments, the ectodomain of a humanized Tslpr protein comprises 6-8 amino acids from the N-terminus of the ectodomain of a rodent Tslpr (e.g., an endogenous rodent Tslpr), followed by a substantial portion of the ectodomain of a human TSLPR protein. In some embodiments, the ectodomain of a humanized Tslpr protein comprises 7 amino acids from the N-terminus of the ectodomain of a rodent Tslpr (e.g., an endogenous rodent Tslpr), followed by amino acids 27-231 of SEQ ID NO: 23. In some embodiments, the humanized Tslpr gene encodes a humanized Tslpr protein that contains an ectodomain as set forth in amino acids 20-231 of SEQ ID NO: 25—this ectodomain comprises 7 amino acids from the N-terminus of a mouse Tslpr ectodomain, followed by amino acids 27-231 of SEQ ID NO: 23 (human Tslpr); and differs from the ectodomain of the human TSLPR protein of SEQ ID NO: 23 in the N-terminus of the ectodomain (“AAAVTSR” (SEQ ID NO: 67) in humanized TSLPR of SEQ ID NO: 25, as opposed to “QGGA” (SEQ ID NO: 68) in human TSLPR of SEQ ID NO: 23) but is identical to the human TSLP ectodomain in the remaining ame 205 amino acids.

[0132] In some embodiments, the humanized Tslpr gene encodes a humanized Tslpr protein that contains a transmembrane-cytoplasmic sequence (i.e., a sequence that includes both the transmembrane domain and the cytoplasmic domain) that is substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein, e.g., an endogenous rodent Tslpr protein. In some embodiments, a transmembrane-cytoplasmic sequence that is substantially identical with the transmembrane-cytoplasmic sequence of an endogenous rodent Tslpr protein exhibits the same functionality (e.g., signal transduction and/or interaction with intracellular molecules) as the transmembrane-cytoplasmic sequence of a rodent Tslpr protein such as an endogenous rodent Tslpr protein. A transmembrane-cytoplasmic sequence or polypeptide that is “substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein” can be (i) a polypeptide that is at least 95% identical in sequence with the transmembrane-cy-

plasmic sequence of a rodent Tslpr protein, or a polypeptide that is at least 98% identical in sequence with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein. A transmembrane-cytoplasmic sequence or polypeptide that is “substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein” can be a polypeptide that is identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein. Alternatively or additionally, a transmembrane-cytoplasmic sequence or polypeptide that is “substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein” can be (ii) a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Tslpr protein by not more than 5 amino acids, a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Tslpr protein by not more than 4 amino acids, a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Tslpr protein by not more than 3 amino acids, a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Tslpr protein by not more than 2 amino acids, or a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Tslpr protein by not more than 1 amino acid. Alternatively or additionally, a transmembrane-cytoplasmic sequence or polypeptide that is “substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein” can be (iii) in some embodiments, a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Tslpr protein only at the N- or C-terminus, e.g., by having addition, deletion or substitution of amino acids at the N- or C-terminal portion of the transmembrane-cytoplasmic sequence. Alternatively or additionally, a transmembrane-cytoplasmic sequence or polypeptide that is “substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein” can be; (iv) a polypeptide having one or more features delineated in (i)-(iii) above, e.g., a polypeptide that is at least 95% identical in sequence with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein, and differs from the transmembrane-cytoplasmic sequence of a rodent Tslpr protein only at the N- or C-terminus by not more than 5 amino acids; or a polypeptide that is at least 95% identical in sequence with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein, and differs from the transmembrane-cytoplasmic sequence of a rodent Tslpr protein only at the N- or C-terminus by not more than 3 amino acids. By “the N- or C-terminal portion of the transmembrane-cytoplasmic sequence” is meant within 5-10 amino acids from the N-terminus of the transmembrane domain or within 5-10 amino acids from the C-terminus of the cytoplasmic domain. In some embodiments, a humanized Tslpr protein contains a transmembrane-cytoplasmic sequence that is substantially identical with the transmembrane-cytoplasmic sequence of a mouse Tslpr protein (such as an endogenous mouse Tslpr protein). In some embodiments, a humanized Tslpr protein contains a transmembrane-cytoplasmic sequence that is substantially identical with the transmembrane-cytoplasmic sequence of a rat Tslpr protein (such as an endogenous rat Tslpr protein).

[0133] In some embodiments, the humanized Tslpr gene encodes a humanized Tslpr protein that contains a signal peptide that is substantially identical with the signal peptide of a rodent Tslpr protein (e.g., an endogenous rodent Tslpr protein). A signal peptide that is “substantially identical with the signal peptide of a rodent Tslpr protein”, can be (i) a

polypeptide that is at least 95% identical in sequence with the signal peptide of a rodent Tslpr protein, or a polypeptide that is identical in sequence with the signal peptide of a rodent Tslpr protein. Alternatively or additionally, a signal peptide that is “substantially identical with the signal peptide of a rodent Tslpr protein” can be (ii) a polypeptide that differs from the signal peptide of an endogenous rodent Tslpr protein by not more than 3 amino acids, a polypeptide that differs from the signal peptide of an endogenous rodent Tslpr protein by not more than 2 amino acids, or a polypeptide that differs from the signal peptide of an endogenous rodent Tslpr protein by not more than 1 amino acids.

[0134] Alternatively or additionally, a signal peptide that is “substantially identical with the signal peptide of a rodent Tslpr protein” can be a polypeptide that differs from the signal peptide of an endogenous rodent Tslpr protein only at the N- or C-terminus, e.g., by having addition, deletion or substitution of amino acids at the N- or C-terminal portion of the signal peptide. Alternatively or additionally, a signal peptide that is “substantially identical with the signal peptide of a rodent Tslpr protein” can be (iv) a polypeptide having one or more features delineated in (i)-(iii) above, e.g., a polypeptide at least 95% identical with the signal peptide of a rodent Tslpr protein and only differing from the signal peptide of a rodent Tslpr protein at the N- or C-terminus by not more than 3 amino acids. By “the N- or C-terminal portion of the signal peptide” is meant within 5 amino acids from the N- or C-terminus of the signal peptide. In some embodiments, a humanized Tslpr protein includes a signal peptide substantially identical with the signal peptide of a mouse Tslpr protein (such as an endogenous mouse Tslpr protein). In some embodiments, a humanized Tslpr protein includes a signal peptide substantially identical with the signal peptide of a rat Tslpr protein (such as an endogenous rat Tslpr protein).

[0135] In some embodiments, the humanized Tslpr gene in the genome of a genetically modified rodent includes a nucleotide sequence of a human TSLPR gene (“a human TSLPR nucleotide sequence”) and a nucleotide sequence of a rodent Tslpr gene (“a rodent Tslpr nucleotide sequence”, such as an endogenous rodent Tslpr nucleotide sequence), wherein the human TSLPR nucleotide sequence encodes at least a substantial portion of the ectodomain of a human TSLPR protein. As described above, examples of a substantial portion of the ectodomain of a human TSLPR can include amino acids 25-231, 26-231, 27-231, 23-228, 23-227, or 23-226 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain comprises amino acids 27-231 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain comprises amino acids 25-231 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain comprises amino acids 23-228 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain comprises amino acids 23-226 of SEQ ID NO: 23. In some embodiments, the human TSLPR nucleotide sequence is a cDNA sequence. In some embodiments, the human TSLPR nucleotide sequence in a humanized Tslpr gene encodes the ectodomain of a human TSLPR protein (e.g., a human TSLPR protein isoform 1 as defined in SEQ ID NO: 23). In some embodiments, the human TSLPR nucleotide sequence is a genomic fragment of a human TSLPR gene. In some embodiments, the human TSLPR nucleotide sequence is a genomic fragment of a human TSLPR gene comprising exon

2 through the codon in exon 6 coding for the last amino acid of the ectodomain of the human TSLPR protein. In some embodiments, the human TSLPR genomic fragment encodes amino acids 27-231 of a human TSLPR isoform 1, absent the 4 amino acids at the N-terminus of the ectodomain of the human TSLPR isoform 1. In some embodiments, the human TSLPR genomic fragment further comprises a 3' portion of intron 1, operably linked to exon 2 through the codon in exon 6 coding for the last amino acid of the ectodomain of the human TSLPR protein.

[0136] In some embodiments, the humanized Tslpr gene in the genome of a genetically modified rodent includes a rodent Tslpr nucleotide sequence and a human TSLPR nucleotide sequence, wherein the rodent Tslpr nucleotide sequence encodes a polypeptide substantially identical to the transmembrane-cytoplasmic sequence of a rodent Tslpr protein (e.g., an endogenous rodent Tslpr protein). In some embodiments, the rodent Tslpr nucleotide sequence present in a humanized Tslpr gene encodes the transmembrane-cytoplasmic sequence of an endogenous rodent Tslpr protein. In some embodiments, the rodent Tslpr nucleotide sequence present in a humanized Tslpr gene is a mouse Tslpr nucleotide sequence; and in some such embodiments, the mouse Tslpr nucleotide sequence comprises a portion of exon 6 (beginning from the codon coding for the first amino acid of the mouse Tslpr transmembrane domain) through exon 8 of a mouse Tslpr gene (e.g., an endogenous mouse Tslpr gene).

[0137] In some embodiments, the humanized Tslpr gene in the genome of a genetically modified rodent includes a rodent Tslpr nucleotide sequence upstream (5') of a human TSLPR nucleotide sequence, wherein the rodent Tslpr nucleotide sequence encodes a polypeptide substantially identical to the signal peptide of a rodent Tslpr protein (e.g., an endogenous rodent Tslpr protein). In some embodiments, the rodent Tslpr nucleotide sequence encoding a polypeptide substantially identical to the signal peptide of a rodent Tslpr protein is a mouse Tslpr nucleotide sequence (e.g., an endogenous mouse Tslpr nucleotide sequence), or a rat Tslpr nucleotide sequence (e.g., an endogenous rat Tslpr nucleotide sequence). In some embodiments, the rodent Tslpr nucleotide sequence encoding a polypeptide that comprises the signal peptide sequence and amino acids (e.g., 6-8 amino acids) from the N-terminus of the ectodomain of a rodent Tslpr protein. In some embodiments, the rodent Tslpr nucleotide sequence encoding a polypeptide that comprises the signal peptide sequence and 7 amino acids from the N-terminus of the ectodomain of a rodent Tslpr protein. In some embodiments, the rodent Tslpr nucleotide sequence is a mouse Tslpr nucleotide sequence which comprises exon 1 of a mouse Tslpr gene (e.g., an endogenous mouse Tslpr gene); and in some such embodiments, the mouse Tslpr nucleotide sequence further comprises a 5' portion of intron 1 of a mouse Tslpr gene.

[0138] In some embodiments, the humanized Tslpr gene is operably linked to rodent Tslpr 5' regulatory sequences such as endogenous rodent Tslpr regulatory sequences, e.g., a 5' transcriptional regulatory sequence(s) such as promoter and/or enhancers, such that expression of the humanized Tslpr gene is under control of the rodent Tslpr 5' regulatory sequence(s).

[0139] In some embodiments, the humanized Tslpr gene is at an endogenous rodent Tslpr locus. In some embodiments, the humanized Tslpr gene is at a locus other than an

endogenous rodent Tslpr locus; e.g., as a result of random integration. In some embodiments where the humanized Tslpr gene is at a locus other than an endogenous rodent Tslpr locus, the rodents are incapable of expressing a rodent Tslpr protein, e.g., as a result of inactivation (e.g., deletion in full or in part) of the endogenous rodent Tslpr gene.

[0140] In some embodiments where a humanized Tslpr gene is at an endogenous rodent Tslpr locus, the humanized Tslpr gene results from a replacement of a nucleotide sequence of an endogenous rodent Tslpr gene at the endogenous rodent Tslpr locus with a nucleotide sequence of a human TSLPR gene.

[0141] In some embodiments, the nucleotide sequence of an endogenous rodent Tslpr gene at an endogenous rodent Tslpr locus that is being replaced is a genomic fragment of an endogenous rodent Tslpr gene that encodes at least a substantial portion of the ectodomain of the rodent Tslpr protein. In some embodiments, the rodent is a mouse, and the mouse Tslpr genomic fragment being replaced encodes at least a substantial portion of the ectodomain of the endogenous mouse Tslpr protein. For example, the ectodomain of a mouse Tslpr of SEQ ID NO: 21 is defined by amino acids 20-243, examples of a substantial portion of the ectodomain can include amino acids 21-243, 22-243, 23-243, 24-243, 25-243, 26-243, 27-243, 20-241, 20-240, 20-239, and 20-238 of SEQ ID NO: 21. In some embodiments, a substantial portion of the ectodomain of a mouse Tslpr protein comprises amino acids 27-243 of SEQ ID: 21. In some embodiments, a substantial portion of the ectodomain of a mouse Tslpr protein comprises amino acids 25-243 of SEQ ID: 21. In some embodiments, a substantial portion of the ectodomain of a mouse Tslpr protein comprises amino acids 20-240 of SEQ ID: 21. In some embodiments, a substantial portion of the ectodomain of a mouse Tslpr protein comprises amino acids 20-238 of SEQ ID: 21. In some embodiments, the mouse Tslpr genomic fragment being replaced comprises exon 2 through the codon in exon 6 coding for the last amino acid of the ectodomain.

[0142] In some embodiments, the nucleotide sequence of a human TSLPR gene that replaces a genomic fragment of a rodent Tslpr gene at an endogenous rodent Tslpr locus is a cDNA sequence. In some embodiments, the human TSLPR nucleotide sequence that replaces a genomic fragment of a rodent Tslpr gene at an endogenous rodent Tslpr locus is a genomic fragment of a human TSLPR gene. In some embodiments, a genomic fragment of a human TSLPR gene that replaces a genomic fragment of a rodent Tslpr gene at an endogenous rodent Tslpr locus includes exons, in full or in part, of a human TSLPR gene, that encode at least a substantial portion of the ectodomain of the human TSLPR protein. Examples of a substantial portion of the ectodomain of a human TSLPR have been described above, e.g., amino acids 23-231, 24-231, 25-231, 26-231, 27-231, 28-231, 23-230, 23-229, 23-228, 23-227, or 23-226 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain of a human TSLPR comprises amino acids 25-231 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain of a human TSLPR comprises amino acids 27-231 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain of a human TSLPR comprises amino acids 23-228 of SEQ ID NO: 23. In some embodiments, a substantial portion of the ectodomain of a human TSLPR comprises amino acids 23-226 of SEQ ID NO: 23. In some embodiments, the

human genomic fragment comprises human TSLPR exon 2 through the codon in exon 6 coding for the last amino acid of the human TSLPR ectodomain.

[0143] In some embodiments, the human TSLPR nucleotide sequence inserted into an endogenous rodent Tslpr locus is operably linked to a genomic sequence of a rodent Tslpr gene that encodes a polypeptide substantially identical to the transmembrane-cytoplasmic sequence of a rodent Tslpr protein (such as an endogenous rodent, e.g., mouse or rat, Tslpr protein). In embodiments where the rodent is a mouse, the genomic sequence of a mouse Tslpr gene comprises, in some embodiments, exon 6 from the codon coding for the first amino acid of the transmembrane domain through exon 8 of a mouse Tslpr gene (e.g., an endogenous mouse Tslpr gene).

[0144] In some embodiments, the human TSLPR nucleotide sequence inserted into an endogenous rodent Tslpr locus is operably linked to a genomic sequence of a rodent Tslpr gene that encodes a polypeptide substantially identical to the signal peptide of a rodent Tslpr protein (such as an endogenous rodent, e.g., mouse or rat, Tslpr protein). In embodiments wherein the rodent is a mouse, the genomic sequence of a mouse Tslpr gene comprises, in some embodiments, exon 1, and optionally intron 1 in full or in part, of a mouse Tslpr gene (e.g., an endogenous mouse Tslpr gene).

[0145] In some embodiments, the rodent is a mouse, and a genomic fragment of an endogenous mouse Tslpr gene at an endogenous mouse Tslpr locus comprising exon 2 through the codon in exon 6 coding for the last amino acid of the mouse Tslpr ectodomain has been replaced with a genomic fragment of a human TSLPR gene comprising exon 2 through the codon in exon 6 coding for the last amino acid of the human TSLPR ectodomain. In some embodiments, a humanized Tslpr gene is formed at the endogenous rodent Tslpr locus and comprises exon 1 of a mouse Tslpr gene, exon 2 through the codon in exon 6 coding for the last amino acid of a human TSLPR gene, and exon 6 beginning from the codon coding for the first amino acid of a mouse Tslpr transmembrane domain through exon 8 of a mouse Tslpr gene.

[0146] In some embodiments, a rodent provided herein is heterozygous for a humanized Tslpr gene in its genome. In some embodiments, a rodent provided herein is homozygous for a humanized Tslpr gene in its genome.

[0147] In some embodiments, a humanized Tslpr gene results in an expression of the encoded humanized Tslpr protein in a rodent. In some embodiments, a humanized Tslpr protein is expressed in cells and tissues in which a counterpart rodent Tslpr protein in a control rodent (e.g., a rodent without the humanized Tslpr gene) is typically expressed, for example, on dendritic cells, CD4+T cells and group 2 innate lymphoid cells, as well as on non-immune cell types like epithelial, endothelial and smooth muscle cells.

[0148] In some embodiments, rodents disclosed herein are incapable of expressing a rodent Tslpr protein, e.g., as a result of inactivation (e.g., deletion in full or in part) or replacement (in full or in part) of the endogenous rodent Tslpr gene.

IL7RA Humanization

[0149] TSLP acts through a heterodimer composed of a chain specific for TSLP (referred to as "TSLPR" or "Tslpr") and the IL7 receptor α chain ("IL7RA" for human and "Il7ra" for non-human or humanized molecule). IL7RA

contains a signal peptide, an extracellular domain (“ECD” or “ectodomain”), a transmembrane domain and an intracellular (cytoplasmic) domain.

[0150] Exemplary sequences, including nucleic acid and protein sequences for human IL7RA, mouse Il7ra, rat Il7ra, and humanized (mouse-human hybrid) Il7ra, are disclosed in the Sequence Listing and summarized in Table 3. An alignment of human IL7RA and mouse Il7ra protein sequences is provided in FIG. 3F.

TABLE 3

SEQ ID NO	Description	Features
41	<i>Mus musculus</i> Il7ra Protein, NP_032398	Length: 459 aa Signal peptide: aa 1-20 Ectodomain: aa 21-238 Transmembrane: aa 239-263 Intracellular: 264-459
42	<i>Mus musculus</i> Il7ra mRNA (CDS), NM_008372	Length: 1380 bp
43	<i>Homo sapiens</i> IL7RA protein, NP_002176	Length: 459 aa Signal peptide: aa 1-20 Ectodomain: aa 21-238 Transmembrane: aa 239-263 Intracellular: aa 264-459
44	<i>Homo sapiens</i> IL7RA mRNA (CDS), NM_002185	Length: 1380 bp
45	Humanized mouse/human chimeric Il7ra Protein	Length: 459 aa Signal peptide: 1-20 (from mouse) Ectodomain: aa 21-238 (aa 21-236 from human and aa 237-238 from mouse) Transmembrane: aa 239-263 (from mouse) Intracellular: aa 264-459 (from mouse)
46	Humanized mouse/human chimeric Il7ra mRNA (CDS)	Length: 1380 bp
47	<i>Rattus norvegicus</i> Il7ra Protein, NP_001099888	Length: 457 aa
48	<i>Rattus norvegicus</i> Il7ra mRNA, NM_001106418.1	Length: 3124 bp

[0151] In some embodiments, the rodents disclosed herein comprise a humanized Il7ra gene in the germline.

[0152] In some embodiments, a rodent disclosed herein comprises a humanized Il7ra gene in its genome that includes a nucleotide sequence of a rodent Il7ra gene (e.g., an endogenous rodent Il7ra gene) and a nucleotide sequence of a human IL7RA gene. As used herein, “a nucleotide sequence of a gene” includes a genomic sequence, an mRNA or cDNA sequence, in full or in part of the gene. As a non-limiting example, a nucleotide sequence of a human IL7RA gene includes a genomic sequence, an mRNA or cDNA sequence, in full or in part of the human IL7RA gene. The nucleotide sequence of the rodent Il7ra gene and the nucleotide sequence of the human IL7RA gene are operably linked to each other such that the humanized Il7ra gene in the rodent genome encodes a humanized Il7ra protein that has a Il7ra protein structure (comprising an ectodomain, a transmembrane domain and a cytoplasmic domain) and performs Il7ra functions (e.g., binds an Il7 protein and forms a heterodimer with Tslpr which binds Tslp).

[0153] “Human IL7RA” gene and protein, as used herein, refers to IL7RA gene and protein of the human origin. In some embodiments, a human IL7RA protein comprises the the amino acid sequence of SEQ ID NO: 43. In some embodiments, a human IL7RA protein comprises an amino

acid sequence at least 95% identical to the the amino acid sequence of SEQ ID NO: 43. In some embodiments, a human IL7RA protein comprises an amino acid sequence at least 98% identical to the the amino acid sequence of SEQ ID NO: 43. In some embodiments, a human IL7RA protein comprises an amino acid sequence at least 99% identical to the the amino acid sequence of SEQ ID NO: 43.

[0154] “Rodent Il7ra” gene and protein, as used herein, refers to Il7rar gene and protein of a rodent (e.g., mouse or rat) origin. In some embodiments, a mouse Il7ra protein comprises the the amino acid sequence of SEQ ID NO: 41. In some embodiments, a mouse Il7ra protein comprises an amino acid sequence at least 95% identical to the the amino acid sequence of SEQ ID NO: 41. In some embodiments, a mouse Il7rar protein comprises an amino acid sequence at least 98% identical to the the amino acid sequence of SEQ ID NO: 41. In some embodiments, a mouse Il7rar protein comprises an amino acid sequence at least 99% identical to the the amino acid sequence of SEQ ID NO: 41. In some embodiments, a rat Il7ra protein comprises the the amino acid sequence of SEQ ID NO: 47. In some embodiments, a rat Il7ra protein comprises an amino acid sequence at least 95% identical to the the amino acid sequence of SEQ ID NO: 47. In some embodiments, a rat Il7ra protein comprises an amino acid sequence at least 98% identical to the the amino acid sequence of SEQ ID NO: 47. In some embodiments, a rat Il7ra protein comprises an amino acid sequence at least 99% identical to the the amino acid sequence of SEQ ID NO: 47.

[0155] In some embodiments, a genetically modified rodent contains a humanized Il7ra gene in its genome, wherein the humanized Il7ra gene encodes a humanized Il7ra protein that contains an ectodomain that is substantially identical with the ectodomain of a human IL7RA protein. In some embodiments, an ectodomain that is substantially identical with the ectodomain of a human IL7RA protein exhibits the same functionality (e.g., ligand binding properties) as the ectodomain of a human IL7RA protein. An ectodomain or polypeptide that is “substantially identical with the ectodomain of a human IL7RA protein” can be a polypeptide that is at least 95% identical in sequence with the ectodomain of a human IL7RA protein; a polypeptide that is at least 98% identical in sequence with the ectodomain of a human IL7RA protein; or a polypeptide that is at least 99% identical in sequence with the ectodomain of a human IL7RA protein. An ectodomain or polypeptide that is “substantially identical with the ectodomain of a human IL7RA protein” may be a polypeptide that is 100% identical in sequence with the ectodomain of a human IL7RA protein. Alternatively or additionally, an ectodomain or polypeptide that is “substantially identical with the ectodomain of a human IL7RA protein” can be (ii) a polypeptide that differs from the ectodomain of a human IL7RA protein by not more than 10 amino acids, a polypeptide that differs from the ectodomain of a human IL7RA protein by not more than 7 amino acids, a polypeptide that differs from the ectodomain of a human IL7RA protein by not more than 5 amino acids, a polypeptide that differs from the ectodomain of a human IL7RA protein by not more than 4 amino acids, a polypeptide that differs from the ectodomain of a human TSLPR protein by not more than 3 amino, a polypeptide that differs from the ectodomain of a human TSLPR protein by not more than 2 amino acids, or a polypeptide that differs from the ectodomain of a human TSLPR protein by not more than 1

amino acid. Alternatively or additionally, an ectodomain or polypeptide that is “substantially identical with the ectodomain of a human IL7RA protein” can be (iii) a polypeptide that differs from the ectodomain of a human IL7RA protein only at the N- or C-terminal portion of the ectodomain, e.g., by having addition, deletion and/or substitution of amino acids at the N- and/or C-terminal portion of the ectodomain (i.e., within 5-10 amino acids from the N or C terminus of the ectodomain). Alternatively or additionally, an ectodomain or polypeptide that is “substantially identical with the ectodomain of a human IL7RA protein” can be (iv) a polypeptide that has one or more of the features delineated in (i)-(iii) above, e.g., a polypeptide that is at least 95% identical in sequence with the ectodomain of a human IL7RA protein and differs from the ectodomain of the human IL7RA protein only at the N- or C-terminal portion of the ectodomain by not more than 5 amino acids; or a polypeptide that is at least 98% identical in sequence with the ectodomain of a human IL7RA protein and differs from the ectodomain of the human IL7RA protein only at the N- or C-terminal portion of the ectodomain by not more than 3 amino acids. In some embodiments, a human IL7RA protein comprises the amino acid sequence as set forth in SEQ ID NO: 43, and its ectodomain is defined by amino acids 21-238 of SEQ ID NO: 43. In some embodiments, the humanized II7ra gene encodes a humanized II7ra protein whose ectodomain is substantially identical with the ectodomain of the human IL7RA protein as set forth in SEQ ID NO: 43, i.e., substantially identical with amino acids 21-238 of SEQ ID NO: 43. In some embodiments, the humanized II7ra protein comprises an ectodomain that comprises amino acids 21-238 of SEQ ID NO: 43. In some embodiments, the humanized II7ra protein comprises an ectodomain that comprises amino acids 21-237 of SEQ ID NO: 43. In some embodiments, the humanized II7ra protein comprises an ectodomain that comprises amino acids 21-236 of SEQ ID NO: 43. In some embodiments, the humanized II7ra protein comprises an ectodomain that comprises amino acids 22-238 of SEQ ID NO: 43. In some embodiments, the humanized II7ra protein comprises an ectodomain that comprises amino acids 24-238 of SEQ ID NO: 43.

[0156] In some embodiments, the humanized II7ra gene encodes a humanized II7ra protein having an ectodomain that comprises the ectodomain of a human IL7RA or a substantial portion thereof, followed by amino acids from the C-terminus of the ectodomain of a rodent II7ra (e.g., an endogenous rodent II7ra). A “substantial portion of the ectodomain” of a human IL7RA (or a rodent IL7ra) protein refers to a polypeptide that is nearly the full ectodomain of a human IL7RA (or a rodent IL7ra) protein. In some embodiments, a substantial proportion of an ectodomain includes at least 95% of the full length ectodomain sequence. In some embodiments, a substantial proportion of an ectodomain includes at least 98% of the full length ectodomain sequence. In some embodiments, a substantial proportion of an ectodomain differs from the ectodomain by lacking not more than 10 amino acids at the N- or C-terminus of the ectodomain. In some embodiments, a substantial proportion of an ectodomain differs from the ectodomain by lacking not more than 7 amino acids at the N- or C-terminus of the ectodomain. In some embodiments, a substantial proportion of an ectodomain differs from the ectodomain by lacking not more than 5 amino acids at the N- or C-terminus of the ectodomain. In some embodiments, a substantial

portion of an ectodomain differs from the ectodomain by lacking not more than 3 amino acids at the N- or C-terminus of the ectodomain. For example, the ectodomain of the human IL7RA protein as set forth in SEQ ID NO: 43 is defined by amino acids 21-238, and examples of a substantial portion of the ectodomain can include amino acids 22-238, 23-238, 24-238, 21-237, 21-236, 21-235, of the human IL7RA protein as set forth in SEQ ID NO: 43. In some embodiments, a substantial portion of the ectodomain of human IL7RA comprises amino acids 21-236 of SEQ ID NO: 43. In some embodiments, a substantial portion of the ectodomain of human IL7RA comprises amino acids 21-237 of SEQ ID NO: 43. In some embodiments, a substantial portion of the ectodomain of human IL7RA comprises amino acids 22-238 of SEQ ID NO: 43. In some embodiments, a substantial portion of the ectodomain of human IL7RA comprises amino acids 23-238 of SEQ ID NO: 43. In some embodiments, the ectodomain of a humanized II7ra protein comprises a substantial portion of the ectodomain of a human IL7RA, followed by 1-3 amino acids from the C-terminus of the ectodomain of a rodent II7ra (e.g., an endogenous rodent II7ra). In some embodiments, the ectodomain of a humanized II7ra protein comprises amino acids 21-236 of SEQ ID NO: 43, followed by 2 amino acids from the C-terminus of the ectodomain of a rodent II7ra. In some embodiments, the humanized II7ra gene encodes a humanized II7ra protein that contains an ectodomain comprising amino acids 21-238 of SEQ ID NO: 45—this ectodomain comprises amino acids 21-236 of SEQ ID NO: 43 (human IL7RA) and the last 2 amino acids (“GW”) from the C-terminus of the ectodomain of mouse II7ra, and differs from the ectodomain of the human IL7RA protein of SEQ ID NO: 43 in the two amino acids at the C-terminus of the ectodomain (with “GW” in humanized II7ra of SEQ ID NO: 45, as opposed to “EM” in human IL7RA of SEQ ID NO: 43) and is otherwise identical to the human IL7RA ectodomain.

[0157] In some embodiments, the humanized II7ra gene encodes a humanized II7ra protein that contains a transmembrane-cytoplasmic sequence (i.e., a sequence that includes both the transmembrane domain and the cytoplasmic domain) that is substantially identical with the transmembrane-cytoplasmic sequence of a rodent II7ra protein, e.g., an endogenous rodent II7ra protein. In some embodiments, a transmembrane-cytoplasmic sequence that is substantially identical with the transmembrane-cytoplasmic sequence of an endogenous rodent II7ra protein exhibits the same functionality (e.g., signal transduction and/or interaction with intracellular molecules) as the transmembrane-cytoplasmic sequence of a rodent II7ra protein such as an endogenous rodent II7ra protein. A transmembrane-cytoplasmic sequence or polypeptide that is “substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein” can be (i) a polypeptide that is at least 95% identical in sequence with the transmembrane-cytoplasmic sequence of a rodent II7ra protein, or a polypeptide that is at least 98% identical in sequence with the transmembrane-cytoplasmic sequence of a rodent II7ra protein; in some embodiments. A transmembrane-cytoplasmic sequence or polypeptide that is “substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein” can be a polypeptide that is identical in sequence with the transmembrane-cytoplasmic sequence of a rodent II7ra protein. Alternatively or additionally, a transmembrane-cytoplasmic sequence or

polypeptide that is "substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein" can be (ii) a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Il7ra protein by not more than 5 amino acids, a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Il7ra protein by not more than 4 amino acids, a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Il7ra protein by not more than 3 amino acids, a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Il7ra protein by not more than 2 amino acids, a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Il7ra protein by not more than 1 amino acid. Alternatively or additionally, a transmembrane-cytoplasmic sequence or polypeptide that is "substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein" can be (iii), a polypeptide that differs from the transmembrane-cytoplasmic sequence of a rodent Il7ra protein only at the N- or C-terminus, e.g., by having addition, deletion or substitution of amino acids at the N- or C-terminal portion of the transmembrane-cytoplasmic sequence. Alternatively or additionally, a transmembrane-cytoplasmic sequence or polypeptide that is "substantially identical with the transmembrane-cytoplasmic sequence of a rodent Tslpr protein" can be (iv) a polypeptide having one or more features delineated in (i)-(iii) above, e.g., a polypeptide that is at least 95% identical in sequence with the transmembrane-cytoplasmic sequence of a rodent Il7ra protein, and differs from the transmembrane-cytoplasmic sequence of a rodent Il7ra protein only at the N- or C-terminus by not more than 3 amino acids. By "the N- or C-terminal portion of the transmembrane-cytoplasmic sequence" is meant within 5-10 amino acids from the N-terminus of the transmembrane domain or within 5-10 amino acids from the C-terminus of the cytoplasmic domain. In some embodiments, a humanized Il7ra protein contains a transmembrane-cytoplasmic sequence that is substantially identical with the transmembrane-cytoplasmic sequence of a mouse Il7ra protein (such as an endogenous mouse Il7ra protein), or with the transmembrane-cytoplasmic sequence of a rat Il7ra protein (such as an endogenous rat Il7ra protein).

[0158] In some embodiments, the humanized Il7ra gene encodes a humanized Il7ra protein that contains a signal peptide that is substantially identical with the signal peptide of a rodent Il7ra protein (e.g., an endogenous rodent Il7ra protein). In some embodiments, the humanized Il7ra gene encodes a humanized Il7ra protein that contains a signal peptide that is substantially identical with the signal peptide of a human IL7RA protein (e.g., the human IL7RA protein as set forth in SEQ ID NO: 43). A signal peptide that is "substantially identical" with the signal peptide of a reference protein (either a human IL7RA protein or a rodent Il7ra protein), can be (i) a polypeptide that is at least 95% identical in sequence with the signal peptide of the reference protein, or a polypeptide that is identical in sequence with the signal peptide of the reference protein. Alternatively or additionally, a signal peptide that is "substantially identical" with the signal peptide of a reference protein can be (ii) a polypeptide that differs from the signal peptide of the reference protein by not more than 3 amino acids, a polypeptide that differs from the signal peptide of the reference protein by not more than 2 amino acids; in some embodi-

ments, or a polypeptide that differs from the signal peptide of the reference protein by not more than 1 amino acid.

[0159] Alternatively or additionally, a signal peptide that is "substantially identical" with the signal peptide of a reference protein can be (iii) a polypeptide that differs from the signal peptide of the reference protein only at the N- or C-terminus, e.g., by having addition, deletion or substitution of amino acids at the N- or C-terminal portion of the signal peptide; or (iv) a polypeptide having one or more features delineated in (i)-(iii) above, e.g., a polypeptide that is at least 95% identical with the signal peptide of a reference protein and differs from the signal peptide of a reference protein only at the N- or C-terminus by not more than 3 amino acids. By "the N- or C-terminal portion of the signal peptide" is meant within 5 amino acids from the N- or C-terminus of the signal peptide. In some embodiments, a humanized Il7ra protein includes a signal peptide substantially identical with the signal peptide of a mouse Il7ra protein (such as an endogenous mouse Il7ra protein). In some embodiments, a humanized Il7ra protein includes a signal peptide substantially identical with the signal peptide of a rat Il7ra protein (such as an endogenous rat Il7ra protein). In some embodiments, a humanized Il7ra protein includes a signal peptide substantially identical with the signal peptide of a human IL7RA protein (e.g., the human IL7RA protein as set forth in SEQ ID NO: 43).

[0160] In some embodiments, the humanized Il7ra gene in the genome of a genetically modified rodent includes a nucleotide sequence of a human IL7RA gene ("a human IL7RA nucleotide sequence") and a nucleotide sequence of a rodent Il7ra gene ("a rodent Il7ra nucleotide sequence", such as an endogenous rodent Il7ra nucleotide sequence), wherein the human IL7RA nucleotide sequence encodes at least a substantial portion of the ectodomain of a human IL7RA protein. In some embodiments, the human IL7RA nucleotide sequence is a cDNA sequence. In some embodiments, the human IL7RA nucleotide sequence in a humanized Il7ra gene encodes the ectodomain of a human IL7RA protein (e.g., the human IL7RA protein of SEQ ID NO: 43). In some embodiments, the human IL7RA nucleotide sequence is a genomic fragment of a human IL7RA gene. In some embodiments, the human IL7RA nucleotide sequence is a genomic fragment of a human IL7RA gene comprising from the codon in exon 2 that encodes the first amino acid in the mature protein sequence through exon 5 (i.e., through the codon that encodes the amino acid residue that is two amino acids before the start of the transmembrane segment of the human IL7RA protein. In some embodiments, the human IL7RA genomic fragment encodes amino acids 21-238 of a human IL7RA protein (e.g., the human IL7RA protein as set forth in SEQ ID NO: 43). In some embodiments, the human IL7RA genomic fragment encodes amino acids 21-237 of a human IL7RA protein (e.g., the human IL7RA protein as set forth in SEQ ID NO: 43). In some embodiments, the human IL7RA genomic fragment encodes amino acids 21-236 of a human IL7RA protein (e.g., the human IL7RA protein as set forth in SEQ ID NO: 43). In some embodiments, the human IL7RA genomic fragment encodes amino acids 21-235 of a human IL7RA protein (e.g., the human IL7RA protein as set forth in SEQ ID NO: 43). In some embodiments, the human IL7RA genomic fragment encodes amino acids 22-238 of a human IL7RA protein (e.g., the human IL7RA protein as set forth in SEQ ID NO: 43). In some embodiments, the human IL7RA genomic fragment

encodes amino acids 24-238 of a human IL7RA protein (e.g., the human IL7RA protein as set forth in SEQ ID NO: 43). In some embodiments, the human IL7RA genomic fragment further comprises a 5' portion of intron 5.

[0161] In some embodiments, the humanized Il7ra gene in the genome of a genetically modified rodent includes a rodent Il7ra nucleotide sequence and a human IL7RA nucleotide sequence, wherein the rodent Il7ra nucleotide sequence encodes a polypeptide substantially identical to the transmembrane-cytoplasmic sequence of a rodent Il7ra protein (e.g., an endogenous rodent Il7ra protein). In some embodiments, the rodent Il7ra nucleotide sequence present in a humanized Il7ra gene encodes the transmembrane-cytoplasmic sequence of an endogenous rodent Il7ra protein. In some embodiments, the rodent Il7ra nucleotide sequence present in a humanized Il7ra gene is a mouse Il7ra nucleotide sequence; and in some such embodiments, the mouse Il7ra nucleotide sequence comprises a 3' portion of intron 5 and exon 6 through exon 8 of a mouse Il7ra gene (e.g., an endogenous mouse Il7ra gene).

[0162] In some embodiments, the humanized Il7ra gene in the genome of a genetically modified rodent includes a rodent Il7ra nucleotide sequence upstream (5') of a human IL7RA nucleotide sequence, wherein the rodent Il7ra nucleotide sequence encodes a polypeptide substantially identical to the signal peptide of a rodent Il7ra protein (e.g., an endogenous rodent Il7ra protein). In some embodiments, the rodent Il7ra nucleotide sequence encoding a polypeptide substantially identical to the signal peptide of a rodent Il7ra protein is a mouse Il7ra nucleotide sequence (e.g., an endogenous mouse Il7ra nucleotide sequence), or a rat Il7ra nucleotide sequence (e.g., an endogenous rat Il7ra nucleotide sequence). In some embodiments, a mouse Il7ra nucleotide sequence in a humanized Il7ra gene comprises the portion of exon 1 of a mouse Il7ra gene (e.g., an endogenous mouse Il7ra gene) that codes for the signal peptide of the mouse Il7ra; in some embodiments, the mouse Il7ra nucleotide sequence also comprises the 5' UTR of exon 1 of the mouse Il7ra gene.

[0163] In some embodiments, the humanized Il7ra gene is operably linked to rodent Il7ra 5' regulatory sequences such as endogenous rodent Il7ra regulatory sequences, e.g., a 5' transcriptional regulatory sequence(s) such as promoter and/or enhancers, such that expression of the humanized Il7ra gene is under control of the rodent Il7ra 5' regulatory sequence(s).

[0164] In some embodiments, the humanized Il7ra gene is at an endogenous rodent Il7ra locus. In some embodiments, the humanized Il7ra gene is at a locus other than an endogenous rodent Il7ra locus; e.g., as a result of random integration. In some embodiments where the humanized Il7ra gene is at a locus other than an endogenous rodent Il7ra locus, the rodents are incapable of expressing a rodent Il7ra protein, e.g., as a result of inactivation (e.g., deletion in full or in part) of the endogenous rodent Il7ra gene.

[0165] In some embodiments where a humanized Il7ra gene is at an endogenous rodent Il7ra locus, the humanized Il7ra gene results from a replacement of a nucleotide sequence of an endogenous rodent Il7ra gene at the endogenous rodent Il7ra locus with a nucleotide sequence of a human IL7RA gene.

[0166] In some embodiments, the nucleotide sequence of an endogenous rodent Il7ra gene at an endogenous rodent Il7ra locus that is being replaced is a genomic fragment of

an endogenous rodent Il7ra gene that encodes at least a substantial portion of the ectodomain of the rodent Il7ra protein. In some embodiments, the rodent is a mouse, and the mouse Il7ra genomic fragment being replaced encodes at least a substantial portion of the ectodomain of the endogenous mouse Il7ra protein. Examples of a substantial portion of the ectodomain of the endogenous mouse Il7ra protein include amino acids 22-238, 23-238, 24-238, 21-237, 21-236, or 21-235 of the endogenous mouse Il7ra protein (e.g., SEQ ID NO: 41). In some embodiments, the mouse Il7ra genomic fragment being replaced encodes amino acids 21-235 of the endogenous mouse Il7ra protein (e.g., SEQ ID NO: 41). In some embodiments, the mouse Il7ra genomic fragment being replaced encodes amino acids 21-236 of the endogenous mouse Il7ra protein (e.g., SEQ ID NO: 41). In some embodiments, the mouse Il7ra genomic fragment being replaced encodes amino acids 21-237 of the endogenous mouse Il7ra protein (e.g., SEQ ID NO: 41). In some embodiments, the mouse Il7ra genomic fragment being replaced encodes amino acids 21-238 of the endogenous mouse Il7ra protein (e.g., SEQ ID NO: 41). In some embodiments, the mouse Il7ra genomic fragment being replaced encodes amino acids 22-238 of the endogenous mouse Il7ra protein (e.g., SEQ ID NO: 41). In some embodiments, the mouse Il7ra genomic fragment being replaced encodes amino acids 23-238 of the endogenous mouse Il7ra protein (e.g., SEQ ID NO: 41). In some embodiments, the mouse Il7ra genomic fragment being replaced comprises from the codon in exon 1 that encodes the first amino acid of the mature Il7ra protein through exon 5, and in some embodiments, through a 5' portion of intron 5, of the mouse Il7ra gene.

[0167] In some embodiments, the nucleotide sequence of a human IL7RA gene that replaces a genomic fragment of a rodent Il7ra gene at an endogenous rodent Il7ra locus is a cDNA sequence. In some embodiments, the human IL7RA nucleotide sequence that replaces a genomic fragment of a rodent Il7ra gene at an endogenous rodent Il7ra locus is a genomic fragment of a human IL7RA gene. In some embodiments, a genomic fragment of a human IL7RA gene that replaces a genomic fragment of a rodent Il7ra gene at an endogenous rodent Il7ra locus includes exons, in full or in part, of a human IL7RA gene, that encode at least a substantial portion of the ectodomain of the human IL7RA protein. In some embodiments, the human IL7RA genomic fragment encodes amino acids 21-238 of a human IL7RA, e.g., the human IL7RA as set forth in SEQ ID NO: 43. In some embodiments, the human IL7RA genomic fragment encodes amino acids 21-237 of a human IL7RA, e.g., the human IL7RA as set forth in SEQ ID NO: 43. In some embodiments, the human IL7RA genomic fragment encodes amino acids 21-236 of a human IL7RA, e.g., the human IL7RA as set forth in SEQ ID NO: 43. In some embodiments, the human IL7RA genomic fragment encodes amino acids 21-235 of a human IL7RA, e.g., the human IL7RA as set forth in SEQ ID NO: 43. In some embodiments, the human IL7RA genomic fragment encodes amino acids 22-238 of a human IL7RA, e.g., the human IL7RA as set forth in SEQ ID NO: 43. In some embodiments, the human IL7RA genomic fragment encodes amino acids 24-238 of a human IL7RA, e.g., the human IL7RA as set forth in SEQ ID NO: 43. In some embodiments, the human genomic fragment comprises the codon in exon 1 that encodes the first amino acid of the mature human IL7RA protein through

exon 5, and in some embodiments, through a 5' portion of intron 5 of a human IL7RA gene.

[0168] In some embodiments, the human IL7RA nucleotide sequence inserted into an endogenous rodent Il7ra locus is operably linked to a genomic sequence of a rodent Il7ra gene that encodes a polypeptide substantially identical to the transmembrane-cytoplasmic sequence of a rodent Il7ra protein (such as an endogenous rodent, e.g., mouse or rat, Il7ra protein). In embodiments where the rodent is a mouse, the genomic sequence of a mouse Il7ra gene comprises, in some embodiments, exon 6 through exon 8 of a mouse Il7ra gene (e.g., an endogenous mouse Il7ra gene); in some embodiments, a 3' portion of intron 5 through exon 8 of a mouse Il7ra gene (e.g., an endogenous mouse Il7ra gene).

[0169] In some embodiments, the human IL7RA nucleotide sequence inserted into an endogenous rodent Il7ra locus is operably linked to a genomic sequence of a rodent Il7ra gene that encodes a polypeptide substantially identical to the signal peptide of a rodent Il7ra protein (such as an endogenous rodent, e.g., mouse or rat, Il7ra protein). In embodiments wherein the rodent is a mouse, the genomic sequence of a mouse Il7ra gene comprises, in some embodiments, the portion of exon 1 of a mouse Il7ra gene (e.g., an endogenous mouse Il7ra gene) that codes for the signal peptide of mouse Il7ra; and in some embodiments, the 5' UTR of exon 1 and the portion of exon 1 of a mouse Il7ra gene (e.g., an endogenous mouse Il7ra gene) that codes for the signal peptide of mouse Il7ra.

[0170] In some embodiments, the rodent is a mouse, and a genomic fragment of an endogenous mouse Il7ra gene at an endogenous mouse Il7ra locus comprising from the first codon in exon 1 coding for the first mature Il7ra amino acid through exon 5 (or in some embodiments, through a 5' portion of intron 5) has been replaced with a genomic fragment of a human IL7RA gene comprising from the first codon in exon 1 coding for the first mature IL7RA amino acid through exon 5 (or in some embodiments, through a 5' portion of intron 5). In some embodiments, a humanized Il7ra gene is formed at the endogenous rodent Il7ra locus and comprises 5'UTR and the signal-peptide coding portion of exon 1 of a mouse Il7ra gene, the mature amino acids coding portion of exon 1 through exon 5 of a human IL7RA gene, and exon 6 through exon 8 of a mouse Il7ra gene; and in some such embodiments, intron 5 of the humanized Il7ra gene includes a 5' portion from human intron 5 and a 3' portion from the endogenous mouse intron 5.

[0171] In some embodiments, the rodent is a mouse comprising a humanized Il7ra gene at the endogenous mouse Il7ra locus, wherein the humanized Il7ra gene encodes a humanized Il7ra protein that comprises a signal peptide at least substantially identical to the signal peptide of a human IL7RA protein, an ectodomain at least substantially identical to the ectodomain of the human IL7RA protein, and the transmembrane-cytoplasmic domains of the endogenous mouse Il7ra protein. In some embodiments, the ectodomain of a humanized Il7ra protein comprises the full length ectodomain of a human IL7RA protein. In some embodiments, the ectodomain of a humanized Il7ra protein comprises (i) nearly the full length ectodomain of a human IL7RA protein except for 2 amino acids at the C-terminus of the ectodomain of the human IL7RA protein, and (ii) 2 amino acids at the C-terminus of the ectodomain of the endogenous mouse Il7ra protein. In some embodiments, the rodent is a mouse comprising a humanized Il7ra gene at the

endogenous mouse Il7ra locus as described in CN 111808882A, incorporated herein by reference in its entirety.

[0172] In some embodiments, a rodent provided herein is heterozygous for a humanized Il7ra gene in its genome. In some embodiments, a rodent provided herein is homozygous for a humanized Il7ra gene in its genome.

[0173] In some embodiments, a humanized Il7ra gene results in an expression of the encoded humanized Il7ra protein in a rodent. In some embodiments, a humanized Il7ra protein is expressed in cells and tissues in which a counterpart rodent Il7ra protein in a control rodent (e.g., a rodent without the humanized Il7ra gene) is typically expressed, for example, on T-lymphocytes.

[0174] In some embodiments, rodents disclosed herein are incapable of expressing a rodent Il7ra protein, e.g., as a result of inactivation (e.g., deletion in full or in part) or replacement (in full or in part) of the endogenous rodent Il7ra gene.

Additional Genetic Features

[0175] In some embodiments, rodents disclosed herein further comprise a humanized Sirp α gene in their genome. Humanization of a rodent Sirp α gene has been described in, e.g., WO 2015/042557 A 1 (Regeneron Pharmaceuticals Inc.) and US20190373867A1 (Beijing Biocytogen), incorporated herein by reference in their entireties.

[0176] In some embodiments, the humanized Sirp α gene encodes a humanized Sirp α protein comprising the extracellular domain, in full or in part, of a human SIRP α protein. In some embodiments, the humanized Sirp α gene encodes a humanized Sirp α protein comprising an extracellular portion of a human SIRP α protein responsible for ligand binding (i.e., binding to CD47). In some embodiments, the humanized Sirp α gene encodes a humanized Sirp α protein comprising amino acid residues 28-362 of a human SIRP α protein, e.g., the human SIRP α protein as set forth in GenBank Accession No. NP_001035111.1. In some embodiments, the humanized Sirp α gene encodes a humanized Sirp α protein comprising the transmembrane and cytoplasmic domains of a rodent Sirp α protein (e.g., an endogenous rodent Sirp α protein). In some embodiments, a humanized Sirp α gene comprises exons 2, 3, and 4 of a human SIRP α gene. In some embodiments, a humanized Sirp α gene is located at an endogenous rodent Sirp α locus. In some embodiments, a humanized Sirp α gene is formed as a result of a replacement of exons 2-4 of an endogenous rodent Sirp α gene at an endogenous rodent Sirp α locus by exons 2-4 of a human SIRP α gene. In some embodiments, a humanized Sirp α gene is located at an endogenous rodent Sirp α locus and comprises exon 1 of the endogenous rodent Sirp α gene, exons 2-4 of a human SIRP α gene, and exons 5-8 of the endogenous rodent Sirp α gene, wherein the humanized Sirp α gene is operably linked to the rodent Sirp α promoter at the endogenous rodent Sirp α locus. In some embodiments, a rodent is heterozygous for a humanized Sirp α gene. In some embodiments, a rodent is homozygous for a humanized Sirp α gene. In some embodiments, a rodent comprising a humanized Sirp α gene expresses a humanized Sirp α protein, such as a protein comprising the ectodomain of a human SIRP α protein and the transmembrane-cytoplasmic domains of a rodent Sirp α protein. In some embodiments, rodents disclosed herein are incapable of expressing

an endogenous rodent Sirpa α protein (e.g., as a result of disruption or replacement of an endogenous rodent Sirpa α gene).

[0177] In some embodiments, rodents disclosed herein further comprise in their genome a humanized Tpo (thrombopoietin) gene. Humanization of a rodent Tpo gene has been described in, e.g., U.S. Pat. No. 8,541,646 (Regeneron Pharmaceuticals Inc., Yale University, and Institute for Research in Biomedicine IRB), and Rongvaux et al. (Proc Natl Acad Sci USA. 2011; 108(6): 2378-2383), incorporated herein by reference in their entireties. In some embodiments, the humanization comprises replacement of an endogenous rodent Tpo gene with a human TPO gene. In some embodiments, a rodent expresses a human TPO protein from a humanized Tpo gene. In some embodiments, a rodent is heterozygous for a humanized Tpo gene. In some embodiments, a rodent is homozygous for a humanized Tpo gene. In some embodiments, a rodent comprising a humanized Tpo gene is incapable of expressing an endogenous rodent Tpo protein (e.g., as a result of disruption or replacement of an endogenous rodent Tpo gene).

[0178] In some embodiments, rodents disclosed herein further comprise in their genome a humanized GM-CSF/IL-3 locus, where an endogenous rodent GM-CSF gene is replaced with a human GM-CSF gene and an endogenous rodent IL-3 gene has been replaced with a human IL-3 gene. Humanization of a rodent GM-CSF/IL-3 locus has been described in, e.g., U.S. Pat. No. 8,541,646 (Regeneron Pharmaceuticals Inc., Yale University, and Institute for Research in Biomedicine IRB) and Willinger et al. (PNAS, 108(6):2390-2395, 2011), both incorporated herein in their entireties. In some embodiments, a rodent is heterozygous for a humanized GM-CSF/IL-3 locus. In some embodiments, a rodent is homozygous for a humanized GM-CSF/IL-3 locus. In some embodiments, a rodent expresses human GM-CSF and human IL-3 from a humanized GM-CSF/IL-3 locus. In some embodiments, rodents disclosed herein are incapable of expressing an endogenous rodent GM-CSF protein and incapable of expressing an endogenous rodent IL-3 protein (e.g., as a result of disruption or replacement of an endogenous rodent GM-CSF/IL-3 locus).

[0179] In some embodiments, rodents disclosed herein have their endogenous RAG2 gene disrupted; and in some embodiments, a rodent is homozygous for the disruption (RAG2-/ or RAG knockout) and is incapable of expressing an endogenous RAG2 protein. In some embodiments, rodents disclosed herein have their endogenous IL-2RG gene disrupted; and in some embodiments, a rodent is homozygous for the disruption (IL-2RG-/ or IL-2RG knock-out) and is incapable of expressing an endogenous IL-2R G protein (also known as “γc”). RAG2 and IL-2RG double knock-out (DKO) rodents are known immunodeficient rodents (see, e.g., Traggiai E et al. (2004) Development of a human adaptive immune system in cord blood cell-transplanted mice, Science 304:104-107, incorporated herein by reference in its entirety) and readily available commercially (e.g., from Taconic Biosciences, Inc., New York).

[0180] In some embodiments, rodents disclosed herein comprise in their genome a humanized Tslp gene and a humanized Sirpa α gene, and are homozygous null for both RAG2 and IL-2RG genes. In some such embodiments, a rodent further comprises in its genome a humanized Tpo

gene, and/or a humanized GM-CSF/IL-3 locus. A rodent can be heterozygous or homozygous for a humanized gene.

[0181] In some embodiments, rodents disclosed herein comprise in their genome a humanized Tslp gene, a humanized Tslpr gene, and a humanized Sirpa α gene, and are homozygous null for both RAG2 and IL-2RG genes. In some such embodiments, a rodent further comprises in its genome a humanized Tpo gene and/or a humanized GM-CSF/IL-3 locus. Rodents can be homozygous or heterozygous for a humanized gene.

[0182] In some embodiments, rodents disclosed herein comprise in their genome a humanized Tslp gene, a humanized Tslpr gene, a humanized Il7ra gene, and a humanized Sirpa α gene, and are homozygous null for both RAG2 and IL-2RG genes. In some such embodiments, a rodent further comprises in its genome a humanized Tpo gene, and/or a humanized GM-CSF/IL-3 locus. Rodents can be homozygous or heterozygous for a humanized gene.

Rodent Species and Strains

[0183] In some embodiments, rodents of this disclosure include, as non-limiting examples, a mouse, a rat, and a hamster. In some embodiments, a rodent is selected from the superfamily Muroidea. In some embodiments, a rodent of this disclosure is from a family selected from Calomyscidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamster, New World rats and mice, voles), Muridae (true mice and rats, gerbils, spiny mice, crested rats), Nesomyidae (climbing mice, rock mice, with-tailed rats, Malagasy rats and mice), Platacanthomyidae (e.g., spiny dormice), and Spalacidae (e.g., mole rates, bamboo rats, and zokors). In some embodiments, a rodent of this disclosure is selected from a true mouse or rat (family Muridae), a gerbil, a spiny mouse, and a crested rat. In some embodiments, a mouse of this disclosure is from a member of the family Muridae.

[0184] In some embodiments, a rodent is a mouse. In some embodiments, the rodent is a mouse of a C57BL strain selected from C57BL/A, C57BL/An, C57BL/GrFa, C57BL/KaLwN, C57BL/6, C57BL/6J, C57BL/6ByJ, C57BL/6NJ, C57BL/10, C57BL/10ScSn, C57BL/10Cr, and C57BL/Ola. In some embodiments, a rodent is a mouse of a 129 strain selected from the group consisting of a strain that is 129P1, 129P2, 129P3, 129X 1, 129S1 (e.g., 129S1/SV, 129S1/Svlm), 129S2, 129S4, 129S5, 129S9/SvEvH, 129/SvJae, 129S6 (129/SvEvTac), 129S7, 129S8, 129T1, 129T2 (see, e.g., Festing et al., 1999, Mammalian Genome 10:836; Auerbach et al., 2000, Biotechniques 29(5):1024-1028, 1030, 1032). In some embodiments, a rodent is a mouse that is a mix of a 129 strain and a C57BL/6 strain. In some embodiments, a rodent is a mouse that is a mix of aforementioned 129 strains, or a mix of aforementioned BL/6 strains. In some embodiments, a rodent is a mouse of a BALB strain, e.g., BALB/c strain. In some embodiments, a rodent is a mouse that is a mix of a BALB strain and another aforementioned strain.

[0185] In some embodiments, a rodent is a rat. In some certain embodiments, a rat is selected from a Wistar rat, an LEA strain, a Sprague Dawley strain, a Fischer strain, F344, F6, and Dark Agouti. In some embodiments, a rat strain as described herein is a mix of two or more strains selected from the group consisting of Wistar, LEA, Sprague Dawley, Fischer, F344, F6, and Dark A gouti.

Tissues and Cells of Genetically Modified Rodents

[0186] In some embodiments, disclosed herein is an isolated rodent cell or tissue whose genome comprises a humanized Tslp gene, a humanized Tslpr gene, a humanized Il7ra gene, or a combination thereof. In some embodiments, an isolated rodent cell or tissue further comprises one or more of the additional genetic modifications described above (e.g., a humanized Sirpa gene, RAG2-/ and IL-2RG-/, a humanized Tpo gene, or a humanized GM-CSF/IL-3 locus).

[0187] In some embodiments, a tissue is selected from adipose, bladder, brain, breast, bone marrow, eye, heart, intestine, kidney, liver, lung, lymph node, muscle, pancreas, plasma, serum, skin, spleen, stomach, thymus, testis, ovum, and a combination thereof.

[0188] In some embodiments, a cell is selected from an epithelial cell, a keratinocyte, a dendritic cell, lymphocyte (e.g., a B or T cell), macrophage, mast cell, and basophil. In some embodiments, an isolated rodent cell is a rodent embryonic stem cell. In some embodiments, an isolated rodent cell is a rodent egg, or a rodent sperm.

Compositions and Methods for Making Humanized Rodents

[0189] Disclosed herein is a targeting vector (or nucleic acid construct) comprising a human TSLP nucleotide sequence, a human TSLPR nucleotide sequence, or a human IL7RA nucleotide sequence, desired to be integrated into a rodent locus to form a humanized gene as described herein.

[0190] In some embodiments, a targeting vector comprises a human TSLP nucleotide sequence which encodes at least a substantial portion of the mature protein sequence of a human TSLP protein as described hereinabove. In some embodiments, the human TSLP nucleotide sequence encodes a polypeptide comprising amino acids 29-159 of SEQ ID NO: 3. In some embodiments, the human TSLP nucleotide sequence comprises exon 1 beginning from the codon for the first amino acid of the mature protein through the STOP codon in exon 4 of a human TSLP gene.

[0191] In some embodiments, a targeting vector comprises a human TSLPR nucleotide sequence which encodes at least a substantial portion of the ectodomain of a human TSLPR protein as described hereinabove. In some embodiments, the human TSLPR nucleotide sequence encodes a polypeptide comprising amino acids 27-231 of SEQ ID NO: 23. In some embodiments, the human TSLPR nucleotide sequence comprises exon 2, through the codon in exon 6 encoding the last ectodomain amino acid, of a human TSLPR gene.

[0192] In some embodiments, a targeting vector comprises a human IL7RA nucleotide sequence which encodes at least a substantial portion of the ectodomain of a human IL7RA protein as described hereinabove. In some embodiments, the human IL7RA nucleotide sequence encodes a polypeptide comprising amino acids 21-236 of SEQ ID NO: 43. In some embodiments, the human IL7RA nucleotide sequence comprises from the codon in exon 1 that encodes the first amino acid of the mature IL7RA protein, through exon 5 (and in some embodiments, through a 5' portion of intron 5) of a human IL7RA gene.

[0193] The targeting vector also includes 5' and 3' rodent sequences flanking the human nucleotide sequence to be integrated, also known as 5' and 3' homology arms, that mediate homologous recombination and integration of the

human nucleotide sequence into the target rodent locus (e.g., an endogenous rodent Tslp locus, an endogenous rodent Tslpr locus, or an endogenous rodent Il7ra locus), so as to form a humanized gene as described herein above. Typically, the 5' and 3' flanking rodent sequences are the nucleotide sequences that flank the corresponding rodent nucleotide sequence at the target rodent locus that is to be replaced by the human nucleotide sequence. In some embodiments, a targeting vector comprises a humanized gene as described herein above. In some embodiments, a targeting vector comprises a humanized Tslp gene comprising a human TSLP nucleotide sequence and a rodent Tslp nucleotide sequence, as described herein above. In some embodiments, a targeting vector comprises a humanized Tslpr gene comprising a human TSLPR nucleotide sequence and a rodent Tslpr nucleotide sequence, as described herein above. In some embodiments, a targeting vector comprises a humanized Il7ra gene comprising a human IL7RA nucleotide sequence and a rodent Il7ra nucleotide sequence, as described herein above.

[0194] In some embodiments, a targeting vector comprises a selection marker gene. The selection marker gene can be inserted in an intron of the human genomic sequence to be integrated. In some embodiments, a selection marker gene is provided as a self-deleting cassette which can be deleted after a successful integration of the human nucleotide sequence.

[0195] In an exemplary embodiment, a targeting vector is generated from a bacterial artificial chromosome (BAC) clone carrying a rodent Tslp, Tslpr, or Il7ra genomic DNA using bacterial homologous recombination and VELOCI-GENE® technology (see, e.g., U.S. Pat. No. 6,586,251 and Valenzuela et al. (2003) *Nature Biotech.* 21(6):652-659, incorporated herein by reference in their entireties). As a result of bacterial homologous recombination, a rodent genomic sequence is deleted from the BAC clone, and a human nucleotide sequence is inserted, resulting in a modified BAC clone carrying the human nucleotide sequence, flanked with 5' and 3' rodent homology arms. In some embodiments, the human nucleotide sequence can be a cDNA sequence or a human genomic DNA. The modified BAC clone, once linearized, can be introduced into rodent embryonic stem (ES) cells.

[0196] In some embodiments, the present invention provides use of a targeting vector as described herein to make a modified rodent embryonic stem (ES) cell. A targeting vector can be introduced into a rodent ES cell by, e.g., electroporation. Both mouse ES cells and rat ES cells have been described in the art. See, e.g., U.S. Pat. Nos. 7,576,259, 7,659,442, 7,294,754, and US 2008-0078000 A 1 (all of which are incorporated herein by reference in their entireties) that describe mouse ES cells and the VELOCI-MOUSE® method for making a genetically modified mouse; US 2014/0235933 A 1 (Regeneron Pharmaceuticals, Inc.), US 2014/0310828 A 1 (Regeneron Pharmaceuticals, Inc.), Tong et al. (2010) *Nature* 467:211-215, and Tong et al. (2011) *Nat Protoc.* 6(6): doi:10.1038/nprot.2011.338 (all of which are incorporated herein by reference in their entireties) that describe rat ES cells and methods for making a genetically modified rat, which can be used to make a modified rodent embryo, which in turn can be used to make a rodent animal.

[0197] In some embodiments, ES cells having a desirable human nucleotide sequence (e.g., human TSLP, human

TSLPR, or human IL7RA nucleotide sequence) integrated in the genome can be selected. In some embodiments, ES cells are selected based on loss of rodent allele and/or gain of human allele assays. In some embodiments, selected ES cells are then used as donor ES cells for injection into a pre-morula stage embryo (e.g., 8-cell stage embryo) by using the VELOCIMOUSE® method (see, e.g., U.S. Pat. Nos. 7,576,259, 7,659,442, 7,294,754, and US 2008-0078000 A 1, all of which are incorporated by reference in their entireties), or methods described in US 2014/0235933 A 1 and US 2014/0310828 A 1, which are both incorporated by reference in their entireties. In some embodiments, an embryo comprising the donor ES cells is incubated and implanted into a surrogate mother to produce an F0 rodent. Rodent pups bearing a human nucleotide sequence can be identified by genotyping of DNA isolated from tail snips using loss of rodent allele and/or gain of human allele assays.

[0198] In some embodiments, rodents heterozygous for a humanized gene can be crossed to generate homozygous rodents.

[0199] A humanized rodent as described herein (i.e., a rodent comprising a humanized Tslp gene, a humanized Tslpr gene, a humanized Il7ra gene, or a combination thereof) can be bred or crossed with another rodent. Accordingly, methods of breeding as well as progenies obtained from such breeding are also embodiments of this disclosure.

[0200] In some embodiments, a method is provided which comprises breeding a first rodent as described hereinabove, e.g., a rodent whose genome comprises a humanized Tslp gene, a humanized Tslpr gene, a humanized Il7ra gene, or a combination thereof, with a second rodent, resulting in a progeny rodent whose genome comprises the humanized Tslp, Tslpr, and/or Il7ra gene(s). The progeny may possess other desirable phenotypes or genetic modifications inherited from the second rodent used in the breeding. In some embodiments, the progeny rodent is heterozygous for the humanized gene or genes from the first rodent. In some embodiments, the progeny rodent is homozygous for the humanized gene(s) from the first rodent. In some embodiments, the second rodent used in breeding comprises one or more of an additional genetic modifications such as a humanized Sirpa gene, RAG2^{-/-} and IL-2RG^{-/-}, a humanized Tpo gene, or a humanized GM-CSF/IL-3 locus.

[0201] In some embodiments, a progeny rodent is provided whose genome comprises a humanized Tslp gene, a humanized Tslpr gene, a humanized Il7ra gene, or a combination thereof, wherein the progeny rodent is produced by a method comprising breeding a first rodent whose genome comprises the humanized gene or genes, with a second rodent. In some embodiments, the progeny rodent is heterozygous for the humanized gene or genes from the first rodent. In some embodiments, the progeny rodent is homozygous for the humanized gene or genes from the first rodent.

[0202] In some embodiments, disclosed herein is an in vitro method for generating a genetically modified rodent cell, comprising introducing into a rodent cell a targeting vector comprising a human TSLP nucleic sequence that encodes at least a substantial portion of the mature protein sequence of a human TSLP protein, flanked by rodent homology arms that mediate integration of the human TSLP nucleotide sequence into an endogenous rodent Tslp locus, which results in replacement of a rodent Tslp genomic DNA

with the human TSLP nucleic acid sequence to form a humanized Tslp gene as described herein, thereby generating a genetically modified rodent cell. In some embodiments, the rodent cell is mouse cell or a rat cell. In some embodiments, the rodent cell is a rodent ES cell, and the method generates a genetically modified rodent ES cell.

[0203] In some embodiments, disclosed herein is an in vitro method for generating a genetically modified rodent cell, comprising introducing into a rodent cell a targeting vector comprising a human TSLPR nucleic sequence that encodes at least a substantial portion of the ectodomain of a human TSLPR protein, flanked by rodent homology arms that mediate integration of the human TSLPR nucleotide sequence into an endogenous rodent Tslpr locus, which results in replacement of a rodent Tslpr genomic DNA with the human TSLPR nucleic acid sequence to form a humanized Tslpr gene as described herein, thereby generating a genetically modified rodent cell. In some embodiments, the rodent cell is mouse cell or a rat cell. In some embodiments, the rodent cell is a rodent ES cell, and the method generates a genetically modified rodent ES cell.

[0204] In some embodiments, disclosed herein is an in vitro method for generating a genetically modified rodent cell, comprising introducing into a rodent cell a targeting vector comprising a human IL7RA nucleic sequence that encodes at least a substantial portion of the ectodomain of a human IL7RA protein, flanked by rodent homology arms that mediate integration of the human IL7RA nucleotide sequence into an endogenous rodent Il7ra locus, which results in replacement of a rodent Il7ra genomic DNA with the human IL7RA nucleic acid sequence to form a humanized Il7ra gene as described herein, thereby generating a genetically modified rodent cell. In some embodiments, the rodent cell is mouse cell or a rat cell. In some embodiments, the rodent cell is a rodent ES cell, and the method generates a genetically modified rodent ES cell.

Methods Employing the Humanized Rodents

[0205] Rodents disclosed herein provide a useful in vivo system and source of biological materials for identifying and testing compounds for their potential to treat human diseases, including particularly diseases associated with TSLP signalling, such as Th2-driven allergic diseases, asthma, and cancer.

[0206] In some embodiments, rodent animals disclosed herein are used to develop agents that target TSLP signaling through, e.g., targeting human TSLP, human TSLPR, or human IL7RA. In some embodiments, rodents disclosed herein are used to screen and develop candidate agents (e.g., antibodies) that specifically bind to human TSLP, human TSLPR, or human IL7RA. In some embodiments, rodent animals disclosed herein are used to determine the binding profile of an agent (e.g., an antibody). In some embodiments, rodent animals disclosed herein are used to measure the effect of blocking or modulating human TSLP, TSLPR, or IL7RA activity. In some embodiments, a rodent animal disclosed herein is exposed to a candidate agent that binds to and inhibits human TSLP, and is analyzed for effects on human TSLP-dependent processes.

[0207] In some embodiments, a genetically modified rodent described herein is used as a model of allergic diseases. In some embodiments, the allergic disease involves airway inflammation (e.g., asthma).

[0208] In some embodiments, the ova-alum model of lung inflammation is used to assess the Tslp signaling. The ova-alum model of lung inflammation has been well documented in the art (Al-Shami et al., JEM Vol. 202, No. 6, 829-839, 2005; Chu et al., J. Allergy Clin Immunol 2013; 131:187-200, incorporated herein by reference in their entireties). In some embodiments, OVA emulsified in aluminum hydroxide, or aluminum hydroxide alone (as control) is administered intraperitoneally to rodent animals (e.g., mice such as mice humanized for one or more of Tslp, Tslpr, and/or Il17ra as disclosed herein, or wild type mice without humanization). Mice are then challenged intranasally with OVA, and are subsequently analyzed for parameters indicative of lung inflammation, including, e.g., serum ova-specific IgE and ova-specific-IgG1, goblet cell metaplasia, and/or lung tissue eosinophilia. In some embodiments, lung expression of Muc5ac, a representative mucin gene overexpressed in airways of asthmatic lungs, is analyzed after the challenge and may serve as a surrogate endpoint for goblet cell metaplasia. In an exemplary protocol, 50 µg of OVA emulsified in 2 mg of aluminum hydroxide or 2 mg of aluminum hydroxide alone is administered intraperitoneally to rodent animals (e.g., mice such as mice doubly humanized for Tslp and Tslpr, mice triply humanized for Tslp, Tslpr, and Il17ra, as disclosed herein, or wild type mice without humanization, on days 1 and 14). A nesthetized mice are challenged intranasally with 150 µg of OVA in PBS for 4 days, starting on day 21. Mice are analyzed 24 hours after the last challenge for serum Ova-specific IgE and Ova-specific-IgG1, goblet cell metaplasia, and/or lung tissue eosinophilia. In some embodiments, lung expression of Muc5ac, a representative mucin gene overexpressed in airways of asthmatic lungs, is analyzed after the challenge and may serve as a surrogate endpoint for goblet cell metaplasia.

[0209] In some embodiments, airway inflammation can be induced in a rodent by intranasal administration of an allergen (e.g., house dust mite extract or “HDM” model) in one or more doses for a period of time, and airway inflammation can be measured based on mucus accumulation, eosinophilic infiltrating cells in bronchoalveolar lavage fluid, levels of total circulating IgE, and/or alteration in expression profile measurable by microarray expression analysis. The effect of a candidate therapeutic agent can be determined by measuring whether the extent of airway inflammation, either in the ova-alum model or the HDM model, is reduced as a result of the administration of the agent. The allergen used for inducing airway inflammation and the agent being tested can be administered simultaneously or at different times. In some embodiments, the allergen is given to the rodent in one or more doses, and the agent being tested is administered to the rodent after at least one dose of the allergen has been given to the rodent.

[0210] In some embodiments, the allergic disease involves skin inflammation or atopic dermatitis. Skin inflammation can be induced in a rodent by creating skin injury and exposing the injured skin to an allergen (e.g., bacterial toxin or house dust mite extract) in one or more doses for a period of time. The effect of an agent can be determined by measuring whether skin inflammation (as determined by assessing, e.g., IgE levels, pruritis, thickening of the epidermis, and other typical symptoms of atopic dermatitis) is reduced as a result of administration of the agent.

[0211] In some embodiments, rodent animals disclosed herein are used as a animal model for cancer such as a

Th2-driven cancer, in order to, e.g., assess the efficacy of a therapeutic drug targeting human cancer cells. In various embodiments, a rodent animal disclosed herein is engrafted with human cancer cells, and a drug candidate targeting such human cancer cells is administered to the rodent animal. The therapeutic efficacy of the drug is then determined by monitoring the human cancer cells in the rodent animal after the administration of the drug, e.g., by assessing whether growth or metastasis of the human cancer cells in the rodent animal is inhibited as a result of the administration of the drug. Human cancer cells suitable for engraftment into a rodent animal include, e.g., breast cancer cells, lung cancer cells, pancreatic cancer cells, colon cancer cells, melanoma, among others. Drugs that can be tested in the non-human animals include both small molecule compounds, i.e., compounds of molecular weights of less than 1500 kD, 1200 kD, 1000 kD, or 800 dalton, and large molecular compounds (such as proteins, e.g., antibodies), which have intended therapeutic effects for the treatment of human diseases and conditions by targeting (e.g., binding to and/or acting on) human cells.

[0212] The present description is further illustrated by the following examples, which should not be construed as limiting in any way. The contents of all cited references (including literature references, issued patents, and published patent applications as cited throughout this application) are hereby expressly incorporated by reference in their entireties.

EXAMPLES

[0213] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices and/or methods claimed herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the disclosure.

Example 1. Generation of Humanized Tslp Mice

[0214] The mouse Tslp locus was humanized by using VELOCIGENE® technology (see, e.g., U.S. Pat. No. 6,586,251 and Valenzuela et al. (2003) High-throughput engineering of the mouse genome couple with high-resolution expression analysis, Nat. Biotech. 21(6): 652-659, both incorporated herein by reference in their entireties). The resulting humanized Tslp locus included a mouse Tslp promoter, mouse Tslp exon 1, mouse Tslp exon 2 in part (from the 5' end of exon 2 through the codon encoding the last amino acid of the mouse Tslp signal peptide), human TSLP exon 1 in part (from the codon encoding the first amino acid of the mature human TSLP protein to the 3' end of exon 1) through the STOP codon in human TSLP exon 4, followed by a mouse Tslp 3' UTR and downstream mouse genomic sequences. See FIGS. 1A-1C.

[0215] To humanize a mouse Tslp locus, a targeting nucleic acid construct was generated based on the following mouse and human sequences:

TABLE 4

	NCBI GeneID	RefSeq mRNA ID	UniProt ID	Genomic Assembly	Location
Mouse Tslp	53603	NM_021367	Q9JIE6	GRCm38/ mm10	chr18: 32, 815, 383-32, 819, 79 (+)
Human TSLP	85480	NM_033035	Q969D9	GRCh38/ hg38	chr5: 111, 070, 062-111, 078, 026 (+)

TABLE 5

	Genome Build	Start	End	Length (bp)
5' mouse Arm	GRCm38/ mm10	Chr18: 32701299	Chr18: 32815620	114322
Human Genomic Fragment 1	GRCh38/ hg38	Chr5: 111071975	Chr5: 111, 073, 902	1928
Human Genomic Fragment 2	GRCh38/ hg38	chr5: 111, 073, 903	Chr5: 111, 076, 074	2172
3' mouse Arm	GRCm38/ mm10	Chr18: 32819107	Chr18: 32884365	65259

[0216] The targeting nucleic acid construct contained from 5' to 3':

[0217] (i) a 5' mouse homology arm of 114.3 kb upstream of the codon in mouse Tslp exon 2 that encodes the first amino acid of the mature mouse Tslp protein; see FIG. 1B;

[0218] (ii) a human TSLP genomic sequence of 1.9 kb designated as "Human Genomic Fragment 1", which begins from the codon in human TSLP exon 1 that encodes the first amino acid of the mature human TSLP protein (amino acid 29), and ends at 257 bp after the end of human TSLP exon 3; see FIG. 1B;

[0219] (iii) a selection cassette of 4.4 kb designated as "Floxed HUb-Puro" (a puromycin resistance gene operably linked to a human ubiquitin promoter, flanked by LoxP sites), inserted in intron 3 of human TSLP; see FIGS. 1B;

[0220] (iv) a human TSLP genomic sequence of 2.2 kb designated as "Human Genomic Fragment 2", which begins from 258 bp after the end of human TSLP exon 3 and ends at the STOP codon in human TSLP exon 4; see FIG. 1B; and

[0221] (v) a 3' mouse homology arm of about 65.3 kb, which includes the 3' UTR sequence of mouse Tslp exon 5 and the downstream mouse genomic sequence; see FIG. 1B.

[0222] The targeting nucleic acid construct was electroporated into F1H4 mouse embryonic stem (ES) cells. Successful integration was confirmed by a modification of allele (MOA) assay as described, e.g., in Valenzuela et al., *supra*. Primers and probes used for the MOA assay for detecting the presence of human TSLP sequences and confirms the loss and/or retention of mouse Tslp sequences are described in Table 6, and their locations are shown in FIG. 1B.

TABLE 6

7466hTU	
Fwd	CAGATGCGGACATCCAAAGGAT (SEQ ID NO: 9)
Probe (FAM)	TACTCACAAAGCATAGTGCTATGTGCA (SEQ ID NO: 10)
Rev	CCCTTCCTCAAGCCATAAC (SEQ ID NO: 11)
7466hTD	
Fwd	GCCCAGTGTACTACTCAAAGGTA (SEQ ID NO: 12)
Probe (Cal)	TACTGCAATCCTCTTTAAAATAAGC (SEQ ID NO: 13)
Rev	CCCATTGCTCTAGATGTGTCACAGA (SEQ ID NO: 14)
7466mTU	
Fwd	GGCTGACAACAGATATGGATATTGG (SEQ ID NO: 15)
Probe (FAM)	ACTGCTTGGTACAGAAATGGGAATCC (SEQ ID NO: 16)
Rev	CACGGCTTCATGTCTTAGCTG (SEQ ID NO: 17)
7466mTD	
Fwd	GTGCTGAGAGACAGGGCATTC (SEQ ID NO: 18)
Probe (Cal)	TGGAGAACGCACATGCAATCATACCGT (SEQ ID NO: 19)
Rev	GCCTGAGTGGCACTATGTTTC (SEQ ID NO: 20)

[0223] After a correctly targeted ES cell clone was selected, the puromycin selection cassette was excised. The coding sequence of the humanized Tslp gene and the encoded amino acid sequence are set forth in SEQ ID NO: 6 and SEQ ID NO: 5, respectively. An alignment of mouse Tslp (SEQ ID NO: 1), human TSLP (SEQ ID NO: 3), and humanized Tslp (SEQ ID NO: 5) protein sequences is provided in FIG. 1F.

[0224] Positively targeted ES cells were used as donor ES cells and microinjected into a pre-morula (8-cell) stage mouse embryo by the VELOCIMOUSE® method (see, e.g., U.S. Pat. Nos. 7,576,259, 7,659,442, 7,294,754, and US 2008-0078000 A 1, all of which are incorporated herein by reference in their entireties). The mouse embryo comprising the donor ES cells was incubated in vitro and then implanted into a surrogate mother to produce an F0 mouse fully derived from the donor ES cells. Mice bearing a humanized Tslp gene were identified by genotyping using the MOA assay described above. Mice heterozygous for the humanized Tslp gene were bred to homozygosity.

[0225] To determine whether mice homozygous for the Tslp humanization expressed the humanized Tslp protein, mice were euthanized and bled via cardiac puncture. Blood was collected into serum separator tubes and serum prepared. Human TSLP levels in the serum was determined using Human Quantikine TSLP ELISA (R & D systems; Cat #DTSLP0) according to manufacturer's instructions. Recombinant murine Tslp (R & D systems Cat #555-TS-010) at 1000 pg/mL was also used as a negative control to validate species specificity of the ELISA (data not shown) and normal human serum (NHS) was used as positive control. Mice heterozygous for the Tslp humanization as described above were found to express mature human TSLP in serum (FIG. 1G).

Example 2. Generation of Humanized Tslpr Mice

[0226] The mouse Tslpr locus was humanized by using VELOCIGENE® technology (see, e.g., U.S. Pat. No. 6,586,251 and Valenzuela et al. (2003) High-throughput engineering of the mouse genome couple with high-resolution expression analysis, Nat. Biotech. 21(6): 652-659, both incorporated herein by reference in their entirities). The resulting humanized Tslpr locus included a mouse Tslpr promoter, mouse Tslpr exon 1 (including the 5' UTR and sequence encoding the mouse Tslpr signal peptide and the first 7 amino acids of the mouse Tslpr mature protein), mouse Tslpr intron 1 in part (up to 328 bp before exon 2), human TSLPR intron 1 in part (beginning at 909 bp before exon 2), human TSLPR exon 2 through the first 47 bp of exon 6 (encoding substantially the human TSLPR ectodomain, i.e., from amino acid 27 to just before the transmembrane domain), mouse Tslpr exon 6 beginning from the 48th bp through exon 8 (encoding the mouse Tslpr transmembrane and intracellular domains, and including the mouse Tslpr 3' UTR), followed by downstream mouse genomic sequences; see FIGS. 2A-2C.

[0227] To humanize the mouse Tslpr locus, a targeting nucleic acid construct was generated based on the following sequence information:

TABLE 7

	NCBI Gene ID	RefSeq mRNA ID	UniProt ID	Genomic Assembly	Location
Mouse Tslpr	57914	NM_001164735	Q8CII9	GRCm38/mm10	chr5: 109, 554, 709-109, 558, 993 (-)
Human TSLPR	64109	NM_022148	Q9HC73	GRCh38/hg38	Chr X: 1, 187, 549-1, 212, 750 (-)

TABLE 8

	Genome Build	Start	End	Length (bp)
5' mouse Arm	GRCm38/mm10	Chr5: 109557943	Chr5: 109586999	29057
Human Insert	GRCh37/hg37	ChrX: 1314968	ChrX: 1328710	13743
3' mouse Arm	GRCm38/mm10	Chr5: 109422337	Chr5: 109555580	133244

[0228] The targeting nucleic acid construct contained from 5' to 3':

[0229] (i) a 5' mouse homology arm of about 29.1 kb up to 328 bp before mouse Tslpr exon 2; see FIG. 2B;

[0230] (ii) a self deleting selection cassette containing a neomycin resistance gene operably linked to a human ubiquitin promoter, flanked by LoxP sites ("Floxed HUb-Neo"), see FIG. 2B;

[0231] (iii) a human TSLPR nucleic acid sequence of 13743 bp, which begins from 909 bp before exon 2 through the first 47 bp in exon 6 of human TSLPR, which encodes substantially the human TSLPR ectodomain, i.e., from amino acid 27 to amino acid 231 (in human TSLPR: amino acids 1-22 constituting the signal peptide and amino acids 232 to 252 constituting the transmembrane domain), see FIG. 2B; and

[0232] (iv) a 3' mouse homology arm of about 133.2 kb, which begins from 48th bp in exon 6 through exon 8, encodes the mouse Tslpr transmembrane domain and intracellular domain, and includes the mouse Tslpr 3' UTR followed by downstream mouse genomic sequences; see FIG. 2B.

[0233] The targeting nucleic acid construct was electroporated into mouse embryonic stem(ES) cells. Successful integration was confirmed by a modification of allele (MOA) assay as described, e.g., in Valenzuela et al., *supra*. Primers and probes used for the MOA assay for detecting the presence of human TSLPR sequences and confirms the loss and/or retention of mouse Tslpr sequences are set forth in Table 9, and their locations are indicated in FIG. 2B. After a correctly targeted ES cell clone was selected, the neomycin selection cassette can be excised. The genomic sequences of the targeted (humanized) Tslpr allele with and without the cassette are set forth in SEQ ID NO: 63 and 64, respectively. The coding sequence of the humanized Tslpr gene and the encoded amino acid sequence are set forth in SEQ ID NO: 26 and SEQ ID NO: 25, respectively. An alignment of mouse Tslpr (SEQ ID NO: 21), human TSLPR (SEQ ID NO: 23), and humanized Tslpr (SEQ ID NO: 25) protein sequences is provided in FIG. 2F.

TABLE 9

7558hTU	
Fwd	TGCCTCACCGTGAACCTTCATG (SEQ ID NO: 29)
Probe (FAM)	CGTCTCTCTGTCTAGCAGAAGGA (SEQ ID NO: 30)
Rev	TCACCTGCACGGTTCTAAATTG (SEQ ID NO: 31)
7558hTD	
Fwd	CAGCCGCACGTATGTG (SEQ ID NO: 32)
Probe (Cal)	TGACAGCCGCTTTCATTTGTTCA (SEQ ID NO: 33)
Rev	GGACAGCTTGGTTGGGA (SEQ ID NO: 34)
7558mTU	
Fwd	GCTAGCTGCTCATTTGATATTG (SEQ ID NO: 35)
Probe (FAM)	AGAACGCTTCCATATTGAGCCCC (SEQ ID NO: 36)
Rev	GGGCGACACCTCATTTGAT (SEQ ID NO: 37)
7558mTD	
Fwd	GGGTCTGGGTAAGATGAACTCA (SEQ ID NO: 38)
Probe (Cal)	TCGGCTCTGGATGCTTGACA (SEQ ID NO: 39)
Rev	CATCCGGGTACCAATGATG (SEQ ID NO: 40)

[0234] Positively targeted ES cells were used as donor ES cells and microinjected into a pre-morula (8-cell) stage mouse embryo by the VELOCIMOUSE® method (see, e.g., U.S. Pat. Nos. 7,576,259, 7,659,442, 7,294,754, and US 2008-0078000 A 1, all of which are incorporated herein in their entirities by reference). The mouse embryo comprising the donor ES cells was incubated in vitro and then implanted into a surrogate mother to produce an F0 mouse fully

derived from the donor ES cells. Mice bearing a humanized Tslpr gene were identified by genotyping using the MOA assay described above. Mice heterozygous for the humanized Tslpr gene were bred to homozygosity.

Example 3. Generation of Humanized Il7ra Mice

[0235] The mouse Il7ra locus was humanized by using VELOCIGENE® technology (see, e.g., U.S. Pat. No. 6,586,251 and Valenzuela et al. (2003) High-throughput engineering of the mouse genome couple with high-resolution expression analysis, Nat. Biotech. 21(6): 652-659, both incorporated herein by reference in their entirities). The resulting humanized Il7ra locus included a mouse Il7ra promoter, mouse Il7ra exon 1 in part (including the 5' UTR and the first 68 bps beginning from the start codon, and encoding the mouse Il7ra signal peptide and the first 3 amino acids of the mouse Il7ra mature protein), human IL7RA exon 1 in part (the last 14 bps in exon 1), human IL7RA intron 1, human IL7RA exon 2 through exon 5, human IL7RA intron 5 in part, mouse Il7ra intron 5 in part, mouse Il7ra exon 6 through exon 8 (encoding the last two amino acids of the mouse Il7ra ectodomain, the transmembrane domain and intracellular domain of mouse Il7ra, and including the mouse Il7ra 3' UTR). See FIGS. 3A-3F.

[0236] To humanize the mouse Il7ra locus, a targeting nucleic acid construct was generated based on the following sequence information:

TABLE 10

	NCBI Gene ID	RefSeq mRNA ID	UniProt ID	Genomic Assembly	Location
Mouse Il7ra	16197	NM_008372	P16872	GRCm38/mm10	chr15: 9, 505, 788-9, 530, 176 (-)
Human IL7RA	3575	NM_002185	P16871	GRCh38/hg38	chr5: 35, 852, 695-35, 879, 603 (+)

TABLE 11

	Genome Build	Start	End	Length (bp)
5' mouse Arm	GRCm38/mm10	Chr15: 9529675	Chr15: 9578484	48810
Human Insert	GRCh38/hg38	Chr5: 35857046	Chr5: 35874277	17232
3' mouse Arm	GRCm38/mm10	Chr15: 9386119	Chr15: 9510439	124321

[0237] The targeting nucleic acid construct contained from 5' to 3':

[0238] (i) a 5' mouse homology arm of about 48.8 kb up (mouse Il7ra 5' sequence through exon 1 in part, i.e., the 5' UTR and the first 68 bps beginning from the start codon); see FIG. 3B and FIG. 3E;

[0239] (ii) a Human Genomic Fragment 1 of 126 bp (SEQ ID NO: 69) (which includes the last 14 bps of exon 1 and the first 112 bps of intron 1 of human IL7RA); see FIG. 3B and FIG. 3E;

[0240] (iii) a self deleting selection cassette of about 5.2 kb containing a hygromycin resistance gene operably linked to a human ubiquitin promoter, flanked by LoxP sites ("Floxed HUb-Hyg"); see FIG. 3B;

[0241] (iv) a Human Genomic Fragment 2 of 17106 bp, which includes a 3' portion of intron 1, exon 2 through exon 5, and a 5' portion of intron 5 of human IL7RA; see FIG. 3B; and

[0242] (v) a 3' mouse homology of about 124.3 kb, which includes a 3' portion of intron 5, exon 6 through exon 8 of mouse Il7ra (including the mouse Il7ra 3' UTR), followed by downstream mouse genomic sequences; see FIGS. 3B and 3F. Exon 6 through exon 8 of mouse Il7ra encodes the last two amino acids (Gly-Trp) of the ectodomain, the transmembrane domain and intracellular domain of mouse Il7ra.

[0243] The targeting nucleic acid construct was electroporated into F1H4 mouse embryonic stem (ES) cells. Successful integration was confirmed by a modification of allele (MOA) assay as described, e.g., in Valenzuela et al., *supra*. Primers and probes used for the MOA assay for detecting the presence of human IL7RA sequences and confirms the loss and/or retention of mouse Il7ra sequences are set forth in Table 12, and their locations are indicated in FIG. 3B. After a correctly targeted ES cell clone was selected, the hygromycin selection cassette can be excised. The genomic sequences of the targeted (humanized) Il7ra allele with and without the cassette are set forth in SEQ ID NO: 65 and 66, respectively. The coding sequence of the humanized Il7ra gene and the encoded amino acid sequence are set forth in SEQ ID NO: 46 and SEQ ID NO: 45, respectively. An

alignment of mouse Il7ra (SEQ ID NO: 41) and human IL7RA (SEQ ID NO: 43) protein sequences is provided in FIG. 3F.

TABLE 12

7266hTU2	
Fwd	GGGATCAATACTATGGGTGGTTATAA (SEQ ID NO: 49)
Probe (FAM)	ACCTCAGTATTCTCAAGAAAG (SEQ ID NO: 50)
Rev	CTACACTTGGGAGTGAAATGCATT (SEQ ID NO: 51)
7266hTD	
Fwd	GGAGGGCACTCTTACACTTTC (SEQ ID NO: 52)
Probe (Cal)	TTGGAGAACATTGACTTGCCTGCTGTC (SEQ ID NO: 53)
Rev	CCTCTGCTTCTTGTTCTTCACA (SEQ ID NO: 54)
7266mTU	
Fwd	CAGGGCAAGCAAGAATTAGCA (SEQ ID NO: 55)
Probe (FAM)	TGTGGGTATTAATCACCAAGGACAGAGGG (SEQ ID NO: 56)

TABLE 12-continued

Rev	ACAAGCCATTGCGACTTGTCA (SEQ ID NO: 57)
7266mTD2	
Fwd	TGGGTCAAGTTGGCTATCCAT (SEQ ID NO: 58)
Probe (Cal)	TCTTTCCCAGAACAAATGAAGATGCTATGG (SEQ ID NO: 59)
Rev	TGCTTGGGTACTGTCCTGAAG (SEQ ID NO: 60)

[0244] Positively targeted ES cells were used as donor ES cells and microinjected into a pre-morula (8-cell) stage mouse embryo by the VELOCIMOUSE® method (see, e.g., U.S. Pat. Nos. 7,576,259, 7,659,442, 7,294,754, and US 2008-0078000 A 1, all of which are incorporated herein in their entireties by reference). The mouse embryo comprising the donor ES cells was incubated in vitro and then implanted into a surrogate mother to produce an F0 mouse fully derived from the donor ES cells. Mice bearing a humanized IL7ra gene were identified by genotyping using the MOA assay described above. Mice heterozygous for the humanized IL7ra gene were bred to homozygosity.

Example 4. Ova-alum induced type 2 driven inflammation in wild type, double humanized mice (*Tsp^{hu/hu}/Tslpr^{hu/hu}*) and triple humanized mice (*Tslp^{hu/hu}/Tslpr^{hu/hu}/IL7ra^{hu/hu}*)

[0245] To confirm that the various humanized mice strains have comparable pathology in a model of type 2 driven inflammation, the ovalbumin (OVA)/alum-induced lung inflammation model was employed, wherein a role for TSLP has been previously reported (Chu, et al., J Allergy Clin Immunol 2013; 131:187-200.el-8, the entire contents of which are incorporated herein by reference). Traditional type 2 inflammation endpoints such as circulating levels of antigen specific IgE and IgG1, lung tissue eosinophil infiltration and lung expression of Muc5ac, a representative mucin gene overexpressed in airways of asthmatic lungs, and a surrogate endpoint for goblet cell metaplasia (GCM) (Wills-Karp, et al., Science 1998; 282:2258-61, the entire contents of which are incorporated herein by reference) were assessed in three strains of mice: wild type mice (WT), double humanized mice (*Tslp^{hu/hu}/Tslpr^{hu/hu}*), and triple humanized mice (*Tslp^{hu/hu}/Tslpr^{hu/hu}/IL7R^{hu/hu}*). The humanization for each of the Tslp, Tslpr and IL7R molecules is as described in Example 1, 2 and 3, respectively.

[0246] As the lung is a highly vascularized organ, cells infiltrating the lung (lung tissue) from those circulating in the lung vasculature (lung circulating) were distinguished using a CD 45-based intravascular labeling technique (Anderson, et al., Nat Protoc 2014; 9:209-22, the entire contents of which are incorporated herein by reference) prior to gating on eosinophils. As expected, TSLP/OVA administration induced an increase in lung tissue eosinophils at comparable levels across mouse strains (FIG. 4A). In addition, TSLP/OVA induced comparable levels of lung expression of Muc5ac (FIG. 4B) as well as comparable levels of circulating levels of Ova specific IgE (FIG. 4C) and Ova specific IgG1 (FIG. 4D).

Methods

[0247] Ova-alum-induced lung inflammation. 50 µg of OVA (grade V; Sigma Aldrich) emulsified in 2 mg of aluminum hydroxide (Sigma Aldrich) or 2 mg of aluminum hydroxide alone was administered intraperitoneally to WT Balb/c mice on days 1 and 14. A nesthetized mice were challenged intranasally with 150 µg of OVA (grade III; Sigma Aldrich) in 20 µL of PBS for 4 days, starting on day 21. Mice were analyzed 24 hours after the last challenge.

[0248] At the end of the study, mice were sacrificed and blood and lung collected for analysis of eosinophil infiltrates in lung tissue, lung gene expression by real-time qPCR and circulating serum immunoglobulin levels.

[0249] Flow cytometric analysis. To enable flow cytometric analysis of circulating versus tissue-infiltrating immune cells in the lung, mice were injected intravenously with an anti-CD45 BV 650 antibody (BD Biosciences) 5 minutes prior to sacrifice to selectively label immune cells still in the vasculature while leaving cells that had infiltrated the lung parenchyma unlabeled. Mouse caudal lung lobes were digested to prepare a single-cell suspension using a solution of Liberase TH (Roche) and DNase I (Roche), followed by mechanical dissociation. Cells were then stained with LIVE/DEAD Fixable Dead Cell Stain (BD Biosciences) to allow exclusion of dead cells followed by antibodies against: CD45, CD26, Siglec-F, Ly6G, Ly6C, CD11b, CD19, SIRPa, CD23, CD 127, Sca-1, CD44, CD4, CD8, TCRb, CD69 CD62L (BD Biosciences); CD64, XCR1, I-A/I-E, CD11c, CD301b (Biolegend); MerTK, ST2 (eBioscience). Samples were acquired on an LSR Fortessa X-20 or a FACSymphony cell analyzer using the HTS attachment (BD). Data analysis was performed using FlowJo v10 Software (BD).

[0250] Measurement of serum IgE and antigen-specific IgE or IgG1. Whole blood was collected into Microtainer SST serum tubes and pelleted by centrifuging at 15,000 g for 10 min at 4° C. Serum samples were used to determine concentrations: total IgE concentrations by IgE sandwich ELISA OptEIA kit (BD Biosciences); total anti-Ova IgE and anti-Ova IgG1 concentrations by indirect ELISA (Chondrex); total anti-HDM IgE by sandwich ELISA (Chondrex); and total anti-HDM IgG1 titers by in-house sandwich ELISA. Manufacturer's instructions were followed for all ELISA kits.

[0251] Measurement of Muc5ac. Lung Muc5ac gene expression was detected in harvested lung tissue by real time qPCR and normalized to a housekeeping gene. Briefly, at the end of the study, mice were exsanguination and the accessory lobe of the right lung from each mouse was removed, placed into tubes containing 400 µL of RNA Later and stored at -20° C. All samples were homogenized in TRIzol and chloroform was used for phase separation. The aqueous phase, containing total RNA, was purified using MagMAX™ for Microarrays Total RNA Isolation Kit (Ambion by Life Technologies) according to manufacturer's specifications. Genomic DNA was removed using RNase-Free DNase Set (Qiagen). mRNA was reverse-transcribed into cDNA using SuperScript® VILO™ Master Mix (Invitrogen by Life Technologies). cDNA was diluted to 2 ng/µl and 10 ng cDNA was amplified with the SensiFAST Probe Hi-ROX (Meridian) using the ABI 7900HT Sequence Detection System (Applied Biosystems). An internal control housekeeping gene was used to normalize any cDNA input differences. Fold change relative to control mice of lung tissue mRNA expression levels were measured and expressed relative to housekeeping mRNA expression.

TABLE 13

Group	MAID	Genotype	Sensitization i.p.	Challenge, i.n.	# of mice (initial/harvest)
A	50500	Wild Type (C57BL/6NTac(75%)/ 129S6SvEvTac(25%))	saline + alum	saline	7/7
B	50500	Wild Type (C57BL/6NTac(75%)/ 129S6SvEvTac(25%))	Ova(gV) + alum	Ova (gIII), 150 µg	8/8
C	7467/7559	Tslp ^{hu/hu} /Tslpr ^{hu/hu}	saline + alum	saline	7/7
D	7467/7559	Tslp ^{hu/hu} /Tslpr ^{hu/hu}	Ova(gV) + alum	Ova (gIII), 150 µg	8/8
E	7267/7467/7559	Tslp ^{hu/hu} /Tslpr ^{hu/hu} / Il7ra ^{hu/hu}	saline + alum	saline	8/8
F	7267/7467/7559	Tslp ^{hu/hu} /Tslpr ^{hu/hu} / Il7ra ^{hu/hu}	Ova(gV) + alum	Ova (gIII), 150 µg	7/7

Conclusions

[0252] Ova-alum model induced comparable levels of type 2 driven inflammation in double humanized (Tslp^{hu/hu}/

Tslpr^{hu/hu}) and triple humanized (Tslp^{hu/hu}/Tslpr^{hu/hu}/Il7ra^{hu/hu}) mice, based on analysis of lung eosinophil infiltration, lung gene expression analysis and circulating antibody anti-body levels.

SEQUENCE LISTING

```

Sequence total quantity: 69
SEQ ID NO: 1      moltype = AA length = 140
FEATURE          Location/Qualifiers
source           1..140
mol_type = protein
organism = Mus musculus

SEQUENCE: 1
MVLLRSLFIL QVLVRMGLTY NFSNCNFTSI TKIYCNIIFH DLTGDLKGAK FEQIEDCESK 60
PACLLKIEYY TLNPPIPAGC LPDKTFARRT REALNDHCPG YPETERNDGT QEMAQEVQNI 120
CLNQTSQILR LWYSFQMSPPE 140

SEQ ID NO: 2      moltype = DNA length = 423
FEATURE          Location/Qualifiers
source           1..423
mol_type = other DNA
organism = Mus musculus

SEQUENCE: 2
atggttcttc tcaggagcct cttcatcttg caagtacttag tacggatggg gctaacttac 60
aactttcta actgcaactt cacgtcaatt acgaaaaat attgttaacat aatttttcat 120
gacctgactg gagatggaa aggggctaag ttcgagcaaa tcgaggactg tgagagcaag 180
ccagcttgc tcctgaaaat cgactatct actctcaatc ctatcctgg ctgccttca 240
ctccccgaca aaacatttgc ccggagaaca agagaagccc tcaatgacca ctgcccaggc 300
taccctgaaa ctgagagaaa tgacggact caggaatgtt cacaagaatg cccaaatcatc 360
tgcctgaatc aaacctcaca aattctaaga ttgtggatt ccttcatgca atctccagaa 420
taa                                         423

SEQ ID NO: 3      moltype = AA length = 159
FEATURE          Location/Qualifiers
source           1..159
mol_type = protein
organism = Homo sapiens

SEQUENCE: 3
MFPFALLLYVL SVSFRKIFIL QLVGLVLTYD FTNCDFEKF AAYLSTISKD LITYMSGTKS 60
TEFNNTVSCS NRPHCLTEIQ SLTFNPTAGC ASLAKEMFAM KTKAALAIWC PGYSETQINA 120
TQAMKKRRKR KVTTNKCLEQ VSQLOQGLWRR FNRPLLKQQ 159

SEQ ID NO: 4      moltype = DNA length = 480
FEATURE          Location/Qualifiers
source           1..480
mol_type = other DNA
organism = Homo sapiens

SEQUENCE: 4
atgttccctt ttgccttact atatgttctg tcagtttctt tcagggaaaat cttcatctta 60
caactttag ggctgggttt aacttacgac ttcaactt gtgacttga gaagataaa 120
gcagcctatc tcagttactat ttctaaagac ctgattacat atatgttgg gaccaaaaat 180
accgagttca acaacaccgt ctcttgc aatcgccac attgccttac tgaatccag 240
agcctaaccct tcaatcccac cgccggctgc gctgcgtcg ccaaagaat gttcccatg 300
aaaactaagg ctgccttagc tatctggtgc ccaggctatt cggaaaactca gataaatgtc 360

```

-continued

```

actcaggcaa tgaagaagag gagaaaaagg aaagtccacaa ccaataatg tctggacaa 420
gtgtcacaat tacaaggatt gtggcgtcg ttcataatcgac ctttactgaa acaacagtaa 480

SEQ ID NO: 5      moltype = AA length = 150
FEATURE          Location/Qualifiers
REGION           1..150
note = Hybrid Tslp protein: (mouse signal P + human isoform
       1 ecto + C-ter)
source            1..150
mol_type = protein
organism = synthetic construct

SEQUENCE: 5
MVLLRSLFIL QVLVRMGLTY DFTNCDFEKI KAAYLSTISK DLITYMSGTK STEFNNTVSC 60
SNRPHCLTEI QSLTFNPTAG CASLAKEMFA MKTKAALAIW CPGYSETQIN ATQAMKKRRK 120
RKVTTNKCLE QVSQQLQGLWR RFNRPLLKQQ 150

SEQ ID NO: 6      moltype = DNA length = 453
FEATURE          Location/Qualifiers
misc_feature     1..453
note = Mouse/Human Tslp mRNA (CDS): (mouse signal P + human
       isoform 1 ecto + C-ter)
source            1..453
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 6
atggttttc tcaggaggcct cttcatccgt caagtactag tacggatggg gctaactac 60
gacttcacta actgtgactt tgagaaggat aaaggcgcct atctcagtag tatttctaaa 120
gacctgatta catatatggat tgggaccaaa agtaccggat tcaacaacac cgtctctgt 180
agaatacggc cacatggcct tactgaaatc cagagcctaa cttcaatcc caccggccgc 240
tgccgcgtgcg tcgccaagaat aatgttcgcct atgaaaacta aggctgcctt agctatctgg 300
tgccgcgtgcg atccggaaatc tcagataaatc gctactcgagg caatgaaaggaa gaggagaaaa 360
aggaaaatgca caaccaataatc attgtggaa caagtgtcac aattacaagg atttgtggcgt 420
cgcttcataatc gacccatctt gaaacaacag taa 453

SEQ ID NO: 7      moltype = AA length = 136
FEATURE          Location/Qualifiers
source            1..136
mol_type = protein
organism = Rattus norvegicus

SEQUENCE: 7
MVLFRYLFIL QVVRRLALTYN FSNCNFEMIL RIYHATIFRD LLKDLNGILF DQIEDCDSRT 60
ACLLKIDHHT FNPVPGCPSL PEKAFAKTK AALINYCPGY SETERNGTL MTREIRNICL 120
NQTSQILGLW LSCIQS 136

SEQ ID NO: 8      moltype = DNA length = 411
FEATURE          Location/Qualifiers
source            1..411
mol_type = other DNA
organism = Rattus norvegicus

SEQUENCE: 8
atggttttc tcagggtaccc ctttatccgt caagtggtag ggctggcact aacttacac 60
ttttcttaact gtaacttcga gatgttttgg agaardatatac atgcaataat tttcgtgac 120
ctgcttaaagg atttgaatgg gatctgttc qacccaaatcg aggactgtga cagcaggaca 180
gtttgtctcc tgaaaatcga ccaccatacc ttcaatccgt tccctggctg cccgtcactc 240
cccgagaaatcg ctgtcgctt gaaaatcgaa gggggccctca ttaactactg cccaggctac 300
tctgaaaatcg agagaatatgg tactctggaa atgacacgaa aatcagaaa catctgcctg 360
aatcaaacatc cacaattctt aggattgtgg ttcaatctt a 411

SEQ ID NO: 9      moltype = DNA length = 22
FEATURE          Location/Qualifiers
misc_feature     1..22
note = synthetic oligonucleotide
source            1..22
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 9
cagatgcgga catccaaagg at 22

SEQ ID NO: 10     moltype = DNA length = 26
FEATURE          Location/Qualifiers
misc_feature     1..26
note = synthetic oligonucleotide
source            1..26
mol_type = other DNA
organism = synthetic construct

SEQUENCE: 10

```

-continued

tactcacaag catagtgcta tgtgca	26
SEQ ID NO: 11 moltype = DNA length = 20	
FEATURE Location/Qualifiers	
misc_feature 1..20	
note = synthetic oligonucleotide	
source 1..20	
mol_type = other DNA	
organism = synthetic construct	
SEQUENCE: 11	
cccttcctc aaggcataac	20
SEQ ID NO: 12 moltype = DNA length = 23	
FEATURE Location/Qualifiers	
misc_feature 1..23	
note = synthetic oligonucleotide	
source 1..23	
mol_type = other DNA	
organism = synthetic construct	
SEQUENCE: 12	
gcccaagtgt a ctactcaaag gta	23
SEQ ID NO: 13 moltype = DNA length = 25	
FEATURE Location/Qualifiers	
misc_feature 1..25	
note = synthetic oligonucleotide	
source 1..25	
mol_type = other DNA	
organism = synthetic construct	
SEQUENCE: 13	
tactgcaatc ctctttaaaa taagg	25
SEQ ID NO: 14 moltype = DNA length = 24	
FEATURE Location/Qualifiers	
misc_feature 1..24	
note = synthetic oligonucleotide	
source 1..24	
mol_type = other DNA	
organism = synthetic construct	
SEQUENCE: 14	
ccatttgtct agatgtgtca caga	24
SEQ ID NO: 15 moltype = DNA length = 25	
FEATURE Location/Qualifiers	
misc_feature 1..25	
note = synthetic oligonucleotide	
source 1..25	
mol_type = other DNA	
organism = synthetic construct	
SEQUENCE: 15	
ggctgacaac agatatggat attgg	25
SEQ ID NO: 16 moltype = DNA length = 25	
FEATURE Location/Qualifiers	
misc_feature 1..25	
note = synthetic oligonucleotide	
source 1..25	
mol_type = other DNA	
organism = synthetic construct	
SEQUENCE: 16	
actgcttggt acagaatggg aatcc	25
SEQ ID NO: 17 moltype = DNA length = 21	
FEATURE Location/Qualifiers	
misc_feature 1..21	
note = synthetic oligonucleotide	
source 1..21	
mol_type = other DNA	
organism = synthetic construct	
SEQUENCE: 17	
cacggcttca tgtcttagct g	21
SEQ ID NO: 18 moltype = DNA length = 21	
FEATURE Location/Qualifiers	
misc_feature 1..21	
note = synthetic oligonucleotide	

-continued

```

source          1..21
               mol_type = other DNA
               organism = synthetic construct
SEQUENCE: 18
gtgctgagag acagggcatt c                                21

SEQ ID NO: 19      moltype = DNA  length = 26
FEATURE          Location/Qualifiers
misc_feature     1..26
note = synthetic oligonucleotide
source           1..26
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 19
tggagaagca catgcaatca taccgt                                26

SEQ ID NO: 20      moltype = DNA  length = 21
FEATURE          Location/Qualifiers
misc_feature     1..21
note = synthetic oligonucleotide
source           1..21
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 20
ggctgagtgg cactatgttt c                                21

SEQ ID NO: 21      moltype = AA  length = 370
FEATURE          Location/Qualifiers
source           1..370
mol_type = protein
organism = Mus musculus
SEQUENCE: 21
MAWALAVILL PRLLAAAAAA AAVTSRGDVT VVCHDLETVE VTWGSGPDHH GANLSLEFRY  60
GTGALQPCPR YFLSGAGVT GCILPAARAG LLELALRGG GAMVFKARQR ASAWLKPRPP 120
WNVTLLWTPD GDVTWSWPB SYLGLDYEVQ HRESNDDDEA WQTTSGPCCD LTVGGLDPVR 180
CYDFRVRASP RAAHYGLEAQ PSEWTAVTRL SGAASAGDPC AAHLPLASC TASPAPSAL 240
APPLPLGC LAALLTLSLL LAALRLRRVK DALLPCVPDP SGSFPGLFKEK HHGNFQAWIA 300
DAQATAPPAR TEEEDDLIHT KAKRVEPEDG TSLCTVPRPP SFEPRPGPGG AMVSVGGATF 360
MVGDSGYMTL                                              370

SEQ ID NO: 22      moltype = DNA  length = 1113
FEATURE          Location/Qualifiers
source           1..1113
mol_type = other DNA
organism = Mus musculus
SEQUENCE: 22
atggcatggg cactcgccgt cacttcctg cctcggtctc ttgcggcgcc agcgccggcg 60
ggccgggtga cgtcacgggg tgatgtaca gtgtctgcg atgacctgga gacggtgagg 120
gtcacgtggg gtcggggcc cgaccacac ggcccaact tgagctgga gttccgttat 180
ggcactggcg ccctgcaacc ctgcggcgca tatttctgt cccgcgtgg tgtcaactcc 240
gggtgcattc tccccggccg gagggggggg ctgtctggac tggcactggc cgacggaggc 300
ggggccatgg tggtaatggc taggcgcgc gctgtccgcg ggttgcggcc ccccccac 360
tggaatgtga cgctgtctg gacaccaac qgggacgtga ctgtctctg gcctgcccac 420
tcctacctgg gcctggacta cgagggtgcg caccgggaga gcaatgacga tgaggacgcc 480
tggcagacga cctcaggggc ctgtgtgd ttgacagtgg gggggctcga cccctacgc 540
tgctatgact tccgggttcg ggcgtcgccc cggggccgcg actatggct ggaggcgccag 600
ccttagcgagt ggacagcggtt gacaaggctt tccggggcag catccgggg tgacccttc 660
ggcccccacc ttccccctct agcctctgt accgcaagcc ccccccaccc cccggccctg 720
ggcccccacc ttccccctct gggctggccg ctacgcgcg tgctgacact gtccctgtc 780
ctggccccc tcgggttcg cagggtggaa gatgcgtgc tgccctgctg ccctgacccc 840
agccggctct tccctgact ctttggaaa acatccggga atttccaggc ctggatttgc 900
gacggcccagg ccacagcccc gccagccagg accgaggagg aagatgaccc catccacacc 960
aaggctaaaga ggggtggagcc cgaggacggc acctccctct gcaccgtgcc aaggccaccc 1020
agtttcgacg caagggggcc gggaggcgcc gccatggtgt cagttggccg ggccacgttc 1080
atggtggccg acagcgctc catgaccctg tga                                1113

SEQ ID NO: 23      moltype = AA  length = 371
FEATURE          Location/Qualifiers
source           1..371
mol_type = protein
organism = Homo sapiens
SEQUENCE: 23
MGRLVLLWGA AVFLGGWMA LGQQGAAEGV QIQIIYFNLE TVQVTWNASK YSRNTLTFHY  60
RFNGDEAYDQ CTNYLLQEGH TSGCLLDAEQ RDDILYFSIR NGTHPVFTAS RWMVYLLKPS 120
RSPKHVRFWSH QDAVTVCSD LSYGDLLYEV QYRSPFDTEW QSKQENTCNV TIEGLDAEKC 180
YSFWVVRVKAM EDVYGPDTYP SDWSEVTCWQ RGEIRDACAE TPTPPKPKLS KFILISSLAI 240

```

-continued

LLMVSLLLLS	LWKLWRVKKF	LIPSPDPKS	IFPGLFEIHQ	GNFQEWTDT	QNVAHLHKMA	300
GAEQESGPEE	PLVVQLAKTE	AESPRMLDPQ	TEEKEASGGG	LQLPHQPLQG	GDVVTIGGFT	360
FVMNDRSYVA	L					371

SEQ ID NO: 24	moltype = DNA length = 1116					
FEATURE	Location/Qualifiers					
source	1..1116					
	mol_type = other DNA					
	organism = Homo sapiens					
SEQUENCE: 24						
atggggcgcc	tgggtctgct	gtggggagct	gccgttttc	tgctggagg	ctggatggct	60
ttggggcaag	gaggaggcgc	agaaggagta	cagattcaga	tcatctactt	caattttagaa	120
accgtgcagg	tgacatggaa	tgccagaaa	tactccagga	ccaacctgac	tttccactac	180
agattcaacg	tgatgaggac	ctatgaccat	tgccaccaact	accccttcca	ggaaggtcac	240
acttcgggt	gcctctttaga	cgcagacgc	cgagacgact	ttctcttattt	ctccatcagg	300
aatgggaccc	acccctttt	cacccgcaatg	cgctggatgg	tttattactt	gaaacccatg	360
tccccgaage	acgttagatt	ttcgtggcat	caggatgcg	tgacgggtac	gtgttctgac	420
ctgtcttacg	gggatctctt	ctatgaggat	cagtacccga	gccccttcca	caccgagtgg	480
cagtccaaac	aggaaaataac	ctgcaacgtt	accatagaag	gttggatgc	cgagaagtgt	540
tacttttt	gggtcagggt	gaggatctatg	gaggatgtat	atggggcaca	cacataccca	600
agegactgtt	cagaggatgc	atgtggcg	agaggcgaga	ttcgggatgc	ctgtgcagag	660
acaccaacgc	ctcccaaacc	aaagtgtcc	aaattttattt	taattttccag	cctggccatc	720
cttctgtatgg	tgtctcttctt	ccttctgtct	ttatggaaat	tatggagagt	gagaaggttt	780
cttatttcca	gggtgcggaga	ccccaatttc	atcttcccc	ggcttttga	gatacaccaa	840
ggsaacttcc	aggagtggat	cacagacacc	cagaacgtgg	ccacccctca	caagatggca	900
ggtcagagc	aagaaaatgg	ccccgaggag	ccccctgttag	tccagtttgc	caagactgaa	960
ggcggatctc	ccaggatgtt	gggccccac	accggaggaa	aaaggaggctc	tggggatcc	1020
cttcaggatcc	cccaccggc	ccttcaaggc	ggtgatgttg	tcacaatccg	gggcttcacc	1080
tttgtatgtat	atgaccgctc	ctacgtggcg	tttgtatgtat			1116

SEQ ID NO: 25	moltype = AA length = 358
FEATURE	Location/Qualifiers
REGION	1..358
	note = Hybrid Tslpr protein: (mouse signal P + most human ecto + mouse TM+mouse C-ter)
source	1..358
	mol_type = protein
	organism = synthetic construct

SEQUENCE: 25						
MAWALAVILL	PRLLAAAAAA	AAVTSAEGV	QIQIIYFNLE	TVQVWNASK	YSRTNLTFHY	60
RFNGDEAYDQ	CTNYLLOEGH	TSGCLLDABQ	RDDILYFSIR	NGTHPVFTAS	RWMVYLLKPS	120
SPKHVRFSWH	QDAVTVCSD	LSYGDLLYEV	QYRSPFDTEW	QSKQENTCNV	TIEGLDAEKC	180
YSFWVRVKAM	EDVYGPDTYP	SDWSEVTCWQ	RGEIRDACAE	TPTPPKPLS	KLLPLGCGLA	240
ALLTLSLLLA	ALRLRRVKDA	LLPCVPDPMSG	SFPGLFEKHH	GNFQAWIADA	QATAPPARTE	300
EEDDLIHTKA	KRVEPEDGTS	LCTVPRPPSF	EPRGPGGGM	VSVGGATFMV	GDGYMTL	358

SEQ ID NO: 26	moltype = DNA length = 1077
FEATURE	Location/Qualifiers
misc_feature	1..1077
	note = Hybrid Tslpr mRNA
source	1..1077
	mol_type = other DNA
	organism = synthetic construct

SEQUENCE: 26						
atggcatgg	cactcgccgt	catectctgt	cctcggttcc	ttcgccgggc	agccggcgccg	60
ggggcggtga	cgtcacgggc	agaaggagta	cagattcaga	tcatctactt	caattttagaa	120
accgtgcagg	tgacatggaa	tgccagaaa	tactccagga	ccaacctgac	tttccactac	180
agattcaacg	tgatgaggac	ctatgaccag	tgccaccaact	accccttcca	ggaaggtcac	240
acttcgggtt	gcctctttaga	cgcagacgc	cgagacgaca	ttctcttattt	ctccatcagg	300
aatggggatc	accccggttt	caccggatgt	cgctggatgg	tttattactt	gaaacccatg	360
tcccccggcc	acgtgaggat	ttcgtggcat	caggatgcg	tgacgggtac	gtgttctgac	420
ctgtcttacg	gggatctctt	ctatgaggat	cagtacccga	gccccttcca	caccgagtgg	480
cagtccaaac	aggaaaataac	ctgcaacgtt	accatagaag	gttggatgtc	cgagaagtgt	540
tactcttgc	gggtcagggtt	gaaggcttat	gaggatgtat	atggggcaca	cacataccca	600
agegactgtt	cagaggatgc	atgtggcg	agaggcgaga	ttcgggatgc	ctgtgcagag	660
acaccaacgc	ctcccaaacc	aaagtgtcc	aaactcttc	ccctgggtc	cgcccttagca	720
gcgcgtgtga	cactgtccct	gctctggcc	cccttgaggc	ttcgccagggt	gaaagatgc	780
ctgctgcctt	gcgtccctga	ccccagcgcc	tccttccctg	gactcttga	gaagcatcac	840
ggaaacttcc	aggccgttat	tgccggaccc	caggccacag	ccccggccgc	caggaccgag	900
gaggaagatg	acccatcca	caccaaggat	aaagggttg	agcccggaga	cggcacccctc	960
cttcggcc	tgccaaaggcc	accaggatcc	gagcccaagg	ggccgggggg	cgggccatc	1020
gtgtcgtatgg	ggggggccac	tttcatggtg	ggcgacacgc	gttacatgac	cctgtgtat	1077

SEQ ID NO: 27	moltype = AA length = 360
FEATURE	Location/Qualifiers
source	1..360

-continued

```

mol_type = protein
organism = Rattus norvegicus
SEQUENCE: 27
MRAVTWAIVA MLLPRVLGAI PTRTPRTGGV GDTLSVAIVC HDLESVEVTW GPGSAHHGLS 60
ANLSLEFRYGNQVPQPCPHY FLLDSVRAGC VLPMGKGLLE VVLREGGGAK LFSRKKASA 120
WLRPRPPWNVTLSWVGDTVAVSCPSPHSYPG LEYEVQHRDD FDPEWOSTSA PFCNLTVGGL 180
DPPGRCYDFRV RATPQDFYYG PEARPSKWTV VASLQGVGPT GSCTGPTLPR TPGTPTPPLA 240
LAAGLAVALL TLVLLALLRMRRVKEALLP GVPDPRGSFPL GLEFEKHHGNF QAWIADSQAA 300
VPTVPEQDKDDVIRPQTKGVETQEDDDVI APGSPCLGGG ALMSVGASF LMGDSGYTTL 360

SEQ ID NO: 28      moltype = DNA length = 1209
FEATURE
source          1..1209
mol_type = other DNA
organism = Rattus norvegicus
SEQUENCE: 28
acccttagaac tcgcggacccc gccggggccc cgccccatac atgcgagctg tgacctgggc 60
catcgccgcg atgcctctgc cgggggtttt gggggcgtt ccggcaggaga cgccacggac 120
agggggcgtc ggtgacaccc tctctgttc cattgtttgc catgaccttg agagegttgg 180
agtcacgctgg gggccgggtt ctgcggccaca tgggctgtca gcggatcca gcctggagtt 240
ccggtatggaa aaccagggtcc cccagccctg cccacactac tttctgttgg acagegttgg 300
agcaggctgtgt gtcctccccc tggggaaagggg gcttctgggg gtgggtgtgc gtgaggggagg 360
cggagccaaag ctgttctccc ggaagaagaaa ggcatcggcc tggctgggg cccgeccctcc 420
atggaaacgtc accctcgatgtt gggtaggggg cactgttgc tttctctggc cctcccaactc 480
tttaccctggg ctggaaatatg aggtgcagca cagagatgac ttggacccctg aatggcgttc 540
gaccctctgca ccattctgca acctgtacatgtt gggcgccgtt gaccctggc gctgtacga 600
cttccgggtt cggggcgacgc cccaggattt ctactatggc cccggggccg ggcccaaccaa 660
gtggacacggc tgccggcagcc tgccggggat gggacccaca ggctctggca ctggcccccac 720
cctcccgaggg accccccgggg ccccccacccc acctctegcc ctggcctgtg gccttgcgg 780
ggccctgttc accctgtgtc tgctctggc ctggctgtgg atgcgcagggg tgaaggaaagc 840
ctctgtgtcctt ggtgtccccc acccctgggg ccccttccctt ggccttcccttgg agaaaacatca 900
ttggaaacttc caggcttggaa tgccaggatgtt ccggctgtgtt gttcccttccgg tcccaagagca 960
ggacaaaatgatgtatgtca tccggccctca gaccaagggggg gtggaaactc aggaggatgt 1020
tgatgttattt gccccgggggtt ccccatgtctt tgggggggggg gcccctgtgtt cgggtggccgg 1080
ggcctctgttc ctgtatggggag acaggggttca caccacccctt tgacaacacctt gtgttgaccc 1140
ctgcctggac cccctgtgtt gtcactttatg ccccgcttca tttgcataaa tatgaattttt 1200
ttatctgg 1209

SEQ ID NO: 29      moltype = DNA length = 21
FEATURE
misc_feature      1..21
source          1..21
note = Synthetic Oligonucleotide
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 29
tgccctcaccg tgaacttcat g 21

SEQ ID NO: 30      moltype = DNA length = 25
FEATURE
misc_feature      1..25
source          1..25
note = Synthetic Oligonucleotide
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 30
cgtctctctgttgtcttagcag aagga 25

SEQ ID NO: 31      moltype = DNA length = 23
FEATURE
misc_feature      1..23
source          1..23
note = Synthetic Oligonucleotide
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 31
tcacctgcac ggtttctaaaa ttg 23

SEQ ID NO: 32      moltype = DNA length = 18
FEATURE
misc_feature      1..18
source          1..18
note = Synthetic Oligonucleotide
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 32

```

-continued

cagccgcacg tcatgttg	18
SEQ ID NO: 33 moltype = DNA length = 27 FEATURE Location/Qualifiers misc_feature 1..27 note = Synthetic Oligonucleotide source 1..27 mol_type = other DNA organism = synthetic construct	
SEQUENCE: 33 tgacagccgc cttttcattt tgttca	27
SEQ ID NO: 34 moltype = DNA length = 19 FEATURE Location/Qualifiers misc_feature 1..19 note = Synthetic Oligonucleotide source 1..19 mol_type = other DNA organism = synthetic construct	
SEQUENCE: 34 ggacagcttt ggtttggga	19
SEQ ID NO: 35 moltype = DNA length = 24 FEATURE Location/Qualifiers misc_feature 1..24 note = Synthetic Oligonucleotide source 1..24 mol_type = other DNA organism = synthetic construct	
SEQUENCE: 35 gcttagctgct catttgatata ttcg	24
SEQ ID NO: 36 moltype = DNA length = 27 FEATURE Location/Qualifiers misc_feature 1..27 note = Synthetic Oligonucleotide source 1..27 mol_type = other DNA organism = synthetic construct	
SEQUENCE: 36 aagaagcgctt tccatattca tgagccc	27
SEQ ID NO: 37 moltype = DNA length = 20 FEATURE Location/Qualifiers misc_feature 1..20 note = Synthetic Oligonucleotide source 1..20 mol_type = other DNA organism = synthetic construct	
SEQUENCE: 37 gggcgcacacc tcatttgat	20
SEQ ID NO: 38 moltype = DNA length = 22 FEATURE Location/Qualifiers misc_feature 1..22 note = Synthetic Oligonucleotide source 1..22 mol_type = other DNA organism = synthetic construct	
SEQUENCE: 38 gggctctgggt aagatgaact ca	22
SEQ ID NO: 39 moltype = DNA length = 21 FEATURE Location/Qualifiers misc_feature 1..21 note = Synthetic Oligonucleotide source 1..21 mol_type = other DNA organism = synthetic construct	
SEQUENCE: 39 tcggctctg gatgcttgac a	21
SEQ ID NO: 40 moltype = DNA length = 20 FEATURE Location/Qualifiers misc_feature 1..20 note = Synthetic Oligonucleotide	

-continued

-continued

```
aagtgcctga atttcaggaa actacaagag atatattca tcgagacaaa gaaattctta 300
ctgattggaa agagaataat atgtgtgaag gtggagaaaa agagtcatac ctgaaaaaaaa 360
atagacccaa ccactatagt taaaaccttag gtccttttgc acctgagtgt cgtctatcg 420
gaaggagcoca atgactttgt ggtgacattt aatacatcac acttgaaaaaa gaagtatgt 480
aaagttttaa tgacatgtgt agcttaccgc caggaaaaagg atgaaaaacaa atggacgcat 540
gtgaattttat ccagcacaaa gctgacactc ctgcagagaa agctccaaacc ggcagcaatg 600
tatgagatta aagttcgatc catccctgt cactattttaa aaggcttcgt gaggatgg 660
agtccaaaggta attacttcgt aactcccgag atcaataataa gtcaggggaa gatggatct 720
atcttactaa ccatcagcat tttaggttt ttctctgtcg ctctgttgtt catcttgccc 780
tgcgtgttat gaaaaaaaag gattaagct atcgatgtgc ccagtcctcc cgatcataag 840
aagactctgg aacatctttg taagaaccca agaaaaatgtgag tttcaatctt 900
gaaaagttcc tggactgcca gattcatagg gtggatgaca ttcaagctag agatgaaatg 960
gaaggttttc tgcaagatac gtttctcg caactagaag aatctgagaa gcagaggctt 1020
ggaggggatg tgcaagagcc caactggccca tctggaggatg tagtcatcac tccagaaagc 1080
tttggaaagag attcatcgatc ccatcgatc gctggaaatg tcagtgcatt tgacgccc 1140
attctctctt cttccaggcc ccttagactgc aggaggaaatg gcaaaatgtt ggctcatgt 1200
taccaggacc tcctgttttag ccttggact acaaacagca cgctgcccccc tccatattct 1260
ctccaatctg gaatctgtac attgaaccca gttgctcagg gtcagcccat tcttacttcc 1320
ctggatcaa atcaagaaga agcatatgtc accatgttcca gtttctacca aaaccagtga 1380
```

```
SEQ ID NO: 45 moltype = AA length = 459
FEATURE Location/Qualifiers
REGION 1..459
note = mouse/human hybrid Il7ra protein
source 1..459
mol_type = protein
organism = synthetic construct
```

```
SEQUENCE: 45
MMALGRAFAI VFCLIQAVSG ESGYAQNQDLS DAEELDDYDF SCYSQLEVNG SQHSLTCAFE 60
DPDVNITNLPE FEICGALVEV KCLNFRKLQE IYFIETKFL LIGKSNCVK VGEKSLTCKK 120
IDLTTIVKPE APFDLSSVYR EGANDFVVTF NTSHLQKKYV KVLMHDVAYR QEKENWKTH 180
VNLSSTKLTL LQRKLQPAAM YEIKVRSIPD HYFKGFWESEW SPSYYFRTPPE INNSSGGWDP 240
VLPSVTILSL PSVFLLVILA HVLWKKRIKP VVWPSPDHK KTLEQLCKP KTSLNVSFNP 300
ESFLDCQIHE VKGVEARDEV ESFLPNDLPA QPEELETQGH RAAVHSANRS PETSVSPPET 360
VRRESPRLCR ARNLSTCNAP PLLSSRSPDY RDGDRNRPPV YQDLLPNNSGN TNVPVPVPQP 420
LPFQSGILIP VSQRQPISTS SVLNQEEAYV TMSSFYQNK 459
```

```
SEQ ID NO: 46 moltype = DNA length = 1380
FEATURE Location/Qualifiers
misc_feature 1..1380
note = mouse/human hybrid Il7ra mRNA
source 1..1380
mol_type = other DNA
organism = synthetic construct
```

```
SEQUENCE: 46
atgatggctc tgggttagagc ttccgtata gttttctgtc taattcaagc tggatggatc 60
gaaagtggct atgctcaaaa tggagacttg gaagatgcaag aactggatga ctactcattc 120
tcatgtata gccagttggaa agtgcatttgc tcgcagactc cactgacttg tgcttttgc 180
gaccaggatg tcaacatcac caatctggaa ttggaaatat gtggggccct cgtggaggta 240
aagtgcctga atttcaggaa actacaagag atatattca tcgagacaaa gaaattctta 300
ctgattggaa agagaataat atgtgtgaag gtggagaaaa agagtcatac ctgaaaaaaaa 360
atagacccaa ccactatagt taaaaccttag gtccttttgc acctgagtgt cgtctatcg 420
gaaggagcoca atgactttgt ggtgacattt aatacatcac acttgaaaaaa gaagtatgt 480
aaagttttaa tgacatgtgt agcttaccgc caggaaaaagg atgaaaaacaa atggacgcat 540
gtgaattttat ccagcacaaa gctgacactc ctgcagagaa agctccaaacc ggcagcaatg 600
tatgagatta aagttcgatc catccctgt cactattttaa aaggcttcgt gaggatgg 660
agtccaaaggta attacttcgt aactcccgag atcaataataa gtcaggaggatggatct 720
gtcttgcataa gtgtcaccat tcttagtttgc ttctctgtcg ttttgcatttgc 780
catgtgttat gaaaaaaaag gattaaatgttgc gtcgtatgtcc ctgttcctcc cgatcataag 840
aaaactctgg aacaactatg taagaagccca aaaacgatgtc tgaatgtgag tttcaatccc 900
gaaaagttcc tggactgcca gattcatggatc gatggaggcc tggaaatggccgg ggcggatgt 960
gaaaagttcc tggcccaatgtc tcttcgtca cagccagagg agttggagac acaggagcac 1020
agagccgctg tacacagtgc aaacccgtcg cctgagactt cagtcagccccc accagaaaca 1080
gtttagaagag agtcaccctt aagatgcctg gcttagaaaaatgc tggatgttgc caatggccct 1140
ccactccccc ctcttagtgc ccctgactatc agatgttgc acagaaatgttgc gcttcgttgc 1200
tatcaagact tgcgtccaaa ctctggaaatc gtttctgtcc ctgtccctgt ccctcaacca 1260
ttgccttcc agtcggaaat cctgtatcca gtttctgtca gacagccat ctccacttcc 1320
tcagttactgtc atcaagaaga agcgtatgtc accatgttcca gtttctacca aaacaatgt 1380
```

```
SEQ ID NO: 47 moltype = AA length = 457
FEATURE Location/Qualifiers
source 1..457
mol_type = protein
organism = Rattus norvegicus
```

```
SEQUENCE: 47
MMALGRAFAI VFCLLQAASG ESGNAQDGDL DAEAPDDHSF WCHSQLEVGD NQHSLTCAFN 60
```

-continued

DPDIKTTNLE	PQICGALLGI	DCLTLNKLRE	MYFIKTSKFL	LIGNSSVCVK	LGKMDVICKI	120
LDISTIVKPE	APSNLKVYR	KEANDFLVTF	NTSHSTKKVY	TALKHDVAYR	PERGESNWTH	180
VYLFHTTRTI	LQRKLQPKAV	YEIKVRSIPN	HEYFKGFWSE	WSPSSTFETP	DSKYQGGWDP	240
VILPSIILLSL	FSMVLLVILA	HVLWKRIKP	VVPSLDPHK	KTLEQLCKP	KKNLNVSFNP	300
ESFLDCQIHE	VNGIQARDEV	ESFLQNDLPP	RPGELEKQGH	RATVHGANSWP	SEISGSTPET	360
FRRESPRLCL	ARNLSTCNTP	AFLSSRSPDY	REGDGNRSHV	YQDLLPSSRN	TNGTVPQPFP	420
LQSGILIPVS	QGQPISTSSV	LNQEEAYVTM	SSFYQNK			457

SEQ ID NO: 48	moltype = DNA length = 3124
FEATURE	Location/Qualifiers
source	1..3124
	mol_type = other DNA
	organism = Rattus norvegicus
SEQUENCE: 48	
agagctgggt ttggctcc cctcttcat tcacttgcgc acacaagtgt gcttcttc 60	
tcttctct ctcagaatga tggctctgg tagagcttc gctatagtt tctgcttaact 120	
tcaagctgtc tctggagaaa gtggcaatgc ccaggatggaa gatctagagg atgcggaaacc 180	
agatgatcac tccttcgtgt gcccacagc gcttggaaatgt gatggaaatc agcactcact 240	
gacgtgtgtc ttaatgacc cagacataaa aaccataat ctggaaatttc aaatatgtgg 300	
ggctcttcata ggcatgattt gcctaaacttataataagctt caagagatgtt attttataaaa 360	
gacatcaaaa ttcttactga ttggtaacag cagtgtatgt gtgaagctg gaaaaatgg 420	
tgtatgttgc aaaattttggtt acataaggac aatagttaaa ccttgaggccgc cttcttaacct 480	
gaaaggatgtt tatacgaaaag aagcaaatgtt cttttttggat aatcttataatc catctcactc 540	
aacaaagaaaa tatgtaacatg cattaaagca tgatgtggcc taccggccag aaagggttgg 600	
aagtaactgg acgcacatgtat attttttcca tacaagaaca acaatcttac agaaaaaact 660	
acaaccaaaa gcaatgtatgtt aaatcaatgtt ccgcatttcccaatcatg aatacttcaa 720	
aggcttcgtgg agtggatgttgc gtccaaatgtt tacctttggaa acaccaatgtt ccaatgtatca 780	
aggggggatgg gatccgggtt tgccaaatgtt catcttcgttgc atgggtttctt ctatgggttt 840	
gttgggttattt ttagccccatg tgctatggaa aaaaaggatgtt aaacctgttgc tatggccat 900	
tcttcctgtat cataagaaaa ctctggaaaca actatgttgc aagccaaaaa agaattttggaa 960	
tgtggatgttgc tatacgaaaatgtt gtttccatgttgc ctggccatgtt catggatgttgc atggcatatca 1020	
agccaggatgtt gaaatgttgc gctttctgttca aatatgttgc ctccacggc ctggggatgtt 1080	
ggagaagcag ggacatagatg cactgtaca cgggtcaaaatc tggccatctg agatttcagg 1140	
cagcacacca gaaacgttcc gaagagaatc accccataaga tgcctggctt gaaatcttcaag 1200	
cacatgtcaat accccctgtat tccttccttgc taggttcccttgc gactacagag aagggttgcgg 1260	
aaataggatgttcatgtgtatc aagactgtgttgc gcaagcttc agaaacacaa atggcactgtt 1320	
ccctcaacca ttcccttccttgc agtggatgttgc cttgtatccatg gtttctcaag gacagccat 1380	
ctctacttcttcttgc tcaatgttgc atcaagaaga agcatatgttgc actatgttgc tcttttacca 1440	
aaacaaatgtt attataagaaatgttgc cttttccatgttgc aaccaatgttgc gatcaatgttgc 1500	
atggaaatgttgc ttagatgttgc gtctccatgttgc tagtctttatgttgc aagagaaatgttgc caacatgttgc 1560	
ttgctacaca tcttcatgttgc tctaaagaaatgttgc ctttttgc tcttagatgttgc aagacatgttgc 1620	
ttcaaaaggatgttgc cttttccatgttgc gtttccatgttgc tcatatgttgc acaaattgttgc 1680	
caattttatgttgc aattttatgttgc agatgttgc aagatgttgc gaaatgttgc aggagggttggaa 1740	
tacaggaaga agagaaggatgttgc ttagatgttgc gtttccatgttgc taggttccatgttgc tataatgttgc 1800	
gcacatgttgc ttagatgttgc gtttccatgttgc aacaaatgttgc tacaatgttgc gtttccatgttgc 1860	
tagaattgtt atttttttgc tctatgttgc tgaatgttgc aatgttgc aatgttgc ttttttttgc 1920	
gttcaggatgttgc tttttccatgttgc aacatgttgc gcatgttgc cactatgttgc ctttttttgc 1980	
catgttgc tttttccatgttgc gtttccatgttgc gtttccatgttgc aatgttgc ttttttttgc 2040	
aatccaaatgttgc gtttccatgttgc gtttccatgttgc aatgttgc aatgttgc aatgttgc 2100	
tgtatgttgc ttagatgttgc gtttccatgttgc gtttccatgttgc ctttttttgc 2160	
gaacatgttgc ttagatgttgc gtttccatgttgc aatgttgc aatgttgc aatgttgc 2220	
gttggggatgttgc gtttccatgttgc aatgttgc aatgttgc aatgttgc 2280	
aacccaaaaatgttgc gtttccatgttgc aatgttgc aatgttgc aatgttgc 2340	
tcttcctgttgc gtttccatgttgc aatgttgc aatgttgc aatgttgc 2400	
cctacatgttgc gtttccatgttgc aatgttgc aatgttgc aatgttgc 2460	
ttaccccaatgttgc gtttccatgttgc aatgttgc aatgttgc aatgttgc 2520	
acctcgttgc ttttttttgc aatgttgc aatgttgc aatgttgc 2580	
tactcaatgttgc aatgttgc aatgttgc aatgttgc 2640	
tgttgc ttttttttgc aatgttgc aatgttgc aatgttgc 2700	
cattaaatgttgc gtttccatgttgc aatgttgc aatgttgc aatgttgc 2760	
catgttgc ttttttttgc aatgttgc aatgttgc aatgttgc 2820	
atactcgttgc aatgttgc aatgttgc aatgttgc 2880	
tatgttgc ttttttttgc aatgttgc aatgttgc aatgttgc 2940	
gaactatgttgc ttttttttgc aatgttgc aatgttgc aatgttgc 3000	
tatgttgc ttttttttgc aatgttgc aatgttgc aatgttgc 3060	
ctcttcatgttgc gtttccatgttgc aatgttgc aatgttgc aatgttgc 3120	
ggaa	3124

SEQ ID NO: 49	moltype = DNA length = 27
FEATURE	Location/Qualifiers
misc_feature	1..27
	note = synthetic oligonucleotide
source	1..27
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 49	

-continued

gggatcaata ctatgggtgg tttataaa	27
SEQ ID NO: 50	moltype = DNA length = 20
FEATURE	Location/Qualifiers
misc_feature	1..20
	note = synthetic oligonucleotide
source	1..20
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 50	
acctcagtagt tctcaagaag	20
SEQ ID NO: 51	moltype = DNA length = 24
FEATURE	Location/Qualifiers
misc_feature	1..24
	note = synthetic oligonucleotide
source	1..24
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 51	
ctacacttgg gagtgaaatg catt	24
SEQ ID NO: 52	moltype = DNA length = 21
FEATURE	Location/Qualifiers
misc_feature	1..21
	note = synthetic oligonucleotide
source	1..21
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 52	
ggagggact cttacacttt c	21
SEQ ID NO: 53	moltype = DNA length = 24
FEATURE	Location/Qualifiers
misc_feature	1..24
	note = synthetic oligonucleotide
source	1..24
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 53	
ttggagaatg acttgccgc tgtc	24
SEQ ID NO: 54	moltype = DNA length = 23
FEATURE	Location/Qualifiers
misc_feature	1..23
	note = synthetic oligonucleotide
source	1..23
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 54	
cctctgcttc ctgtttttc aca	23
SEQ ID NO: 55	moltype = DNA length = 22
FEATURE	Location/Qualifiers
misc_feature	1..22
	note = synthetic oligonucleotide
source	1..22
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 55	
cagggaacg aagaatttag ca	22
SEQ ID NO: 56	moltype = DNA length = 28
FEATURE	Location/Qualifiers
misc_feature	1..28
	note = synthetic oligonucleotide
source	1..28
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 56	
tgtgggtatt aatcaccagg acagaggg	28
SEQ ID NO: 57	moltype = DNA length = 23
FEATURE	Location/Qualifiers
misc_feature	1..23
	note = synthetic oligonucleotide

-continued

```

source          1..23
               mol_type = other DNA
               organism = synthetic construct
SEQUENCE: 57
acaagccatt tgcagtattt tca                                23

SEQ ID NO: 58      moltype = DNA  length = 21
FEATURE
misc_feature       Location/Qualifiers
1..21
note = synthetic oligonucleotide
source            1..21
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 58
tgggtcagtt tggctatcca t                                21

SEQ ID NO: 59      moltype = DNA  length = 30
FEATURE
misc_feature       Location/Qualifiers
1..30
note = synthetic oligonucleotide
source            1..30
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 59
tcttttccca gaacaatgaa gatgttatgg                                30

SEQ ID NO: 60      moltype = DNA  length = 22
FEATURE
misc_feature       Location/Qualifiers
1..22
note = synthetic oligonucleotide
source            1..22
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 60
tgctttgggt actgtcctga ag                                22

SEQ ID NO: 61      moltype = DNA  length = 9475
FEATURE
misc_feature       Location/Qualifiers
1..9475
note = Targeted Tsip allele, genomic DAN (total 9475 bp)
misc_feature       1..238
note = Mouse Sequence
misc_feature       18..20
note = Start Codon
misc_feature       18..21
note = Coding Exon 1
misc_feature       239..2166
note = Human Genomic Fragment 1
misc_feature       2167..6610
note = Puro Self-Deleting Cassette
misc_feature       2167..2172
note = Nhel
misc_feature       2173..2198
note = I_Ceu
misc_feature       2205..2238
note = LoxP1
misc_feature       6571..6604
note = LoxP2
misc_feature       6605..6610
note = Xhol
misc_feature       6611..8782
note = Human Genomic Fragment 2
misc_feature       8780..8782
note = Stop Codon
misc_feature       8783..9475
note = Mouse Sequence
source             1..9475
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 61
cacgttcagg cgacagcatg ggtgactatg ggctgtcgac ggactggaa ggggtggta  60
gggctgatac ccgagcacag tctttgcagg tctggaggct ctccccgctt agagggcag  120
ttccacggaa aacagatgtt gaactgtgtt tcagtgaaa tttttcttac ttgtgtctt  180
tccagttctt ctcaggagcc tcttcatctt gcaagtacta gtacggatgg ggctaactt  240
cgacttcact aactgtgact ttgagaagat taaaggcagcc tatctcagta ctatttctaa  300
agacacctgatt acatatatgaa gtggggtaag tgaagaagct tttttaaaac aaatgtattt 360

```

-continued

tcatcagagg	agtccggata	cacacactct	acaatattaac	ttttaggaa	agaaaaataa	420
tttagaaaaa	atcatggccc	cacatttgt	caaggattct	tacaagtgt	atccaatata	480
ctaatctaaa	atgattatct	agaaaattggc	acattctaag	tgtgcagatg	ctgatgagga	540
gcaggtattt	atagacagcg	cgttatgcgt	caaaggatgt	ctatccttgc	ctaaagtgtt	600
actctgacta	tgctgtaaaaa	agcaggaggt	aagagcttaa	gaaagaggag	taaaaagagat	660
aattctcatg	agataaaactc	taaggattga	tgtgtgtc	cagggttc	cagtgtttt	720
gatgtttcag	gatgttattt	attacagaata	atgggttact	tggaaattttt	tttaacatata	780
agtagtaatc	atttctgtt	ttaacataat	ttttagacag	agtttgattt	catgaatggc	840
cacagtagac	atgcggacat	ccaaaggatg	gcattattac	tcacaagcat	agtgtatgt	900
gcagttatgg	cttggggaa	gggggggggg	agggtgcgcct	ctgagac	aaccctttgg	960
tgtgtttca	agcactaaacc	agcactata	aatggctat	tcaactgc	gtcaatgaca	1020
tagaaaaaaag	gtacccgtgt	ggaaactgtt	ttcaggggcac	ctttaaaggcc	ttggagcaaa	1080
gggtgggggg	atgattttcc	tttgggactt	aaaagtctt	acccttcttgc	tccttatttt	1140
cttcttccca	gaccaaaatgt	accegttca	acaacacccgt	ctcttgc	atccgggtga	1200
gttagagagtt	cagtgtgtc	ggctttctcc	agggagacgc	caggcattt	ggagagggag	1260
tatccctgtt	cgtcagaact	tccggaggt	qcttgggtc	ccggacggcc	ccggccgggg	1320
aaaggggaca	tctgggctgt	cagagcgggg	ctgcccctag	cttgggacaa	cacttctgtt	1380
ccaaatctttag	gagggaaatgt	ctcttccgg	aggaaaggcc	aattgggaaac	ttggacgagg	1440
gaacgttgtt	agggggccacca	cctgtgtgggg	tcggcgcct	cgcgetccg	gtccggatt	1500
tttgcagocct	ccggccctgt	gagacttggg	aggagcgc	gtgggtgaca	gtctttcgc	1560
gacgggtgc	ctccgcaccc	ctcgccacgc	ccctgctccc	ccgcgttgg	tttttcttgc	1620
cttctactca	ccctgcaccc	tttcttctgt	ctctcgtact	gtgttccccg	ctccctccctg	1680
acettcttcc	cttcccttctt	cacttcaattt	tcaccaactt	tttctctctc	tgggttttc	1740
tcttttttctt	gttaaacttttgc	ccgccttata	gcaagccat	tgccttacttgc	aatccagag	1800
cctaacccttca	aatccacccg	ccgggttgcgc	gtcgctegcc	aaagaaatgt	tcgcctatgaa	1860
aactaaggctt	gccttagtca	tctgtgtcc	aggcttatttgc	taagacttgc	taagcccgaa	1920
gcctcagacg	tttgcgtgtac	cttggggctt	accccttataat	aaatggggc	tttgggtgcag	1980
aagtctgttct	tttatttttgc	tttaggtttt	atcttcgaa	gagcaacaa	ggccgggtaaa	2040
agtggttaga	tgtcgtttag	acccacgttgc	ataccggaa	tcaaaacttac	ctatattttc	2100
ggttctgtata	ctgttttgc	tgaattatgg	ttcttaaaccct	tagggcaat	tttcaagcta	2160
tgtatgatca	gtcgcttcc	ttagggaccgt	tatagttactt	tagcataact	tcgtatagca	2220
tacattatac	gaagttatct	aggccgcctc	agaaggccata	gagccacccg	catcccccac	2280
atgcctgttca	tttgcgttccc	aatcttcccc	cttgctgtcc	tgccccaccc	caccccccac	2340
aatagaatgt	cacccacttca	gacaatgcga	tgcaatttcc	tcattttttt	agggaaaggac	2400
agtgggaggt	gcaccccttca	gggtcaaggaa	aggcacccggg	gaggggcaaa	caacagatgg	2460
ctggcaacta	gaaggccacag	tcgaggctga	tcagcgcgttgc	sttagtacatc	gatgcatggg	2520
gtcgtgtgc	cttttgcgtc	ggggcgttgc	gggtcgtgggg	ccggcgttgc	gcacccgggt	2580
tgccgggtcat	gcacccgttgc	cgccgttcc	ccggcaccc	gacgtcgttgc	gtgacgggttgc	2640
agcccgagcgc	cttcgttgc	gggggttgc	ggggcgttgc	gggtctcc	aggcggggca	2700
ccccggggcc	tcggccgttgc	tccacttccgg	ggagcacac	gggcgttgc	agacccttgc	2760
ccttgggtgc	ggggcgttgc	ccggcgttgc	ccaggaacca	ccgggggttcc	ttggggccgt	2820
ggggcgttgc	ggggcgttgc	atctgttgc	gcccggccac	ccgggaaacccg	ctcaactcgg	2880
ccatcgccgg	gcgcgttcc	gcgcgttcc	cccccgttcc	gacgttcc	ggcgttgc	2940
agaccggccac	cgccgttgc	tcgttgc	ccccacactt	gcccgttgc	agcccgacgc	3000
gcgttgcggaa	gagtttttgc	agtcgttgc	cccgcttgc	gtggcggttcc	ggatcgacgg	3060
tgtggcggtt	gggggggttgc	tcggcgttgc	ccggcgttgc	gggtcgttgc	gccctgggg	3120
cgtcgttgc	gggggggttgc	ccgcacccgttgc	gggttacttgc	gggtcatgttgc	tagttcc	3180
cattgtgttca	tttataacttgc	ccgtatatact	atgcccgtat	ttaatgttca	acacgttca	3240
aaaaaaaggcc	aaaaacggcc	agaaatttgc	ggacaatttca	ttatgttca	actgttca	3300
acatatttgc	ccaaatgttca	acatttcaaa	aggtgcctaa	aaaacttac	aaaacacact	3360
cgcccaaccc	gagccgtat	ttcaaaacccg	ggatgttgc	tacttaccaaa	gatagggtaca	3420
taaaaccggac	caaagaaact	gacgcgttcc	ttatcccttcc	cctcaccaga	ggtccggcgc	3480
ctgtcgatttca	aggaggttcc	accccttgc	cgaaaccttgc	gtcttgc	ggagaaaaccc	3540
ctaccgcaca	cttaccggca	ggtggcccca	ccctgttca	taagccaca	gaacgggttgc	3600
cgttcacgaca	cgacggggc	ggccgttcc	aaagggttgc	gtgcacttgc	caacggccac	3660
gccttgcata	cgccccccttgc	aaacacac	ttccacttgc	ttccacttgc	tgacaaactt	3720
cacgttgcgg	tcccttgcgt	gttcc	ccatcttcc	cgatataac	ttttccgc	3780
tttagcgttgc	tttgcgttgc	tttgcgttgc	ggcccccaccc	atggccccc	cttgcgttca	3840
acgaccccttca	accccttgc	acaacgttgc	ttccatcaat	actcggttgc	agccggccat	3900
tttgcgttgc	ccccccaaacc	ccccgttgc	ggcaaccc	ttccgttgc	ccggccgttgc	3960
cccttgggg	tttgcgttca	cgccgttgc	ccacccgttgc	ggccggccgc	caacggaaaccc	4020
ccggccgttgc	cagccgttgc	ctacttca	agtgacgttgc	acagcgatcc	acaaaacaaga	4080
accggccgttgc	aaatccggc	tgccgttgc	caccccttgc	ggccgttgc	ggccgttgc	4140
ataatcatcg	gggttcc	ccccacccgg	atcccttgc	agaatcgcc	agaagggtact	4200
acttttctc	ccctgttgc	ctcttgc	agaaaaccat	ttcccttgc	ttacccaaat	4260
cccttgcata	aatgttcc	tgctgttact	gggttcttca	ggccgttgc	tatgtacgttgc	4320
ggggccgttgc	cttgcgttgc	ccggcgttgc	gatcggac	ccgttgc	ccttgcgttgc	4380
acgttgcgttgc	gggggggggg	ccggccgttgc	aggcgttgc	ccggccgttgc	ggccgttgc	4440
gaggccatgt	tcccgccgg	tccacttgc	aactcttgc	gggggttgc	ttttccgc	4500
gacatgtata	gatacatgttgc	tgatgttgc	caaaccacaa	cttagatgttgc	gtaaaaaaa	4560
tgcttttttgc	tgatgttgc	tgatgttgc	tttttttttt	taaccat	aaatgttgc	4620
aaacaagtttca	acaacaacaa	tttgcatttca	tttatgttgc	agggttgc	gggggttgc	4680
gagggttttttgc	aaagcaagtttca	aaatgttgc	tggcttgc	ttttccgc	gggggttgc	4740
gccttacatcg	cattttcc	caggcgttgc	atttgc	ttttccgc	cagggttgc	4800
atatagttca	tgacaaatatttca	tacattgttgc	cagccacca	tttgcgttgc	ttttccgc	4860
gaaaacttcc	cgccggccat	atctcgcc	ggccgttgc	ggccgttgc	ttttccgc	4920

-continued

-continued

-continued

tcttgcgcct	ataacttctg	tgaagactta	gttaaattac	ttagcctccg	tgtactgttag	2700
cttcatgggt	aaagtaaatgt	tcatatca	tagtcttata	caggtgttt	ctgaggatta	2760
aattatgtcaa	cacatgtaaa	tgcagttgg	acagtgcctg	gtacacaaca	ggcactcaat	2820
atttatttca	gtcagcaagt	agaggattt	tcttcatgg	gacaagttt	aggaacagag	2880
agagacaagt	gcagatatgt	ttgattgtct	cttattagcc	tagtgaccc	tatatgtcta	2940
cagtcttaggt	agatggacac	gactgtca	ttttttttt	ttttttttt	gagacagaat	3000
ctcgctctgt	tacccaggct	ggaatgcgt	ggcacgatct	cagtcactg	caacccatcat	3060
ctctctgggtt	caagcctcag	cctcccgagt	agctggaa	acaggtgccc	gccaccacgc	3120
ctggctaaact	tttgatattt	tagtagagac	ggggtttac	catattggcc	aggttgtct	3180
cgaattccct	acccatgtat	ctgcgtgc	cggcctccca	aagtgtgga	attacaagca	3240
tgagccacca	tgcccagcca	aaactgtc	tttttagagg	ttgaggat	aaggccatagc	3300
gtcgatctgg	gttgagcttg	aattagaaac	tcaataccag	acagccat	gggaaaccta	3360
tttggcttca	tgcccttctt	tgaaggagac	cctggcaat	ctgcagatgg	ctacaataaa	3420
attcattttaa	ataagagcac	aaacaaaaaa	ctagatca	ttcttgacca	gcatgtgaga	3480
aaggggaggt	ttggagaaat	ttatgttca	ccctcccaag	cccaaatgga	gagttaaga	3540
ctaataataa	tgatatttca	ggttttttt	agatttgc	ttaataaccc	tgtacttta	3600
ttaatttca	taccatgtgt	ctaggaggcc	cagtgtacta	ctcaaaaggta	attcagataa	3660
aggttatatac	tgcaatccctc	ttttttttt	gcccctcgat	gtctgtgaca	catctagaca	3720
atggggcagg	ggggggggaa	ggatgggggg	caggagcatg	cattttgggt	ccaaaaaaata	3780
gacttaggtt	attgaatgtat	gtcttacaa	aggtaataa	tagcttgc	ccatgaggaa	3840
cttggatct	tgtcagggag	gtcttgaat	cagcaatttta	ttcatttact	taatcactca	3900
acaatatttac	atgtttccct	atgtttaa	cactgttact	agtgttatgg	ggaataacta	3960
tgatgcata	taaagaaaaag	catgttta	gagagccaa	ttaaatgaca	cacactctta	4020
agtactgttttt	ttttttttt	ttttttttt	tgagcaat	gtggaggctt	tttgaaggag	4080
gtgtgtgttg	gccttgaagc	aaaagttaggt	gggtacagaa	acaggaaggc	atccccctgg	4140
aaaaggcaca	tgcttagcaca	tagtaagc	gtgttttgg	gacacactga	aagatggatt	4200
tgoatagaga	aggcaatcaa	acctgtctc	aacagtta	aaagatgtg	aaaagtaatt	4260
tttgactattt	attttttat	tctgcagata	aatgttact	aggcaatgaa	gaagaggaga	4320
aaaaggaaag	tcacaaccat	taaatgtctg	gaacaagtgt	cacaattaca	aggattgtgg	4380
cgtcgcttca	atcgaccctt	actgaaacaa	cagtaaaat	agctttcagc	ttctgtctat	4440
aaaatctctt	tcttgggtt	atgttggat	atactaaagg	tgtgacactt	agaggacac	4500
tggtggat	tcttttaat	cagaaggat	tcttaactt	ttttttggca	tatcgcttt	4560
ttcagtagat	gtgttttaaa	tggaaatg	gcaatagacc	gttaatggaa	atatctgtac	4620
tgtaatgac	cagttcttca	gaagtctt	tcacccccc	tgcacacacc	ttactcttag	4680
gcacaaccat	ctgttaggg	aagagaattt	aaaatggaaa	aaaccaatga	4740	
cagcatctaa	accctgttta	aaggcaagg	attttctac	ctgtatgtat	tcttctaca	4800
tttctatgt	aaagtttac	aaacaaagaa	aatgtacgtt	cgggcagtc	ctgcccattat	4860
gagggtgtct	gaaagaagat	tgtggatct	ggggaaaact	gctgagatca	tattgcaat	4920
ccagctgtca	aaagggttcag	acccaggaca	gtacaattcg	tgagcagatc	tcaagagcc	4980
tgcacatcta	cgagatata	atttaaatgt	tgatgataatg	aattttctat	ttatgttgc	5040
agcacttttgc	gaaatataca	tgacttgc	taatgataac	atttctgaat	aaagtaattc	5100
tcaagtttgc						5109

```

SEQ ID NO: 63          moltype = DNA  length = 20473
FEATURE
misc_feature           Location/Qualifiers
1..20473
note = Targeted Tslpr allele 7558, genomic DNA, total 20473
bp
misc_feature           1..1051
note = Mouse Sequence
111..113
note = Start Codon
111..189
note = Coding Exon 1
1052..5860
note = Neo Self-Deleting Cassette
1052..1057
note = Xhol
1058..1091
note = LoxP1
5790..5823
note = LoxP2
5824..5829
note = I_Ceu
5855..5860
note = Nhel
5861..19603
note = Human Sequence
19604..20473
note = Mouse Sequence
20336..20338
note = Stop Codon
source
1..20473
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 63

```

-continued

ggcccccgtt	tcccggtt	ggctctaagg	ggctggcg	ccctcgactc	ggaccggctc	60
ggaccgaaac	actgtcaat	cactgcgg	tcggcgccc	cgccggcac	atggcatgg	120
cactcgccgt	cactcctgt	cctcggtt	ttcgccggc	agccggggcg	gcggccgtga	180
cgtcacgggg	tgaggagtga	ggggggcg	ggctgcgt	caatcgccg	ggtggccgg	240
gccccgagca	gagctaccat	gttgcgtt	gtcccatcat	tgctttcg	cccatcatga	300
atatgaaat	aaggccctcg	gccctccata	gggcgatcg	atagcgctc	gttgcata	360
tcattttgtat	cttgcgtat	geatgagccc	cgccttccc	ccctacgctc	ggcgcttct	420
cctcagtaat	atgcaaatga	gacctaacc	ccgccttgac	ctcattagca	tagtgcgtc	480
gccacaatct	cgctccct	cctgaatatg	caaataaggc	ctctggccg	ctccttctt	540
gcataatcat	atacagctt	cccggttata	tgcaaataac	gttgcoccc	taccgagg	600
tcactcatcg	tttgcgtt	geatatccat	cgggagatac	acatattcat	gagcgatgt	660
tttctgtttt	ccatccctc	atgatata	aatttgatgc	ctgtccat	ggatcactat	720
gcatttgc	attttccca	cgatttacat	atgcacaage	ctcaacgtc	tgctccaacg	780
tcctgtatca	tgaatatgc	gatgagac	caatatctcc	aaatgtatc	tgcccgctc	840
tcatcatata	ctgtatct	catatgcacc	agccacaaag	tettccatcc	ttttccctc	900
atgaatatgc	aaagaatgtc	tcccgatcc	atctccactc	tggttactc	cctgtatc	960
tgtgtatcca	ttggtgcgtt	tgcatagtgg	tgagcccccg	ttccctaccc	cttcttgc	1020
gatcatgtat	atttccat	ggctccgact	tgtcgatata	acttgcata	atgtatgtc	1080
tacgaagttt	tatgcgtcc	agtagcagca	cccacgttca	cettctgt	agtaatgtcc	1140
aacacccccc	ttagtccaaa	cactcgctg	catccatgtg	gttccattt	atacctgaag	1200
cacttgcgtt	ggcctcaatg	ttttaactaga	gcccaccccc	ctgcaactc	gagaccctc	1260
ggatttgc	gtcagtgc	cactggggcg	ttggataat	tcttaaaagg	tcaagttccc	1320
tcagcagcat	tctctgagca	gtctgatag	tggtgtt	cacagtccaa	atccatgtgg	1380
ctgtttacc	cacctgcgt	gccttgggtt	atctatcagg	acctagctca	gaagcagg	1440
tgtggcactt	aacacctaag	ctgagtgc	aactgaacac	tcaagtggat	gccatcttgc	1500
tcacttcttgc	actgtgacac	aagcaactcc	tgatgcca	gcccgtccca	ccccctctat	1560
gccccatattt	ggacatggta	caggctctca	ctggccatgg	tctgtgagg	cttggctcc	1620
tttgacttca	tatttcttag	ggggccatag	tatttata	aggaaagagg	tgctggctcc	1680
caggccacag	cccacaaaat	tccacactgt	cacaggtgg	ctggctcgac	ccaggctgg	1740
tccctgtc	tgagccag	cccgcccaag	ccaggccat	gggaaccccc	aagaagaaga	1800
ggaagggtgc	taccgat	aatttcaatt	tactgaccgt	acaccaaaat	ttgctgtat	1860
taccgggtca	tgcaacg	gatgggtc	gcaagaaact	gatggacat	ttcaggatc	1920
gcccgggtt	ttctgagcat	acctggaaaa	tgcttctgtc	cggttgcgg	tcgtggccg	1980
catgggtca	gttgaataac	cggaatgtt	ttcccgca	acctgaagat	gttcgcgtt	2040
atcttctata	tcttcaggcg	cgccgttcttgc	cgataaaaac	tatccacgca	catttggcc	2100
agctaaacat	gttcatcg	cggttccgg	tgccacgacc	aagtgcac	aatgtgtt	2160
cactgggtt	ggggccgtc	cgaaaaaaa	acgttgc	cggtgaac	gcaaaacagg	2220
taataatataaa	attttaagt	gtataatgt	gtttaactac	tgatttctat	tgtttgtt	2280
ttttaggtc	tagtgcgt	acgcactt	ttcgaccagg	ttcggttact	catggaaaat	2340
agcgcgtcg	cccgaggat	acgtatctg	gcatttctgg	ggatgttta	taacaccc	2400
ttacgtatag	ccgaaattgc	caggatcagg	gtttaagata	tctcaegtac	tgacgttgg	2460
agaatgtta	tccatattgg	cagaacgaaa	acgctggta	gcaccgcagg	tgttagagaag	2520
gcacttgc	tgggggttac	taaattgttgc	gagcgatgg	tttccgtctc	tggtgttagt	2580
gatgatecg	taaactact	gttttgcgg	gtcagaaaa	atgggttgc	cgccgcacat	2640
gccccaccc	actatcac	tcggcccttgc	tcggggat	ttgaagcaac	tcatcgatt	2700
atttacggc	ctaaggat	ctctggtca	agatacttgc	cctggcttgc	acacagtgc	2760
cgtgtcggag	ccgcgcgaga	tatggccgc	gttggagg	caataccgg	gatcatgca	2820
gtctgggttgc	ggaccaatgt	aaatattgtc	atgaactata	tccgttact	ggatgtgaa	2880
acaggggccaa	ttgtgcgc	gcttggat	ggcgattagg	eggccggcc	ctaattcagcc	2940
ataccacatt	tgttaggtt	ttactgtt	taaaaaac	cccacaccc	ccccctgaacc	3000
tgaacataaa	aatgtatgc	atttgttgc	ttaacttgt	tattgc	actataatgtt	3060
acaatataaa	caatagcatc	acaatattca	caaaataagg	atttttca	ctgcatttca	3120
tttgggttgc	gtccaaactc	atcaatgtat	cttatcatgt	ctggatcccc	cggttagat	3180
ttaaacacta	gaactagtgg	atccccggg	atcatggct	ccgcgeccgg	tttggcgcc	3240
tcggccggcc	gccccctcc	tcacggcg	cgctgccc	tcagacgaa	ggcgccacg	3300
ggtctctgt	cttccggccc	ggacgctcg	gacacggcc	cgctgtccat	aagactcg	3360
cttagaccc	cagatcgtc	aaaggacat	ttttaggcgg	gacttgggt	actctaggc	3420
actgggttcc	tttccagaga	gccaacagg	cgaggaaaag	tagtccctc	tcggcgat	3480
tgccgggg	tcttgcgtgg	ggcggttgc	ccgatgttata	aggatgttgc	ccgggttgcgt	3540
ggcacacgt	tttccgtcgc	agccggat	tttggccgg	ttcttgcgtt	tggatcgct	3600
tgatcgat	tttgcgtat	gggggttgc	gggggttgc	gggggttgc	ggccggccgg	3660
ccgcgtcggt	ggacggaa	gttggagag	accgccaagg	gttgcgtat	gggttgcgt	3720
gcaagggtgc	cctgaactgg	gggttgggg	gagcgacgca	aaatggcg	tgttcccgag	3780
tcttgcgttgc	aaagacgttgc	tgaggccgg	tgtgagggtt	ttgaaaca	gtggggggca	3840
tggtggccgg	caagaatcca	aggcttgc	gccttcgtat	atgcggaaa	gtctttattc	3900
gggttgcgtat	ggcttggcc	ccatcttgg	accctgcgt	aaatgttgc	actgactgga	3960
gaactcggtt	tgtgtctgt	tgccggggcg	gcagttatgg	cggtgcgtt	gggcgtgtca	4020
cccgtaatctt	ttggagcg	cgccctcg	gtgtcgat	gttgcgt	gtcaccctt	4080
ataatgcagg	gtggggccac	ctggccgt	gtgtgcgtat	ggcttttctc	cgtcgcagg	4140
cgcagggttcc	gggccttgc	taggttgc	tgaatcgaca	ggcgcggac	ctctggtgc	4200
gggggggata	agtggggcgt	cgtttctt	ggtgcgtt	atgttacat	cttcttaat	4260
agctgaatgt	ccgggttgc	actatgcgt	cggggttgc	gagtgtgtt	tgtgaaat	4320
tttaggcacc	ttttgaaat	taatcatttgc	gttcaatata	taattttgc	tgttagacta	4380
gtaaattgtc	cgctaaat	tggccgtttt	tttagacgt	ttgacaatta	4440	
atcatcgca	tagtatatgc	gcatagtata	atacgaca	gtgaggaa	aaaccatgg	4500
atcgccatt	gaacaagat	gatttctccg	ggccgttgg	tggagag	4560	

-continued

attcggctat	gactgggcac	aacagacaat	cggctgtct	gatgccgcg	tgtccggct	4620
gtcagcgcag	gggcgcggg	ttcttttgc	caagaccgac	ctgtccggc	ccctgaatga	4680
actgcaggac	gaggcgcgc	ggctatctgt	gctggccacg	acggcgcttc	cttgcgceagc	4740
tgtgctcgac	gttgtactg	aagcggaaag	ggactggctg	ctattggcg	aagtgcggg	4800
gcaggatctc	ctgtcatctc	accttgcctc	tgccgagaaa	gtatccatca	tggctgtatgc	4860
aatgcggcgg	ctgcatacgc	ttgatccggc	tacctgccc	ttcgaccacc	aagcgaacaa	4920
tcgcatacgag	cgagcacgt	ctcgatgg	agccggctt	gtcgatca	atgatcttgg	4980
cgaagagcat	caggggctcg	cgcacccga	atgttgcgc	aggctca	cgccatgc	5040
cgacggcgat	gatctcg	tgaccatgg	cgatgcctgc	ttgcgaata	tcatggtgg	5100
aatatggcgc	ttttctgtat	tcatactgt	ttggccggct	gggtgtgg	accgtatca	5160
ggacatagcg	ttggctatcc	gtgatata	tgaaagact	ggcggcgaat	gggtgtaccg	5220
cttcctcg	ctttacggta	tcgcgcctc	cgatcgac	cgccatcgct	tctatcgcc	5280
tcttgcac	ttttcttag	gggatccgt	gtaaatgtc	agaaattgt	gatctat	5340
acaataaaaga	tgttcaacta	aatggaaat	tttctgtca	tactttgt	agaagggtga	5400
gaacagagta	cttacat	aatggaaagg	attggagat	cgggggtgg	gttgggttgg	5460
gatttagata	atgcgtctc	tttacttgc	gtctttact	attgtttat	gataatgtt	5520
catagttgga	tatcataatt	taaacaagca	aaaccaaatt	aaggccagc	tcattcc	5580
cactctat	ctatagat	atagatctt	cgtggatca	ttgttttct	cttgatccc	5640
actttgtgt	tctaaat	gtgggttca	aatgtgtca	tttcatagcc	tgaagaacga	5700
gatcagcgc	ctctgttca	cataactt	atctcgt	ttgttttgc	aagtctta	5760
tccatcgac	ctcgacatgc	agccccat	taacttgc	taatgtatgc	tatacgaat	5820
tatgtacta	actataacgg	tccttaaggta	cgccagatgc	catttgc	ttgtgtgt	5880
gtgtgtgttt	gagaaagaca	gtaaatgt	tcgtatgg	cgttccga	tgccaccc	5940
gttatccaca	ggggatgtgt	ttgttgcata	atgttgcata	tatacagata	cattgtgc	6000
tggcactagt	gggtgtactt	acctttgc	aaaacaaaaa	caaaacagc	cggggcggt	6060
gggtcagcc	tgcaatctca	gcactttag	ttggatgg	gggcggatca	cgaggctcagg	6120
agatcggac	cattcttgc	aacacatgt	ttactaa	ttactaa	ttactaa	6180
tatccaggca	ttgtggccgg	cacctgt	ccctgtact	cgggaggct	aggcaggaga	6240
atggcgtgaa	cccgaggagc	ggagcttgc	gtgagccag	attgcocac	tgcaatcg	6300
cctgggtgac	agagtggag	tctgtctca	acaatacact	acactacact	acactacact	6360
acactacact	acactacact	acaatacata	gcaatacata	gcaatacata	acgtcaggcg	6420
cgttgcgtca	ccgcgttata	ccctgtactt	ttggaggcc	aggcgggttgg	atcatgggt	6480
caggagatcg	agaccatctt	ggctaacc	gtgaaacccc	gtctacta	aaaatacaca	6540
aaatttagca	gggtgtgt	cagggtc	taatccgc	tacttgc	gctggccag	6600
ggaaatcgct	tgaaacccgg	aggcggatgt	tgcaatgc	cgagatcgt	ccatgtact	6660
ccagcctgg	caacagatgt	agactctgt	tcaaaaagaa	aaataattt	aaaaataata	6720
aaaaatagag	ttgccttacc	gtgaacttca	tgcttcttc	tgtgtatgc	agaaggagta	6780
cgattcaga	tatctactt	caatttagaa	accgtgc	tgacatgg	tgccagcaaa	6840
tactccagg	ccaaatctg	tttccactt	aggtaatgt	cccccaaaa	gcgaacccca	6900
cgccaggagg	gtctaaatc	gtcttgc	ggcgtc	atggggat	tttgcgaa	6960
aaagtgtaa	gtatcagact	gtcaagccg	gtatgttgc	tctgttgc	cctcagcc	7020
caccacaacc	acaatctcat	tgccccaa	tttcttgc	aggggatgt	gactcact	7080
aaaaatcaac	tatcttctt	ttttttgtt	ttttttttt	gatgtgg	ctcaatcc	7140
tgcacatcg	gatgtcgt	gtcaatctc	ggctcact	ttccctgc	ttccgggtt	7200
aagccatccc	ctgcctc	cctcccg	agctggatt	acaggcact	gccaccat	7260
ctagctaatt	tttgcattt	tagtagat	gttgcattc	catattgtc	aggccgtt	7320
caaaatcttgc	acctctgt	atccaccc	ctcagcttcc	caaaatgt	ggatgtacgg	7380
cgtgaggcc	ggcattccg	ctgaaaatca	cttagattt	tcacgggaga	ttaacagaga	7440
gttttgcata	cccaagatgc	ttgggtgact	ttaatgttca	tctgttgc	agccggggag	7500
ggaaagact	agtctctgaa	acatttca	gccttaccc	ggcttaccc	caaccctgt	7560
tccctcgat	gtgtttat	ttttttttt	acttgggtt	atgttagac	ccagaatgt	7620
gcgtacac	attgcggaa	gggttttcc	aataattt	atcatgggt	gtatgttct	7680
cgatgttgcata	aaaaaaagaa	taaacggca	agcgatcaga	acaggaaat	ttttaaaacga	7740
agttatgttgc	aaaataagac	tcaccgttgc	gagaccgagg	ttgggtggat	atctgagatc	7800
aggagatcc	gaccatcttgc	ggcaacatcg	tgaaacccca	actctacta	aaatacaaa	7860
actagccgg	cgtggccgc	ggtgcgttgc	atccctgt	ctcaggaggc	tgaggcaaga	7920
gaatcgttcc	aacctgggg	acggatgtca	cggtgaggcc	agatgtact	ccagcttgc	7980
cgacagagcg	agactgtctc	aaaaacaaaa	caaaacaaa	caaaaaccc	acaaaaagaa	8040
aaaaaaaatgt	gtgtttat	gcacgttgc	tcgtatgttgc	ttccctctgt	ttccctctgt	8100
aaaggggcc	tttttttttgc	gggtgttgc	tcgtatgttgc	tatcccgca	tttttttttgc	8160
ctgggggggg	gggggggggg	tttttttttgc	tcacccatgc	tttttttttgc	tttttttttgc	8220
gggttgcac	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8280
tgtatccca	gtcaacttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8340
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8400
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8460
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8520
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8580
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8640
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8700
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8760
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8820
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8880
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	8940
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	9000
tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	9060
catcgat	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	tttttttttgc	9120

-continued

tctccaggaa	ggtcacactt	cggggtgcct	cctagacgca	gagcagcgag	acgacattct	9180
ctatccctcc	atcaggaaatg	ggacggcaccc	cgttttccacc	gcaagtcgt	ggatggttta	9240
ttaccgttaag	tattgtaaag	ccagtcacc	atgttttca	gtacttcct	cagtttatta	9300
ccacaaggac	taaaaaccaa	gctcatgca	atgcccggat	ccatgattac	cgttaactat	9360
tgagaagcaa	gctcaccatg	ccttcagta	cttccctcga	cttattactg	taagttaacga	9420
aaaacccaagc	tccagccagt	cgccggatca	atgattcccg	taactattga	aaaggaaagct	9480
cagcatagtt	ttcagttactt	cettccatca	attaccgtta	gtactgaaa	gctcacgtaa	9540
atcgtcggat	ccatgattac	cgttaattt	gaaaagcaag	ctcagcacgc	ttttcactac	9600
ttccctcagc	tgattaccgt	aagtaccgaa	aagcaatctc	atgatagtcg	ctggatcaat	9660
gattaccgta	accactgaaat	agcaacccag	cctactttt	gtacttcct	tcaggttat	9720
accataagta	ctgaaaagct	catgcaat	acccgatcca	tgattaccat	aactattgaa	9780
aagcaagctc	accatgtttt	tcgtacttc	ttcagttat	taccataagt	actgtataag	9840
caagctcatg	caagtcactg	gatcgtat	taccgtat	attgaaaagc	aagctcacca	9900
tgcttttcag	tacttcctc	agcttattac	cataagtat	gaaaagcaag	ctctagcaag	9960
tcgcaggatc	agatccccgt	aactattgaa	aagcagcccc	geatccttt	cactacttcc	10020
ttcagttat	tgccataaat	aaaaaaagctc	atgcaatata	ccggatccat	gattaccgta	10080
actattgaaa	agcaagctca	acatgctttt	cagtattcc	ttcagtttat	taccataagt	10140
actgaaaagc	aagctctcgc	aagtccggg	atcaatgatt	accataacaa	ttgaaaagca	10200
agetcagcat	gtctttcagt	acttcacatc	gctgtttagt	ataagtaccc	aaaagcaagc	10260
tctccgaatg	cgccggatca	atgattaccg	taacgatgt	aaagcaatcc	cagcacactt	10320
ttcagttacc	cttcatctcc	ttacccatcg	ttactttcag	ttaaaggatcg	aaaatcaagc	10380
tcatggacca	ttggccacta	gagcccggtg	cccaagtcct	cactccaaat	gggaagaaac	10440
cgcccttccca	ggaatgtccc	tcttacacog	acactgggtt	gggattgtat	ctgccccccag	10500
tggggagacc	agatgacccc	ggggactgt	gatttaaggg	aatgattnaa	aggccggggcg	10560
cgggtgtctc	ccgcctgtat	cccaacacta	ttggaggccca	aggccggccgg	atcaatttgc	10620
gtctggatgt	cgagaccaggc	ctcaaccaaa	tggtggaaacc	ccatcttac	aaacaaacaa	10680
acaaacaaaat	aattacccgg	gctgggtggg	catggctgtt	atcctagctg	ttcggggaggc	10740
tgaggcagggg	aaattgtttt	aacctgggg	cgagaggctg	cagtggccca	cggtggtgcc	10800
actgcactcc	accctggggc	atttataat	tcattattt	aaaataataa	aggcccaagg	10860
tggtggctta	ccctgttaat	cccagttact	ttggagacca	aggccggccgg	atcaatttgc	10920
gtctggatgt	cgagaccaggc	cttgcacaa	tggtggaaacc	ccgttcttat	taaaataata	10980
ttaaaaaaaaa	tttagccggc	tggtggcgc	acgcttgc	tcccgactac	tcggggaggct	11040
gaggcagggg	aattgttgc	accctgggg	cgagggtcgc	agtggaccaa	gacgggtccca	11100
ctgcactgca	gcctggcga	tttataat	tattattta	aaataaaataa	ggcccagg	11160
gtgtggcttc	ccctgttaatc	ccatgtttt	ggggggccaa	ggcagggggga	tcacgtgacg	11220
tggggaggttc	gagaccggc	tgaccaat	ggagaaactc	catcttatt	aaaataatac	11280
aattagccgg	gtttgttgtt	gcatgcctgt	aatcccgact	actcgggacgc	ctgaggcagg	11340
agaatcttct	gaatctggg	ggcggagttt	gtgtgtggcc	gagatcgcgc	cattgcactc	11400
cagccgttgc	aacaqaagtg	aaactccatc	tcaaaataat	aaatttcat	aaattaaataa	11460
gggaatataat	tagagatgt	ctctgtggcc	ctgcataac	acacacacac	acacacacac	11520
acacacacac	acacacacac	acagagttag	ctggaaatac	tctctcatcc	tcacccat	11580
cactggatgt	tctctcttct	ttttttttt	tttttgcag	agagggctt	cctctgttgc	11640
ccaggctgtgt	tttcttatgt	gctgttgagaa	ctggctgtt	agtctcgggc	gagggaaatgt	11700
ggggacaaatgt	tagggaaacc	ctgttttccaa	aatgttttat	tttttccat	gaatttgcgt	11760
aggctgttgtt	tcttttttac	ttttttttt	tttagagggtt	ggggaaacgg	atctgttgta	11820
gaatccgggt	agaactatgt	acttttttt	cgccaaat	tttacagata	ctgggtgcgt	11880
ttctctggctt	ataataggtc	accacaaat	ggaggctttaa	aacagcagaa	atttatttctc	11940
tcccaatgtt	ggagcccat	agtctgtat	ggagatgtct	gagagccgc	ttccctctgg	12000
aggttctaa	ggggatccct	tcctgcctt	cccaagtcct	gggggttc	ggcattctcg	12060
ggcttgcgtt	cgcatcactc	cagtctctgc	ctccgttcc	atgtggcc	ctccctctgt	12120
tctcccttc	tgtcttctac	aaggccatct	gtcatttagat	ttaggggaca	cccttactcca	12180
ggatgtatc	acctcaagg	ccttcacca	attacatctc	cagagacgt	atttccaaat	12240
ccggctctat	tccaggctt	gggtttttag	atgtggacag	atgttttgg	ggccactgt	12300
tccattcgt	ataattat	tcagtccctt	ccagggttct	agggggaggt	ccttccttacc	12360
tctccctat	cttgggggtt	ccaggatcc	ctgggttct	ggcccatatca	ctccagttcc	12420
tgcctccgtc	tccacgttgc	ctcccttct	tggtctcg	ctcccttct	gtctcccgaga	12480
aggacacactt	tcattggatt	taaaccctt	ccttctccag	tatgaccaat	tcctaactaa	12540
ctgaatctat	aatgtatcta	actaactgtaa	tctataatgt	tcctttttt	ttttttttt	12600
tttttttgc	tagtctcgat	ctgttacccaa	ggctgggggg	cagtggatca	atctcggtc	12660
accgcaactt	ccgcetcccc	gggttcaagcg	atttctctgc	ctcagccatca	ctaatacg	12720
ggatttacaa	cgctggccac	catgtctgt	ttttttttat	agacgggggg	tttagcatat	12780
ggccaggctg	gtctcgaaat	cctgtactca	gggtgatccac	ccgcctcg	cttctaaagg	12840
atcttatttt	taaatacagt	tccattctga	gtttctgggg	agttgggatt	ttaacatata	12900
ttttttgtt	ggacttattt	tagccgtaa	cajacacaca	ggacattttc	cgccaaattt	12960
tagagatgtt	cttccttcac	aaacatcag	gttctcggtt	ctctgggtt	agcttctct	13020
ataaaaatgtt	tgaggacggg	tgaacccctt	gaccctata	gttataagg	gaggagggtt	13080
acaggctaga	gaaaggggat	gaggtcagcc	tgtcacaatc	agctcagaga	ggggggacgt	13140
cgcttccgtt	atttcttctt	ctcagtgtaa	cccagttccc	cgaagcacgt	gagatttgc	13200
tggcatcagg	atgcacgtac	ggtgacgtgt	tctgacccgt	cctacgggg	tctccctat	13260
gagggtcagt	accggagccc	cttcgacacc	gagtggcagg	tgagccgggc	ggcccg	13320
caaggccatgt	gtggctgatc	gtccccccagg	tgccgggtgt	gggattcggt	gtttcatcg	13380
acctcgctcc	cctctgtctt	caccccttct	aattccactc	tgctgtatct	tcctgagaga	13440
gctcttagtcc	agcttggctt	tttcatgttt	ctctctgtgt	ctctgagg	tctccagaga	13500
aagagaacca	ataatatgtc	tgtctgtct	tctatcaatc	tattatctt	tctatctatc	13560
aatcttatcta	tatcattcta	ttttatctt	acctctatct	atgtatctat	atcttctat	13620
ttccctcttct	tcacatctat	tctcatatct	ttttatctt	atctctgtt	13680	

-continued

ttaaatctat	tcattatctat	tttatctctat	tctctgtctt	tcaatctatc	atctatttta	13740
tcttataact	ctctttgttc	tatctatctc	tctatggctc	tatccatatac	tattttatct	13800
accaaacttc	ttttatctat	ctatgtatgg	tcaatcttct	atatatatac	tccctatctc	13860
tatgtatgtc	aactatctat	cacccatctat	taactaccca	ttatctctat	tctaccatct	13920
actatcttat	ctatgtatctt	atctatctat	gtatgtatct	atacatctat	catctatccg	13980
tctctatctat	tctaagtata	atctatctat	ctactctgtat	tcatctgtct	gtctgtctct	14040
ctatctatct	aatgtatcat	ctatctatct	ctctatcatc	tgtctatgtat	tcatctatct	14100
ctctatctat	gtctatcat	ctatgtatca	tctatctctc	tctcatact	ctatcatcta	14160
tgtatcatct	atctatctct	ctatcatcta	tctatgtatc	atctgtctct	ctctcatcg	14220
tctatcatct	atgtatcatc	tatctatctat	tcatctgtatc	atgtatcatc	tatcaactct	14280
gtcatcttct	tggtttatct	atgtatcatc	catttttta	tctgttctacc	tctagtctca	14340
tctctatctg	tatctctaca	cacccatgtctc	tctacacaca	cacacacaca	cacagacaca	14400
caaacacagg	cacacagaca	cacacagaca	tgcacagaca	cacacagaca	cacacagaca	14460
cacacaggca	cacacacaca	gtcatgtgt	gcctaaacgc	cttttggta	tcagcagact	14520
gcatgtatca	cggtagtctc	ctatgattat	cacacagctg	tectatgtcg	ctgtcccaat	14580
tattttcttc	tatatacatat	ttttctgtat	ccttctctat	gtttagatata	acaaaactct	14640
acccttgcgt	taggtttgtc	tgcagttatc	agtacagtaa	cgtgctgtat	ggctgtgtag	14700
ctgaagagca	atttactata	cagcttaggt	gtgcagcggg	ctagaccgc	taggtgtgt	14760
taagttaaact	ctagaatatt	ctcataatga	agaatattc	tcacatgtaa	tttcccagaa	14820
catgtccccc	tcgttaagca	atgtatgact	gtatatactac	statatgtgt	gtgtacacac	14880
acacatatac	acacacatata	gtacgtaccc	tgtgtacaca	gcttataata	acatataatac	14940
acacgcata	acacacatata	agatcacac	tttataataca	catatataata	cacatgcata	15000
tacacacata	tagatcacaca	gcttataatac	acacatatac	acatacatctt	tatatgcata	15060
tttatacaca	tgtatataca	catcttatac	acggcacatc	atacacacac	acacagctt	15120
tatacacata	tatataccca	cacatataata	cacagcttata	atacacgtat	atatatgtat	15180
atatgcacct	tatatacaca	gcttataatac	acatattttat	acacacgtat	acacacaccc	15240
tatataaaaca	cataatataca	cacatataata	cagcttataat	aacatataata	cacacacata	15300
tatacatatcc	tatataatgc	atattttatac	acatgtatcat	acacatctta	tatacacata	15360
tataatatac	cataatgtca	cagcttataat	acacgtatata	atacacatata	atatgcacct	15420
tataatatacaca	gcttataatac	acatattttat	acacacgtat	acacacaccc	tatacacaca	15480
acacatataca	cataatataca	gcttataatac	acgttataata	acatgtatata	tatacacaca	15540
tgtatataca	cacatgtata	tatacacaaa	citttataata	atatacacac	acagcttata	15600
tacaataatc	atacacacat	atatacacac	tttataataca	cacatataata	cacacacata	15660
tatacagagc	tttataatcac	agcttataata	cacatataata	tacacacgta	tatacacaccc	15720
taatataatc	acgcttataata	tacacatata	tacacacata	cataatataca	caacacacgt	15780
acacagctta	tatatacaca	tttataataca	cacatataata	cataatataca	tttataatcca	15840
atataatatac	atcttataata	catagttctt	atacacacag	atatacacac	accttataca	15900
cacaacttat	atatacaca	tttataatac	acaccttata	tatacagctt	atatatacac	15960
acatataataa	atatacataat	agatgtatata	tattttgtata	tatatctata	aaatataata	16020
aactatata	gttataactgt	atatacatata	tagaacattc	atctgtatct	tttataatccat	16080
tttataatctgt	aaagatatgt	agatacagcc	tggatgcagt	ggctcacacc	tttataatcca	16140
gcacttttggg	ggggcgagga	gggttggatca	cctgagggtc	ggagttcaag	accagcttgg	16200
ccaaacgttgt	gaaacctatcat	ctctacta	aatacaaaaa	tttagccaa	atgtgtgtgc	16260
ctgttaatccg	agctactcg	gagggttgg	cacaagaat	gcttgcaccc	gacaggcaga	16320
gggttgcagt	agcccgagacc	gcaccaactgc	actccagcc	ggggcaacaga	gcaagactct	16380
gtctcagtaa	ataaataaaat	aatatattaa	aaataataata	aagtaaatac	aggccagggca	16440
cagtggctca	tgccctgtat	ccccatgtact	tttggaggcc	aggccaggagg	atcgcttgag	16500
cccaaggagg	gttggaccgc	ttggggcaaca	gagtgagacc	ccatcttctt	ttttttttt	16560
agacacagtc	ccgcttgc	acccaggctg	gagtgagctg	gtgcgatctc	tgctgtctac	16620
aaccttgc	ccccagggtt	aagcgattct	cctgcctca	cctcccaat	agctgggatt	16680
acaggccacc	gcacccaccc	ctggcttaata	ttttgtatata	cagtagagac	ggggtttctc	16740
catgttggcc	aggctgttct	cgaacttgc	acccatgggt	atccacccgc	ctcagcttcc	16800
caaaggctgt	gttggaccgc	agtggccac	ttgtgtccgc	ctcgccgc	cattttqaa	16860
gtcagcgtaga	ctgtgtaccc	ttccggaa	aaactcttgc	cagacagggtt	acatcactaa	16920
tcatgtgt	tgtgtgtgt	tgtgtgtgt	tgtgtgtgt	tatgtgtat	16980	
tttcttccagt	ccaaacaggaa	aaataatctc	aacgttccaa	ttttgtatata	ggatgcggag	17040
aagtgttata	ttttcttgggt	cagggttgg	gtatgttgg	atgtatata	ttttgtatata	17100
tacccaaagcg	acttggtcaga	ggtgacatgc	ttggcagatgc	ttttgtatata	gggttataatgt	17160
tgtttacacgg	cagtgtccca	tagcttgc	accaggctgg	agtggccata	ttttgtatata	17220
tccctggggg	ttgggggggg	gggttggatca	tttcgggggg	gggggggggg	ttttgtatata	17280
ttcttggggg	ttgggggggg	gggttggatca	tttcgggggg	gggggggggg	ttttgtatata	17340
tccctggggg	ttgggggggg	gggttggatca	tttcgggggg	gggggggggg	ttttgtatata	17400
gccttcgagg	ttgggggggg	gggttggatca	tttcgggggg	gggggggggg	ttttgtatata	17460
gccttccttag	gggggggggg	gggggggttgc	tttcgggggg	gggggggggg	ttttgtatata	17520
tcctgccttc	gggggggggg	gggggggttgc	tttcgggggg	gggggggggg	ttttgtatata	17580
tcctatcttc	ccccgggggt	gggggggggg	tttcgggggg	gggggggggg	ttttgtatata	17640
tcctgccttc	ctgggggggt	gggggggggg	tttcgggggg	ttttgtatata	ttttgtatata	17700
gggtgtccgtc	tttcctggga	gggtgggggg	gggtgggggg	ttttgtatata	ttttgtatata	17760
gggtgtccgtc	tttcctggga	gggtgggggg	gggtgggggg	ttttgtatata	ttttgtatata	17820
gggtgtccgtc	tttcctggga	gggtgggggg	gggtgggggg	ttttgtatata	ttttgtatata	17880
gggtgtccgtc	tttcctggga	gggtgggggg	gggtgggggg	ttttgtatata	ttttgtatata	17940
gggtgtccgtc	tttcctggga	gggtgggggg	gggtgggggg	ttttgtatata	ttttgtatata	18000
gggtgtccgtc	tttcctggga	gggtgggggg	gggtgggggg	ttttgtatata	ttttgtatata	18060
gggtgtccgtc	tttcctggga	gggtgggggg	gggtgggggg	ttttgtatata	ttttgtatata	18120
gggtgtccgtc	tttcctggga	gggtgggggg	gggtgggggg	ttttgtatata	ttttgtatata	18180
gggggggggg	tttcctgggg	ttgggggggg	ttttgtatata	ttttgtatata	ttttgtatata	18240

-continued

```

gggtgggagggg agggtgtcct gccttccctgg gaggtggggag ggaggggtgtc ctgccttcga 18300
gggtgggagggg agggtgtcct gccttccctgg gaggtgggtgt ctgagaacgc tcagcctct 18360
gtcatcctcc agggccccat ctgaaagtta ttctctct tttttcatc tggggctgtct 18420
ttcaacttggg agagtttct ttctttgtt ttttgagaaa acattctcat ggtggccagg 18480
ctggagtgca gtggcgcgat ctgcggctcc tgcaacatct gtctcccacg ttcaatcgat 18540
tctcccgctc cagccctcccg agtgcctggg attacagtgt acacgcaccc acacctgtt 18600
aaatctttt attttttattt tttttatattt tagagggagt ctcagtctgt 18660
ggtccaggct ggagttcagt ggcacggct tggctcaactg caacccctccgc ctccggatgt 18720
caagtgattc ttctgcctca gcctcccaag tagctggac tacaggcaag caccaccaag 18780
cccgccataat gttttagttt tttagtgggg tggcggttcc ccataattggc caggetgtc 18840
tcaacttgc acatcttgta tggccctccg tggccctccca aaagtgtctgg gattaaaggc 18900
gtgagccacc ggcggccggc ttgcacgtat gttttcagggg ggcacatgattt aaggagcacaca 18960
gcaccaaca cacgaaagca agctctcata tgctgttaac acctccagca accagaagcc 19020
tccaaaggct acatgttggg cctgcctca ctccctggg gtggctgtgg gatgtgttgt 19080
tgcggcagaga cgggttctgc ctggccaggat tttttccat aggaatgaaa atttgctgac 19140
actaacatcc attaaaaaaa aaaaataggat ccatctctac taaaatataca aaaatttagcc 19200
cggtgtgggt gcggtatgcct gtcatcccg ctgctcaggaa ggctgagaca ggagaatcgc 19260
tttgcggcgg gagaacgggg ttgcacgttag ctgagatggaa ggcacactgcac tccagcctgg 19320
gcaacagatc ggggttctgc ctggccaggat tttttccat aggaatgaaa atttgctgac 19380
acgaatattt aaaaaaaaaa aaaaacaaaaa aaaaacaaaaa caacgaaac caagaaaaaaa 19440
aaacgaacac caaaaaatga gggagactgg ttagggatga gatgtacatc cacgttggaa 19500
acgtacacgc gacgcgtatc ttgaaaaacttg acagccgcctt tttcattttt tttcagatgc 19560
ctgtgcacag acaccaacgc ctcccaaaccctt aagactgttgc acacttctgc ccctgggtg 19620
cgccctatgc gggctgtca ctgtctccctt gtcctgtggcc gccctggggc ttgcagggtg 19680
aggggttcc gaggagtcat ggggtcatgg tggggtaattt gcatgttca cggcgatgac 19740
gtcaccactg tgatgtacgc atgttccggg tggggccatgt gcatgggggt gtcaaggtaa 19800
ccctgacccc tgaccctgaa cccagggttg aaagatgcgc tgcgtgcctg cgtccctgac 19860
cccaaggccgt ctccctccctt actttttggaa aagcatcaggc ggaacttcca ggtgcgcggg 19920
gggggggggggg gggtcaggat cgctgtgggg ggtcaacttcc tgcggccggaa gagtgaggggc 19980
atgaggcagg gggatgtatgg gatgtacagg cgtcacgggc cactgcctga ctccaggcac 20040
cgctccctccccc cccctccccc caccctccatc cctccatccccc cccctccac acacacac 20100
ccttcgtcg caggcttggaa ttgcggacgc ccaggccaca gcccgcac ccaggacccga 20160
ggaggaatg gacccatcc acaccaaggg taagagggtt gaggccgggg acggcacctc 20220
cctctgcacc gtgccaaggc caccctggat cgagccaaagg gggccggggag gccccggccat 20280
gggtgtcaatgg gggggggccca cgttcatgtt gggcgacagg ggctacatgaa ccctgtgacc 20340
ttgaagtgtcacttgcctacttgc tggggatctt ccctgttccatc aaataattca 20400
aactcacaat ttctgtgcct gtctgtatgc aaatgtgttc acaaataattc aaataaaaatg 20460
caaatgttat gct 20473

```

```

SEQ ID NO: 64 moltype = DNA length = 15741
FEATURE Location/Qualifiers
misc_feature 1..15741
note = Targeted Tslpr allele 7559 (without cassette),
genomic DNA, total 15741 bp
misc_feature 1..1051
note = Mouse Sequence
misc_feature 111..113
note = Start Codon
misc_feature 111..189
note = Coding Exon 1
misc_feature 1052..1128
note = Deleted Neo Self-Deleting Cassette
misc_feature 1052..1057
note = 5Xhol
misc_feature 1058..1091
note = LoxP
misc_feature 1097..1122
note = I_Ceu
misc_feature 1123..1128
note = Nhel
misc_feature 1129..14871
note = Human Sequence
misc_feature 14872..15741
note = Mouse Sequence
misc_feature 15604..15606
note = Stop Codon
source 1..15741
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 64
ggcccccggct tcccggttgc ggctctaagg ggcttggggc ccctcgactc ggaccggctc 60
ggaccgaaacc agctgtcaat cactgcacgg tccggggccccc cggccggcgac atggcatggg 120
cactgcgggt catcctcctg cctcggttgc ttggggccggc agcggccggcg gggccgggtga 180
cgtcacgggg tgaggagtga ggggggggggg ggctgtgttgc caatgcggc ggtgggggggg 240
ggcccgagcaaa gagtttccatcat gttgttttgc ttccatcat tgcgttttgc cccatcatga 300
atatgcataat aaggcctctaa gggcgatcgatc atagcgcttc gtttgcataat 360

```

-continued

tcatTTTgtat	cttgcgtat	gcatgagccc	cggccctcccc	ccctacgcgc	ggcgctttct	420
ccttcagaat	atgcAAATG	gaccTaaacc	ccgcocTTgac	ctcattAGca	tagtgctGCC	480
gcacacaatCT	cgctcCTCT	cctgaatATG	caaataAGGC	ctctgggCcg	ctccCTTCTT	540
gcataTTCA	atACAGCTT	cccGGTTATA	tgcAAATAAC	gcttcGCCc	tacCGAGGTC	600
tcactCATCG	ctTCCTCATTT	gcatatCCAT	cgggAGAGATAc	acatATTcat	gagCGATGta	660
tttCTGTCTT	ccatCCCTC	atGAATATAG	aatttgatGcC	ctgtCCatAT	ggatCACAT	720
gcattTGcat	atTTTCCCA	cgattTACAT	atgcACAAAGC	ctcaACGCT	tgctCCAAAG	780
tcctGTatCA	tgAAATATGCA	gatGAGACCT	caGATCTCCG	aaATTAATG	tgCCCGCTC	840
tcatCATATA	ctGCTATTCT	catATGCACC	agccACACAAAG	tcttCCatCC	tttCCCTCTC	900
atGAATATGc	AAAGAATGCT	tcccccAGTCC	atCTCCACTC	tggttCActG	cctGCTCAT	960
tgtGTatCCA	ttggTCGCTT	tgcataTGG	tgagCCCCG	ttccCTACG	tttCTTTCG	1020
gatCATGtat	atTCAAATG	ggctCCGACT	tgtcGAGATA	actTCGtATA	atgtATGCTA	1080
tacGAAGTta	tgCTTAGtA	tataACGTC	ctaAGGTAG	gagCTAGCC	tttCTGAAgT	1140
tggTGTGTTG	ggTGTGTTG	gaaAGACAGT	aaggTGGATC	gatGGGGACA	gttTCCGATG	1200
ccacCTTAgG	tatCCACAGG	ggatGTTGTT	ttggatACAT	gattGATCTA	tacAGATAcA	1260
tctGTGcatG	gCAGTGTGG	gtGAATACAT	cTTTGCaaa	aACAAACAA	AAAGCAGCCG	1320
ggcgcGGTGG	ctcaCgCTG	caatCTCAGo	actTTAGGTG	gatGAGGCGG	gcggatCacG	1380
aggTCAGGAG	atCAGAGACCA	tcCTGGCTTA	cacAGTAAA	ccccatCTCT	actAAAAGTA	1440
caaaaaAAATA	tccAGGCTAG	gtggGGGCA	cTGTAGCC	cAGTACTCG	ggaggGCTGAG	1500
gcAGGAGAA	ggCgtGAACC	cgGAGGEGG	agCTGCAgT	gagCCGAGAT	tgCgCCACTG	1560
cagtCCAGCC	ttGGGTGACAG	agtGAGAGTC	tgtCTCACAC	aataCACTAC	actACACTAC	1620
actACACTAC	actACACTAC	actACACTAC	aataCAATGC	aataCAATGC	aataCAATAC	1680
gtcAGGEGCG	gtggCTACG	cCTGTAATCC	cAGTACTTG	ggaggCcgAG	gcggGTGgAT	1740
catGAGGTCA	ggAGATCAG	accATCTGG	ctaACACGCT	gaaACCCCTG	ctCTACTAAA	1800
aataCAAAA	atAGCAGG	tgtGGTgAcA	ggtGCTGTA	atCCCGCTA	ctCGGGAGGc	1860
tGAGGcAGGG	GAATCGCTG	aACCCGGAG	gCggGAGGTT	cAGTgACCGG	AGATCGTGC	1920
attGTACTCC	AGCCTGGGCA	ACAGATGAT	ACTCTGTCTC	AAAAGAAAAA	ATAAAATTAA	1980
aaaaAAATAA	AAATAGAGT	gcCTCACGCT	gAACTTCATG	cgtCTCTG	tgtCTAGCAG	2040
aaggAGTACA	gATTGAGATC	ATCTACTTC	ATTAGAAAC	cgtGcAGGtG	ACATGGAAATG	2100
ccAGCAATA	CTCCAGGACC	AACCTGACTT	TCCACTACAG	GTAAGTGGCC	CCCAGAAAGC	2160
GAACCCCAcG	GGACGGGGGC	TCAAAATCgO	TCTTCTGAGC	CgtCAGOGAT	TGGGAATGCT	2220
tGAGAACAAA	AGTGAATAAAGC	ATCAAGACTG	GCAAGCCGGA	ATGTTGTTG	TGTGAAACCC	2280
tcAGCCCTCA	CCACAAACCC	AAATCTATTG	CCCCAAACCT	TCTTGCCTAAG	GGATGGCTGA	2340
ctCACTGTCA	AAATCAACTA	CATTCTTTT	TTTGTtTGT	TTTATTTG	GTcGGAGGT	2400
cactCTGTG	CCACGCTGGA	gtGAGTGG	gcaATCTCG	ctcaCTGCA	cCTCTGCTC	2460
ccGGGTTCAA	GGCATTTCC	TGCTCTGAC	TCCCAGTAG	CTGGGATTAC	AGGCACCTG	2520
caccatGCT	AGCTAATTT	TGTATTTTA	GTAGAGATG	TGATTACCA	TATTGTCAG	2580
ggcggTTCA	AACTCTGAC	CTCATGTGAT	CCACCTGCCT	CAGCCTCCCA	AAGTGTGTTG	2640
atGACAGGCG	tgAGGcACGG	CATCCTGGAT	GAAAATCACC	TAGATTCTC	ACGGGGAGAT	2700
aacAGAGAGT	tttGTTcAcc	caGAGCTG	GGTGAACCT	AAGTCTTATC	TGCTAGGcAG	2760
ccGGGGAGGG	AAAGACTCAG	TCTCTGAAAC	ATTICACAGC	CTTACCCGG	GCTACCCCA	2820
accCTGTGTC	TCCCTGTATG	GACTTTATT	TTATTTTAC	TTTGGTTAG	TTAGACACCC	2880
AgAAgATGc	gtACGAAACAT	TGCAAGAAGG	GTtTTTCAA	TAATTTAT	CATGGGTGGA	2940
TGATTCTCA	ttttGTAAC	AAAGAGATA	AAcGGCAAAAG	CgtCAGAGAC	AGGGAAATT	3000
taAAACAGAG	TtAtTTGAA	AATAAGACTG	ACCGTTGGGA	GACCGAGGTG	GGTGGATCAT	3060
ctGAGATCAG	GAATTCCAGA	CCATCCTGG	CAACATGGT	AAACCCCAAC	TCTACTAAAA	3120
atACAAACAC	TAAGCCGGC	TGGCGGCG	TGCTGTAA	CCAGCTACT	CAGGAGGCTG	3180
AgGCAAGAGA	ATCCTCTAA	CCTGGGAGAC	GGAGTTCAcG	GTGAGCCGAG	ATTGCACTC	3240
AgCCTGGCGC	ACAGAGCAG	ACTGCTCAA	AAACAAACAA	AAACAAACAA	AAAACCTCAC	3300
AAAAGAGAAA	AAAAAGTGC	TGGATTTTG	ACGTAGTGC	AGAATTCAcG	TCACTTTCTT	3360
cCTCTGAA	AGGGGGAGT	CTTGGGGGG	GTGTTGGCT	ATGCCTGTA	TCCCTGACT	3420
ttGGGAGGT	GAGGGGGGGG	GGGGTGGATC	ACCTGAGGTc	AGGATGTTCA	GACCAGCCTG	3480
gccaACATGG	TGAAACCTG	TCTCTACTAA	AAATACAAA	AAATTAGCCG	GGCGCGGGGG	3540
cgtGcGCTG	TAATCCcAGC	AACTTGGGAG	GCTGAGGCG	GAGAATCGCT	TGAATCCGGG	3600
AgGcAGAGGT	TGCACTGGG	CGAGATCCTG	CCAGCTGGG	CAACAAAGAAC	3660	
AAAACCTGT	TTCAAAACAA	AAACAGACAA	ATAAAACAA	GGCCGGGCGC	GGTGGCTCAC	3720
gcCTGTAATC	CCAGCACTC	GGGAGGCGA	GGCGGGTGG	TACACCTGAG	TcAGGAGATC	3780
gAgACAGGCC	TGGTCAACAT	GGCgAAATCC	CATCTCTATT	AAAAACACAA	AAATTAGCTG	3840
GGGGTGGTGG	TGCGTGCCTG	TAATCCAGC	TACTCAGGAG	GCAGAGGCG	GAGAATCGCT	3900
TGAACCCGGG	AGGCAAGAG	TGCAATGAG	CGAGATCCTG	CCACTGCACT	CCAGECTCAG	3960
GGACAGAGCG	AGACACCCAT	TAAATTTAA	AAAGGGCGT	TGGTAGCTA	4020	
cacCTCTCAT	TCCAGCAGT	TGGGGGCGCA	AGGTGTATGG	ATCACCTGAG	GTCAGGAGTT	4080
ctAGACCCAGC	CTGGCCCCAA	CATGGTAAA	CCCTGTCTCC	AGTAAACACTA	CAAAAATTAG	4140
CTGTATATGG	TGGCAGGTG	CTGTAATCC	AGCTACTCAG	GAGGCTGAGA	CAGGAGAAT	4200
GCTTGAACTC	GGGGAGGAGA	GGTTGAGT	AGCTGAGATE	GGCGCATTG	ACTCCAACT	4260
GGGCGACAAG	AGCAAGACCC	CATCTCTAA	TAATAAGAC	ATGTTTTT	GTtTTGTTG	4320
TGAATGGTCA	TGTTTTAA	CCACAGATC	AAcGGTGTAG	AGGCTATGA	CCAGTGCACC	4380
AACTACCTTC	TCCAGGAGG	TCAACACTCG	GGGTGCCTCC	TAGACGCGA	GCAGCGAGAC	4440
GACATCTCT	ATTCCTCAT	CAGGAATGGG	ACGCACCCCG	TTTCAACCGC	AAGTCGCTG	4500
ATGGTTTATT	ACCGTAAGTA	TTGTAAGGCG	AGCTCACCAT	GTTTTCACT	ACTCCCTCA	4560
GCTTATTAC	ACAAAGACTG	AAAACCAAGC	TCTGAAAT	CGCCGGATCC	ATGATTACCG	4620
TTAACTATTG	AGAAGCAAGC	TCAACATG	TTTCACTGACT	TCTGCACT	TATTACTGTA	4680
AGTAACGAAA	AAACCAAGCTC	CAGCAGTCG	CGGGATCA	GATTCCCGTA	ACTATTGAAA	4740
AGGAAGCTA	GCATAGTTT	CAGTACTCC	TTCAGCTTAT	TACCGTAAGT	ACTGAAAGAC	4800
TCACTGAAAT	CGTCGGATCC	ATGATTACCG	TAATAATTGA	AAAGCAAGCT	CAGCACGCTT	4860
TTCACTACTT	CTTCAGCTG	ATTACCGTAA	GTACCGAAAA	GAATCTCAT	GATAGTCG	4920

-continued

ggatcaatga ttaccgtAAC	cactgaaaAG caacccAGCC	tactttcgc tactccTTc	4980			
aggtttatac cataagtACT	gaaaAGctCA tgcaaattAC	cgatCCTATG attaccATAA	5040			
ctattgaaaa gcaagCTcAC	catgttttC tgacttCCT	cagCTTATTA ccataAGtAC	5100			
tgataaaGca agctcatGC	agtcaCTGA tcagtGATTA	ccgtAGTGTAT tgaaaAGCAA	5160			
gctcacCATG ctTTcAGTA	cttcTTcAG	tttattACCA taagTACTGA	aaAGCAAGtC	5220		
ctagcaAGTC goaggatCAG	atTcccGTA	ctattgaaaa AGCAGCCCAGC	atccTTTCA	5280		
ctacttCCT cagCTTATTG	ccataAAATAA	aaaAGCTCAT	gcaAAATAACG ggatCCATGA	5340		
ttaccgtAC tattgAAAAG	caagCTCAAC	atgCTTTCA	tgatTTCCtT cagCTTATT	5400		
ccataAGTAC tggAAAGCAA	getctCGCA	gtcGCCGGAT	caatGATTAC cataACAATT	5460		
gaaaAGCAAGC	tttCTAGTA	ttcCTTCAcG	tgatttATCAT aAGTACCGAA	5520		
aagcaAGtC tgcAGtC	cgggatCA	gattACCGA	acgattGAAG AGCAATCCA	5580		
gcacACTTT cAGTACCCt	tcatTCCTT	acCTTCAGT	actTTCTGAA aAGTCTGA	5640		
aatcaAGCTC atggACCATT	ggccACTAGA	gcccGGTGC	cagCTCTCA ctccaAGTGG	5700		
gaagAAACCGC	gcTTCCAGG	aagtTCCCT	ttacACGcAC actGTTGGG	gattGAAT	5760	
gccccCAGTG	gggAGGCTG	attGTTGAA	cctGGGGAGG	agAGGCTGCA gtGAGCCACG	6060	
tttGtGccAC	tGCACTCCAG	cctGGGCGAT	ttataAAATTc	atttAAATTAA aATAAATAAG	6120	
gcccAGGgtG	gtGGCTTAC	cctGTAATC	cagtACTTGT	ggAGGACCAAG	gccccGGGAT	6180
cacttGAGGT	ctGGAGTTG	agaccAGCT	caccaACATG	gtGAAACCCC	atCTCTACAA	5940
acaAAACACAA	AAACAAAAAA	ttAGCCGGG	ttGtGGGCGA	tgCCCTGTA	atCTAGCTGT	6000
cgggAGGAGCTG	aggcAGGGA	attGTTGAA	cctGGGGAGG	agAGGCTGCA	gtGAGCCACG	6060
tttGtGccAC	tGCACTCCAG	cctGGGCGAT	ttataAAATTc	atttAAATTAA aATAAATAAG	6120	
gcccAGGgtG	gtGGCTTAC	cctGTAATC	cagtACTTGT	ggAGGACCAAG	gccccGGGAT	6180
cacttGAGGT	ctGGAGTTG	agaccAGCT	tGCAACACTG	gtGAAACCCC	gtCTCTATTAA	6240
aaaATAATTt	aaaaAAATT	agccAGGCGT	ggTGGCACAC	gtTTGTAATC	ccAGCTACTC	6300
gggAGGAGCTG	ggcAGGGA	ttGtGGTAA	cctGGGGAGG	gaggGCTGCA	tgAGGCAAGA	6360
cggTGCACt	gOACTGcAGC	ctGGGCGATT	tataAAATTt	ttatTTAAAA	ataAAATAAGG	6420
cccAGGGCGG	ttGGCTTCC	ctGTAATC	agtACTTGT	gaggGCAAGG	caggGGGATC	6480
acgtGACGtG	gggAGGtG	gaccAGCT	accaACATG	agAAACACTC	tctCTATCAA	6540
aaatacataAA	ttAGCCGGG	ttGtGGTGT	ttGtGCTGTA	tcccAGCTAC	tcGGGAGCCT	6600
gaggcAGGAG	aatCTCTG	atCTGGGG	cgGAGTTGT	gttGAGOCGA	gatCAGCAGCA	6660
ttGCACTCA	gcCTGGACAA	caAGGTGAA	actCCATCTC	aaATAAAATTAA	atttAAATTAA	6720
ttaaATAAGG	gAAttAAATT	gAGGTGCTC	ctGGTGCCT	gtCTGCTC	acacACACAC	6780
acacACACAC	acACACACAC	acACACACAC	agAGTGA	gtGAAACACTC	tctCATCTC	6840
atCCCACTCA	ctGGGATGTC	tctCTCTT	ttttTTTTT	tttGAGAGAG	aggGTCTCC	6900
tctGTTGCC	aggCTGTTT	tcttatGtG	gttGAGAACT	ggCTGTTAAG	tctCGGGC	6960
ggaAAATGAGG	gACAAATGTA	ggggAAACCT	gtttCCAAA	tgttttATTCT	ttatCTCTAGA	7020
atttCTGTAAG	gtGTGTTT	ttttttACTT	tttttTTTTT	tagAGGTAGG	ggAAACGGA	7080
ctGTTGAGA	atCCGGTGA	aactATGAAC	tcttttATTG	cgAAATTACT	tacAGATACT	7140
gggtGCGTT	ctTGGGCTAT	aatAGGTAC	cacAAACTG	aggCTTAA	cAGCAGAA	7200
ttatTCCTC	ccAGTCTTC	AGCCCATG	tctGAGATG	AGATGCTG	gAGCCG	7260
ccCTCTGGAG	gttCTAAGGG	aggACTCTC	ctGCTCTC	cagCTCTGG	ggGCTCCAGG	7320
catCCCTGG	cttGtGCG	catACTCA	gtCTCTGCT	ccGTC	cttG	7380
cctCTGTGTC	tcTCTTCTG	tctttacAA	ggGcacCTGT	cattAGATT	AgGGGACACC	7440
ctactCCAGG	atGATCTC	ctcaAGGTC	tticACCTA	tacATCTG	GAAGGCCT	7500
ttccAAATCC	ggTCTC	caggGCT	ttGtGCTG	gttGAGAG	gttGAGAG	7560
gcCACTGTC	cattCAGT	atttATTC	agttCCTC	aggGTTCTG	ggGGAGGCTC	7620
tttCTACCTC	tcccAGETC	tggGGGCTC	aggCATECCT	ggGTTGTG	ccccCATEACT	7680
ccAGTCTGTC	ctCCGCTC	cacGTTG	cctCCCTGT	gtCTGEGT	cttCTCTGT	7740
ctCCGAGAAG	gACACCTG	attGTTA	gaaCCCTTC	tttCAGTA	tgACCTCATC	7800
ctaActAACT	gAAtCTATAA	tGtGCTAA	taactGAATC	tataATGATC	ttttTTTTT	7860
ttttTTTTT	tttGAGATA	gtCTGEGT	gtCAACCCAGG	ttGGGAGGCA	ttGTTCAAT	7920
ctCGGCTAC	cgcaACCTC	gcCTCCCCGG	ttaCAAGCT	tctCCtGCT	cAGCTC	7980
aaTAGCTGG	attACAAAGC	ctGGCACCA	tGCTGTAT	tttagTAGAG	ACGGGGTTT	8040
AGCATATTTG	ccAGGTG	tGCAACTC	tGACTTCA	tGATTCACCC	gcCTCGGCT	8100
tctAAAGGAT	ctTATTTA	aataCAGTC	cattCTG	AGTCTGGGAG	ttGGGATTT	8160
aaCATATTT	tttGtGGGG	acttAA	tttGtGAA	ACACACAGG	ACATTTCCG	8220
cagaATTtTA	gAGGTTAAT	tttGtGAA	acCTACAGG	tetGGAGGT	ctGGTGAAG	8280
tttCTCTTAT	aaaAGTAATG	aggACGGGTG	aaCCCCAGGA	CCCAATAAGGT	AttaAGGGGA	8340
ggAGGGGTAC	aggCTAGAGA	aAGGGGATG	ggTCAGCCTG	tcACACATCAG	ctCAGAGGAG	8400
aggGAAGCTG	ctTCGTTAT	tttGtGTTCT	cAGTGAAC	cAGTCCCCG	aAGCACGtGA	8460
gatTTCTGtG	gCAtAGGAT	tgAGTGA	tgACCTG	tgACCTG	taCAGGGGATC	8520
tcctCTATCA	gttCTG	cgGAGCCCT	teGACACGGA	tgGAGG	AGCCGGGCGG	8580
ccCGCAGCTCA	ggGEGATGGT	ggCTGAGGT	ccccAGGTG	cgGGCTGTG	gattGCTGT	8640
tttCATCAGAC	ctCGCTCCC	tctGtCTAC	ccttCCTGA	ttCCACTCTG	ctGtATCTC	8700
ctGAGAGAGC	tctGTC	tttGtGTTCT	tGATGTT	tGATGTTCT	ctGAGGGGT	8760
tccAGAGAGC	tttGAGAGA	aatATGTC	tGtGtG	tatCAATCT	tttATCTATC	8820
tatCTATCAA	tCTATCAA	tatC	tatCT	tatCT	tatCTAT	8880
cattCTATT	ccCTCTCTT	caatotATCA	tctATCTATC	tctATCTATT	ttatCTCTAT	8940
ctCTGTCTT	caatCTATCT	cattCTATT	tatCTCTATC	tctGtCTT	aatCTATCAT	9000
cttATTTATC	tatTAATTA	cttGtCTA	tatGCTCTA	tccATATCTA	9060	
ttttATCTAC	caACTCTT	ttatCTATCT	atGtATGTT	aatCTTCTAT	atATATC	9120
cctATCTCA	tGtGTTCA	ctatCTATCA	tctCTATCA	actACCCATT	atCTCTATT	9180
taccATCTAC	tatCTTATCT	atGtATTTAT	tatCTATCT	atGtATCTAT	AcATCTATCA	9240
tctATCCGTC	tctATCTATC	taAGTATCAT	tatCTATCT	actCTG	tatCTGCTGT	9300
ctGtCTCTCT	atCTATCTAA	tGtATCATCT	atttATCTCT	tatCTATCTG	tctATGtATC	9360
atCTATCTCT	atCTATCTG	tctATCATCT	atGtATCATCT	tatCTCTCTC	tcatC	9420
atCATCTATG	tatCATCTAT	ctatCTCT	atCATCTATC	tatGtATCAT	tGtGtCTCT	9480

-continued

ctcatcgctc	tatcatctat	gtatcatcta	tctatctatc	atctgtctat	gtatcatcta	9540	
tcaactctgt	catactctgt	tttcatctat	gtatcatcta	tttctttatc	tgtctacetc	9600	
tagtcctatc	tctatctgt	tctatcacaca	cctgtctctc	tacacacaca	cacacacaca	9660	
cagacacaca	aacacaggca	cacagacaca	cacagacatg	cacagacaca	cacagacaca	9720	
cacagacaca	cacaggcaca	cacacacagt	catgtgtgc	ctaaccacct	tttggtcata	9780	
agcagactgc	atgtatcag	gtatgtctct	atgattatata	cacagactgc	ctatgcagct	9840	
gtcccaatta	ttttttctta	tatcatatata	tttctgttacc	ttctctatgt	tttagatatac	9900	
aaataactac	ccttgcttta	gggtttgtctg	cagtatttca	tacagtaacg	tgctgtatgg	9960	
ctgtgttagct	gaagagcaat	ttactatatac	gcttaggtgt	gcagcgggt	agaccagcta	10020	
ggtgtgtgt	agtaaaactct	agaatatttca	cataatcaccc	aaatcaccc	acaatgaatt	10080	
tcccaaaaa	tgccccatc	gttaaaca	gcatgactgt	atatctact	atatgtgt	10140	
gtacacacac	acatatacac	acacatatagt	acgttaccc	tgtacacagc	tttatatac	10200	
atataatacac	acgcatacac	acacatatagt	atacacagct	tatatacaca	tatataataca	10260	
catgcataca	cacacatata	gatacacac	tttatatac	acatatac	ataccctata	10320	
tatgcataat	tatacatatg	tatatacaca	tcttatacata	geacacat	acacacacac	10380	
acagcttata	tacatata	tataccaca	catatataca	cagcttata	acacgttata	10440	
atatgtatata	atgcaccta	tatacacago	tttatatac	atatttatac	acacgttatac	10500	
acacaccta	tataaaacaca	tatatacaca	catataca	gctttatataa	catatataca	10560	
cacacatata	tatcatac	ttatatgc	atttatac	atgtatatac	acatcttata	10620	
tacacatata	tatatacata	tatgtgcaca	gctttatatac	acgttata	acatatatat	10680	
atgcaccta	tatacacagc	tttatatac	atatttatac	acacgttatac	acacaccgt	10740	
tatcacacaca	catacacaca	tatacacago	tttatatac	agcttatac	caggtatata	10800	
tacacatag	tatatacaca	catgtatata	tacacaaact	tttatatac	atacacacac	10860	
agcttataat	caatacatat	acacatata	atacacac	tatatacaca	catatataca	10920	
cacacatata	tacagagctt	atatacacag	tttatacata	catatata	cacacgtata	10980	
tacacaccta	atatacacag	tttatacata	catatataca	cacacatata	tatatacaca	11040	
acacacgtac	acagcttata	tatacata	tatacaca	catatagata	catagttata	11100	
atatacacat	atatacacat	tttatacata	tagtttata	acacagat	atacacacac	11160	
cttatacaca	caacttata	atacaca	ttatatac	accttata	tacagcttata	11220	
atatacacac	atataataat	atatacata	atatacata	atatacata	atatacata	11280	
catataataaa	ctatataatgt	ataaaactgt	atatacata	atatacata	atatacata	11340	
atatccattt	atatgtt	aaatgtt	atacaggctg	gatgcagtt	ctcacac	11400	
taatcccac	acttttggag	gccgaggagg	gttgatacc	tgagg	tcagg	11460	
cagcctggcc	aacgtgtt	gaaatccat	ctactagaa	tacaaaatt	agccaagcat	11520	
ggtgtgtgt	gtaatcccg	ctactcggt	gggtgagg	caagaat	tgcc	11580	
caggcaggg	ttgcgtgt	ccgagaccgc	accactgc	ttccgc	gcaacagagc	11640	
aagactctgt	ttcgttaat	aaataataa	tatattaaa	taataataa	gttaatac	11700	
gccaggcaca	gtggctat	cctgtat	cgtactgtt	ggagg	ccag	11760	
cgttgcgg	cagggtgt	tttacagg	tgagg	ccact	tgcc	11820	
cttttttag	acacatccc	gtctgtc	ccaggctt	gtgcgtgt	gcatct	11880	
tttgcata	ccttcgc	ccaggctt	gcatgtt	ttcc	tccca	11940	
ctgggattac	aggcacc	ccaccgc	ggctat	tgtattat	ca	12000	
ggtttcttca	tttttggcc	gtctgtc	acttgc	ccagg	cc	12060	
cageccttca	aaatgtt	tttacagg	tgagg	ccact	tgcc	12120	
tttttgcata	cagcgtact	gttgcata	ccgg	aggaa	acttgc	12180	
atcaactatc	attgtgtgt	tgtgtgtgt	tgtgtgtgt	tgtgtgtgt	tgtgtgtgt	12240	
tgtgtgtgt	tcttccat	aaacaggaa	atacatgc	ca	gttgc	12300	
atgcgttact	tttgcata	gggtgaa	agggtt	tttgcata	gttgc	12360	
cagacacata	cccaacgc	ttgttgc	tttgcata	gggtgaa	agggtt	12420	
gtatgtt	tttacacgg	gtgttccata	gttgc	tttgcata	gggtt	12480	
cactgc	ccggggat	gggggggg	tttgc	tttgcata	gggtt	12540	
tttgcata	ccggggat	gggggggg	tttgc	tttgcata	gggtt	12600	
tttgcata	ccggggat	gggggggg	tttgc	tttgcata	gggtt	12660	
gtgtgtt	ccggggat	gggggggg	tttgc	tttgcata	gggtt	12720	
gggtgtgt	tttgc	tttgcata	gggtt	tttgcata	gggtt	12780	
gggggggt	tttgc	tttgcata	gggtt	tttgcata	gggtt	12840	
gggggggt	tttgc	tttgcata	gggtt	tttgcata	gggtt	12900	
gggggggt	tttgc	tttgcata	gggtt	tttgcata	gggtt	12960	
gggggggg	tttgc	tttgcata	gggtt	tttgcata	gggtt	13020	
gggggggg	tttgc	tttgcata	gggtt	tttgcata	gggtt	13080	
gggggggg	tttgc	tttgcata	gggtt	tttgcata	gggtt	13140	
gggggggg	tttgc	tttgcata	gggtt	tttgcata	gggtt	13200	
gggggggg	tttgc	tttgcata	gggtt	tttgcata	gggtt	13260	
gggggggg	tttgc	tttgcata	gggtt	tttgcata	gggtt	13320	
gggggggg	tttgc	tttgcata	gggtt	tttgcata	gggtt	13380	
gggggggg	tttgc	tttgcata	gggtt	tttgcata	gggtt	13440	
gggggggg	tttgc	tttgcata	gggtt	tttgcata	gggtt	13500	
tttgcata	gggtt	tttgcata	gggtt	tttgcata	gggtt	13560	
ggcc	tttgcata	gggtt	tttgcata	gggtt	tttgcata	gggtt	13620
ggcc	tttgcata	gggtt	tttgcata	gggtt	tttgcata	gggtt	13680
ggcc	tttgcata	gggtt	tttgcata	gggtt	tttgcata	gggtt	13740
tgcc	tttgcata	gggtt	tttgcata	gggtt	tttgcata	gggtt	13800
caatcgatc	ttccgc	tttgcata	gggtt	tttgcata	gggtt	13860	
acctgattaa	atctttat	tttttttta	tttttttta	tttttttta	tttttttta	tttttttta	13920
cagtctgtt	tccaggctt	agttc	tttgcata	gggtt	tttgcata	gggtt	13980
cccgagttca	agtgtt	tttgcata	gggtt	tttgcata	gggtt	14040	

-continued

ccaccaagcc	cgcctaatgt	ttgtatTTT	agttagggatg	gcgttcccc	atattggcca	14100
ggctggcttc	gaactcctga	cctctgtatc	cgccgcctc	ggcccccAA	agtgtggga	14160
ttaaaggcgt	gagccacccgc	gcccgcctt	tgacgtatgt	ttcaggGGG	catgattaa	14220
ggagcacacgc	caccaacaca	cggaaAGca	cctctatATG	ctgtAAACAC	ctccAGCAAC	14280
cagaagecctc	caaaggctac	atgttggacc	tgccCTTA	tcctcgGGG	ggctgtggga	14340
tgtgtgtttg	tccagagaca	cggtgtctct	ttccaggata	ttttccatAG	gaatgaaaAT	14400
ttgctgacac	taacattcat	taaaaaaaa	aaataggTc	atctctactA	aaaatacAAA	14460
aattageccg	gtgtgttgc	ggatgcctgt	catcccAGGT	gctcaggAGG	ctgagacAGG	14520
agaatcgctt	gagtccggga	gacggaggTT	gcagtGAGT	gagatggAGC	cactgcACTC	14580
cagcctggcc	aacacAGTGA	ggtttgcgt	caaaaaaaa	aaaaaaaAGA	atgaaaAGAT	14640
ttgctgacac	gaatattac	aaaaaaaa	aacaaaACAA	aaaACAAACA	acgagaACCA	14700
agaaaaaaaa	acgaacacca	aaaaatgagg	gagactggT	aggggatgaga	tgtaacatca	14760
cgttggaaac	gtacagccgc	acgtcatgtt	gaaaactgac	agccgeCTT	tcattttgtt	14820
tcagatgcct	gtgcagagac	accAAcGc	cccAAACCC	actgttccAA	actcttGCC	14880
ctgggctgc	gcctagcgc	gtctgtaca	tcgtccCTG	tcgtggccG	cctgaggCtt	14940
cgcagggtg	gggttccga	ggagtcatgg	ggctatggT	ggtaattTC	gatgtctacG	15000
gcgtatgcgt	caccactgt	atgacgtcat	gttcgggtc	ggggcatggc	atgggggtgt	15060
caaggtaacc	ctggggcttc	accctgtgg	ccagggtgaa	agatgcgtG	ctgcctcg	15120
tccctgtcccc	cageggctcc	tccctggac	tctttagaa	gtatcacGGG	aacttccagg	15180
tgccgggggg	gggggggggg	gtcaaggatc	ctgtgggggg	tcacttccT	tccccggaga	15240
gtgaggggat	gaggcaggGG	gatgtggga	gtgacaggCG	tcacgggca	ctgcctgact	15300
ccaggcaacc	ctccccc	cctccccc	cccccttccc	ccaccccc	ccctccacac	15360
acacaacccc	tttgcgtca	ggcgtggat	ggggacggcc	aggccacAGC	ccggccAGC	15420
aggaccgagg	aggaAGATGA	cctcatccac	accaaggGTA	agagggtgga	gccccggagac	15480
ggcacctccc	tctgcaccgt	gccaaggCCA	cccagcttc	agccaaggGG	gccccggagge	15540
ggggccatgg	tgtcaGTTGG	cgggggccacg	ttcatggtg	gwgacacGGG	ctacatgacc	15600
ctgtgaccc	ggagtGACTG	ccgtctata	cttcaggGTC	aggtcaCTC	ctgttctaa	15660
ataattcaaa	ctcacaacatc	ctgtgcctgt	ctgtatgca	atgtggtcac	aaatattcaa	15720
ataaaatgca	aatgtatgc	t				15741

```

SEQ ID NO: 65      moltype = DNA  length = 26915
FEATURE
misc_feature
1..26915
note = Targeted Il7ra allele, genomic DNA (total: 26915 bp)
1..184
note = Mouse Sequence
117..119
note = Start Codon
185..310
note = Human Genomic Fragment 1
311..5528
note = Hyg Self-Deleting Cassette
317..350
note = LoxP1
5458..5491
note = LoxP2
5529..22634
note = Human Genomic Fragment 2
22635..26915
note = Mouse Sequence
25217..25219
note = Stop Codon
source
1..26915
mol_type = other DNA
organism = synthetic construct

```

SEQUENCE: 65						
acagagctgg	tttgggtctc	cctctctctc	attcaCTGc	acatACAAGC	gtgttCTTC	60
tctattttt	ctctctctc	ctctctct	ctctctct	ctctctct	ctcagaatga	120
tggctctgg	tagatgttc	gtctatgtt	tctgcttaat	tcaagtGTT	tctggagaaa	180
gtggctatgc	tcaaaaatgg	gagtatTC	taagtTTT	tatggattt	ggattatTCG	240
taagcatgtt	tcaagggtt	cgttcccta	acagacCTGA	gtcaggcact	gggttGAAT	300
gcagtttgg	gtcgagataa	cttgcgtataa	tgtatgtat	acgaagtta	atgcatggcc	360
tccgcgcgg	gtttggcgc	ctccccc	ctcacGGCA	gCGCTGCAC	420	
gtcagacgaa	ggggcGAGC	agcgtcc	tccccc	cgacGCGC	ggacAGCGG	480
ccgcgtgc	taagactcgg	ccttagAAC	ccatGATC	cagaAGGAC	ttttAGGAC	540
ggacttgggt	gactctaggg	caCTGTTT	cttcccaAG	agcggAAACAG	gCGAGGAA	600
gtagtccctt	ctcggcgatt	ctcgggggg	atctccGTT	ggcgggtGAAC	gccgatGATT	660
atataaggac	ggccgggtg	tggcACAGCT	agttccGTC	cagccggat	ttgggtcgcg	720
gttcttgttt	gtggatcgt	gtgtatGCA	cttgggtAGT	agcggggCTG	tgggtGgcc	780
ggggctttcg	tggccggccgg	ggcgtcggt	gggacggaa	cgtgtggaga	gaccgcAA	840
ggctgtatgc	tgggtccgg	agcaaggTT	cctgtatG	gggttgggg	ggacgcGAGC	900
aaaatggcgg	ctgttccga	gtcttga	atggacGCTT	gtgaggcGGG	ctgtgaggTC	960
gttgaaacaa	ggtggggggc	atgggtggcg	gcaagaACCC	aaggcttga	ggccttcgt	1020
aatgcgggaa	agctcttatt	cgggtgagat	gggctggggc	accatCTGG	gaccctgacG	1080
tgaagtttgt	cactgactgg	agaactcgg	ttgtcgtctg	ttggggggc	ggcagtatG	1140
gcgggtcgct	tggggcgt	accegtac	ttggggacgc	gcgcctc	cgtgtcgta	1200

-continued

cgtcaccctgt	tctgttgct	tataatgcag	gggtggggcca	cctgcccgtt	ggtgtgcgggt	1260
aggctttcttcc	cctgtcgagg	acgcagggtt	cgggccttagg	gttagcttc	ctgaatcgac	1320
aggcgccgga	cctctggta	ggggagggtt	aagtggggcg	tcagttttc	tggtcggttt	1380
tatgtaccta	tcttcctaag	tagctgaago	tccggttttt	aactatgcgc	tcgggggttgg	1440
cgagtgtgtt	ttgtgaagtt	ttttaggcac	cttttgaat	gtaatcattt	gggtcaatat	1500
gtatatttca	gtgttagact	agtaaatgtt	ccgctaaat	ctggccgtt	ttggctttt	1560
tgtagacgt	gttgacaatt	aatcatecg	atagtatate	ggcacatgt	aatacgacaa	1620
ggtgaggaaac	taaaccatga	aaaagctga	actcaccggc	acgtctgtcg	agaagtttct	1680
gatcgaaaag	ttcgacagcg	tgtccgacct	gatcagctc	tcggaggggcg	aagaatctcg	1740
tgtttcagc	ttcgatgtag	gaggggcggt	atatgtctt	cgggtaataa	gtcgccgcga	1800
tggttttac	aaagatcg	atgttttac	gcactttcg	tcggccgcgc	tcccgatcc	1860
ggaagggttt	gacatgggg	aattcagcg	gaggcttgcac	tattgcattt	ccggccgtgc	1920
acagggtgtc	acgttgcag	acctgcctg	aaccgaactt	cccgctgttc	tgcaagccgg	1980
cgccggaggcc	atggatgcga	ttgtcgccg	cgatcttagc	cacacgacgg	ggttcgccc	2040
attcgatcg	caaggaatcg	gtcaatcat	tatcatggcg	gatttcat	gcgcgatgtc	2100
tgtatccccat	gtgtatca	gccaactgt	gatggacgac	accgtca	cgteccgtcgc	2160
gcaggcttc	gatgagctg	tgcttggc	cgaggactgc	cccgaaagtcc	ggcacctctgt	2220
gcacgggat	ttcggttcca	acaatgtct	gacggacaaat	ggccgcataa	cagegggtcat	2280
tgactggc	gaggcgatgt	tcggggat	ccaatacgag	gtcgccaaaca	tcttcttctg	2340
gaggccgttgg	tggcttgc	tggacagcg	gacgcgtac	ttcgagcgg	ggcatccgga	2400
gettgcagg	tcggccggc	tccggcgta	tatgtcttc	attggcttt	accactcta	2460
tcagagctt	gttgacggc	atttcgatg	tgcaagttcg	ggcgagggtc	gtcgacacgc	2520
aatcggtcg	tccggacgg	ggactgtcg	cgctacacaa	atcgcccgca	gaagcgccg	2580
cgctcgacc	gatgggtgt	tagaagtt	cgccgtatgt	ggaaacccgac	gccccagcac	2640
tctgtccagg	gcaaaaggaa	agggggatcc	gctgtaaatc	tgcaagaaatt	gtatgtctat	2700
taaacaataa	agatgtccac	taaaatggaa	gttttcttgc	tcataacttgc	ttaagaagg	2760
tgagaacaga	gtacccat	tttgatgg	aggattggag	ctacgggggt	gggggtgggg	2820
tgggatttgc	taaatgcctg	ctctttact	aaggcttctt	actattgc	tatgataatg	2880
tttcatatgt	ggatatcata	attnaaacaa	gcaaaaccaa	attaaggggcc	agctcatcc	2940
tcccactat	gatctatata	tctatagatc	tctcggttgc	tcatttttt	tctcttgcatt	3000
cccaacttgc	gttctcaatgt	actgtgttgc	ccaaatgttgc	cagtttca	gcctgaagaa	3060
cagatcg	agccctgtt	ccacatcac	tttcatctca	gtattttt	gccaaatgtt	3120
aattccatca	gacccgcacc	tgcaagccct	agcccgccgc	ccagtagcag	cacccacgtc	3180
caccttctgt	ctagtaatgt	ccaacaccc	cctcagttca	aacactgc	tgcatccat	3240
tggctccat	ttataactcg	agcacttgc	ggggccctca	tgttttacta	gagcccaccc	3300
ccctgcaact	ctgagaccc	tcggatgttgc	tcgtcagtgc	ctcaactggg	cggtggataa	3360
tttcttaaaa	ggtcaagttc	cctcagcago	atttctcg	cagtcgttgc	atgtgtgtt	3420
ttcacagttc	aaatccatgt	ggctgtttca	cccacctgc	ttggccttgg	ttatctatca	3480
ggacacttgc	tagaaacgg	tgtgtggc	ttaaacactt	agctgtgt	ctaactgtt	3540
actcaacttgc	atggatctt	tgtcaatct	tgactgtgc	acaagactt	cctgtatgc	3600
aagcccttgc	cacccctctc	atgccccat	tttgacatgg	tacaggctt	cacttgc	3660
ggtctgttag	gtctcggtt	tctttgtact	cataattcc	agggggact	agtatctata	3720
agaggaaag	ggtctgtgtt	cccaaggcc	agccccacaaa	attccacat	cttcacaggtt	3780
gggtgggtcg	accagggtgg	tgtccctgt	tctgagccag	ctccggccca	agccactgacc	3840
atgggtatcc	ccaagaagaa	gaggaaagg	cgtagccat	taaattccaa	tttactgtacc	3900
gtacacaaaa	atttgcctgc	attaccgttgc	gatgcacg	gtgtgaggt	tcgcaagaa	3960
ctgtatggc	tgttcagggt	tcggccagg	ttttctgtgc	ataccgttgc	aatgttctg	4020
tccgttttgc	gtctgtggc	ggcatgttgc	aaagttaata	acccggaaat	gtttccgc	4080
gaaccttgc	atgttcgc	ttatcttca	tatcttcagg	ccgcgggtt	ggcagtaaaa	4140
actatccagc	aacatttgc	ccagctaaat	atgtttcat	gtcggtccgg	gtcgccacga	4200
ccaaatgttgc	gcaatgttgc	tttactgttgc	atcgccgg	tccgaaaaa	aaacgttgc	4260
ggccgttgc	gtcggaaac	ggctcttgc	ttcgaacgc	ctgatttgc	ccagggttgc	4320
taactatcg	aaaatgttgc	tcgtcgcc	gatatacg	atctgttgc	tctgggtt	4380
gcttataaca	ccctgttgc	tatagccaa	attgcccagg	tcagggttaa	agatatctca	4440
cgtactgtgc	gtggggaaat	gtttaatccat	atggcagaa	cgaaaacgtt	gtttagcacc	4500
cgagggtgttgc	agaaggact	tagectgggg	gtaaactaaat	ttggcgccgg	atggatttcc	4560
gttctgtgttgc	tagtgcgttgc	tccgaaataa	tacctgttt	ggccgggtc	aaaaaaatgtt	4620
gttgcgcgc	catctgcac	cagccagct	tcaactcg	ccctggaa	gattttgc	4680
gcaactatc	gattgttgc	cgccgttgc	gtaaatataa	aatttttgc	tgtataatgt	4740
gtttaactatc	tgtttgttgc	tttttaggttgc	actctgttgc	tgatgttgc	gagataacttgc	4800
gtctgtgttgc	gacacatgt	ccctgttgc	ggccgcgg	atatggcc	cgctgggttgc	4860
tcaatacccg	agatcatgc	agctgtgttgc	tggaccaat	taaattatgt	catgaactat	4920
atccgttacc	ttggatgttgc	aacaggggca	atggtgcgc	tgctggaa	tggcgatgt	4980
tctagataatcg	taatgtatcat	aatcagccat	atcacat	tagagggtt	acttgc	5040
aaaaaacatcc	cacacatccc	cctgttgc	aaacatataaa	tgaatgttgc	tgttgttgc	5100
aaacatgttgc	tagttgcgc	caatccgc	tgacgttgc	tccgcacat	taccatgttgc	5160
tctgtgttgc	aaaataataa	taacoggca	ggggggatct	aagcttgc	taaataatgt	5220
tcataatcg	ccatatcaca	tctgttagagg	ttttacttgc	ttttaaaaac	ctcccacacc	5280
tcccccgttgc	cctgttgc	aaaatgttgc	caattgttgc	tttttttt	acttgc	5340
cttataatcg	tttcaatataa	agcaatgttgc	tcacaaat	cacaaatataa	gcatttttt	5400
cactgtatcc	tagttgtgttgc	ttgttcaaaac	tcatatgttgc	atcttcat	gtctgttgc	5460
acttgcata	atgtatgttgc	tacgttgc	tgctgttgc	tataacggc	ctaagggttgc	5520
gagcttagca	tttccacat	attcgttgc	tttttttaat	gtttaccac	catgacagg	5580
ggcaggggat	caataactat	gggtgtttat	aagaccttgc	tatttgc	aaggaaatgc	5640
tttcaatcc	aagtgtatgttgc	cttaatataa	gaatgttgc	tctgttgc	caaaaatgtt	5700
gtctcatgttgc	atgtatgttgc	ttgttgc	ggaaaatgttgc	caaagttaat	ttacccat	5760

-continued

aggagatcaa	actggattca	ttttgttga	cttttaaga	aatcctgaaa	gcataacctt	5820
caggataagg	taatgtacag	aagaatago	tttgtctca	gtgaccagt	ctatatctc	5880
agcaccta	aa tca	tttgtggcta	gaatatgta	gacatcca	aacttttga	5940
aaatacttta	gttttgagag	atattatgt	gatTTTaa	aaataactg	ctagagaaag	6000
atctaaatga	gttttactcat	tgaatatacad	tgaattgc	ccacacca	aaattggcca	6060
atgttaataa	ttcttttgg	gatctaaaaa	acttagtacc	gagaagocaa	ccctgccc	6120
acataaaacac	atgttaatta	taacaaaact	aggcagaagc	ttctaaacagc	agcaggaggc	6180
atgtggaaat	tttagaccatc	aacttgc	tgcaattaa	gcccttctc	tttaagagt	6240
aaaaactatt	ttggctataga	caatataaa	catatcgcc	taatgact	gcttatgc	6300
tttgagttat	gtatattacg	aggatggaa	ttccctagaa	tttctcat	agggaaatgt	6360
cagagagttt	gacatTTT	acatgtttt	actcaactt	ttggggatga	tttattat	6420
atgcttaact	ttgccttgg	ttccacaaa	gactgtgg	aggcaggaaa	cataaatctt	6480
actctcttc	atgtcatcta	tactca	ttcaccc	tgatcata	atttttaaa	6540
tatataagaa	tgcttagt	aaagctgg	ttcactca	cttttaa	ttcagat	6600
tttagaagat	tataattacc	ctattcacat	gattacgt	aaataact	cagtttggg	6660
tataggaatt	cacatccat	tgctgtt	tgaatgt	caatTTT	atcatcacaa	6720
ggatgatcaa	gagaagaaag	ggatactt	aaaaatcca	aatcattac	actattatc	6780
aactaactcc	attcgttag	aagaagactt	ctagatgaca	ctggcttgc	tatgatacat	6840
attccacaca	atthaattt	ttatggata	atatgtct	atattat	aaatatgaat	6900
aatattaaat	attgacatc	taaagaataa	tagattaa	cattattca	aagctctat	6960
taatttcaa	accatgtaa	ttataacacc	gtcaattgc	ataaaactt	taaagagaag	7020
ctcaaatgtt	tcatgtat	tttcagaatt	agaatttctt	tttac	tcattactt	7080
tttctcagaa	aatattat	tcatgtca	tccttatt	atcctact	tttctca	7140
taacctt	tttcaat	ttcagtatt	gtctatgca	cgagttt	tattaa	7200
catgtcttag	agaagttgc	tacgtac	aggaccac	gttagtac	cagaattaa	7260
acgcacatct	gtccagct	aacaccac	gtcttacca	ctgttacat	taactact	7320
tagccaagaa	tttttca	ca	ca	tttttca	tttttca	7380
tttataatgt	atttgcagg	atTTT	tttttca	tttttca	tttttca	7440
tactgaaag	ccatgttag	gttctt	tttttca	tttttca	tttttca	7500
tataaaatggc	tcattgtt	tttgc	tttttca	tttttca	tttttca	7560
gtttagtggg	tgctgtacat	tgcttgc	tttttca	tttttca	tttttca	7620
aagccgacc	acaggatgt	tgaatccaa	taataatac	tgttctgt	atagaat	7680
tggaaagaa	aatgtcag	ca	ca	ca	ca	7740
tagaaagct	caactgcaca	gggaa	aaat	ca	ca	7800
cattatgtt	tgctgtat	agaagg	ggc	ttt	ttt	7860
tttgcttgg	tgca	tttgc	tttgc	tttgc	tttgc	7920
ctgtgttgt	tgca	tttgc	tttgc	tttgc	tttgc	7980
tttgactgaa	ccaac	tttgc	tttgc	tttgc	tttgc	8040
tttccat	tttgc	tttgc	tttgc	tttgc	tttgc	8100
ctctgggaca	atcaact	tttgc	tttgc	tttgc	tttgc	8160
gaagcatctt	atttctag	ctgtat	tttgc	tttgc	tttgc	8220
acttgcac	tctgagaat	tttgc	tttgc	tttgc	tttgc	8280
atatttctt	acatattat	tttgc	tttgc	tttgc	tttgc	8340
tgttagattt	attatgg	tttgc	tttgc	tttgc	tttgc	8400
atcacat	tttgc	tttgc	tttgc	tttgc	tttgc	8460
gcatctgt	agaatctat	tttgc	tttgc	tttgc	tttgc	8520
gtatgtacaa	cattcacc	tttgc	tttgc	tttgc	tttgc	8580
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	8640
ttaatttgg	atgc	tttgc	tttgc	tttgc	tttgc	8700
ctgcaagata	gtatcatt	tttgc	tttgc	tttgc	tttgc	8760
attatgatt	gtat	tttgc	tttgc	tttgc	tttgc	8820
gtgtctt	tttgc	tttgc	tttgc	tttgc	tttgc	8880
agtttataa	caaaaa	tttgc	tttgc	tttgc	tttgc	8940
gaggttactt	actcattat	tttgc	tttgc	tttgc	tttgc	9000
agcg	tttgc	tttgc	tttgc	tttgc	tttgc	9060
gcctt	tttgc	tttgc	tttgc	tttgc	tttgc	9120
gagtctgt	tttgc	tttgc	tttgc	tttgc	tttgc	9180
taacagtc	atgttgc	tttgc	tttgc	tttgc	tttgc	9240
tcattctat	gtatgt	tttgc	tttgc	tttgc	tttgc	9300
tttgaggacc	catatgt	tttgc	tttgc	tttgc	tttgc	9360
gttttaatgg	tttgc	tttgc	tttgc	tttgc	tttgc	9420
caaaagaa	aatatgt	tttgc	tttgc	tttgc	tttgc	9480
cttctgaa	tttgc	tttgc	tttgc	tttgc	tttgc	9540
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	9600
ccaaactt	atc	tttgc	tttgc	tttgc	tttgc	9660
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	9720
tttgc	tttgc	tttgc	tttgc	tttgc	tttgc	9780
tctatgc	atgttgc	tttgc	tttgc	tttgc	tttgc	9840
tggtaataa	atttcat	tttgc	tttgc	tttgc	tttgc	9900
tgggaa	actt	tttgc	tttgc	tttgc	tttgc	9960
acaat	tttgc	tttgc	tttgc	tttgc	tttgc	10020
tggcattt	tttgc	tttgc	tttgc	tttgc	tttgc	10080
tttactaa	ag	tttgc	tttgc	tttgc	tttgc	10140
tgttgc	tttgc	tttgc	tttgc	tttgc	tttgc	10200
ctgaggct	tttgc	tttgc	tttgc	tttgc	tttgc	10260
caaagtaat	caagatcc	tttgc	tttgc	tttgc	tttgc	10320

-continued

gacaattctc	cacagtctat	agtccaaaca	agccctgaat	tccagtttt	gtcaatttat	10380
gggagacttc	tgcacattt	tatggatgc	tttctgtgc	agtccttaga	taaacatgt	10440
gttggacttg	agtgtgtac	tgtgttct	gtctgcctct	gttcacttcc	ctaacacatt	10500
ttccaggaaat	aaaatatgtc	aaaagaacct	gaaccagtcc	gatgtccaca	atctaggctg	10560
gaaatggatt	gcactaaaaac	agccataaca	actcattcaa	acaaggact	cattttcatg	10620
ggcaaattcac	tctcccacac	ggagggttga	ctttggcttc	ttaaccagc	tggctgggt	10680
gctgagttt	cacccgtt	tctcttggcc	aagctgaggt	tgacacttct	gttcaacttc	10740
attcacacca	tatttgacca	cttcttgc	cactcaaaca	tacttaccc	ttAACATATC	10800
tcttgacttt	tcctgtcata	ttgtaatctg	tccagagcc	cctcttattt	ggtttccaa	10860
tttgaggatcg	atatttgcgt	tggaaggga	ctgccttaag	aaagaaaacgt	tttcaagtgg	10920
aaatatatgt	atgagcttt	taatagatg	actcctggag	ttcagagcc	ttaaaaggat	10980
gccccagttc	acaagacagc	cataccgtca	tccctgttgc	tccatgtc	attaatttca	11040
tttctcaaat	catggaaatg	agctgagaat	accattttag	atcccttc	aattcccaac	11100
agtaccagaa	acttgcata	ggttggggcc	tgttaattgg	tatttcacac	atactttcc	11160
tacaatataat	ttctataactc	aagaatggaa	cttaaaagtta	ttgtcttagt	tttccacat	11220
ccccatgttta	cctaaatattc	aaaaatggga	ccccggctcc	agtcctccct	tctatattat	11280
tttatcaaat	cgtgacaaca	ttaccatctt	cagatcttc	cacccgtatgt	ttgtcctaag	11340
cttatttccct	ggttatgtc	tagtttaccc	aaaaattccg	tttttatttt	tatctgtt	11400
caagttggaa	aagectatct	accaccaacaa	ggaacacaca	tcccttagta	ctttgagaca	11460
cacacacacaa	tacacaccta	cttctttaag	ccttaaaat	ccgcacactt	aaaagatagc	11520
agttaaacaa	agtaacagg	tgggagaaca	gttttaagg	atgtcccaa	aataatcaat	11580
acattttagcc	agttaaattaa	cttacattt	cttcaccaat	ctcttagttt	catgactgt	11640
ggagcttac	cagtcaactt	cagaccacaa	taaaccacaa	gtgaaaggatt	ctgtacacaa	11700
agctaggcgc	ctctccccc	cattttactt	cctggccagc	tcaactcga	ccagacacaa	11760
aggttccctt	ttttgtgcag	agttcaggaa	ccattctcg	aaggactcat	ttgagcacat	11820
gcagagaga	gtgtacacac	atccgttca	ccaagggaa	ccaacacaca	tttgtgggt	11880
taggttagta	aggcccttcc	tagaacacac	tccttaggt	ttaaaacaaa	tttacatcggt	11940
taatggaaag	aatttttca	tatagccaa	cttacccaga	ggaattttc	ttctgcccag	12000
atcttcactt	ccaatttgc	ccagtttatac	cttcttagag	ctatttggct	gagcttaaac	12060
agcacatagg	aaaaacaaat	tggtaactgt	gtttatcaca	gaagaggaaa	attaaattt	12120
gggttggaa	aggaaaaataa	ccctatgtat	tactttttat	tctacccat	caatgagaat	12180
atataccctt	gttacttctt	taattttatc	attttttatc	tattttttt	tgctttttt	12240
tttgattaca	atgcatttt	ggggtaaaat	ttatgtgtgg	taaaatgcac	aaaaattaag	12300
tgaatttgg	gaatgtcta	tgacccgt	ccattccat	ggttaaagata	tagaacttat	12360
ttttccctt	gaaggatgt	tcatgttctt	ttccagttca	tcttcatacc	ccaggagca	12420
tcataatttct	aaatttctt	accctttgtt	tttgcgcatt	ttctgtatgt	tcttattat	12480
agaatactct	ttattttttt	ctgtttttt	tcatthaac	agttttgtt	agagtttagc	12540
atgttgcgt	ccatctcata	gctcatctt	tcaattgtca	agtagtaatt	ccactgtatg	12600
aatataccac	aaattttttt	tttcttctt	tcttgcgtaa	cattttgtt	ttttcaagtt	12660
tgagactatt	attttttag	ttgtgttca	cattttgg	caaatcgat	tgtgtatata	12720
tattttattt	tttctgggg	ataaaaccc	agaatggaa	tgctgtgtca	taaggttac	12780
atgtatctaa	gtttataaga	aaccgc	catttttca	aaagtggat	accattctac	12840
tcccttc	gogatgtatc	atcatttgca	acgtttgact	ttgggatagt	12900	
atctcgtag	gtttttattt	cgccattttt	aaataacaaa	tgttgcgcag	ctttccat	12960
acttggctt	ttgcctgtct	tctttgggt	agtatctgtt	aaaagactt	agttttttgt	13020
cctttgtt	ttgctggata	tgagtttctt	atacattctg	tatacatttc	ctttgtcaga	13080
tagatgtat	gtatcttattt	tctatgttca	agtttgcatt	tttattttct	tacttgtgcg	13140
tttaataaa	caagatgttt	ttttttat	gttgcgtat	aatatatcat	ttatttttt	13200
ttatattgt	tgctttttgt	atcttgcata	agataactt	gcctactccc	aaagtggaa	13260
agatattttt	tcatgtttt	ttttaaatgt	tctacagttt	tagcctttat	atttatgttt	13320
ttaattttt	attatactt	aagtccatgg	gtacatgtgc	acaacgtgt	gtttttgtac	13380
atatgtat	atgtgcgtat	ttgggtgt	gcaccgat	actcgat	tacatttagt	13440
atatcttc	atgtatcc	ccccccccc	tccacccat	gactggccct	ggtgtgtat	13500
gttccc	ctgtgtccaa	gtgtctt	cgttcaattt	ccatctatga	gtgagaacat	13560
gcagtgttt	atttttgtc	tttgcgtat	tttgcgtata	atgtgtttt	ccagcttcat	13620
ccatgtccct	ataaaaggaca	tgaatctatc	ctttttat	gtgtatgt	atccatgtt	13680
gtatatgtc	cacattttct	taatccgtc	tatcattgtat	ggacatttgg	tttgcgttca	13740
agttttgtc	atgtgtat	gtgtgtat	aatcgatcat	gtgcgtatgt	ttttatagca	13800
gcgttattt	tactcttgc	ttgtatatacc	cgtatgg	atggctgggt	caaataatgt	13860
ttctatgtat	ggatcttgc	ggactccgca	cactgttctt	cacaatgtt	tgatgtttt	13920
acagtccccc	caacactgtt	aaagtgttcc	tattttctca	cattccccc	agcaccttt	13980
gtttccgtac	tttttataat	tcaccattt	aacttgcgtt	agatgtgtat	tcattgtgtt	14040
tttgatttgc	atttctctt	tggccattt	tggctaatat	ccagaatcta	caatgaactc	14100
aaacaaat	acaacaaaaaa	aacacacaa	ccccatcaaaa	agtggggcaaa	ggatgtatgaa	14160
agacacttct	aaaaaaaga	cattttatc	gccaatcaaa	aaaaatggaa	atgtctatca	14220
taatgttca	ttagagaaac	gcaatcaaa	ttgtgtt	ttgttctt	tgtttatgc	14280
attggctaa	acctctgtt	caccactgaa	tagaaatgtt	gaaatgtgtt	attctgtcg	14340
tgtcctgtc	ttagggaaac	aattcatgtt	cacaatttca	gcactaaata	tgtatattaa	14400
tataggctt	tgtaaatgt	tttctatc	tttgcgtat	ttttttttt	ttttttttt	14460
ctgtgagttt	ttaatcatgaa	tttgcgtat	tttgcgtat	tttgcgtat	tttgcgtat	14520
gattgttatt	aaccaggat	tttgcgtat	tttgcgtat	tttgcgtat	tttgcgtat	14580
ttaattttt	aatctttaac	ctgtttttt	tttgcgtat	tttgcgtat	tttgcgtat	14640
gtattaaat	tagtgcgtt	ttttttttt	tttgcgtat	tttgcgtat	tttgcgtat	14700
tatttgcata	tcaacttctt	tttgcgtat	tttgcgtat	tttgcgtat	tttgcgtat	14760
ctagcttca	aaaataggtt	gagaagggtc	attcttctt	cagtttctaa	aataatttgcgtat	14820
gtcagattgt	cacttattt	tttgcgtat	tttgcgtat	tttgcgtat	tttgcgtat	14880

-continued

caagcataga	gtttctttg	ggggaaagt	tattgataat	aagtttaat	tctttgagag	14940
aatatataact	gttcaaataat	tccatttcta	tgtggtcag	atttactaat	tttggtttat	15000
aaaacacattt	tccatcacat	taagtattata	tatacattaa	aatagcattt	aaaatttcct	15060
tattatactt	ttaacatctg	catgtctat	agtgatatact	cctcttacat	tccagatatt	15120
agtaatttat	atatttgtt	ttcttaacca	ctcttgtag	ggttcaccag	ccaaaattac	15180
ctataaaaat	ccattacgtt	acccatcaag	tatatgtat	attatgtata	taaccctta	15240
tactatgtt	tcattttctt	taacactat	ttttaatcaat	atttttaca	gcttatttt	15300
cttacatata	tcctatgga	acataaaaa	aagcaattac	tttttaactt	aaacaaagta	15360
tttggtttc	agtgtatcaat	tataaaaata	tagaaatttc	ccataatttt	ataataatgt	15420
cttgactatt	tcaggctcaa	ttgcattcaa	ttcttaactt	atcattacta	agttatcatg	15480
cagcagaatt	ccataaaggatt	ttaatcttatt	atctcttcat	cctgaacatg	cctccacta	15540
ccccccacca	tacccatgaa	cagagttaaa	gtcaacata	catcaatgt	catatgatac	15600
tatccactg	catacaggaa	ctccctacgt	aatcaagaca	tatcccctt	ttattccatc	15660
agtggggccc	tcgtggaggt	aaagtgcctt	aatttcaggaa	aactacaaga	gatataattt	15720
atcgagacaa	agaattttctt	actgttggaa	aagagcaata	tatgtgtgaa	ggttggagaa	15780
aagagtctaa	cctgcaaaaa	ataagaccta	accactatag	gtaaaggatt	gtatataaaa	15840
gtatgggtt	cactttggg	ctactgaaa	acactgtgtc	ttggacattt	gtaggttaaa	15900
agtagacaaa	tagtggaaac	aacttgcata	agataatagc	taattcccta	ctgtaaattt	15960
ttataataaa	tggaaatggct	gaaattttata	cttccctgc	gtgaaaagaa	tctgaggatc	16020
ttcaaaaccca	ggtgtgaaag	atagtgttt	tgcaaaccta	catgaagggg	ctaactggag	16080
ctgggcttcc	tgtcatccat	cacaggtgtc	cttcccttcc	ttatctgtcc	tttcccttct	16140
tacctgtct	tctcccaaatt	tccttgcgtt	cttctccca	aatccccaca	acattctgag	16200
taagttttagc	taacttatact	agttttttta	aaaagcatat	atgccttctc	tatttgtcag	16260
agttttctac	aaaaaaaaaa	gggaattcaat	aggaggatag	atagatagat	cattgtatgg	16320
agagatttct	attaagaaaat	tgactttttt	ggttgtggaa	actggcaatc	gcaaaaatcc	16380
ataaggaacg	ccagtaggtc	agaaaatttcg	gaaagagtgc	agtatttgagc	ctaaattccg	16440
caggcgaaga	aactcaagca	gattttctgt	attgtactt	tgagacagac	ttgttcttcc	16500
ttcagggaaac	ctctgtctt	gctcttaggg	ccttctactg	atgggtgtat	gccccaccaca	16560
tcacggaaagg	caatctactt	tactcaaagt	ttactgtatt	aaatgttaac	catgtcttaa	16620
aaataactttt	agcattccctt	attcgctcc	ccttcaacc	tcaaaaaagaa	aattaaaggt	16680
aagagagacaa	tactcttag	agataagaaa	gagaagaaa	cctagettag	ctttgtctca	16740
gtttttttc	actaaagatg	aaaaatagag	aggtaaaggaa	gaagttccat	gtgtgaacaa	16800
ttaacttgc	aaaaggccaa	tgttagtagaa	aaagagacatt	aggcagatgg	ctgtgcatgt	16860
tggccacaca	gaagcagcat	tggccatgac	cagtgtgggt	cctgggttag	ggaagagaac	16920
tggctttgc	acaacacaggc	tatctcttgc	gttataaaaa	ggttgggttct	gatcatttgg	16980
agatgagggtc	cctatggata	gggcaccata	tctaaatggaa	caccatttac	attgcaataa	17040
tacattcagt	tctctggagag	tgagcagaga	aggcagagggt	tctcgttctt	ctgacaagggt	17100
cctggagcat	caggggagag	cccatttcta	caaactccca	caccagcatg	caagccctta	17160
catgcacata	agacactcaca	acacccaaag	agccctccagg	tgacatctgc	caccctccaaa	17220
tccccatcat	ccacatgtct	aatgcacttgc	cagtcttcat	ccccccagg	actgcaaatc	17280
tgacatgcct	cctccgaacg	gcaaggggga	gagggtacgt	ttgtacacac	actgtgtatg	17340
gcataggccc	cttggaaagg	ggttagtgc	gtcttctggg	gtatggcaa	gcacccctgg	17400
caacggcaga	agagagggtg	tggaggcat	tctcacggat	gcatctccct	ctaggfccta	17460
atgggacact	tccatataatgg	aacttacatt	taagtgcatt	taaacttggat	gtttctgtatt	17520
gagccccccaga	gocagtcgtc	cactgcccac	acctgcaccc	tcacttcccc	ttgtttaagc	17580
atcttccaa	ccagtaaggc	tgaagaggga	agcatctgc	cttcccttac	ctcttagcag	17640
agtagatgtt	tatgtattt	cagatgtat	aagaatctat	tccctctgaa	gtattgtttg	17700
atgaatgagc	ccctttttct	aatttgcata	aaagaatcat	ttgagttga	ggaaaactgt	17760
ccagggggca	cgaggaccag	ccgttgcgtt	atgtacaaag	gtagagaaac	aaaagctaaa	17820
tgaagaagag	tgagcctcag	aatcaaaagaa	ctggatttgg	atccctttaa	accattttac	17880
aggggccctga	atgtatattt	cttctctgtt	attcgtttt	tttataataa	tgctgtgtat	17940
aagtgcattt	tgttttgcata	cagcataaag	aaagcatgca	gtacttagga	gtatgtttt	18000
tcccttcaatt	ctcttattat	aaaaatgg	gacacggggca	ggggcttcag	ctcagaaggc	18060
cttgcgttgc	atggatggaa	gagcagggac	aagagagagg	ggcaaaaggca	ttgcccagcat	18120
tttctgttcg	gtgtttctcc	acccacttgc	tttccctctt	agtcaggggc	18180	
atttttccctt	ttgtataact	tccctttta	caacccatcc	aagggtgaaa	aaacaaaggtca	18240
ttaacttttt	ttcgttactt	ctaaggccaa	gcagccagaa	caggccatgt	ccactacgaa	18300
taagtgcata	caacaagagc	tagccaaac	tctgcattgt	gggtgcatt	ttattggcc	18360
ggcaagtaac	tttaaatccca	agcttacact	ctactgcatt	aaagtgcatt	gaacccgcatt	18420
cttctgtgc	atccacttgc	tttcccttgc	tttccctctt	agtcaggggc	18480	
acaactaaact	tcccaggctg	tgaccaacaa	gcagccaa	ggccaggccaa	gggaagtc	18540
aggaccccttcc	taggaatca	atacccctt	ctgggtttgt	tctgcctgaa	ataataacaa	18600
tcccttccca	acagcttagc	atgtgtggag	catttgcatac	taacagcaac	cctgcaaggc	18660
aggaaggccag	tagggagagg	cccaaggagg	attcgcatt	aaggcagatg	gactgcacaa	18720
ggggacccccc	ttggggatcc	ctggaggctt	tttgcagggtt	ccaggatgtca	gacccttcatt	18780
gtcactgttag	cttgcaggccat	gtcaacatgt	cacagcatat	aacctaattt	tattacaaga	18840
ataaagactc	agagttttaa	tactctgtt	ttggggctca	tttagtaacaa	gttctccat	18900
attcaaaaagg	caaagtggat	gtttttttgt	gtaaaattaa	cactatgtc	tgtaacaaaat	18960
aagccccccaa	acatataact	tctcaaaacac	cgttagtttta	tttcttactc	acatcagat	19020
aaaatggat	tttttaacc	tgcaatgttt	gtttctccca	gcagtatttgc	gggcactttc	19080
catcttgcgg	ttccaccgtc	tgttaatgc	gactccatgt	ggttggaaagg	gacggaggcc	19140
aggagtccaca	atgggtgttgc	tgtctggccc	aggggtggaa	tggatgtgc	tttcttctgc	19200
ccacccctact	cacaaggccca	cacccactgt	caagagaggc	tggagaatgc	ggactggatt	19260
taaaccaccaag	aagaagaaat	ggttttcttgc	atagttggcc	atttactgac	acaaaaagg	19320
tcaaaatgtac	ttgcagagga	gatgaatttt	aaataactata	attatttctt	ttgctgcct	19380
ttagacagaa	tttatttctt	tttcccttcc	agttaaacct	gaggctcc	ttgacccgt	19440

-continued

tgtcgctat	cgggaaggag	ccaatgactt	tgtggtaca	ttaatacat	cacacttgca	19500
aaagaagtat	gtaaaaagt	taatgcacga	tgtagctac	cgccaggaaa	aggatgaaaa	19560
caaatggacg	gtatgtat	caactacatt	aataaaataa	aaactatga	atgtttcta	19620
tttggcgc	ctagtagtgc	attccccctg	ggagggccca	acaatttgc	ttcaaaatc	19680
tacaccttac	tgaaaagaatc	tcccaatatt	ggcccccattg	aaacctggat	cttccctgat	19740
gcatacttct	ctagctctgg	ttgtttctt	ctgtcttaat	tttggcttc	agaatgttc	19800
tacatttagtg	agttggataa	caatatagtat	tgaggccaa	ttaatctct	gtattcaggg	19860
gcctcaaaa	gtgtcatgtc	taggccact	ttcataggca	aatcaggccaa	aatgtatatac	19920
tgcttatgtat	caccaggctg	tagccacatt	ctggctttag	agattcatgg	gaccagcatg	19980
aggtaaaagaa	aagaggccata	atgttgctt	ttgttttgtt	tttattttaa	agcccaaggt	20040
cttgggtttt	gaagtaaagac	cttaatgtt	acccttata	atcaggagag	ttacttagat	20100
gtctcttca	tgatgttgg	aggtggaaat	gatttggcag	tccctgaat	ttatgttggg	20160
gaggagggtgg	cagaagagtg	gagtgtacca	ggttatgaga	tttctttaa	cccaccaacc	20220
taacttctgt	tctttctgc	cctcagatgt	gaagaagada	tgtatgttcc	tcttcttca	20280
gtcttcttta	ttcttgcgt	cctgtttttt	caggccaa	ttggccttgg	ttgttgcag	20340
tgtgtatgc	gatgccactt	gcataatgt	aacaactgc	ccaaacccacc	tgctccctcc	20400
ttctactcac	ccacccccc	cttgatctgt	ccatcttca	ttatttcatct	gaaaatttgc	20460
ccaaatggaa	agcaacttag	tggagaaagg	aaggattatgt	aataatgt	gccaggacaa	20520
tttagttaact	aaaaagaaaa	atagataat	tcaataaaat	catgaattt	tttggatgtt	20580
agtcttgc	atgcacttgc	gttggatgt	aatggccca	tcttgcgtca	ctgcaacactc	20640
cgccctccgg	gttcaagcaa	ttctccatc	tcagccctcc	aagtacctgt	gattacaggc	20700
acccgcctatc	atgcggcgat	aattttgtt	tttttgtaga	gttgggggtt	caccatgtt	20760
gcccaggctgg	tcttgcact	ctcacctcg	gtgtatgtc	caccctcagcc	tcccaaagt	20820
ctgggatttac	aggcataa	ccacacgca	gcacaaaaat	gtttaat	aaaaaaaat	20880
aactaaatgc	ctagccac	tcatataaca	acaacaaaat	accagatgt	ttaaggaat	20940
tatataaaag	tgaaaactcta	aacaattt	aaaaatttata	gccaatgtt	tacataatct	21000
tgacatgaag	aagaacat	taagoatca	agotgttaga	gaaaagaaag	gatttagagca	21060
tgcaactaca	ttaaaagtgg	aggtttat	atgtcaac	acacaataat	aaaaatcaa	21120
aaatgc	aaat	ttaaaagtta	gcttaat	ccacataaa	agctgtat	21180
cattaataga	taaaggactc	ttataatca	ttaaaaaaac	aaatatcaca	atagaaaaat	21240
gagcaaaaaaa	atggggaaaa	atctcaataa	gtatggata	gataatattca	ataaaatata	21300
gaaaatgac	taattatca	ataatatac	atataatag	caatggactt	ctttttatct	21360
gtcaatgtt	taggtgg	tttttttaat	cttaaagata	atacactgt	ttgttgagac	21420
ttttgtct	ttatca	tcacaatgt	aaatggcgtc	tttctggaga	gaaatgtt	21480
ctgctca	acttaactca	acccat	tccctttaat	atgtcaac	tttggatgtt	21540
aagaagaaga	tattgtat	ttggaaaggga	gatcctggc	agtcctacta	tcacctgt	21600
aagacccatc	atccatct	cctcccttgc	cactcacaac	atcccttata	agtcagatt	21660
ctgtccctaa	ttttgtgtt	gactccttta	cgtatcag	ctcccttattc	taacaat	21720
gagacaactt	cagagaatgc	ttatgggtt	aaaggaatct	caattgtat	gattttggag	21780
atttagggca	caccttctt	cccatctttaat	gaatgtact	gactctact	ctctagcat	21840
tgaattttatc	cagcaca	ctgcacact	tgccagagaa	gcttcaacccg	gcagcaat	21900
atgagattaa	agttcgat	atccctgtatc	actat	ttttaa	aggcttctgg	21960
gttcaatgtt	ttacttc	actccatc	tcataat	tc	tcaggtaag	22020
aggtttttt	ttccctc	tgatgttgc	tgtcaatgtt	ttggagca	tgagggaaag	22080
attttgtt	aaatctgc	aaat	gacatgtt	cccttggagg	gtacttctt	22140
gagaatgtat	tgctgtgt	ttttgcgtt	ttttgttgc	acaaggaa	agggggatgt	22200
gggtccctt	taggttgc	tttagtacaa	ccatctgtat	ttcttgc	tgccatata	22260
tttgcacaaa	actccccc	actactgc	tttgcacaa	tttgc	tttgc	22320
ctgtgttcc	taaggccct	ttaaagca	cttcttattgg	tgtcaggat	gcaggcaat	22380
ggggctgtcc	ttatgttct	tttcc	gatgttgc	ttttggac	ttttggac	22440
aatgttgc	actgttgc	tctcc	aaaatttgc	acagggggt	acatccctt	22500
catcatctcc	tgctgtgtt	tctt	tttgc	tttgc	tttgc	22560
ggtagctt	atgttagt	acgtt	tttgc	tttgc	tttgc	22620
cccaagtca	tgcccaagta	gtgtatgtt	ttccca	tttgc	tttgc	22680
tttctcttca	tcaaaat	gtttca	aaat	tttgc	tttgc	22740
atcaactat	cttcaat	tcc	tttgc	tttgc	tttgc	22800
ttcttatatt	ccaggaggat	gggtt	tttgc	tttgc	tttgc	22860
ctctgtt	ttgttgc	tctt	tttgc	tttgc	tttgc	22920
agtaaacaag	agggttattt	tttgc	tttgc	tttgc	tttgc	22980
agttttaaa	taacagactt	tttgc	tttgc	tttgc	tttgc	23040
tttttagatc	ccatgtt	tttgc	tttgc	tttgc	tttgc	23100
agacataaga	caaacaat	tttgc	tttgc	tttgc	tttgc	23160
gcatctgtc	atttgc	tttgc	tttgc	tttgc	tttgc	23220
tgtgtgtcg	tgcgtgtgt	tat	tttgc	tttgc	tttgc	23280
gggttct	ttttttat	tttgc	tttgc	tttgc	tttgc	23340
atgtgtgt	gtctacaggc	tttgc	tttgc	tttgc	tttgc	23400
acottgttctc	tttgc	tttgc	tttgc	tttgc	tttgc	23460
aatttgc	taaaactct	tttgc	tttgc	tttgc	tttgc	23520
caagataat	tttgc	tttgc	tttgc	tttgc	tttgc	23580
ggtttattt	ttggattt	tttgc	tttgc	tttgc	tttgc	23640
taagaatgtt	tttcaat	tttgc	tttgc	tttgc	tttgc	23700
catgttca	tggatgtt	tttgc	tttgc	tttgc	tttgc	23760
tgtat	tttgc	tttgc	tttgc	tttgc	tttgc	23820
cctcggcaat	tttgc	tttgc	tttgc	tttgc	tttgc	23880
ataat	tttgc	tttgc	tttgc	tttgc	tttgc	23940
cttacttcc	agtaaagaca	tttgc	tttgc	tttgc	tttgc	24000

-continued

```

aggtctcatt gtagctccat ataaacacca atactgcctc cctgcaaaacc tcactctcg 24060
ctttaggtaa ctttgaca taattacatt gtctcattca caatagatcg ttagcaagga 24120
gctctgttct atccactct taaaaccaaga gcatgatact gtcagagaaa ataagggttt 24180
tgtccagtaa cagaaatgtt ttccaaatct acctcaaata aggtgaaga gttgttttg 24240
tgcccttc ttcgtccgtt tggttcaagt atgaatgtt cttgggttta ggattaaacc 24300
tgtcgatgg cttagtctcc ccgtatcaa gaaaactctg gaacaactat gtaagaagcc 24360
aaaaaacggta attgtcgag gtggggaaag aaacaccata atgtgaaat cttagtctaa 24420
gaatgattaa gactgacact caacttacgg tcttttatat atcacataaa tgaaaggctt 24480
ttaagactc tgaagaataa agccaagata tgccacaggg caggggggtg gggaaaatc 24540
aatatttact taaaatgtgg agtactacag ctccgtcaga agtgaagcca actgtcattt 24600
tttcacatcg tttgtgttcaatcagaa gtttcaatcagaa cggttttagt tccgtatca 24660
aatgtatagg akgcgtctt tgccacgctt ctaacgcttc tgccttc tgcagagct 24720
gaatgtgagt ttcatccccg aaagtttctt ggactgcca attcatgagg tgaaaggcgt 24780
tgaaggcagg gacgagggttgg aaagtttctt gcccaatgtt ctccctgcac agccagagga 24840
gttggagaca caggagaca gagccgtgtt acacagtgc aaccgtcgc ctgagactt 24900
agtcagccca ccagaaacag tttagaaagata gtcaccccta agatgcttgg cttagaaatct 24960
gagtacctgc aatggccctc cactccttc ctctaggctc cctgactaca gagatggta 25020
cagaaatagg cttccgtgt atcaagactt gtcggcaaaac tctggaaaca caaatgtccc 25080
tgccctgtc ctcacatccat tgcccttc tgcgggaaatctt ctgtatccag ttttcagag 25140
acagcccatc tccacttc tcaactgttcaatcagaa gtcgtatgtca ccatgtctag 25200
tttttaccaa aacaaatgaa ttataagaaa acccttccat cgacaacccaa atgatca 25260
agatggaaag tctggaaatgc ttgtctccc ccgtactgtca cagaagagaa agtcaacgtg 25320
accttgcatac acatgttcag catttcaaga aatcatgtt ccgttcttgc tccgtatcc 25380
ttgcacaaag caggaagaat ctgtttccc tttgtgttgc tttagtcataa gagtccat 25440
gacccaatta aatttgcaaa actcgtttaa gtgaagaaag aaagatagac aaaagaagat 25500
agaaggatgt ggtgaatgca ggaagaagaa aatgaaagat gtgagtgtt ggtctatcat 25560
tcaaatgtac tattttatccaa gcaactatacc acttttctca ttttcttccat acaataat 25620
tacaatgtgg gtttccat tataactttt atttttcttgc tcatagatgc tgaatttgc 25680
agtagagatt ttaagtgtata tccaaatttt tctttcgtt acagatgagg cacatcc 25740
aacttcaccc ctctcttgc atgaaacctgtt cctatttgc tttagtcaaa atcaccacta 25800
agtggatgtt tatgtgtcc atttccaaatccttgc tttagtcaaaatccat 25860
ataatataaca taagactaa atgttatatg tctaaagagaa atgttgcattt atggcattt 25920
tacttaaagt ggctataggg atgaacatga aggacaaatg acattttatgg gtgtggcata 25980
ccatgaccat gtgtcaagg aagtggggaa aagaaaaaaa aagcacaag atcatttgc 26040
tttgggggtt tttttttttt gaaaacaaaatc tcaagaaatggc atggtttaga agccgagaag 26100
ttcagagtc agttatcaag accatgttccat tccgtctgtt atttccat ggtttctctg 26160
tgacattgtt ggaggaaacta tggccatctt acaggagttt aacatccat agtgaatgg 26220
gtccctcttat gtgagtccctc ctatgtgtgg agacaccatt aagaactacc ccaagttcta 26280
catctctgga tattgtcttca actacagaaa aaggggggctt cgcacaccac aatgatgtcc 26340
ctaccttgaaa ctatgtctc acggaaacaaa agaagatggg taatgttccat aatccat 26400
gttgattttt gactgtcaatgtt cacaattttgc aatccctgtt gtgtataacc aatccctgt 26460
agaaaacaac aaataactgtt aagataactgtt ggttgggtgc cttagcatat aatccat 26520
taatgttgc tatttttttgc tttgttgc tttgttgc tttgttgc tttgttgc tttgttgc 26580
cattatattc agataaccc acacatgttcatatgttgc tttgttgc tttgttgc tttgttgc 26640
gcaatgtac atactgtttt ggttgc tttgttgc tttgttgc tttgttgc tttgttgc tttgttgc 26700
caaaacttgc ggtcagagac aatatgttcaatcagaa acagatgttcatatgttcatatgtt 26760
tgtgtttttt aatgttgc aatgttgc aatgttgc aatgttgc aatgttgc aatgttgc aatgttgc 26820
aatctcttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 26880
tgcccttc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 26915

```

```

SEQ_ID NO: 66          moltype = DNA      length = 21774
FEATURE                Location/Qualifiers
misc_feature           1..21774
note = Targeted Il7ra allele, without cassette (total 21774
bp)
misc_feature           1..184
note = Mouse Sequence
misc_feature           117..119
note = Start Codon
misc_feature           185..310
note = Human Genomic Fragment 1
misc_feature           311..387
note = Deleted Hyg Self-Deleting Cassette
misc_feature           317..350
note = LoxP
misc_feature           388..17493
note = Human Genomic Fragment 2
misc_feature           17494..21774
note = Mouse Sequence
20076..20078
note = Stop Codon
source                 1..21774
mol_type = other DNA
organism = synthetic construct
SEQUENCE: 66
acagagctgg tttgggtctc cctctctctc attcacttgc acataacaagc gtgcttctc 60

```

-continued

tctattcttt	ctctctctct	ctctctctct	ctctctctct	ctcagaatga	120
tggctctggg	tagagtttc	gctatagttt	tctgcctaata	tcaaggtgtt	180
gtggcatatgc	tcaaaatggt	gagtatttc	taagttttct	tatggatttt	240
tagcatgggt	ttaggttatt	cagttcccta	acagaccgtg	gtcaggact	300
gcagtttgag	gtcgagataa	cttcgtataa	tgtatgtat	acgaagttat	360
ataacggtcc	taaggtagcg	agctagcaa	ttccccatca	ttcagtcatt	420
ttaaccacc	atgacagggg	gcaggggatc	aataactatgg	gtgggttata	480
attctcaaga	aggaaatgc	ttcactccca	agtgttagatc	ttaaatgttg	540
ctgctcttac	aaaaagaatg	ctcatgtaga	tgtatgtact	gtacttgtag	600
aaagtaattt	tacccgtca	ggagatcaa	ctggattcat	tttgggttgc	660
atccgtaaag	dataacttc	aggataaggt	aatgtacaga	agcaatagct	720
tgaccagtgc	tatatcctca	gcacccataa	cagtggctag	aatatagtag	780
actttgaaa	gtgtttcaa	aatactttag	tttgagaga	tttatgttag	840
aataactgc	tagagaaaga	tctaaatgtt	ttaactcat	gaaataact	900
cacccaaca	aattggccat	atgtataat	tctttttggg	atctaaaaaa	960
agaagccaa	cctgcccata	cataaacaca	ttgtataatt	aacaaaacta	1020
tctaacagca	gcaggaggca	tgtggattt	tagaccatca	acttgcct	1080
ccctttcttct	ttaaggtt	aaaactattt	ggctatagac	aatataa	1140
aatgactcg	cttgcatt	ttgagtcatt	taattacgg	ggatggaaat	1200
tttgcattaa	ggaaatgtc	agagatgtt	acattttta	cattatata	1260
gggggatgt	tattattct	tgcttaactt	tgccttggat	ttccacaaag	1320
ggcaggaaac	ataaaatctt	ctcttttca	tgtcatat	actcactat	1380
gatcatacta	ttttttaaat	ataaagaat	gtttagttgaa	agctgggtt	1440
tttttaagg	ttaggttttt	ttagaagat	ttaattaccc	tattacat	1500
aataacttcc	agttttgggt	atggaaatc	acattcattt	gtgttgc	1560
aattttctga	tcatcacaag	gtatgcag	agaagaaagg	gatactttt	1620
atcatttaca	sttataatca	actaaatc	ttcagtagga	agaagactc	1680
tggcttgc	atgatcata	ttccacaa	ttaattttt	tatgtttaga	1740
taaccttta	aatatgata	atattaattt	ttgagcattt	aaagaataat	1800
attatttcaa	agctctatgt	aatttcaaa	ccatagtaat	tataacaccc	1860
taaactttt	aaagagaagc	tcaatgtt	catgtat	ttcagaat	1920
tttacctttt	cattactt	ttctcagaa	atattatact	cattat	1980
tccttactgt	gttctaagct	acccctttgt	aaatatccat	tcagtgattt	2040
gagtttacat	attagaacac	atgtttttaga	gaagttgc	acctgacaga	2100
tagatcatt	agaattttaa	cgcacatctt	tccagcttca	acaccacgg	2160
tgtgtatcatt	aactactt	accaaaatgtt	tttgcatttgc	acgtcatgt	2220
tttgcatttt	gocatcacat	tttataagtc	attgaaggaa	attttcttgc	2280
aactctgcc	cataatatct	actgaaaago	cagtggctg	cttcctaaa	2340
tttaggtco	gaaacatgt	ataatggct	cattgtat	tgtatgtt	2400
gtggcagtgg	gagtccctt	ttatgtgggt	gctgacat	gttaggtgt	2460
ttaaagaatc	gtgaagacaa	agccgacca	caggatgt	gaatccaaat	2520
gttctgtgt	tagattgg	ggaagagaaa	atgtcaggac	agtgtgagga	2580
aggtcagac	cactgcattt	agaaagctc	cactgcacag	ggaagaaatc	2640
aaatttagtgg	gtgttcttc	attatttct	gtgttcatca	gaaggagggc	2700
tgaactaca	taaagagctt	ttgtgtgtt	cagaactgt	aactggatgg	2760
tggccagaaa	aaacaatgcc	tgtgtgtgt	agcagtgc	acacccatgg	2820
gtctgttgc	atttgcatt	ttgtactgaa	caacctgttgc	ttcaactgttgc	2880
acagtca	tttataactt	ccccatttt	cctactgt	tatgttgc	2940
tattcgacca	gcccgggtc	tctggacaa	tcaactggaa	tttgatttttgc	3000
tctccagtgt	aaagccctgg	aagcatctaa	tttctgttgc	tgtatgttgc	3060
gaagcagtcc	taggttcata	cttgcatttgc	ctgagaatgg	cttgcatttgc	3120
ctcagggtcc	atgggggttgc	tattttgtca	catatttttgc	ccagcttcac	3180
gtaaaacata	cataaaaaat	tgatgttca	ttatgggttgc	tacaaaaacag	3240
caaaaactat	gtgtgacaga	tcacatctt	caaaagtaat	agcaaaaaaa	3300
ggttcccccac	tttcttccac	catttcgttca	gaatctatca	gatactgcgt	3360
atctataaga	acagaacatgc	tatgttcaaa	attcacagg	agtttccatca	3420
ctgcccatttgc	taattttttt	tccctatca	cgtttgttgc	agtcatttgc	3480
ggaaataatc	agtgcactt	ttaattgggt	tgccttttta	ggcaaggggaa	3540
aaaaaaaaac	aaatttgcac	tgcaatgttgc	cttgcatttgc	agacaaaaaa	3600
aataactatgg	aggggatgg	ttatgttttgc	taatggatgtt	aaaagtggaa	3660
tggggataat	ggaaataaaag	tgtcttttgc	tttgcatttgc	atgaaacatc	3720
atgttagcaga	aaaaacttca	gtttaataatc	agaaaagaaat	gtgttcaatgc	3780
ttaacttc	aaatatttgc	aggttactt	ctcattatgt	tggatttttgc	3840
ggaaaacttgc	ttaggttgc	gctgtttttgt	tttgcatttgc	tttgcatttgc	3900
aagcattttt	ttgtctttgc	cccttgggtt	tttgcatttgc	gaatactaca	3960
ctatttcatt	tctgcacac	agtcatttgc	tttgcatttgc	tcatgcatttgc	4020
atgcatttt	ttgttttgc	aacagcttgc	tgtttgttgc	ttcccaggag	4080
tgcagaaatc	gtatgttgc	catttcatttgc	tgcatttgc	tttgcatttgc	4140
gcactca	acctgtgc	tttgcatttgc	tttgcatttgc	tttgcatttgc	4200
aatatgggt	ggggatgg	tttgcatttgc	tttgcatttgc	tttgcatttgc	4260
atgtcttttgc	taatggccac	aaaagaaatc	atgttgc	taatggat	4320
ctaaggaaatc	ccccaaaggcc	tcctgaaact	ccttgcatttgc	cacaaaaac	4380
atctcccttc	acgggttc	tttgcatttgc	tttgcatttgc	tttgcatttgc	4440
tggggatccc	acatcccttc	tcagaatttgc	aatccctgcgt	tcctcataac	4500
acttctcacc	aaaaatgttgc	tttgcatttgc	cgagacaatc	cagtgttgc	4560
tgagagtttgc	actgcatttgc	tttgcatttgc	tttgcatttgc	tttgcatttgc	4620

-continued

gagaaaaggta	tgtatgtat	ctatgcctca	gttccctcac	ctgtaaaaatg	agataaacctg	4680
ccttcacaggaa	aggctgtgtat	ggttaaaaat	tttcatcata	taaatcatc	caaatagtgc	4740
gccagtgaat	aacgagtaat	ggggaaagcaa	cattaaatta	taattctgtg	aatattgacc	4800
taaacttctac	catcttgaca	caatttgact	tcagatgatc	ctctcaatgt	aaatttcca	4860
aaaatccaca	ggaataagtt	ggcattttgt	ttcacaaggat	ctcacagaaa	agacaagga	4920
aaagagttcg	gtttgaaagt	ttactaaagg	tctcagggaa	ctttatcttc	tcctctccct	4980
tcatccataa	gtcatcttt	gttgceraagg	gttactatc	tggtgtattt	gagaactac	5040
tctagcttga	aattctgacc	tgaggctatc	tccaaatcta	tatccgaatg	acctacttt	5100
tagttgtgt	cttagtgac	aaagtaaatc	aagatccacc	agtagataa	gaaggcttc	5160
taacattccat	agacactgag	acaattctcc	acagtctata	gtccaaacaa	gccctgatt	5220
ccagtttttg	tcaattttg	ggagcttct	gcatcttattt	atggagtgt	ttctgtcga	5280
gtccttagat	aaacatgctg	ttggacttga	gtatgtact	gtgttctctg	tctgcctctg	5340
ttcaacttccc	taacacat	ttcaggata	aaatatgtca	aaagaacctg	aaccagtcg	5400
atgtcccaaa	tctaggctc	aaatggatgg	cactaaacca	gccataacaa	ctcattcaaa	5460
caaggcactc	attttcatgg	geaaatca	ctccccacacg	gaggtttgac	tttgctct	5520
ttaaccacgt	ggctgggtgg	ctgatgttc	atcttgggtt	ctcttgccca	agctgaggat	5580
gacccttctg	ttcaacttca	ttcacaccat	atttgaccac	ttccctgccc	actcaaacat	5640
acttacccctt	taacatatct	cttgcactt	cctgtcatat	tgtaatctgt	ccagagctc	5700
ctcttattttg	gttttcaat	tggttcaga	tatttcagtt	ggaaaggagac	tgccctaaga	5760
aagaaacggtt	ttcagtgaa	aaatatatgt	tgagctttt	aatatgtaa	ctccctggat	5820
tcagagccct	taaaaggatg	cccagttca	caagacagcc	atacggcat	ccttgattgt	5880
ccattgtcata	ttaatccat	tctccaaatc	atggaaatg	gtgtgaaata	ccattttaga	5940
tectccctaa	atttccaaaca	gttccagaaa	cttgcatacg	gttggggcct	gtatttgat	6000
atttcacaca	tactttcc	acaatataat	tctatactca	agaattgtac	taaaatgtt	6060
tgtcttagtt	tctccacatc	ccatgtttac	ctaaattca	gaaatgggac	cccgtccca	6120
gttccccctt	ctatattat	tttacaaatc	gtgacaacat	taccatctc	agatcttcc	6180
acctgatgtt	tgtcttcaagc	ttatccctgt	gtatctgtat	agcttaccc	aaaattcggt	6240
tttttattttt	atccgttcc	aaatggggaa	agcctatcta	ccccaaacaa	gaacacaact	6300
cccttagtaac	tttgcagac	acacacat	acacacatc	tctttaaagc	ctaaacaatc	6360
gcacactcta	aaagatagca	gttaacaaaa	gttaacgattt	gggagaaacag	ttttaaggaa	6420
tgtccaaaaa	ataatataac	catttgcac	gtttaattaa	ttaacatttc	ttcaccatc	6480
tctagttttt	atgactgtag	gagtttaccc	agtcaacttc	agaccaacat	aaaccaagg	6540
tgaagattc	tgtacaaaa	gcttagggac	tctccctgc	atttaacctc	ctggccagct	6600
cactcgaagc	cagacaaca	ggttcctt	tttgcaga	gtccaggaa	catttcgaa	6660
aggactcatt	ttgagacat	cagagaaag	tgtagacaca	tccagttcac	caagggaa	6720
caacacacat	tgtgggtgt	aggttagt	aaaaggcttcc	agaacacat	cctttaggat	6780
taaacaaat	taatcggtt	aatggaaaga	tttgcattt	atacgaaac	ttaccaggag	6840
gaactttct	tctgcggcaga	tcttcaactc	caatttgacc	cgatatacc	tcttttagagc	6900
tatttgggtt	agcttaaaca	gcacatagaa	aaaacaaat	ggtaactgt	tttacacag	6960
aagagggaaa	ttaatattag	ggttggggaa	ggaaaataac	cctatgat	tacttttatt	7020
ctacccttac	aatgagaata	tatacttgc	ttacttctt	aattttata	tttatttactt	7080
atttttctt	gttttctgt	ttgattacaa	tgattttag	gggtaaaatt	tatgtgttgt	7140
aaaatccaca	aaaatgtat	gaatgttgc	gatctgtat	gacctgtat	cattccat	7200
gttaagat	aaacttatt	tttccctgt	aaaggatgtt	catgttcc	ttccat	7260
cttcatacc	caggagcaat	cataattctc	aattcttata	cccttgggtt	tttgcaggat	7320
tctgtatgtt	tttattata	gaatactt	tattttttc	tgttttctt	catttaacca	7380
gtgtttgtgt	gagttgtcc	tgtgtatgc	catctcatat	ctcatctt	caatgtctaa	7440
gttagtaattc	cactgtat	ataatccaca	aattttat	tctttctt	tttgatgaac	7500
atttgggtt	tttcaagttt	gagacttata	ttttttatgt	tgctgttac	attcttggac	7560
aaatcagttt	gtgtatata	attttcattt	ttctggggta	taaaacctca	gaatggaa	7620
gtctgtgtat	aaatgttgc	tgtagtctaa	tttataaagaa	accgcggca	agtttttca	7680
agtgggttata	ccatttcatt	ctcccttcag	cgatgcata	gagatataca	tcatgttgc	7740
cgttgtactt	ttggatagta	tctcgatgg	tttttaattc	cgatgttca	aataacaat	7800
gttgagccgc	tttccatata	cttggcttt	tgctgtctt	cttggggcta	gtatctgtt	7860
aaagcactga	gtttagttgc	ctttttgtt	tgctgttat	gagtttctt	tacattctgt	7920
atacatcttcc	tttgcata	agatgttgc	catcttattt	cttattctgt	gtttgcatt	7980
ttattttctt	actgggtgcgt	tttataaagc	aaagttttt	ttttttttt	atggatgtt	8040
atatatattt	tatatttctt	tatatgtat	gtcttttgc	ttcttgcata	gataacttt	8100
ctcaactccaa	aaatgtggaa	gattttttct	tttataatgtt	ctacagttt	8160	
agccctttata	tttagttttt	tttataattt	tttataactt	agtttgc	8220	
caacgtgtat	tttgcata	tgatgtatca	tttgcata	tttgcata	8280	
ctcgatcttt	acatttaggt	tatctctt	tgatctatcc	ccccctct	tccacat	8340
actggccctg	gtgtgtatgc	ttcccttcc	tggttcaag	tgcttcttac	gttcaat	8400
catctatgtat	tgagaacat	cagtgttgc	ttttttgtt	tttgcata	8460	
tgatgggttcc	cagcttcatc	catgttcc	taaaggatcat	gaacttcc	ttttttatgg	8520
ctgcataatgt	ttccatgtgt	tatatgttgc	acatcttctt	aatccatgt	atcattgtat	8580
gacatttggc	ttgggtccaa	gtctttgtca	ttgttgcata	tgctgcata	atcgtat	8640
tgcataatgtat	tttataatgtat	catgttata	actcttgc	ccccctct	tccacat	8700
tggctgggtt	aaatgtat	tctagcttgc	gatcccttgc	actgttcttcc	8760	
acaatgtgttgc	aactgtttt	cagtccatc	aaacgtgtat	tttttgc	8820	
atcccttcata	gtacccat	tttgcata	tttgcata	tttgcata	8880	
gatgggtatgt	cattgtgttgc	ttgatttgc	tttgcata	tttgcata	8940	
cagaatctac	aatgtactca	aaacaaat	caagaaaaaa	acaacaca	ccatcaaaaa	9000
gtggggcaag	gatgttgc	tttgcata	tttgcata	tttgcata	9060	
catgaaaaaa	ttgttgcata	tttgcata	tttgcata	tttgcata	9120	
tttttcttctt	gtcttgcata	tttgcata	tttgcata	tttgcata	9180	

-continued

aaagtggata	tccctgtcgt	gtcctggct	tagggaaaca	attcatgtc	acaatttcag	9240
cactaaatat	gatataact	ataggcttt	gtaaatgc	tttatcagat	tgaggaagt	9300
tctttctatt	tcttattgc	tgtgagttt	taacatgaat	agatgcattc	atgttattaa	9360
attatgttt	gaatgatttgc	attgattata	accaggttat	ttatgttttc	tagtcttta	9420
acatggcaaa	ttatattgtat	taattttga	atctttaacc	tgctttgggt	tcctgagatg	9480
tgccttactt	tataattatg	tattnaaatt	agtgtgttag	tattttcttg	tgaaagt	9540
cttatacatt	tttgaggat	atttgtctat	caacttctt	tctctaata	tttggccagg	9600
tttgggtacc	aggattaagc	tagttcaaa	aaatagggtt	agaagggtca	ttccctcttc	9660
agtttctaaa	ataatttgt	tcagattgac	actatttctt	tccttataca	tttgatagaa	9720
tttaccagaa	tataaccatc	aagcatagag	ttttcttgg	ggggaaagt	tttgatataa	9780
agtttaattt	tttgagaga	aatataat	ttgaaatatt	ccatttctat	gtgggtcaga	9840
tttactaattt	tgtgtttata	aaacatattt	cattacatc	aagtttattat	atacattaaa	9900
atagcattta	aaatccctt	attataactt	taacatctgc	atgttctata	gtgatatactc	9960
cttcttacatt	ccagattata	gtatattata	tattnngttt	tcttaaccac	tcttgtttag	10020
gttcaccaggc	caaattacc	tattnaaatc	cattacgtt	ccatcaagt	atatgtgata	10080
ttatgtatata	aacccttata	actatgtt	cattttctt	aacactttt	ttatcatata	10140
ttttttacag	ctcttatttc	ttacatata	tcctatggaa	cataaaaaa	agcaattact	10200
tttaatctt	aaacaaatgt	tttgttttca	gtgatcaat	ataaaaaat	agaaatttcc	10260
cataattttt	taaatatgtc	tttgactattt	caggttcaat	tgcatactat	tctaaagtaaa	10320
tcatcaatc	gtatcatgc	agcagaaagc	cataagattt	taatttcatat	tctcttattc	10380
ctgaacatgc	ctccactcac	ccacccacat	acctatgac	agagttaaag	tcaaaatata	10440
atcaatgtgc	atatgatact	atccactgc	atcaggaaac	tccttacttg	atcaagacat	10500
atcccccttt	tattctaca	gtggggccct	cgtgggggtt	aagtgcctg	atttcaggaa	10560
actacaagat	atataattca	tcgagaaaaa	gaaaatttca	ctgattggaa	agagcaat	10620
atgtgtgaag	gttggagaaa	agagtctaac	ctgaaaaaa	atagaccta	ccactatagg	10680
taagaagttg	tatataaaag	tatgttgc	acttttggc	tacctgaaaa	cactgtgt	10740
ggacatttgc	taggtttaaa	tgagacaaa	agtggaaaca	actggcaata	gataatag	10800
aattccctac	tgttaatttt	tataatataat	gaaaagctt	aaatttatac	tttctgcag	10860
tgaaagaattt	ctgaggatct	tcaaaaccag	gtgtgaaaga	tagtgtttgt	gcaaaacct	10920
atgaagtggc	taactggagc	tgggttctt	gtcatccatc	acaggtgtcc	tttcttccct	10980
tatctgttcc	ttcccttcc	acctgttcc	ctcccaaattt	ccttgtggc	tttccccca	11040
atccccacaa	cattctgat	aaagttagt	aacttata	gttattttaa	aaagcatata	11100
tgcccttctt	attagtcaga	gtttctaca	aaaaaaaag	ggaatataa	ggaggataga	11160
tagatagatc	attgtatag	gagatttcta	ttaagaaatt	gactttgt	tttggggaa	11220
ctggcaatcg	caaaaatcca	taaggccaag	cagttaggtt	gaaattcagg	aaagagtgc	11280
gtatttgc	taatttccgc	aggccaaag	actcaaggac	attttctgt	ttgtactt	11340
gagacagact	tgctttctt	tcagggaacc	tctgttctt	ctctagaggc	tttctactga	11400
tgaggtgtat	cccaccacat	cacggaaagg	aatctactt	actcaaaagg	tactgtat	11460
aatgtttaacc	atgttctttaa	aataatttta	gcatccctt	ttcgctcccc	tttcaaccct	11520
caaaaagaaa	ataaaggat	agagacaaat	acttatttt	gatggat	gataagaaag	11580
ctagctcagc	tttgcgttca	ttttgttca	ctaagatgt	aaaatagaga	ggtaaaggag	11640
aagttccatg	tgtgaacaat	taacttgt	aaaggcaat	gttagtagaa	agagacatta	11700
ggcagatggc	tgtgtatgt	ggccacacat	aaggcaggat	ggccatgacc	agtggggc	11760
ctgggttaggg	gaagagaact	ggctttagaca	acaacagggt	atctctgg	ttttaaaaaaag	11820
ttgggttctt	atatttgc	gttaggttcc	ctatggat	ggcaccat	cttaagggtt	11880
accattttaca	ttgcaatata	acatttgc	ctctgagat	gagcagagaa	ggcagagg	11940
ctcagtttgc	tgacaaatgc	ctggacatc	aggggagatc	ccatcttac	aaaactccac	12000
accaggatgc	aaggccat	atgcacataa	gcactacaa	cacaccaaa	gcctccagg	12060
gacatctgc	acccatcaat	ccccatata	catatgtca	atgcacttgc	agtctccatc	12120
ccccagcaga	ctgcaatct	gacatgc	ctccgaacgg	caagggggag	aggtacgtat	12180
gttacacaca	ctgtgtatgg	cataggcccc	tttggaaagg	gtatgttgc	tcttttgggg	12240
ctatggcaag	cacccttgc	caagcaggaa	gagagggttgc	ggaggcatgt	ctcacggtag	12300
catcttcttgc	tagttctta	tggacactt	cattaatgg	acttattt	aagttagt	12360
aaactggatg	tttctgttgc	agccccagag	ccagtgttcc	actgcccacca	cctgcaccc	12420
cacttccctt	tttttaaag	tcttccaaacc	cgatgttgc	gaagaggggaa	gcatctgc	12480
tttccactt	tcttagcaga	gtatgttgc	atgttatttgc	atgttgcata	agaatctatt	12540
ccctcttgc	tatttgc	ttatgttgc	ccttttttca	atttgcataa	agaaatattt	12600
tgagttgtat	ggaaaactgtc	cagagggac	gaggaccagg	cgttgtata	tgttacaagg	12660
tagagaaaca	aaagttataat	gaagaaggt	gaggcttgc	atcaaagaa	tggatttgg	12720
tccctttaaa	ccattttaca	ggggcttgc	tgtatataa	ttctctgt	tttgcattt	12780
tatcaatata	gttgggtata	agtgttgc	gttttgc	agcataatgc	aaggatgc	12840
tactttaggg	atgtgttctt	ccttcaattt	ctcttattt	aaaatgttgc	cacagggcag	12900
gggcttgc	tcaagaaggcc	tttgggtata	tttgc	tttgc	tttgc	12960
gcaaggat	tgccgcattt	ctctgttgc	ctgttcttca	cccaactgc	tttgc	13020
ttcccttctt	tttgcaggca	tttgc	tttgc	tttgc	tttgc	13080
agggttggaaa	acaaatgtat	tttgc	tttgc	tttgc	tttgc	13140
aggcagtcac	cactacgat	tttgc	tttgc	tttgc	tttgc	13200
gggtgcattt	tatttggcc	tttgc	tttgc	tttgc	tttgc	13260
aagtctgtat	tttgc	tttgc	tttgc	tttgc	tttgc	13320
gttgcaccc	cacccca	tttgc	tttgc	tttgc	tttgc	13380
ggccaggac	ggaatgttca	tttgc	tttgc	tttgc	tttgc	13440
ctgcctgaa	taataccat	tttgc	tttgc	tttgc	tttgc	13500
aacagcaacc	ctgcaaggca	tttgc	tttgc	tttgc	tttgc	13560
aggcagtcag	actgacat	tttgc	tttgc	tttgc	tttgc	13620
caggatgc	acccttcat	tttgc	tttgc	tttgc	tttgc	13680
acctaattttt	attacaagaa	tttgc	tttgc	tttgc	tttgc	13740

-continued

tagtaacaag ttctccaata ttcaaaggc aaagtggatg tggttttagtg taaaattaac	13800
actagctgc gtaacaataa agccccaaa catatgatat ctc当地acc gtaggttat	13860
ttctcaacta catcagagtc aaaatggatg ttctcaactt gcaactgggg cttcccccag	13920
cagtattagg ggcacttcc atcttgtgg tccaccgtct gtaatgcagg actccaagt	13980
gtggaaaggc acggagcaga ggagtcacac atgggtgtgt gtctggcca gggtggaaagt	14040
ggatgtgcat ttcttcgca cacccacto acaaggccac accccactgc aagagaggct	14100
ggagaatgcg gactggattt aaaaaaggaa agaagaaatg gtttctgaa tagttggca	14160
tttactgaca caaaaagggt caaagtact tgcaaggagtg atgaattttt aataactata	14220
ttatcttcctt ggctgcctt tagacagaat ttatcttctt ttctttcca gttaaacctg	14280
aggctccctt tgacactgtgt gtcgtctat gggaggagc caatgactt gtggtgacat	14340
ttaatacatc acacttgca aagaatgtat taaaaggatggat aatgcacgt gtatctacc	14400
gccaggaaaa ggtatggaaac aatggacgg tatgtatgtt aactacatta ataaaataaa	14460
aacttatgaa tggtttctat ttgttggeco tagtagtgc ttcccctgg gagggccaa	14520
caattttgc tccaaatctt accttctact gaaagaatctt cccaaatattt gcccattgaa	14580
aacctggatc ttccctgtat catacttcc tagctctgtgt ttgtttctt tgctctaatt	14640
ttgtcttca gaatgttttccatattgtat gtttgataac aatataqattt gaggccaaat	14700
taatcctctg tattcagggg cctcaaaaag tgcatgtct agtgcaccc tcataaggca	14760
atcaggcaaa atgtatatctt gcttgcatac accaagtgcg agccacattc tggcttatga	14820
gattcatggg accaggatcgat ggttaaggaa agaggcataa tggttgcctt tggtttgtt	14880
ttattnaaaa gcccaaggc ttgttgggtt agtaaagcgc ttaatttt cccttcataa	14940
tcaggagagt tacttagatg ctcttcat gatttggatg gtttggatg atttggcagt	15000
ccctgaaaat tattttgggg aggagggtgc agaagagtgg agtgcaccc gttatgtat	15060
ttctcttaac ccaccaaccc aacttctgtt cttctgcac ctcaggatgt aagaagagat	15120
gtgatttttctt ctccctcaag ttctttat ttttgcgtc ctgttttttcc agggcaagat	15180
tggccttgg tttttgcgtt gtgtatgcag atgcaacttgc cataaatgtt acaactgccc	15240
caaacccactt gtccttcctt tctacttcaccc cacccttccatc ttgatctgc cattttcat	15300
tattcatctg aaaaatggcactt aatggatgttggatg aatggatgttggatg atttggcagt	15360
ataaatgttgc ccaggacaat tagtttacta aaaaaggaaa tagataattt caataaaatac	15420
atgaattttt ttgatgttgc gtccttgcata gtcattccagg ttggatgtca atggcgcatt	15480
cttggctcac tgcacccctcc gcctcccccggg ttcaagcaat tctcccatc tgcctccca	15540
agtacatgttgc atacaggcc cccgcatac tgcggggatc atttttgtat tttttagat	15600
ctggggtttcc accatgttgc ccaggctgtt ctgttgcacttccatc ttatcttgc	15660
acccctcgcc cccaaatgtgc tgggattaca ggcatataaggcc aacacgcaccc cccaaaatttgc	15720
ttttaattaa aaaaatattaa actaaatgcg tagccaccc tataataacaa caacaaaata	15780
ccagatgatt taaggatgtt atataaaatg gaaactctaa acaaattttaga aaaaattttag	15840
ccaaatgttgc acataatctt gacatgaga agaacatttc aagcatcaaa gctgttagaa	15900
aaaaaaaagg attgagacat gcaactatc aaaaatggaa ggtttatata tgcacacaca	15960
cacaataatc aaaaatcaaa aatgcaattt taaaatgttgc cacataaaca	16020
gtctgtatgtt gtttgcgtt atttttatcatc taaaatgttgc cacataaaca	16080
aatatcatcaca aaaaatggaaatg agcaaaaaaa ttggggaaaaa tctcaataag tatggatag	16140
ataatattca aaaaatatgtt aaaaatgttgc aatatttcaaa taaaatcaca taaaatatgt	16200
aatggacttc tttttgcgtt tcaatattgtat agatgttgc ttttttatc taaaatgttgc	16260
taactctgtt gtttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16320
ttcttggagat aatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16380
tgtgaaaggaa tagagatgtt gtttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16440
gtgttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16500
ttctttatca gtttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16560
ttcttattttca aaaaatgttgc agacaaatgttgc agagaatgttgc ttttgcgtt ttttgcgtt	16620
aatttgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16680
cactctactt tctatgttgc gtttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16740
cttccatccgg cggatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16800
ggcttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16860
tcaggatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16920
ggggatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	16980
cactcttata aaaaatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17040
caaggatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17100
ccttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17160
tagcttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17220
gtcaggatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17280
cttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17340
caggatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17400
aagaaggaaatg gagatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17460
gatgttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17520
accggatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17580
agacatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17640
gaatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17700
tcaccatttc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17760
aaaaaaaggatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17820
acttcaggatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17880
gcaatataatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	17940
aggccaaatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	18000
tgtgttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	18060
atatacatatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	18120
gtatgttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	18180
catgtgttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	18240
tttttattcaatgttgc ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt ttttgcgtt	18300

-continued

ttaccacccc	tgtcagatta	attggtcagt	aaactctgag	tatctgtctg	cctccaccac	18360
tccacatatac	atagaggta	agatacatgt	tatcatacat	tgctatccaa	actcagtct	18420
tcaaaaatgt	atgacaagag	gtttatttt	tggatttatt	ccctaggcca	tgacgcccc	18480
ccccaaaaaa	agaattctt	aagaagtgtt	ttccaaatat	ttttccaca	gcctcctaaa	18540
ggacttagag	gtgattaccc	atgctaaca	ggagtctatt	tgatctcatg	actttctgca	18600
cacaaattca	catgatttt	gtatTTGCT	ctgtggtaga	accatgocct	gtgaattact	18660
cagtgttca	gaaagtgc	ctcgcaatt	ttgtattcc	aggacaaaaa	gtgctcta	18720
ttgaaaaaac	ctaccataaa	ataattttct	tgaatagctt	agaacgtatt	cccaatttcc	18780
actggatta	aagtaaaacc	tttacttcca	gtaaagacag	tggataagat	gacaatacca	18840
acagtggaca	taaaagacca	ggtctcattg	tagtccata	taaagaccaa	tactgcctc	18900
ctgcaaaac	cacttccg	tttagggat	tttgcacat	aattacatgt	tctcattcac	18960
aatagatcg	tagcaaggag	ctctgttca	tccactctt	aaaccaaggag	catgatactg	19020
tcagagaaaa	taaggtgtt	gtccgtaac	agaaatgttt	tcacaatcta	cctcaataa	19080
gtgtgaaagag	ttgtttgtt	gccttctt	tctgcccgtt	gttcaagta	tgaatgttt	19140
ctgggttttag	gattaaacct	gtcgatggc	ctagtctcc	cgatcataag	aaaactctgg	19200
aacaactatg	taaagacca	aaaacgtt	ttgcttggag	ttggggaaa	aacaccataa	19260
tgttgaatc	tttagtctaag	aatgat	actgacact	aacttacggt	cttttatata	19320
tcacataat	gaaagtcc	ttaagactt	gaagaataaa	gccaagat	gccacaggc	19380
aggggggtgg	ggaaaaatca	atattactt	caaggtgg	gtatcacagc	tcagtcaagaa	19440
gtgaagccaa	ctgtcattt	ttcacatgt	gtgtcaattt	tacaagaaag	tttgcataac	19500
gttttagttt	cctgaatcaa	atgtatagca	gcccctt	gcccgcctc	taacgctct	19560
gcctttct	gcagagtctg	aatgtggat	tcaatccca	aagtttctg	gactgcccaga	19620
ttcatcgat	gaaaggcg	gaagccagg	acggagg	aagtttctg	cccaatgt	19680
ttcctgcaca	gocagaggag	ttggagac	aggggacacag	agccgtgt	cacagtgc	19740
acogctegcc	tgagacttca	gtcagcc	cagaaacagt	tagaagagag	tcacccctaa	19800
gatgcctg	tagaaatctg	agatctgc	atgccc	actccttcc	tctaggtccc	19860
ctgactacag	agatgttgac	agaaaatagg	ctctgtgt	tcaagactg	ctgccaact	19920
ctggaaac	aaatgtcc	gtccctgtcc	tcaaccatt	gcctttccag	tcgggatcc	19980
tgataccat	tttcagaga	cageccat	ccacttctc	agtaactgt	caagaagaa	20040
cgtatgtc	catgtctgt	ttttacca	acaatgtt	tataagaaa	cccttccatc	20100
gacaacc	tgatcact	gatggaaat	ctggatgt	tgctctccc	cgtagctc	20160
agaagagaaa	gtcaacgt	ccttgc	tacatttgc	attctaa	atcattttc	20220
tcttctact	cagaacgt	tgcaca	aggaa	aggat	tgtttccct	20280
tagtctata	agtccat	acccaattt	aatttgc	ttcagtt	tgaagaagaa	20340
aaagatagaca	aaagaagata	gaaggatgt	gtgtatgc	gaagaagaaa	atgaaagat	20400
tgagtgg	tgctatcatt	caatttgc	atttatcc	caactatcca	ctcttctat	20460
ttcttctca	caataatatt	acaatgtgg	tttatccatt	ataactttt	tttcttgc	20520
catagatgt	gaagttgaaa	gtagagatt	taagtgtat	ccaaatttt	cttcagcta	20580
caqatggc	acacatcc	acttcc	tctcttgc	tgaacctgtc	ctatgtgt	20640
gtgtcaaa	tcaccat	gtggatgtt	atgtatgc	ttatccaa	tgatgtgtt	20700
tggaaagaaa	aaatgttgc	taatttac	taaagcataa	ctgtat	ctaaagagaga	20760
tgtggatgg	ttgtcattt	actttaa	actttaggt	gtataggg	tgaatcgt	20820
cattttatgg	tgtgcata	catgttgc	tgtcaaa	aggggggaaa	agaaaaaaa	20880
agcacaaga	tcatttgatt	gtttttgtt	aaaat	aaactaa	caagaagacaa	20940
ttagtttgc	gocgaga	tccagat	ttatca	ccatgttt	ctgtgtgt	21000
ttatccatt	gtttctgt	gacattgt	gaggaactat	ggccatct	caggatgt	21060
acatttacca	gtgtatgg	tcctctat	tgatgtctt	tatgtgt	gacaccat	21120
agaactacc	caagtctac	atctctgt	attgcgtt	ctatcaga	agggggtgt	21180
gcacacc	atgatgtcc	tacgttgc	ttatgt	ttatgt	ttatgt	21240
aagtattca	aattcaat	ttgatttgc	actgc	actatgtt	ttatgt	21300
tgtatacc	atctcttgc	gaaaaca	aataact	gatactgt	ttatgt	21360
ttagcattt	aattttttgc	aagtgttgc	attgttgc	ttgatgg	ttatgt	21420
gtcatgtt	gtatccat	attatatttca	gtatc	accatc	atgttgc	21480
atattctca	ggactgc	caatgttca	ttactgg	tttgc	tttgc	21540
ggttatttca	aaaggaaatcc	aaaatcttgc	gtcagagac	atatgc	aaaatcttgc	21600
aagtacttgc	tccaaat	gtgaaatata	atgaa	ggttacaa	ttatcaat	21660
actatgttt	gatccagg	atctcaat	ttctctgt	ttatcaat	ttatcaat	21720
ctcttctat	ccagactttt	gccttcaat	acaagcat	gcgtt	ttatccat	21774

SEQ ID NO: 67 moltype = AA length = 7
 FEATURE Location/Qualifiers
 REGION 1..7
 note = synthetic peptide
 source 1..7
 mol_type = protein
 organism = synthetic construct

SEQUENCE: 67
 AAAVTSR

7

SEQ ID NO: 68 moltype = AA length = 4
 FEATURE Location/Qualifiers
 REGION 1..4
 note = synthetic peptide
 source 1..4
 mol_type = protein
 organism = synthetic construct

-continued

SEQUENCE: 68	
QGGA	4
SEQ ID NO: 69	moltype = DNA length = 126
FEATURE	Location/Qualifiers
misc_feature	1..126
	note = synthetic oligonucleotide
source	1..126
	mol_type = other DNA
	organism = synthetic construct
SEQUENCE: 69	
ctatgctcaa aatggtgagt catttctaa gtttctttagt gattttggat tatctgttagc 60	
atggtttcag gttattcaagt tccctaaca ag acctgagtcg ggcactgggt ttgaatgcag 120	
tttgag	126

What is claimed is:

1. A genetically modified rodent animal comprising in its genome:
a humanized Tslp gene comprising:
a rodent Tslp nucleic acid sequence, and
a human TSLP nucleic acid sequence,
wherein the humanized Tslp gene encodes a humanized Tslp polypeptide comprising a mature protein sequence substantially identical to the mature protein sequence of a human TSLP protein.
2. The genetically modified rodent animal of claim 1, wherein the humanized Tslp polypeptide comprises a mature protein sequence having at least 95% identity to the mature protein sequence of the human TSLP protein.
3. The genetically modified rodent animal of claim 1, wherein the humanized Tslp polypeptide comprises a mature protein sequence identical to the mature protein sequence of the human TSLP protein.
4. The genetically modified rodent animal of any one of claims 1-3, wherein the humanized Tslp protein comprises a signal peptide substantially identical to the signal peptide of a rodent Tslp protein.
5. The genetically modified rodent animal of claim 4, wherein the humanized Tslp protein comprises a signal peptide having at least 95% identity to the signal peptide of a rodent Tslp protein.
6. The genetically modified rodent animal of claim 4, wherein the humanized Tslp protein comprises a signal peptide identical to the signal peptide of an endogenous rodent Tslp protein.
7. The genetically modified rodent animal of any one of the preceding claims, wherein the human TSLP nucleic acid sequence encodes at least a substantial portion of the mature protein sequence of the human TSLP protein.
8. The genetically modified rodent animal of claim 7, wherein the human TSLP nucleic acid sequence encodes the mature protein sequence of the human TSLP protein.
9. The genetically modified rodent animal of claim 8, wherein the human TSLP nucleic acid sequence comprises exon 1 from the codon for the first amino acid of the mature protein sequence, through the STOP codon in exon 4, of a human TSLP gene.
10. The genetically modified rodent animal of any one of claims 1-9, wherein the rodent Tslp nucleic acid sequence comprises exonic sequences of a rodent Tslp gene that encode the rodent Tslp signal peptide.
11. The genetically modified rodent animal of claim 10, wherein the rodent animal is a mouse, and the rodent nucleic acid sequence comprises exon 1, and a 5' portion of exon 2 coding for signal peptide amino acids, of a mouse Tslp gene.
12. The genetically modified rodent animal of any one of claims 1-9, wherein the rodent Tslp nucleic acid sequence comprises the 3' UTR of a rodent Tslp gene.
13. The genetically modified rodent animal of any one of claims 10-12, wherein the rodent Tslp gene is an endogenous Tslp gene.
14. The genetically modified rodent animal of claim 1, wherein the rodent animal is a mouse, and the humanized Tslp gene comprises (i) exon 1, and a 5' portion of exon 2 coding for signal peptide amino acids, of a mouse Tslp gene, and (ii) exon 1 from the codon for the first amino acid of the mature protein sequence, through the STOP codon in exon 4, of a human TSLP gene.
15. The genetically modified rodent animal of claim 14, wherein the humanized Tslp gene further comprises the 3' UTR of the mouse Tslp gene.
16. The genetically modified rodent animal of any one of claims 1-15, wherein the humanized Tslp gene is operably linked to a rodent Tslp promoter.
17. The genetically modified rodent animal of claim 16, wherein the rodent Tslp promoter is the endogenous rodent Tslp promoter.
18. The genetically modified rodent animal of any one of claims 1-17, wherein the humanized Tslp gene is located at an endogenous rodent Tslp locus.
19. The genetically modified rodent animal of claim 18, wherein the humanized Tslp gene is formed as a result of replacement of a rodent Tslp genomic DNA at an endogenous rodent Tslp locus with the human TSLP nucleic acid.
20. The genetically modified rodent animal of claim 19, wherein the humanized Tslp gene is formed as a result of replacement of a rodent genomic DNA comprising exonic sequences encoding at least a substantial portion of the mature protein sequence of the endogenous rodent Tslp protein, with the human TSLP nucleic acid which encodes at least a substantial portion of the mature protein sequence of the human TSLP protein.
21. The genetically modified rodent animal of claim 20, wherein the humanized Tslp gene is formed as a result of replacement of a rodent genomic DNA comprising exonic sequences encoding the mature protein sequence of the endogenous rodent Tslp protein, with the human TSLP nucleic acid which encodes the mature protein sequence of the human TSLP protein.
22. The genetically modified rodent animal of claim 21, wherein the rodent animal is a mouse, and wherein the mouse genomic DNA being replaced comprises exon 2 from

the codon for the first amino acid of the mature mouse Tslp protein through the STOP codon in exon 5 of the endogenous mouse Tslp gene, and the human genomic DNA comprises exon 1 from the codon for the first amino acid of the mature human TSLP protein through the STOP codon in exon 4 of a human TSLP gene.

23. The genetically modified rodent animal of any of claims 1-22, wherein the rodent is homozygous for the humanized Tslp gene.

24. The genetically modified rodent animal of any of claims 1-22, wherein the rodent is heterozygous for the humanized Tslp gene.

25. The genetically modified rodent animal of any of the proceeding claims, wherein the rodent expresses the humanized Tslp polypeptide.

26. The genetically modified rodent animal of any of the proceeding claims, whose genome further comprises a humanized Tslpr gene at an endogenous rodent Tslpr locus, a humanized Il7ra gene at an endogenous rodent Il7ra locus, or a combination thereof.

27. The genetically modified rodent animal of any of the proceeding claims, wherein the rodent is a mouse or a rat.

28. An isolated rodent tissue or cell, whose genome comprises a humanized Tslp gene comprising a rodent Tslp nucleic acid sequence and a human TSLP nucleic acid sequence, wherein the humanized Tslp gene encodes a humanized Tslp polypeptide comprising a mature protein sequence substantially identical to a mature protein sequence of a human TSLP protein.

29. The isolated rodent tissue or cell of claim 28, wherein the humanized Tslp polypeptide comprises a mature protein sequence having at least 95% identity to a mature protein sequence of a human TSLP protein.

30. The isolated rodent tissue or cell of claim 28 or 29, wherein the rodent cell is a rodent embryonic stem cell.

31. The isolated rodent tissue or cell of any one of claims 28-30, wherein the rodent is a mouse or a rat.

32. A rodent embryo, comprising the rodent embryonic stem cell of claim 30.

33. A method of making a genetically modified rodent, comprising:

modifying a rodent genome to comprise a humanized Tslp gene, wherein the humanized Tslp gene comprises a rodent Tslp nucleic acid sequence and a human TSLP nucleic acid sequence, and encodes a humanized Tslp polypeptide comprising a mature protein sequence substantially identical with the mature protein sequence of a human TSLP protein; and

making a rodent comprising the modified rodent genome.

34. The method of claim 33, wherein the humanized Tslp polypeptide comprises a mature protein sequence having at least 95% identity with the mature protein sequence of a human TSLP protein.

35. The method of claim 33 or 34, wherein said modifying comprises

introducing a nucleic acid molecule comprising the human TSLP nucleic acid sequence into the genome of a rodent embryonic stem (ES) cell,

obtaining a rodent ES cell in which the human TSLP nucleic acid sequence has been integrated into an endogenous Tslp locus to replace a rodent Tslp genomic DNA thereby forming the humanized Tslp gene, and generating a rodent animal from the obtained rodent ES cell.

36. The method of claim 35, wherein the nucleic acid molecule further comprises a 5' homology arm and a 3' homology arm flanking the human TSLP nucleic acid sequence, and wherein the 5' and 3' homology arms are homologous to nucleic acid sequences at the endogenous rodent locus flanking the rodent Tslp genomic DNA to be replaced.

37. The method of claim 35 or 36, wherein the humanized Tslp gene is operably linked to the endogenous rodent Tslp promoter at the endogenous rodent Tslp locus.

38. The method of any one of claims 33-37, wherein the human TSLP nucleic acid sequence encodes at least a substantial portion of the mature protein sequence of the human TSLP protein.

39. The method of any one of claims 33-38, wherein the rodent is a mouse or a rat.

40. A targeting nucleic acid construct, comprising a human TSLP nucleic acid sequence to be integrated into a rodent Tslp gene at an endogenous rodent Tslp locus, flanked by a 5' nucleotide sequence and a 3' nucleotide sequence that are homologous to nucleotide sequences at the rodent Tslp locus, wherein integration of the human TSLP nucleic acid sequence into the rodent Tslp gene results in a replacement of a rodent Tslp genomic DNA with the human TSLP nucleic acid sequence thereby forming a humanized Tslp gene, and wherein the human TSLP nucleic acid sequence encodes at least a substantial portion of the mature protein sequence of a human TSLP protein.

41. The targeting nucleic acid of claim 40, wherein the rodent is a mouse or a rat.

42. A genetically modified rodent animal comprising in its genome:

a humanized Tslpr gene comprising:
a rodent Tslpr nucleic acid sequence, and
a human TSLPR nucleic acid sequence,
wherein the humanized Tslpr gene encodes a humanized Tslpr polypeptide comprising an ectodomain substantially identical to the ectodomain of a human TSLPR protein.

43. The genetically modified rodent animal of claim 42, wherein the humanized Tslpr protein comprises an ectodomain having at least 95% identity to the ectodomain of a human TSLPR protein.

44. The genetically modified rodent animal of claim 42, wherein the humanized Tslpr protein comprises an ectodomain identical to the ectodomain of a human TSLPR protein.

45. The genetically modified rodent animal of any one of claims 42-44, wherein the humanized Tslpr protein comprises a transmembrane-cytoplasmic sequence substantially identical to the transmembrane-cytoplasmic sequence of a rodent Tslpr protein.

46. The genetically modified rodent animal of claim 45, wherein the humanized Tslpr protein comprises a transmembrane-cytoplasmic sequence having at least 95% identity to the transmembrane-cytoplasmic sequence of a rodent Tslpr protein.

47. The genetically modified rodent animal of claim 46, wherein the humanized Tslpr protein comprises the transmembrane-cytoplasmic sequence of an endogenous rodent Tslpr protein.

48. The genetically modified rodent animal of any one of claims 42-47, wherein the humanized Tslpr protein com-

prises a signal peptide substantially identical to the signal peptide of a rodent Tslpr protein.

49. The genetically modified rodent animal of claim **48**, wherein the humanized Tslpr protein comprises a signal peptide having at least 95% identity to the signal peptide of a rodent Tslpr protein.

50. The genetically modified rodent animal of claim **49**, wherein the humanized Tslpr protein comprises the signal peptide of an endogenous rodent Tslpr protein.

51. The genetically modified rodent animal of any one of claims **40-50**, wherein the human TSLPR nucleic acid sequence encodes at least a substantial portion of the ectodomain of the human TSLPR protein.

52. The genetically modified rodent animal of claim **51**, wherein the human TSLPR nucleic acid sequence comprises exon 2 through the codon for the last ectodomain amino acid in exon 6 of a human TSLPR gene.

53. The genetically modified rodent animal of any one of claims **40-52**, wherein the rodent Tslpr nucleic acid sequence comprises exonic sequences of a rodent Tslpr gene that encode at least a substantial portion of the transmembrane-cytoplasmic sequence of a rodent Tslpr protein.

54. The genetically modified rodent animal of claim **53**, wherein the rodent animal is a mouse, and the rodent Tslpr nucleic acid sequence comprises exon 6 from the codon for the first amino acid of the transmembrane domain through exon 8 of a mouse Tslpr gene.

55. The genetically modified rodent animal of any one of claims **40-54**, wherein the rodent Tslpr nucleic acid sequence comprises exonic sequences of a rodent Tslpr gene that encode the signal peptide of a rodent Tslpr protein.

56. The genetically modified rodent animal of claim **55**, wherein the rodent animal is a mouse, and the rodent nucleic acid sequence comprises exon 1 of a mouse Tslpr gene.

57. The genetically modified rodent animal of any one of claims **53-56**, wherein the rodent Tslpr gene is an endogenous Tslpr gene.

58. The genetically modified rodent animal of claim **40**, wherein the rodent animal is a mouse, and the humanized Tslpr gene comprises (i) exon 1 of a mouse Tslpr gene, (ii) exon 2 through the codon for the last amino acid of the ectodomain in exon 6 of a human TSLPR gene; and (iii) exon 6 from the codon for the first amino acid of the transmembrane domain through exon 8 of the mouse Tslpr gene.

59. The genetically modified rodent animal of any one of claims **40-58**, wherein the humanized Tslpr gene is operably linked to a rodent Tslpr promoter.

60. The genetically modified rodent animal of claim **59**, wherein the rodent Tslpr promoter is the endogenous rodent Tslpr promoter.

61. The genetically modified rodent animal of any one of claims **40-60**, wherein the humanized Tslpr gene is located at an endogenous rodent Tslpr locus.

62. The genetically modified rodent animal of claim **61**, wherein the humanized Tslpr gene is formed as a result of replacement of a rodent Tslpr genomic DNA at an endogenous rodent Tslpr locus with the human TSLPR nucleic acid.

63. The genetically modified rodent animal of claim **62**, wherein the humanized Tslpr gene is formed as a result of replacement of a rodent genomic DNA comprising exonic sequences encoding at least a substantial portion of the ectodomain of the endogenous rodent Tslpr protein, with the

human TSLPR nucleic acid which encodes at least a substantial portion of the ectodomain of the human TSLPR protein.

64. The genetically modified rodent animal of claim **63**, wherein the rodent animal is a mouse, and wherein the mouse genomic DNA being replaced comprises exon 2 through the codon for the last amino acid of the ectodomain in exon 6 of the endogenous mouse Tslpr gene, and the human genomic DNA comprises exon 2 through the codon for the last amino acid of the ectodomain in exon 6 of a human TSLPR gene.

65. The genetically modified rodent animal of any of claims **40-64**, wherein the rodent is homozygous for the humanized Tslpr gene.

66. The genetically modified rodent animal of any of claims **40-62**, wherein the rodent is heterozygous for the humanized Tslpr gene.

67. The genetically modified rodent animal of any of claims **40-66**, wherein the rodent expresses the humanized Tslpr polypeptide.

68. The genetically modified rodent animal of any of claims **40-67**, whose genome further comprises a humanized Tslp gene at an endogenous rodent Tslp locus, a humanized Il7ra gene at an endogenous rodent Il7ra locus, or a combination thereof.

69. The genetically modified rodent animal of any of claims **40-68**, wherein the rodent is a mouse or a rat.

70. An isolated rodent tissue or cell, whose genome comprises a humanized Tslpr gene comprising a rodent Tslpr nucleic acid sequence and a human TSLPR nucleic acid sequence, wherein the humanized Tslpr gene encodes a humanized Tslpr polypeptide comprising an ectodomain substantially identical to the ectodomain of a human TSLPR protein.

71. The isolated rodent tissue or cell of claim **70**, wherein the humanized Tslpr polypeptide comprises an ectodomain having at least 95% identity to the ectodomain of a human TSLPR protein.

72. The isolated rodent tissue or cell of claim **70** or **71**, wherein the rodent cell is a rodent embryonic stem cell.

73. The isolated rodent tissue or cell of any of claims **70-72**, wherein the rodent is a mouse or a rat.

74. A rodent embryo, comprising the rodent embryonic stem cell of claim **72**.

75. A method of making a genetically modified rodent, comprising:

modifying a rodent genome to comprise a humanized Tslpr gene, wherein the humanized Tslpr gene comprises a rodent Tslpr nucleic acid sequence and a human TSLPR nucleic acid sequence, and encodes a humanized Tslpr polypeptide comprising an ectodomain substantially identical with the ectodomain of a human TSLP protein; and

making a rodent comprising the modified rodent genome.

76. The method of claim **75**, wherein the humanized Tslpr polypeptide comprises an ectodomain having at least 95% identity with the ectodomain of a human TSLP protein.

77. The method of claim **75** or **76**, wherein said modifying comprises

introducing a nucleic acid molecule comprising the human TSLPR nucleic acid sequence into the genome of a rodent embryonic stem (ES) cell,

obtaining a rodent ES cell in which the human TSLP nucleic acid sequence has been integrated into an

endogenous Tslpr locus to replace a rodent Tslpr genomic DNA thereby forming the humanized Tslpr gene, and generating a rodent animal from the obtained rodent ES cell.

78. The method of claim **75**, wherein the nucleic acid molecule further comprises a 5' homology arm and a 3' homology arm flanking the human TSLPR nucleic acid sequence, and wherein the 5' and 3' homology arms are homologous to nucleic acid sequences at the endogenous rodent locus flanking the rodent Tslpr genomic DNA to be replaced.

79. The method of claim **77** or **78**, wherein the humanized Tslpr gene is operably linked to the endogenous rodent Tslpr promoter at the endogenous rodent Tslpr locus.

80. The method of any one of claims **75-79**, wherein the human TSLPR nucleic acid sequence encodes at least a substantial portion of the ectodomain of the human TSLPR protein.

81. The method of any one of claims **75-80**, wherein the rodent is a mouse or a rat.

82. A targeting nucleic acid construct, comprising a human TSLPR nucleic acid sequence to be integrated into a rodent Tslpr gene at an endogenous rodent Tslpr locus, flanked by a 5' nucleotide sequence and a 3' nucleotide sequence that are homologous to nucleotide sequences at the rodent Tslpr locus, wherein integration of the human TSLPR nucleic acid sequence into the rodent Tslpr gene results in a replacement of a rodent Tslpr genomic DNA with the human TSLPR nucleic acid sequence thereby forming a humanized Tslpr gene, and wherein the human TSLPR nucleic acid sequence encodes at least a substantial portion of the ectodomain of a human TSLPR protein.

83. The targeting nucleic acid of claim **82**, wherein the rodent is a mouse or a rat.

84. A genetically modified rodent animal comprising in its genome:

a humanized Il7ra gene comprising:
a rodent Il7ra nucleic acid sequence, and
a human IL7RA nucleic acid sequence,
wherein the humanized Il7ra gene encodes a humanized Il7ra polypeptide comprising an ectodomain substantially identical to the ectodomain of a human IL7RA protein.

85. The genetically modified rodent animal of claim **84**, wherein the humanized Il7ra polypeptide comprises an ectodomain having at least 95% identity to the ectodomain of a human IL7RA protein.

86. The genetically modified rodent animal of claim **84**, wherein the humanized Il7ra polypeptide comprises an ectodomain identical to the ectodomain of a human IL7RA protein.

87. The genetically modified rodent animal of any one of claims **84-86**, wherein the humanized Il7ra protein comprises a transmembrane-cytoplasmic sequence substantially identical to the transmembrane-cytoplasmic sequence of a rodent Il7ra protein.

88. The genetically modified rodent animal of claim **87**, wherein the humanized Il7ra protein comprises a transmembrane-cytoplasmic sequence having at least 95% identity to the transmembrane-cytoplasmic sequence of a rodent Il7ra protein.

89. The genetically modified rodent animal of claim **87**, wherein the humanized Il7ra protein comprises the transmembrane-cytoplasmic sequence of an endogenous rodent Il7ra protein.

90. The genetically modified rodent animal of any one of claims **84-89**, wherein the humanized Il7ra protein comprises a signal peptide substantially identical to the signal peptide of a rodent Il7ra protein.

91. The genetically modified rodent animal of claim **90**, wherein the humanized Il7ra protein comprises a signal peptide having at least 95% identity to the signal peptide of a rodent Il7ra protein.

92. The genetically modified rodent animal of claim **90**, wherein the humanized Il7ra protein comprises the signal peptide of an endogenous rodent Il7ra protein.

93. The genetically modified rodent animal of any one of claims **84-92**, wherein the human IL7RA nucleic acid sequence encodes at least a substantial portion of the ectodomain of the human IL7RA protein.

94. The genetically modified rodent animal of claim **93**, wherein the human IL7RA nucleic acid sequence comprises from the codon in exon 2 encoding the first amino acid of the mature human IL7RA protein through exon 5 of a human IL7RA gene.

95. The genetically modified rodent animal of any one of claims **84-94**, wherein the rodent Il7ra nucleic acid sequence comprises exonic sequences of a rodent Il7ra gene that encode at least a substantial portion of the transmembrane-cytoplasmic sequence of a rodent Il7ra protein.

96. The genetically modified rodent animal of claim **95**, wherein the rodent animal is a mouse, and the rodent Il7ra nucleic acid sequence comprises exon 6 through exon 8 of a mouse Il7ra gene.

97. The genetically modified rodent animal of any one of claims **84-96**, wherein the rodent Il7ra nucleic acid sequence comprises the portion in exon 1 of a rodent Il7ra gene that encodes the signal peptide of a rodent Il7ra protein.

98. The genetically modified rodent animal of claim **97**, wherein the rodent Il7ra nucleic acid sequence comprises the 5' UTR portion of exon 1 of the rodent Il7ra gene.

99. The genetically modified rodent animal of any one of claims **95-98**, wherein the rodent Il7ra gene is an endogenous Il7ra gene.

100. The genetically modified rodent animal of claim **84**, wherein the rodent animal is a mouse, and the humanized Il7ra gene comprises (i) a portion of exon 1 of a mouse Il7ra gene comprising the 5' UTR and the sequence encoding the signal peptide of the mouse Il7ra, (ii) the codon in exon 1 of a human IL7RA gene that encodes the first amino acid of the mature human IL7RA protein through exon 5 of the human IL7RA gene; and (iii) exon 6 through exon 8 of the mouse Il7ra gene.

101. The genetically modified rodent animal of any one of claims **84-100**, wherein the humanized Il7ra gene is operably linked to a rodent Il7ra promoter.

101. The genetically modified rodent animal of claim **101**, wherein the rodent Il7ra promoter is the endogenous rodent Il7ra promoter.

102. The genetically modified rodent animal of any one of claims **84-101**, wherein the humanized Il7ra gene is located at an endogenous rodent Il7ra locus.

103. The genetically modified rodent animal of claim **102**, wherein the humanized Il7ra gene is formed as a result of

replacement of a rodent IL7ra genomic DNA at an endogenous rodent IL7ra locus with the human IL7RA nucleic acid.

104. The genetically modified rodent animal of claim **103**, wherein the humanized IL7ra gene is formed as a result of replacement of a rodent genomic DNA comprising exonic sequences encoding at least a substantial portion of the ectodomain of the endogenous rodent IL7ra protein, with the human IL7RA nucleic acid which encodes at least a substantial portion of the ectodomain of the human IL7RA protein.

105. The genetically modified rodent animal of claim **105**, wherein the rodent animal is a mouse, and wherein the mouse genomic DNA being replaced comprises the codon in exon 1 encoding the first amino acid of the mature mouse IL7ra protein through exon 5 of the endogenous mouse IL7ra gene, and the human genomic DNA comprises the codon in exon 1 encoding the first amino acid of the mature human IL7RA protein through exon 5 of a human IL7RA gene.

106. The genetically modified rodent animal of any of claims **84-105**, wherein the rodent is homozygous for the humanized IL7ra gene.

107. The genetically modified rodent animal of any of claims **84-105**, wherein the rodent is heterozygous for the humanized IL7ra gene.

108. The genetically modified rodent animal of any of claims **84-107**, wherein the rodent expresses the humanized IL7ra polypeptide.

109. The genetically modified rodent animal of any of claims **84-108**, whose genome further comprises a humanized Tslp gene at an endogenous rodent Tslp locus, a humanized Tslpr gene at an endogenous rodent Tslpr locus, or a combination thereof.

110. The genetically modified rodent animal of any of claims **84-109**, wherein the rodent is a mouse or a rat.

111. An isolated rodent tissue or cell, whose genome comprises a humanized IL7ra gene comprising a rodent IL7ra nucleic acid sequence and a human IL7RA nucleic acid sequence, wherein the humanized IL7ra gene encodes a humanized IL7ra polypeptide comprising an ectodomain substantially identical to the ectodomain of a human IL7RA protein.

112. The isolated rodent tissue or cell of claim **111**, wherein the humanized IL7ra polypeptide comprises an ectodomain having at least 95% identity to the ectodomain of a human IL7RA protein.

113. The isolated rodent tissue or cell of claim **111** or **112**, wherein the rodent cell is a rodent embryonic stem cell.

114. The isolated rodent tissue or cell of any one of claims **111-113**, wherein the rodent is a mouse or a rat.

115. A rodent embryo, comprising the rodent embryonic stem cell of claim **113**.

116. A method of making a genetically modified rodent, comprising:

modifying a rodent genome to comprise a humanized IL7ra gene, wherein the humanized IL7ra gene comprises a rodent IL7ra nucleic acid sequence and a human IL7RA nucleic acid sequence, and encodes a humanized IL7ra polypeptide comprising an ectodomain substantially identical with the ectodomain of a human IL7RA protein; and

making a rodent comprising the modified rodent genome.

117. The method of claim **116**, wherein the humanized IL7ra polypeptide comprises an ectodomain having at least 95% identity to the ectodomain of a human IL7RA protein.

118. The method of claim **116** or **117**, wherein said modifying comprises

introducing a nucleic acid molecule comprising the human IL7RA nucleic acid sequence into the genome of a rodent embryonic stem (ES) cell,

obtaining a rodent ES cell in which the human IL7RA nucleic acid sequence has been integrated into an endogenous IL7ra locus to replace a rodent IL7ra genomic DNA thereby forming the humanized IL7ra gene, and

generating a rodent animal from the obtained rodent ES cell.

119. The method of claim **118**, wherein the nucleic acid molecule further comprises a 5' homology arm and a 3' homology arm flanking the human IL7RA nucleic acid sequence, and wherein the 5' and 3' homology arms are homologous to nucleic acid sequences at the endogenous rodent locus flanking the rodent IL7ra genomic DNA to be replaced.

120. The method of claim **118** or **119**, wherein the humanized IL7ra gene is operably linked to the endogenous rodent IL7ra promoter at the endogenous rodent Tslpr locus.

121. The method of any one of claims **116-120**, wherein the human IL7RA nucleic acid sequence encodes at least a substantial portion of the ectodomain of the human IL7RA protein.

122. The method of any one of claims **116-121**, wherein the rodent is a mouse or a rat.

123. A targeting nucleic acid construct, comprising a human IL7RA nucleic acid sequence to be integrated into a rodent IL7ra gene at an endogenous rodent IL7ra locus, flanked by a 5' nucleotide sequence and a 3' nucleotide sequence that are homologous to nucleotide sequences at the rodent IL7ra locus,

wherein integration of the human IL7RA nucleic acid sequence into the rodent IL7ra gene results in a replacement of a rodent IL7ra genomic DNA with the human IL7RA nucleic acid sequence thereby forming a humanized IL7ra gene, and

wherein the human IL7RA nucleic acid sequence encodes at least a substantial portion of the ectodomain of a human IL7RA protein.

124. The targeting nucleic acid of claim **123**, wherein the rodent is a mouse or a rat.

125. A genetically modified rodent of any one of claim **1-27**, **42-69**, or **84-110**, further comprising a humanized Sirpa gene, wherein the rodent is homozygous for RAG2^{-/-} and IL2RG^{-/-}.

126. A genetically modified rodent of claim **125**, wherein the rodent further comprises a humanized Tpo gene, and/or a humanized GM-CSF/IL-3 locus.

127. Use of a genetically modified rodent animal as defined by any of claim **1-27**, **42-69**, **84-110**, or **125-126** in the preparation of a rodent animal model of allergic diseases (e.g., asthma or skin inflammation) or cancer.

128. A method of testing a candidate agent for treating an allergic condition, comprising

inducing an allergic condition in a genetically modified rodent animal as defined by any of claim **1-27**, **42-69**, **84-110** or **125-126**;

administering a candidate agent to the genetically modified rodent animal; and

determining whether the candidate agent inhibits the allergic condition in the genetically modified rodent animal.

129. A method of testing a candidate agent for treating cancer, comprising

engrafting human cancer cells in a genetically modified rodent animal as defined by any of claim **1-27, 42-69, 84-110, or 125-126**;

administering a candidate agent to the genetically modified rodent animal; and

determining whether the candidate agent inhibits the growth of the cancer cells in the genetically modified rodent animal.

130. The method of claim **128** or **129**, wherein the candidate agent is a small molecule compound, a nucleic acid, or an antibody.

131. An in vitro method for generating a genetically modified rodent cell, comprising

introducing the targeting nucleic acid construct of claim **40** or **41** into a rodent cell, whereby the human TSLP nucleic acid sequence is integrated into the endogenous rodent Tslp gene resulting in a replacement of a rodent Tslp genomic DNA with the human TSLP nucleic acid sequence to form a humanized Tslp gene, thereby generating the genetically modified rodent cell.

132. The method of claim **131**, wherein the rodent cell is a rodent ES cell.

133. An in vitro method for generating a genetically modified rodent cell, comprising

introducing the targeting nucleic acid construct of claim

82 or **83** into a rodent cell, whereby the human TSLPR nucleic acid sequence is integrated into the endogenous rodent Tslpr gene resulting in a replacement of a rodent Tslpr genomic DNA with the human TSLPR nucleic acid sequence to form a humanized Tslpr gene, thereby generating the genetically modified rodent cell.

134. The method of claim **133**, wherein the rodent cell is a rodent ES cell.

135. An in vitro method for generating a genetically modified rodent cell, comprising

introducing the targeting nucleic acid construct of claim

123 or **124** into a rodent cell, whereby the human IL7RA nucleic acid sequence is integrated into the endogenous rodent Il7ra gene resulting in a replacement of a rodent Il7ra genomic DNA with the human IL7RA nucleic acid sequence to form a humanized Il7ra gene, thereby generating the genetically modified rodent cell.

136. The method of claim **135**, wherein the rodent cell is a rodent ES cell.

* * * * *